New developments in RiPP discovery, enzymology and engineering

Manuel Montalbán-López[a,§], **Thomas A. Scott**[b,§], **Sangeetha Ramesh**[c,d,§], **Imran R. Rahman**[e,§], **Auke van Heel**[f,§], **Jakob H. Viel**[f,§], **Vahe Bandarian**[g], **Elke Dittmann**[h], **Olga Genilloud**[i], **Yuki Goto**[j], **María José Grande Burgos**[k], **Colin Hill**[l], **Seokhee Kim**[m], **Jesko Koehnke**[n], **John A. Latham**[o], **A. James Link**[p], **Beatriz Martínez**[q], **Satish K. Nair**[d,e,r], **Yvain Nicolet**[s], **Sylvie Rebuffat**[t], **Hans-Georg Sahl**[u], **Dipti Sareen**[v], **Eric W. Schmidt**[w], **Lutz Schmitt**[x], **Konstantin Severinov**[y], **Roderich D. Süssmuth**[z], **Andrew W. Truman**[aa], **Huan Wang**[ab], **Jing-Ke Weng**[ac], **Gilles P. van Wezel**[ad], **Qi Zhang**[ae], **Jin Zhong**[af], **Jörn Piel**[b], **Douglas A. Mitchell**[c,d,ag], **Oscar P. Kuipers**[f], **Wilfred A. van der Donk**[d,e,ag,ah]

[a]Department of Microbiology, University of Granada, Spain [b]Institute of Microbiology, ETH Zürich, Zürich, Switzerland [c]Department of Microbiology, University of Illinois at Urbana-Champaign, Urbana, IL, USA [d]Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL, USA [e]Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA [f]Dept. of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, the Netherlands [g]Department of Chemistry, University of Utah, Salt Lake City, UT, USA [h]Institute of Biochemistry and Biology, University of Potsdam, Germany [i]Fundación MEDINA, Granada, Spain [j]Department of Chemistry, Graduate School of Science, The University of Tokyo, Bunkyo, Tokyo, Japan [k]Department of Microbiology, University of Jaén, Spain [l]APC Microbiome Ireland and School of Microbiology, University College Cork, Cork, Ireland [m]Department of Chemistry, Seoul National University, South Korea [n]School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, United Kingdom [o]Department of Chemistry and Biochemistry, University of Denver, Denver, CO, USA [p]Departments of Chemical and Biological Engineering, Chemistry, and Molecular Biology, Princeton University, Princeton, NJ, USA [q]Dept. of Technology and Biotechnology of Dairy Products, Dairy Research Institute-IPLA, Consejo Superior de Investigaciones Científicas-CSIC, Villaviciosa, Spain. [r]Center for Biophysics and Computational Biology, University of Illinois at Urbana-Champaign, Urbana, IL, USA [s]Université Grenoble-Alpes, CEA, CNRS, IBS, Metalloproteins Unit, Grenoble, France [t]Laboratory Molecules of Communication and Adaptation of Microorganisms -MCAM (UMR 7245 CNRS-MNHN), National Museum of Natural History, Paris, France [u]Department of Pharmaceutical Microbiology, University of Bonn, Bonn, Germany [v]Department of Biochemistry, Panjab University, Chandigarh-160014, India [w]Department of Medicinal Chemistry, University of

Utah, Salt Lake City, UT USA [x]Institute of Biochemistry, Heinrich Heine University Düsseldorf, Duesseldorf, Germany [y]Waksman Institute, Rutgers University, Piscataway NJ, and Skolkovo Institute of Science and Technology, Skolkovo, Russia [z]Department of Chemistry, Technische Universität Berlin, Berlin, Germany [aa]Department of Molecular Microbiology, John Innes Centre, Norwich, United Kingdom [ab]State Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center of Nanjing University, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210093, China [ac]Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA [ad]Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands [ae]Fudan University, Shanghai, China [af]State Key Laboratory of Microbial Resources, Institute of Microbiology & University of Chinese Academy of Sciences, Beijing, China [ag]Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA [ah]Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA

Abstract

Ribosomally-synthesized and post-translationally modified peptides (RiPPs) are a large group of natural products. A community-driven review in 2013 described the emerging commonalities in the biosynthesis of RiPPs and the opportunities they offered for bioengineering and genome mining. Since then, the field has seen tremendous advances in understanding of the mechanisms by which nature assembles these compounds, in engineering their biosynthetic machinery for a wide range of applications, and in the discovery of entirely new RiPP families using bioinformatic tools developed specifically for this compound class. The First International Conference on RiPPs was held in 2019, and the meeting participants assembled the current review describing new developments since 2013. The review discusses the new classes of RiPPs that have been discovered, the advances in our understanding of the installation of both primary and secondary post-translational modifications, and the mechanisms by which the enzymes recognize the leader peptides in their substrates. In addition, genome mining tools used for RiPP discovery are discussed as well as various strategies for RiPP engineering. An outlook section presents directions for future research.

Graphical Abstract

This review provides a comprehensive update of the advances in discovery, biosynthesis, and engineering of ribosomally-synthesized and post-translationally modified peptides (RiPPs).

1. Introduction

In 2013, a community effort of scientists working on the biosynthesis of ribosomally synthesized and post-translationally modified peptide (RiPPs) resulted in a comprehensive review that described the commonalities of the many natural products generated from ribosomal peptides.[1] Since the first recognition of RiPPs as a major group of natural products, many advances have been reported on the understanding of their biosynthesis, engineering of their structures, and discovery of new members. These exciting developments resulted in the First International Conference on RiPPs that was held in April 2019 in Granada, Spain, with Oscar Kuipers as Chair and Manuel Montalbán-López, Jörn Piel, Wilfred van der Donk, and Auke van Heel comprising the Organizing Committee. The data presented, in addition to the large volume of new publications, stimulated discussion of a new community effort involving the conference participants. This resulting review outlines the main concepts and overall biosynthetic logic of RiPPs, but will not discuss findings that predate 2013 or on RiPP bioactivities for which we refer to previous work.[1,2] This review will also not comprehensively list all examples of genome mining for new RiPPs and will only focus on examples of new compound classes and new post-translational modifications.

The current work will first discuss new classes of RiPPs that have been discovered (section 2). In some cases, these were known compound classes that were not previously recognized to be generated from a ribosomally produced precursor peptide; in other cases, these RiPPs consist of new natural product classes that had not been previously reported. After the overview of new RiPPs, we will cover new developments in the understanding of biosynthetic enzymes that introduce the primary, class-defining post-translational modifications (section 3), followed by a separate section on substrate recognition and leader peptide removal (sections 4). Section 5 discusses enzymes that install secondary, compound-specific modifications sometimes referred to as tailoring reactions.[3]

As anticipated, the avalanche of available genomic data has not abated since 2013. As such, tools have been developed to help mine the formidable amount of information for the discovery of new RiPPs. Section 6 of this review discusses both the new bioinformatic programs that have been advanced as well as their use for the discovery of new RiPPs.

Because of their genetically encoded precursor peptides, RiPPs are particularly well-suited for synthetic biology approaches to generate novel structures. The 2013 review forecasted the many intriguing possibilities with respect to bioengineering directions and in the intervening time, many of the tantalizing prospects have been realized and other new ideas have been explored. Section 7 of this review will discuss the advances in synthetic biology from making hybrid molecules to introducing novel functionalities, from engineering high-throughput selection systems to employing new bioactivities, and from using *in vitro* translation and post-translational modification systems to incorporation of non-canonical amino acids. We trust that this review will help stimulate another period of sustained growth and discovery in the RiPP field.

1.1 Brief overview of RiPP biosynthesis

RiPP precursor peptides are typically composed of multiple segments (Fig. 1a). The core region (or core peptide) is where the post-translational modifications (PTMs) take place. A leader and/or a follower peptide provides binding affinity for many of the PTM enzymes and is removed at some point during the biosynthesis. In addition, the leader peptide (LP) can serve as an allosteric effector to activate the biosynthetic enzymes, the presence of the leader/follower peptide often keeps the maturing peptide inactive, and in some cases, the LP is required to ensure that the PTMs are carried out in the correct order.[4,5] For cases where the core peptide undergoes multiple types of PTMs, different parts of the leader/follower peptide can be recognized by different biosynthetic enzymes. The term recognition sequence (RS) has been introduced to identify the specific sequences that are required for a specific enzyme to carry out its chemical transformation on the core peptide. For some RiPPs discussed herein, such as the cyanobactins, dikaritins, orbitides, amatoxins, cyclotides, and lyciumins (see the respective sections), the precursor peptide carries multiple core peptides and multiple recognition sequences, such that one peptide results in more than one RiPP product (Fig. 1b). For most RiPPs, numbering of the precursor peptides uses negative numbers for the LP, counting backwards from the last residue of the LP, whereas positive numbers are used for the amino acid residues in the core peptides (Fig. 1A). In some cases, for instance cyanobactins, alternative numbering better allows recognition of conserved features of the core peptides.[6]

As the number of biosynthetic genes has exploded and many new bioinformatics tools have been developed to identify and annotate them (Section 6), naming of the genes and the corresponding proteins with the 26 letters of the alphabet without creating duplication has become challenging. The American Society for Microbiology uses a specific set of guidelines for gene nomenclature in bacterial genetics.[7] Paraphrasing the original definitions, genes are designated by a three-letter, lower-case, italicized locus symbol followed by a single italicized capital letter immediately following the three-letter lower-case locus identification to identify individual associated genes. Unfortunately, our own recommendations in 2013 for RiPP biosynthesis partially ignored this standardization and has led to possible confusion. As the number of genes has rapidly expanded, it has become more and more common to use two (or more) capital letters. For instance (and there are many more examples), for systems covered in this review, RaxST is used in sulfatyrotides (section 2.11), LanKC is used for class III lanthipeptide dehydratases (section 3.1.3), BotCD is used for an enzyme in bottromycin biosynthesis (section 3.7), and AgePT is used for an enzyme in cyanobactin biosynthesis (section 5.3.7.1). Confusion can arise for instance when a precursor is said to be coexpressed with RaxST and this can be interpreted as co-expression with two proteins (S and T) or co-expression with one protein (ST). This confusion can be avoided in several ways. Some authors have chosen to use numbers instead of letters as the second identifier when running out of letters (e.g. PlpA2, section 3.14), others have used lower case letters following the first capital letter (e.g. UstYa, section 3.17), or have used subscript letters (e.g. LanJ$_A$; section 5.1.2). We recommend using such unambiguous nomenclature going forward.

2. New classes of RiPP natural products

With the advent of new sequencing techniques, the number of genome sequences has exploded. Researchers have used this genomic information to connect previously known natural product classes with orphan biosynthetic gene clusters (BGCs) for which the products were not established. In addition, genome mining approaches have led to the discovery of previously unknown RiPP classes by exploring novel BGCs. This section will provide a brief overview of natural products that have been established to be RiPPs since January 2013 in the approximate order of their first recognition as a RiPP. Their biosynthesis, when known, is covered in section 3. If the biosynthesis of a new RiPP has not yet been studied, its BGC will be briefly discussed in this section. In the structure drawings in this review, the PTMs that are class-defining are highlighted in yellow, whereas secondary (sometimes also referred to as "ancillary" or "tailoring") modifications are highlighted in cyan, unless specified otherwise in the figure legend.

Table 1 lists all currently known RiPP classes with the corresponding class-defining primary PTM or feature denoted. The field has rapidly expanded since the previous comprehensive review (circa January 2013) with 17 new classes and is likely to expand further in the coming years. We note that future classification of all RiPPs into single classes may prove difficult in some cases as RiPPs are discovered that are made by natural hybrid pathways utilizing combinations of biosynthetic enzymes from multiple compound classes.

2.1 Thioamitides

Thioviridamide was first reported in 2006.[8] The structure of this apoptosis inducer produced by *Streptomyces olivoviridis* contains a C-terminal 2-aminovinyl-cysteine (AviCys) structure previously found in lanthipeptides and linaridins, hinting at its RiPP origin. However, the most unique part of the structure of thioviridamide and related compounds like JBIR-140 (Fig. 2)[9] are the thioamide bonds in the peptide backbone. In 2013, the BGC of thioviridamide was reported demonstrating that the compound is indeed a RiPP.[10] Since then, studies on its biosynthesis (see section 3.5) have facilitated genome mining approaches that have uncovered other thioamide containing peptides.[9,11–14] The term thioamitides is suggested to describe this family of compounds that have thioamides as the class-defining feature.

2.2 Dikaritins

Ustiloxins are produced by *Ustilaginoidea virens*, a pathogenic fungus affecting rice plants. In 2014, ustiloxin B was reported to be a RiPP, the first characterized example in Ascomycetes (Fig. 3B).[15] Subsequent studies showed that the phomopsins are also made from a ribosomally synthesized precursor peptide (Fig. 3B),[16] and genome mining uncovered new groups of compounds such as asperipin-2a (Fig. 3C).[17] The term dikaritins has been suggested to describe the family of fungal compounds that are made by similar biosynthetic pathways involving crosslinks between a phenolic group derived from Tyr and the side chains of various other amino acids (see section 3.17).[16] Like many cyanobactins (section 3.6), microviridins (section 3.15), amatoxins (section 3.18), orbitides, cyclotides

(section 3.19), and other plant-derived RiPPs (section 2.9), dikaritin precursor peptides contain multiple core peptides that are located in repetitive sequence motifs.

2.3   Guanidinotides

Pheganomycin consists of the non-proteinogenic amino acid (*S*)-2-(3,5-dihydroxy-4-hydroxymethyl)phenyl-2-guanidinoacetic acid connected to a peptide that contains a *tert*-Leu (Fig. 4A). The compound is produced by *Streptomyces cirratus* and has activity against mycobacteria. In 2015, the peptide was reported to be ribosomally synthesized with the non-proteinogenic amino acid appended in a PTM process.[19] Two different pheganomycin core peptides are present in the precursor peptide (Fig. 4B) resulting in a group of congeners. We suggest the name guanidinotides to describe any additional compounds that feature α-guanidino acids attached to ribosomal peptides.

2.4   Mycofactocin

The occurrence of mycofactocin in mycobacteria as a unique redox cofactor with a ribosomal origin was predicted in 2011.[20] A core structure termed premycofactocin has been suggested based on biochemical studies of the biosynthetic enzymes (Fig. 5) (section 3.21),[21] and oligoglycosylated derivatives have been detected in cells.[22]

2.5   Streptides

Streptoccocci use various signaling molecules for intercellular communication. One such molecule of unknown structure was reported to be cyclic and derived from a gene-encoded peptide.[23] In 2015, the structure of the compound was revealed (Fig. 6A), showing that it contained a post-translationally installed Lys-Trp crosslink, and the term streptide was introduced for this group of streptococcal molecules. Gene deletion studies and biochemical experiments confirmed that it was a member of the RiPP class and related molecules have been discovered by genome mining in subsequent studies, some of which have undergone additional bond formation (e.g. Fig. 6B).[24] Streptide BGCs are positively regulated by quorum sensing and are widespread in streptococcal genomes.

2.6   Borosins

N-methylation of backbone amides is a commonly found structural feature in non-ribosomal peptides but it had been absent from RiPPs until the discovery of the omphalotins produced by fungi (Fig. 7).[25,26] As described in section 3.16, the omphalotins are a unique type of RiPP in that the substrate is attached to the enzyme that introduces the *N*-methylations. The term borosin is used for the larger family of fungal products that are made by this unusual biosynthetic strategy.

2.7   Crocagins

Metabolome mining of the myxobacterium *Chondromyces crocatus* Cm c5 resulted in the discovery of the crocagins, which are amongst the smallest RiPPs as they are formed from three amino acids of a precursor peptide (Fig. 8).[27] The BGC was identified by genome sequencing and targeted gene inactivation in the producer strain. Crocagin A was shown to

bind to the carbon storage regulator protein CsrA and as such inhibits CsrA binding to its target RNA.[27]

2.8 Epipeptides

Several new mechanisms of introducing D-amino acids into ribosomally synthesized peptides have been discovered in the past six years (see sections 3.12 and 3.13). The most general method is epimerization by radical *S*-adenosyl methionine (SAM) epimerases as they could in principle epimerize the α-center of the 19 chiral proteinogenic amino acids. Such radical SAM epimerases were discovered in the biosynthesis of proteusins,[28] where epimerization is part of a much larger set of PTMs (see section 3.12). More recently, peptides that appear to only undergo epimerization, with no other PTMs, have been described that also require radical SAM proteins, but from a different subfamily.[29] These peptides were named epipeptides (e.g. Fig. 9).

2.9 Lyciumins

Lyciumins are protease-inhibiting cyclic peptides originally isolated from the Chinese medicinal plant *Lycium barbarum* (goji berry) (Fig. 10A).[30] Current members are characterized by crosslinks between the indole nitrogen of Trp to the α-carbon of a Gly within the peptide while also carrying a pyroglutamate residue at the N-terminus. Lyciumin precursor genes encode both a BURP domain (BURP is an acronym for the four initially identified examples of the domain: BNM2, USP, RD22, and PG1β)[31] and repetitive lyciumin core peptide motifs (Fig. 10B).[32] Heterologous expression of the lyciumin precursor gene alone is sufficient to produce the derived lyciumins in tobacco.[32] The attachment of BURP domain to the precursor peptide suggests that, like the borosins (section 2.6), one or more of the PTMs might be catalyzed by a protein connected to the substrate. Like some other RiPPs (cyanobactins, graspetides, cyclotides, dikaritins, orbitides, and pheganomycin),[1] the precursor peptides of lyciumins contain multiple core peptides (Fig. 10B). Genome mining suggests that lyciumin chemotypes are widespread in flowering plants and will likely have considerable structural diversity.[32]

2.10 Lipolanthines

Lanthipeptide biosynthetic genes had been previously observed near polyketide synthase genes,[33] but whether the encoded proteins indeed cooperate to make a hybrid natural product was unclear until the structure of microvionin was reported[34] (Fig. 11). This molecule constitutes the first example of a lipopeptide where the peptide part is ribosomally synthesized. The compound was isolated from a culture of *Microbacterium arborescens* in a bioactivity-guided screen for antimicrobial natural products. In addition to the unusual lipidation, microvionin contains a decarboxylated analog of labionin termed avionin (Fig. 11). The relationship between avionin and labionin is analogous to that between lanthionine and the AviCys motif found in lanthipeptides ond other RiPPs (e.g. Fig. 2). Genome mining studies demonstrated that BGCs for lipidated class III lanthipeptides are widespread and the name lipolanthines was introduced for this distinct group of RiPPs.[34]

2.11   RaxX and PSY1 sulfatyrotides

The recognition of bacterial biomolecules by plant cell surface receptor kinases commonly mediates resistance against pathogens. In rice, one of these kinases is XA21 that helps detect the Gram-negative pathogen *Xanthomonas oryzae* pv. *oryzae* (Xoo). The *Xanthomonas*-derived activator of XA21 is a peptide termed RaxX (Fig. 12A).[35] Xoo strains evading XA21-mediated immunity carry a RaxX mutation that replaces a Tyr moiety, suggesting this residue is important for recognition of wild-type RaxX. Notably, this Tyr is the site for a post-translational modification resulting in side-chain *O*-sulfation, carried out by the sulfotransferase RaxST encoded in the *rax* locus (Fig. 12B). While Tyr sulfation is common in eukaryotes, RaxST is the first known prokaryotic sulfotransferase involved in post-translational modification. The RaxX peptide was shown to be produced from a 60-amino acid precursor peptide.[35] The precursor has a 38-amino acid LP that ends in a double Gly motif that is often found in RiPPs (see section 4.4.1). Moreover, the RaxX BGC (Fig. 12B) contains a peptidase-containing ATP-binding cassette transporter (PCAT) that removes the LP (see section 4.4.1 for discussion of PCATs). RaxX resembles an 18-residue plant peptide PSY1 that is also sulfated on Tyr and serves as a hormone (Fig. 12C). It was therefore suggested that RaxX is a hormone mimic that benefits Xoo by interfering with host cellular processes.[36,37] PSY1 is also ribosomally synthesized as a 75-amino acid precursor peptide that is not only sulfated but also glycosylated.[38] Thus, both PSY1 and RaxX are RiPPs. Corroborating the virulence factor hypothesis, a synthetic 13-residue sulfated RaxX-derived peptide showed similar effects on root growth in *Arabidopsis* and rice as PSY1.[36] Similar effects were also observed for completely matured RaxX, which was recently identified in Xoo extracts as a 21-residue peptide representing the proteolytically released, sulfated RaxX core peptide.[35] These insights on a functionally unusual RiPP might lead to applications in plant protection. In support of such avenues, exogenously applied sulfated RaxX peptide suppresses infection by virulent Xoo strains in rice.[39] Since the term sulfatides is already used for glycolipids,[40] we suggest the term sulfatyrotides for RiPPs where Tyr sulfation is the primary modification.

2.12   Spliceotides

All of the compound groups discussed thus far were either known to belong to the RiPP group of natural products prior to investigation of their biosynthesis, or they were discovered by bioassay-guided isolation. In 2018 and 2019, several examples were reported of completely new families of RiPPs that were bioinformatically discovered through profiling of genes encoding divergent enzymes from known RiPP BGCs. One such example is the report of a fundamentally new PTM reaction that converts a dipeptide motif into a β-peptide (Fig. 13).[41] During this process, part of one amino acid is excised leading to the name spliceotides for the natural products formed by this unusual reaction (section 3.14).

2.13   Ranthipeptides

Another example of a RiPP group that was identified bioinformatically before the molecule was characterized is the ranthipeptides (radical non-α-carbon thioether peptides).[42,43] Lanthipeptides and sactipeptides are RiPP families with thioether crosslinks. For the sactipeptides, the intramolecular linkages are sulfur to α-carbon thioethers (sactionine) and

include diverse amino acids. Sactionines are introduced by radical SAM enzymes, whereas for lanthipeptides the thioether linkages are to the β-carbons of dehydrated Ser/Thr residues. A bioinformatic search for homologs of the radical SAM enzymes that introduce the thioether crosslinks in sactipeptides resulted in the discovery of a large family of unique proteins. The substrates encoded next to these radical SAM enzymes were previously referred to as SCIFFs (for six Cys in forty-five residues).[42] Characterization of these radical SAM-dependent pathways demonstrated they did not result in sactionines but instead generated crosslinks to the β or γ-carbons of a variety of amino acids.[43] Examples of ranthipeptides are freyrasin produced by *Paenibacillus polymyxa* that contains six thioether links to the β-carbon of Asp residues (S–Cβ) (section 3.10) and thermocellin that contains a thioether cross-linked to the γ-carbon of Thr (Fig. 14A). A β-thioether linkage was also introduced by a homolog of the radical SAM enzyme (NxxcB) that generates the Lys-Trp crosslink in streptide (section 2.5). The resulting product features a thioether linkage between a former Cys and Asn (Fig. 14B).[44]

2.14   Ryptides, rotapeptides, and darobactin

Genome mining for additional radical SAM enzymes regulated by quorum sensing in *Streptococci* resulted in the discovery of enzymes that install different intramolecular linkages than those found in streptide (section 2.5). Examples are C-C crosslinks between Arg and Tyr in ryptides (Fig. 15A)[45] and ether crosslinks between the side chain oxygen of Thr and the α-carbon of Gln in rotapeptides (Fig. 15B).[46] Thus, it is clear that crosslink formation by radical SAM enzymes greatly expands the methods available for macrocyclization of RiPPs. Indeed, a recent bioassay-guided discovery effort resulted in the identification of darobactin from the nematode symbiont *Photorhabdus khanii* HGB1456. Darobactin contains both Lys-Trp and Trp-Trp crosslinks, including an ether linkage between the C7 indole of Trp1 and the β-carbon of Trp3 (Fig. 15C).[47] Genome sequencing demonstrated the molecule was a RiPP generated from a 58-amino acid precursor peptide and the BGC contains a gene (*darE*) encoding a radical SAM enzyme belonging to the SPASM[48] subfamily (Fig. 15D). SPASM is an acronym based on the founding members involved in the maturation of subtilosin, pyrroloquinoline quinolone (PQQ), anaerobic sulfatase-maturing enzyme, and mycofactocin. DarE shares only modest sequence similarity to StrB, the enzyme that installs a Trp-Lys C-C crosslink in streptide (section 3.11).

2.15   Pearlins

A final example of a new RiPP family that was initially noted bioinformatically is the pearlins. Class I lanthipeptide dehydratases transfer glutamate from glutamyl-tRNA to the side chain of Ser/Thr in their precursor peptides followed by glutamate elimination (section 3.1.1).[49] Genome mining revealed divergent dehydratase homologs that lacked the glutamate elimination domain. These proteins uniquely add amino acids from amino acyl-tRNA to the C-terminus of a precursor peptide.[50] Thus, these enzymes were named peptide aminoacyl-tRNA ligases (PEARLs). The identity of the initially added amino acid can vary. In the currently characterized examples, peptide extension is followed by further post-translational modification of the newly appended amino acid to either generate new structures such as 3-thiaglutamate, or previously known natural products such as the ammosamides (Fig. 16). [50,51] To underscore the common biosynthetic logic, the products of these pathways are now

termed pearlins. The pearlins do not have a class-defining PTM. Instead they are unified by a common non-ribosomal aminoacyl-tRNA dependent extension of a ribosomal peptide (section 3.24).

2.16 Atropitides

Tryptorubin A (Fig. 17A) was isolated in 2017 from *Streptomyces* sp. CLI2509, which was in turn isolated from the bracket fungus *Hymenochaete rubiginosa*.[52] The compound contains crosslinks between aromatic side chains resulting in a rigid, polycyclic structure. A recent total synthesis effort showed the compound can exist in two different non-interchangeable forms with identical chemical connectivity, but where the two isomers are not related by the common stereochemical definers: point chirality, E/Z geometry across double bonds, or axial chirality (canonical atropisomerism). The authors suggested the two forms of the molecule be termed non-canonical atropisomers. Importantly, the synthetic efforts demonstrated that only one of these non-canonical atropisomers is produced in nature.[53] Although the initial biosynthetic origin was speculated to be a non-ribosomal peptide synthetase (NRPS),[52] the more recent study suggests that the compound is a RiPP, and that the crosslinks are likely introduced by oxidative cyclization involving a cytochrome P450 enzyme (Fig. 17B). We suggest the name "atropitides" for any subsequently discovered compounds that are similarly biosynthesized and display non-canonical atropisomerism.

2.17 Lanthidins, class V lanthipeptides

The antibiotic cacaoidin (Fig. 18A) is the first reported member of the lanthidins, a new RiPP subfamily with structural elements found in lanthipeptides and linaridins.[54] Cacaoidin was isolated from a strain of *Streptomyces cacaoi* and bears an unprecedented *N,N*-dimethyl lanthionine (NMe_2Lan) that is not found in known lanthipeptides. N-terminal bis-*N*-methylation has been reported for linaridins (e.g. Fig. 27B) and LAPs (section 5.3.5), but these RiPP families lack lanthionines. The molecule also combines other unusual structural features, such as *O*-glycosylation of Tyr with a 6-deoxygulopyranosyl-(rhamnopyranose) disaccharide and a high number of D-amino acids including D-Abu (Fig. 18A). The cacaoidin BGC could not be identified by any prediction software tool and was mapped in the region adjacent to the core peptide structural gene (Fig. 18B). The cluster shows low homology with those of other lanthipeptides or linaridins and suggests an alternative RiPP biosynthetic pathway. Since linaridins are characterized by Dhb residues (see section 3.3), which are not present in cacaoidin, but lanthipeptides are characterized by lanthionine, which is present in cacaoidin, we propose that lanthidins are class V lanthipeptides that are made via a biosynthetically distinct pathway since the BGC does not contain genes for class I-IV lanthionine synthases (section 3.1).[55] Very recent genome mining efforts identified additional members of these class V lanthipeptides that are not discussed here as they appeared after finalization of this review, but that are referenced nonetheless for the interested reader.[56,57]

2.18 Cittilins

After submission of this review this new class of RiPPs was reported that will not be discussed in detail but that are referenced for the interested reader. The cittilins, produced by

Myxococcus xanthus, are bicyclic tetrapeptides with biaryl and aryl-oxygen-aryl ether crosslinks (Fig. 18C).[58] They are made from a 27-amino acid precursor peptide encoded in a BGC that also contains a cytochrome P450 (CitB) and a methyltransferase (CitC). A prolyl endopeptidase that removes the leader peptide is encoded outside of the BGC.

3.   Advances in the understanding of biosynthetic enzymes that install primary post-translational modifications

As noted in Table 1, RiPP families are typically defined by characteristic PTMs called primary modifications. Secondary, compound-specific modifications are introduced by tailoring processes, which complete the biosynthetic pathway. In the past six years, our understanding of the enzymes that catalyze the primary modifications has been greatly improved for previously known RiPPs. Furthermore, many of the enzymes that produce the newly discovered RiPP families discussed in section 2 have been investigated and will also be discussed in the following section.

3.1   Lanthipeptide biosynthesis

Introduction and biosynthesis: Lanthipeptides contain the β-thioether crosslinked bis amino acids lanthionine (Lan) and methyllanthionine (MeLan, Fig. 19A). These structures are formed from initial dehydration of Ser and Thr residues to the corresponding dehydro amino acids dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively (Fig. 19A). Subsequent conjugate addition of Cys thiols to these dehydroamino acids results in Lan and MeLan. Prior to 2013, the stereochemistry of the Michael-type addition was believed to always result in D-(Me)Lan in which the α-stereocenter of the former Ser/Thr residue had D-stereochemistry, but in the intervening years it has become clear that the stereoselective protonation of the enolate intermediate can take place from either the *Re* or *Si* face. Intriguingly, protonation of the enolate is not confined to a single face in a particular peptide, because both DL and LL stereochemistry can result within the same core peptide. [59–61] Recent years have shown that lanthipeptides are encoded in a much wider range of organisms than previously anticipated including archaea and bacteroidetes.[62–64]

Currently five classes of lanthipeptides have been reported that differ in the biosynthetic enzymes that carry out (Me)Lan formation. New knowledge reported on these enzymes is briefly discussed in the following sections for class I-IV. The recent discovery of the lanthidins (section 2.17) revealed the latest independent pathway to lanthionines (class V), [54,56,57] which at present is not yet well understood.

3.1.1   Class I lanthipeptide biosynthesis

Class-defining enzyme: aminoacyl-tRNA dependent dehydratase: *In vitro* reconstitution of the biosynthesis of class II-IV lanthipeptides had been reported prior to 2013,[1] but reconstitution of class I biosynthesis had proven recalcitrant. The explanation for this difficulty came when it was revealed that dehydration by the LanB dehydratases (InterPro families IPR006827 and IPR023809) during class I lanthipeptide biosynthesis requires glutamyl-tRNA, a co-substrate that was not anticipated (Fig. 19B).[49] The discovery of the requirement of glutamyl-tRNA had been foreshadowed by targeted mutagenesis of the NisB

enzyme, the LanB involved in nisin biosynthesis, which resulted in glutamylation of Ser and Thr residues in the precursor peptide, NisA, during heterologous expression in *Escherichia coli*.[65] Reconstitution of the dehydration activity *in vitro* required the macromolecular fraction of *E. coli* cell extract, and the activity was lost upon treatment with RNAse. Subsequent *in vitro* biochemical studies confirmed the requirement of glutamyl-tRNA and demonstrated the need for glutamyl-tRNA synthetase and illustrated that NisB does not amino acylate uncharged tRNA. The discovery that the LanB dehydratases use glutamyl-tRNA also opened up new opportunities to study the biosynthesis of other RiPPs that use homologous enzymes as discussed in section 3.2.

A crystal structure of NisB bound to the LP of its substrate NisA (Protein Databank, PDB: 4WD9) demonstrated the enzyme contained three domains (Fig. 20A).[49] One domain (InterPro family IPR006827) catalyzes the transfer of glutamate from the tRNA to the peptide substrate. Then, the glutamylated peptide is translocated to another domain (InterPro family IPR023809) in which the glutamate is eliminated to form Dha/Dhb. A ping-pong type mechanism in which the glutamyl group is first transferred from the glutamyl-tRNA to the enzyme prior to transfer of the glutamyl moiety to the Ser/Thr in NisA was ruled out by mutagenesis. The LP-binding domain in NisB[49] (termed the RiPP precursor Recognition Element,[66] RRE) will be discussed further in section 4.1.1. Structure elucidation with a non-reactive analog of glutamylated NisA (PDB: 6M7Y) identified the elimination active site of NisB (Fig. 20B), while the glutamyl transfer active site is inferred based on a structure of a biosynthetic enzyme that carries out Glu-tRNA dependent glutamylation of Ser residues during thiopeptide biosynthesis (see section 3.2).[67] Covalent attachment of the LP to the RRE demonstrated that catalysis can take place with the LP occupying only a single binding site ruling out models in which the LP needs to move during catalysis.[68]

Studies with LanB enzymes from different bacterial phyla have shown that the nucleotide sequence in the acceptor stem of the tRNA^{Glu} is critical for the enzyme to accept the cognate glutamyl-tRNA as substrate,[69,70] an observation that explains difficulties in heterologous expression of many class I lanthipeptides. Some RiPP BGCs, such as those of the antifungal pinensins[63] or the thiopeptides,[71] contain split LanB dehydratases (see section 3.2) in which glutamylation and elimination are carried out by separate polypeptides.

Compared to advances in understanding the mechanism of dehydration and LP recognition, the mechanism of cyclization in class I lanthipeptides by LanC enzymes (InterPro family: IPR033889) remains to be investigated in detail. Cyclization has been shown to be reversible for both class I and class II systems,[72] but the mechanism of catalysis is not well understood. Several studies suggest that complex formation involving the dehydratase LanB, the stand-alone cyclase LanC, the LanA substrate and the LanT transporter is important for the overall PTM process. Both LanB (section 4.1.1)[49] and LanC[73] are believed to engage the same region of the NisA LP. The stoichiometry in these solution complexes has been suggested to involve one substrate per NisB dimer,[74] unlike the co-crystal structure of NisB with NisA where the stoichiometry is 1 NisB dimer : 2 NisA peptides. Thus, complex formation appears to result in a rearrangement that is currently not yet understood at the molecular level.

3.1.2   Class II lanthipeptide biosynthesis

Class-defining enzyme: ATP dependent LanM dehydratase: Class II lanthipeptides are biosynthesized by a bifunctional lanthipeptide synthetase (LanM, InterPro family: IPR017146). Activation of the Ser/Thr side chains for dehydration in class II lanthipeptides is achieved by phosphorylation followed by phosphate elimination (Fig. 19B). The cyclization step is catalyzed by a domain that is homologous to the LanC cyclase enzymes in class I lanthipeptide biosynthesis. The first X-ray structure of a bifunctional LanM enzyme was reported for CylM,[75] the synthetase that makes both the small and large subunits of the virulence factor, enterococcal cytolysin, produced by *Enterococcus faecalis*.[59] Surprisingly, the crystal structure showed that the dehydratase domain is structurally similar to mammalian lipid kinases (Fig. 21A). A distinct domain termed the kinase activation (KA) domain holds the activation loop in an active conformation and provides two residues that previously had been shown to be critical for phosphate elimination (Fig. 21B). The structure also explains why ADP must be present for phosphate elimination as phosphorylation and phosphate elimination occur in the same active site (Fig. 21B). No LP binding site could be identified in the structure, but recent hydrogen-deuterium exchange mass spectrometry data suggest that the LP may bind at a site made up of loops connecting the capping helices (see section 4.1.3).[76,77]

Detailed kinetic studies on the process of multiple dehydrations and cyclizations that turn a linear peptide into a polycyclic product have suggested that for enzymes that make a single natural product, substrate and enzyme have co-evolved to result in a well-defined order of catalytic events. The cyclizations become increasingly facile as the compound nears its final cyclization state.[78–80] In contrast, enzymes that have multiple substrates with diverse core peptides are much less efficient in general and the cyclizations become slower as the peptide matures.[78] Thus, a model has been proposed in which highly substrate tolerant enzymes with multiple physiological substrates are inherently slower as they have not co-evolved with one substrate to achieve efficient catalysis. In turn, this allows these substrate tolerant enzymes to generate many different products. The manner by which a single cyclization active site can convert highly divergent substrates into defined polycyclic topologies has been hypothesized to be determined by the sequence of the precursor peptides and not the enzyme.[78,81,82] This model is also supported by studies that show that for some lanthipeptides the stereochemistry of cyclization is determined by the peptide substrate sequence and not the enzyme.[59,60]

3.1.3   Class III lanthipeptide biosynthesis

Class-defining enzyme: NTP-dependent trifunctional LanKC dehydratase: Class III lanthipeptides are generated by trifunctional enzymes (LanKC) that contain lyase, kinase (InterPro family: IPR000719), and cyclase domains (InterPro family: IPR007822). The lyase and kinase domains have clear sequence similarity with the corresponding domains in class IV lanthipeptide synthetases (section 3.1.4), but the cyclase domain is unique amongst lanthipeptide cyclization enzymes, as it lacks the zinc binding residues. Another unusual aspect of class III lanthipeptides is that the cyclization domains form lanthionine or labionin (Lab) or both. Labionins are products of tandem conjugate additions (Fig. 22A), and the factors that determine Lan or Lab formation are not yet understood. Detailed investigation of

the CurKC enzyme involved in curvopeptin biosynthesis demonstrated a C-to-N terminal directionality of processing.[83]

Whereas before 2013 only Lab structures had been reported, in 2014 the first example of a methyllabionin (MeLab) was found in NAI-112, which also is unusual in that it is glycosylated on Trp (Fig. 22B).[84] At present the stereochemistry at the additional chiral center of MeLab is unknown. The BGC of NAI-112 was identified and contains a gene for a glycosyltransferase. An interesting variant of class III lanthipeptides was discovered in which the N-terminus of a Lab-containing peptide was adorned with a fatty acid (see section 3.1.5).[34] This class of compounds has been termed lipolanthines.

3.1.4 Class IV lanthipeptide biosynthesis

Class-defining enzyme: NTP dependent trifunctional LanL dehydratase: Like class III lanthipeptides, class IV lanthipeptides are generated by trifunctional enzymes called LanL that contain lyase, kinase, and cyclase domains (same InterPro families as LanKC: IPR000719 + IPR007822). At present only venezuelin and its congeners have been characterized, although genome sequences and synthetic biology studies suggest that other ring topologies can also be made by LanL-containing gene clusters.[62,85] Recent biochemical experiments showed that the LP of the precursor peptide binds to the kinase domain and that the dehydration process for venezuelin-like compounds occurs in an ordered and directional manner, from N-to-C terminus.[86,87]

3.1.5 Lipolanthine biosynthesis

Class-defining enzymes: combination of PKS/FAS and class III lanthipeptide synthetases: During an antibiotic screening study, microvionin with activity against *Staphylococcus aureus* was discovered in extracts of a *Microbacterium arborescens* culture. [34] Structure elucidation revealed a peptide with two new features comprising an AviCys-Lab moiety named avionin and an N-terminal *N,N*-bismethylated guanidine fatty acid (Fig. 11). The family was termed "lipolanthine" because of its resemblance to non-ribosomal lipopeptides. The BGC pinpointed by searching for the core sequence of microvionin, encodes class III lanthipeptide machinery as well as ten additional genes that were proposed to generate and attach the guanidino lipid moiety (Fig. 23A). These include genes encoding a putative 3-oxoacyl-ACP synthase (MicF) and an acyl carrier protein (MicACP), suggesting a hybrid fatty acid synthase-RiPP pathway. Avionin formation was studied *in vitro* showing that for sulfur bridge formation to occur, MicD, which catalyzes an oxidative decarboxylation of the C-terminal Cys residue, must be present. Through bioinformatic analyses, the authors identified in actinomycete genomes five additional BGCs with gene sets related to that of the microvionin cluster. However, all the actinomycete BGCs contain a gene encoding a putative type I PKS gene with an NRPS loading module instead of fatty acid synthase genes, suggesting two independent pathways to the guanidinylated moiety or a related structure. This hypothesis was confirmed by isolating the peptide product from *Nocardia terpenica*, named nocavionin. Thus, the RiPP segment of the lipolanthines are formed by previously reported features of lanthipeptide machinery: C-terminal decarboxylation by a LanD enzyme previously found in class I and II lanthipeptides (InterPro family: IPR003382; section 5.9), and dehydration and cyclization by a class III

lanthipeptide synthetase to arrive at the novel avionin structure (Fig. 23B). A follow-up study revealed 80 additional BGCs that were divided into four subtypes depending on the type of PKS or NRPS and on the presence or absence of a LanD.[88] LanKC enzymes encoced in BGCs that also encode a LanD were shown to be dependent on the LanD for labionin synthesis suggesting complex formation and/or allosteric regulation.[88] Biochemical insights into how the linkage of the FAS/PKS/NRPS product to the RiPP segment is formed have not yet been reported.

3.2 Thiopeptide biosynthesis

Introduction and biosynthetic pathway: Although thiopeptide biosynthesis had been studied at the genetic level,[1] in 2013 none of the core biosynthetic steps had been reconstituted *in vitro*. At a minimum, thiopeptide biosynthesis requires installation of thiazoles, dehydroamino acids, and cycloaddition of two dehydroamino acids. Biochemical studies on the biosynthesis of thiomuracin demonstrated a strict order of events in which the combined action of a cyclodehydratase (TbtG, YcaO InterPro family: IPR003776) and dehydrogenase (TbtE; InterPro family: IPR020051) (see section 3.4) with a designated LP-binding protein (TbtF) (see section 4.1.1) results in the introduction of six thiazoles in an ordered, but non-directional process (Fig. 24).[71,89] Only after installation of these thiazoles does the dehydratase act on the peptide. For micrococcin P1 biosynthesis, genetic studies suggest that prior to dehydratase activity, one additional PTM has to take place, the oxidative decarboxylation of a C-terminal Thr (section 5.9).[90]

Thiopeptide BGCs were known to contain a split dehydratase reminiscent of LanB lanthipeptide dehydratases. When the structure of the latter was reported (see section 3.1.1), it became clear that the split genes in thiopeptide BGCs encode separate enzymes for Ser glutamylation and elimination to form Dha. The glutamylation enzyme TbtB from thiomuracin biosynthesis (InterPro family: IPR006827) required the use of tRNA^{Glu} from the producing organism *Thermobispora bispora*, as Glu-tRNA from *E. coli* was not accepted. [71] TbtC (InterPro family: IPR023809) was then demonstrated to eliminate the glutamate to introduce four Dha residues in an ordered and directional process.[89] Mutagenesis studies and co-crystallization with a non-reactive analog of Glu-tRNA identified the glutamyl transfer active site of TbtB (Fig. 25).[67] Although TbtB contains a LP-binding motif, catalysis is not LP-dependent. Instead, TbtB specifically binds to the hexathiazole-containing core peptide.[71,89] The functional origin for using a split dehydratase rather than the fused version found in lanthipeptide biosynthesis is not presently clear. Split dehydratases are not limited to thiopeptides, as they are also involved in the biosynthesis of the LAP goadsporin[91] (Fig. 97) and the pinensin family of class I lanthipeptides.[63]

As noted above, a minimalistic thiopeptide biosynthetic pathway requires an RRE, a cyclodehydratase (YcaO), a dehydrogenase, a dehydratase and a [4+2] cycloaddition enzyme. Many thiopeptide BGCs encode multiple copies of one or more of these canonical proteins, sometimes as various fusions of these proteins. Insights into the function of these at first glance redundant proteins was provided for the biosynthesis of sulfomycin produced by *Streptomyces viridochromogenes*.[92] Its biosynthetic gene cluster encodes two YcaO-domain containing proteins SulC and SulD. Heterologous expression in *E. coli* showed that SulC in

complex with the didomain protein SulB (containing RRE and ocin-ThiF domains) converts Cys2 and Thr9 in the precursor peptide to the corresponding thiazoline and methyloxazoline, respectively.[92] These azolines are oxidized to the corresponding azoles by a SulEFG complex that has a non-canonical make-up of fusion proteins (containing RRE, flavin-dependent dehydrogenase, and E1-like adenylase, see section 3.4).[92] Subsequently, SulD in close cooperation with SulEFG converts Thr5, Cys7, and Ser12 to the corresponding azoles. The authors show that a complex is formed by SulDEFG,[92] something that is likely a staple of many RiPP biosynthetic pathways.[93] The study of the sulfomycin biosynthetic enzymes illustrates that many different protein combinations may have evolved in thiopeptide biosynthetic pathways to achieve the same overall transformation as the more simple BGCs.

Class-defining enzyme catalyzes a [4+2] aza-cycloaddition: In 2015, the first experimental confirmation was reported of the proposed [4+2] cycloaddition of two Dha residues to form the 6-membered nitrogenous heterocycle that is ubiquitous in thiopeptides. Exposure of a synthetic substrate that contained all anticipated thiazole and Dha residues to the enzyme TclM (InterPro family: IPR023809), resulted in cycloaddition to form the core scaffold of the thiopeptide thiocillin.[94] The same observations were made for the enzyme TbtD (an ortholog of TclM) with an enzymatically generated substrate. Analysis of the TbtD products demonstrated that the LP was eliminated as a C-terminal carboxamide.[71] Subsequent studies have demonstrated that only the last ten residues of the LP are required for efficient cycloaddition catalyzed by TclM and TbtD,[95] and that the latter enzyme can also catalyze the intermolecular [4+2] cycloaddition of Dha-containing peptides.[96] Interestingly, TclM and TbtD are homologous to TclC and TbtC, which, as discussed above, eliminate glutamate from glutamylated Ser to yield Dha.[97]

A crystal structure of PbtD (an ortholog of TbtD involved in GE2270A biosynthesis) with a product analog bound (PDB: 5W99) provides some insight into the overall cyclization process,[97] but individual amino acids that catalyze the various steps involved in the [4+2] cycloaddition reaction and subsequent water and LP elimination have not yet been identified. The structure of TbtD did show that, although the N-terminal amino acids of the LP are not required for catalysis, they do clearly bind to the LP-binding site (Fig. 26).[89] The reaction catalyzed by TbtD is believed to involve first tautomerization of one Dha to the corresponding iminol, followed by the actual [4+2]-cycloaddition, elimination of water from the hemiaminal, and finally elimination of the leader peptide to form the pyridine (Fig. 26C). The first support of this order of events was obtained with a synthetic substrate analog in which several thiazoles were substituted by oxazoles resulting in a slow substrate. With this analog, the hemiaminal intermediate appears to build up as indicated by MS data. Acidic hydrolysis of the intermediate allowed spectroscopic characterization of the resulting diketone (Fig. 26C).[98] Thiopeptides undergo a plethora of compound-specific secondary PTMs, some of which have been investigated since 2013 and will be discussed in section 5.

3.3 Linaridin biosynthesis

Linaridins (linear arid peptides) constitute a moderately sized RiPP class characterized by the presence of dehydrobutyrine (Dhb) on linear, ribosomal peptides (Fig. 27).[99] Initially classified as lanthipeptides, owing to the presence of Dhb and AviCys moieties, the absence

of lanthipeptide-like dehydratases and the distinct route predicted to form AviCys established linaridins as a separate class of RiPPs.[100] Thus far, five linaridins, namely cypemycin, grisemycin, legonaridin, mononaridin, and salinipeptin have been characterized, which exhibit features such as Dhb, N-terminal dimethylation (and *N*-oxidation), AviCys, L-*allo*-isoleucine, D-amino acids, and dimethylimidazolidin-4-one.[100–104] The only PTM common to all characterized linaridins is the dehydration of Thr to Dhb, which represents the class-defining modification for linaridins. Being a relatively underexplored class of RiPPs, the Dhb-installing enzyme(s) remain unknown, although the most likely candidates are homologs of CypH or the related split LegH/LegE protein. Mutagenesis studies performed on the cypemycin precursor CypA in a heterologous host revealed that the putative dehydratase is capable of dehydrating both Ser and Thr, although Thr is processed more efficiently.[105] The dehydratase activity was shown to be site-specific, as substituting a highly conserved Ser to Thr (S16T) gave no product. The biosynthetic enzymes tolerate changes made to increase the solubility of cypemycin, revealing their promiscuous nature that could potentially be capitalized upon for bioengineering efforts.[105]

3.4 Biosynthesis of linear azol(in)e-containing peptides (LAPs)

Introduction and biosynthesis: Linear azol(in)e-containing peptides (LAPs) comprise a class of RiPP characterized by the presence of thiazol(in)e and/or (methyl)oxazol(in)e heterocycles, resulting from the backbone cyclodehydration of Cys, Ser, and Thr residues (Fig. 28).[1] Although azol(in)e heterocycles are frequently observed in other classes of RiPPs (i.e. thiopeptides, section 3.2; azol(in)e-containing cyanobactins, section 3.6; and bottromycins, section 3.7), the presence of other class-defining post-translational modifications set these compounds apart from LAPs. LAP biosynthesis begins with the ribosomal synthesis of a precursor peptide, comprised of N-terminal leader and C-terminal core regions.[1] Azole installation (Fig. 28C) on the core peptide proceeds in two steps by the action of a trimeric synthetase, as exemplified by studies on the microcin B17 pathway.[106] In the first step, a member of the YcaO superfamily (InterPro families IPR003776 and IPR019938) associates with a partner protein belonging to the E1-ubiquitin activating (E1-like) superfamily and installs azolines in an ATP-dependent manner. In roughly half of all known LAP BGCs, the E1-like and YcaO proteins are fused as a single protein, highlighting the importance of their collective effort in azoline installation.[107] Select azolines are subsequently oxidized to azoles by a flavin mononucleotide (FMN)-dependent dehydrogenase, when encoded in the BGC. The LP is typically removed by a protease and the mature LAP is exported from the producing cell. Other ancillary modifications such as methylation (section 5.3.5), acetylation (section 5.9.1), and dehydration (*e.g.* goadsporin,[91] section 3.2) may further elaborate the structure of LAPs.[108,109] Much of the mechanistic information underlying azoline installation stems from studies on cyclodehydratases involved in the biosynthesis of azol(in)e-containing cyanobactins (as the biosynthesis proceeds *via* generation of a LAP-like intermediate) and LAPs themselves. While YcaOs involved in RiPP biosynthesis have been reviewed elsewhere in great detail,[110] this section will focus on the current state of knowledge about the cyclodehydratases (also called heterocyclases) and dehydrogenases in the LAPs and cyanobactin pathways.

Class-defining enzymes: Azoline-forming YcaOs: Although E1-like and YcaO proteins have been implicated in the installation of azoline heterocycles using ATP hydrolysis, the distinct role of each of these proteins remained elusive until 2012. Genome-mining efforts yielded robust heterocycle-forming enzymes, BalhC and BalhD from *Bacillus* sp. *Al Hakam*, which were suitable to delineate the individual roles of each protein, as they were capable of functioning independently of the BalhB dehydrogenase and amenable for *in vitro* characterization.[111] Subsequent studies using these enzymes showed that BalhD (YcaO) installs azolines in an ATP-dependent manner, albeit slowly.[112] This was the first definitive evidence linking cyclodehydration activity to the YcaO superfamily. However, since the rate of cyclodehydration is enhanced by several hundred-fold in the presence of BalhC (E1-like), the term cyclodehydratase refers to the collective actions of the E1-like and YcaO proteins. Through isotopic labeling studies, ATP hydrolysis was demonstrated to use a non-solvent oxygen nucleophile, ruling out a "molecular machine" mechanism previously proposed for ATP in heterocycle biosynthesis.[112] A mechanistic model for cyclodehydration (Fig. 29) was put forth, where BalhD first catalyzes the nucleophilic attack of the side chain hydroxyl or sulfhydryl group of Ser/Thr/Cys residues onto the backbone carbonyl to reversibly form a hemiorthoamide intermediate. The carbonyl oxygen of this intermediate then goes on to attack the γ-phosphate of ATP to form an *O*-phosphorylated hemiorthoamide intermediate, followed by deprotonation of the amide nitrogen and elimination of the phosphate to yield the azoline.[112] Further evidence for this proposed mechanism was provided using BalhA substrates with ^{18}O labels incorporated at the cyclized amides in the peptide backbone. For this, an azoline-mediated peptide backbone labeling strategy was used, which capitalizes on the hydrolytic lability of azolines.[113] Incorporation of the ^{18}O labels from BalhA into the liberated phosphate bolstered the proposed kinase-like mechanism, whereby heterocyclization occurs *via* direct activation of the peptide backbone.[112,113]

In contrast, TruD, a cyclodehydratase from the trunkamide (an azol(in)e-containing cyanobactin; see section 3.6) pathway, was reported to produce AMP and pyrophosphate (PPi) as byproducts when supplied with PatE2 (a precursor peptide from a related biosynthetic pathway), indicative of an adenylation mechanism.[114] The crystal structure of TruD (PDB: 4BS9) (Fig. 30A) gave the first insight into an azoline-forming cyclodehydratase, which was a dimer composed of three domains. Domains 1 and 2 share structural homology with BalhC and MccB, an adenylase involved in microcin C biosynthesis (section 4.1.3); however, TruD lacks the conserved ATP-binding loops seen in MccB. Domain 3 of TruD, which is homologous to BalhD, constituted a novel fold characterized by a large, negatively charged, shallow cleft. Although not much information regarding substrate recognition and nucleotide binding could be obtained from the TruD crystal structure, biochemical data ruled out a kinase-type mechanism for TruD.[114] A nucleotide-bound crystal structure of LynD (PDB: 4V1T) (Fig. 30B), another cyanobactin cyclodehydratase, revealed that the α-phosphate of the enzyme-bound ATP is obstructed from the peptide substrate, making the previously described adenylation mechanism less likely for heterocyclization.[115] With biochemical data supporting an adenylation mechanism and crystallographic data disfavoring an adenylation mechanism, the ATP chemistry utilized by cyanobactin cyclodehydratases remained unclear. More recent studies using nonhydrolyzable ATP analogs in the heterocyclization reactions catalyzed by LynD and

MicD (a related cyclodehydratase) provided clarity regarding the mechanism.[116] Both LynD and MicD were reported to produce heterocycles on the peptide substrate, PatE2K, upon reaction with ATP analogs harboring a nonhydrolyzable α-β phosphate bond (AMP-CPP and AMP-NPP). However, heterocyclization was not observed when the reaction was carried out using ATP analogs with a nonhydrolyzable β-γ phosphate bond (AMP-PCP and AMP-PNP). Moreover, HPLC analysis of the reaction catalyzed by a MicD fusion enzyme (with an N-terminally fused leader) on a leaderless variant of the peptide substrate revealed accumulation of ADP before decomposing to AMP. Together, these data established that cyclodehydration proceeds *via* a kinase mechanism. Production of AMP and PPi as reaction byproducts has been proposed to occur as a result of a disproportionation or transphosphorylation reaction between P_i and ADP catalyzed by the enzyme.[116]

A nucleotide-bound crystal structure was obtained for an orphan YcaO from *E. coli* (denoted as *Ec*-YcaO; PDB: 4Q86) (Fig. 31).[117] Although not yet firmly associated with a function, information obtained from the crystal structure of *Ec*-YcaO provided valuable insights into understanding the reactions catalyzed by YcaOs in RiPP biosynthesis. *Ec*-YcaO comprises a novel ATP-binding fold, which is conserved among all characterized YcaOs to date. [114,115,117–119] Ala variants of the ATP-binding residues in BalhD predicted through sequence alignment with *Ec*-YcaO exhibited an increased K_M for ATP and were verified to be vital for BalhD cyclodehydration activity *in vitro*, suggesting that ATP utilization is a universal feature of YcaOs.[117] Fittingly, thioamide-forming YcaOs (section 3.5) and macrolactamidine-forming YcaOs (section 3.7), also require ATP to process their cognate substrates.[118–121] Structural alignment of cyanobactin cyclodehydratases TruD and PatD (azoline-forming YcaOs) with *Methanocaldococcus jannaschii* YcaO (*Mj*-YcaO, thioamide-forming enzyme, PDB: 6PE3) revealed that the C-terminal carboxylate in TruD/PatD (and not *Mj*-YcaO) extends into the active site, possibly serving as a base that deprotonates the β-nucleophile of Thr/Ser/Cys. The C-terminal carboxylate is presumed to be kept in the extended conformation due to an abundance of Pro residues, often found as a PxPxP motif, which is conserved among ~90% of the bioinformatically identified azoline-forming YcaOs. [119] Indeed, alterations at the C-terminus of BalhD and McbD abolishes cyclodehydration activity.[117]

While certain YcaO proteins catalyze cyclodehydration, the E1-like partner protein serves as a potentiator and regulator of YcaO. This enhancement was initially demonstrated using the Balh pathway, where BalhC accelerates the rate of azoline installation by BalhD by nearly 1,000-fold.[112] Omission of BalhC from the reaction led to a non-stoichiometric consumption of ATP, which otherwise was tightly coupled to azoline installation;[112] further, the order of ring formation in the absence of BalhC was dysregulated.[113] Fluorescence polarization studies revealed that BalhC engages the LP of BalhA (independently of BalhD), with a K_D commensurate with that of the full-length precursor peptide, establishing its role in substrate recognition and presenting the core to BalhD.[117] This idea is further corroborated by the fact that the N-terminal winged helix-turn-helix (wHTH) domain of BalhC shares structural homology with similar domains found in TruD,[114] LynD,[115] McbB,[122] and NisB[49] (a lanthipeptide dehydratase, section 3.1.1) known to interact with the leader region of their corresponding precursor peptides. This wHTH motif, now recognized as the RiPP precursor recognition element (RRE), is a common feature employed by more than half of all known

prokaryotic RiPP classes to engage their respective LPs (section 4.1.1).[66] In addition to binding the RRE, Phe8 and Leu12 of the substrate McbA were shown to occupy two hydrophobic pockets in McbB1-dom1 and in the McbB1-dom1/McbB2-dom2 interface in the McbBCD synthetase complex (section 4.1.1),[122] rationalizing the importance of an Fxxx(L/I/V) motif in the leader peptide of several LAP precursor peptides previously observed to be critical to bind to synthetases.[123] In certain LAP BGCs, such as the heterocycloanthracins (HCA), a divergent member of the E1-like superfamily, termed the F-protein (InterPro family: IPR022291), is responsible for substrate recognition.[124] *In vitro* studies on the HCA cluster from *Bacillus* sp. *Al Hakam* showed that HcaF (Ocin-ThiF-like domain) is essential for azoline formation catalyzed by HcaD (E1-like protein fused to the YcaO). The N-terminal domain of the fused cyclodehydratase, HcaD, lacks the RRE and indeed does not bind the peptide substrate. Instead, it brings the peptide substrate-bound HcaF and YcaO domain into proximity for catalysis.[124]

Azoline dehydrogenases: Azoline dehydrogenases catalyze the oxidation of azolines installed by the cyclodehydratases to azoles. In microcin B17 biosynthesis, the dehydrogenase McbC is essential for any peptide processing. In contrast, azoline installation occurs in Balh pathway in the absence of the dehydrogenase.[111] Studies on this latter pathway revealed that efficiency and order of processing (of the penta-azoline intermediate BalhA-5Tzn) by BcerB (a surrogate dehydrogenase from an orthologous cluster) was perturbed when BalhC and BalhD were omitted from the reaction.[125] The Balh pathway however tolerates non-cognate dehydrogenases that catalyze non-specific oxidation of azoles, as opposed to the microcin B17 pathway that strictly requires McbC.[125] Crystal structures of McbC bound to the microcin B17 product revealed that the precursor peptide is placed between the FMN cofactor and the conserved Lys-Tyr motif in the active site,[122] previously characterized to be important for BcerB and SaciB (distantly related azoline dehydrogenases) activity.[125] A mechanism for oxidation was proposed, which is supported by recent crystallographic data on the entire microcin B17 synthetase complex (PDB: 6GRI, section 4.1.1).[122]

3.5   Thioamitide biosynthesis

Introduction and biosynthesis: Thioamitides, a name coined in this review, are RiPPs characterized by thioamide(s) in place of amides in the peptide backbone. The founding member of the family, thioviridamide, was reported as an apoptosis inducer with a multitude of post-translational modifications, including five backbone thioamides, a β-hydroxy-N_1,N_3 dimethylhistidinium, AviCys, and an N-terminal pyruvyl moiety to which an acetone moiety was added during isolation.[11,126,127] Since the discovery of the thioviridamide BGC (Fig. 32A) in 2013,[128] several groups have employed genome-mining strategies to uncover their diversity, leading to the characterization of several thioviridamide-like compounds that inhibit growth of various cancer cell lines (Fig. 32B).[9,11–13] These thioamitides each feature three or four backbone thioamides. A putative function has been assigned for each gene in the thioviridamide BGC; however, only the FMN-dependent cysteine decarboxylase TvaF has been biochemically characterized to date.[129] TvaH, a YcaO homolog, has been proposed to install the class-defining thioamide modifications during thioviridamide biosynthesis.[128] TvaI, a TfuA-like protein (InterPro family: IPR012924) cooccurs with TvaH in all identified

thioviridamide BGCs and has been proposed to support thioamidation, although its precise role remains undefined. The characterization of additional thioviridamide-like compounds has revealed that the number of thioamides currently varies from three to five, and identified further rare post-translational modifications, such as Phe hydroxylation and reduction of the N-terminal pyruvyl moiety in thioalbamide.[11]

Class-defining enzyme: thioamide-installing YcaO: Although no biochemical or structural data are currently available for thioamide-forming YcaOs from a bona fide RiPP BGC, studies on non-RiPP YcaOs from methanogenic archaea have provided insights into their roles in thioamidation. Thioamide-forming YcaOs, almost always encoded adjacent to TfuA, are ubiquitous in methanogens and have been proposed to install a conserved thioglycine residue (Gly465) in the α-subunit of methyl-coenzyme M reductase (McrA).[130] Analysis of McrA peptides from *Methanosarcina acetivorans* mutants lacking the *tfuA* and/or the *ycaO* gene revealed that both YcaO and TfuA are essential for thioamidation. Gene complementation experiments further bolstered these findings.[130] More recently, the activity of these enzymes was reconstituted *in vitro* using synthetic peptides corresponding to the McrA sequence flanking Gly465.[118] Thioamidation was sulfide- and ATP-dependent, the latter of which produced ADP and P_i as byproducts, consistent with the kinase mechanism observed for azoline-forming YcaO proteins (section 3.4). Isotope-labeling studies provided evidence for the incorporation of a non-solvent oxygen nucleophile into the liberated P_i. Based on these findings, a mechanism for thioamidation has been put forth as detailed in Fig. 33.[118]

Approximately 10% of methanogens lack an identifiable *tfuA* in their genome. TfuA-independent YcaOs from *Methanocaldococcus jannaschii* (*Mj*-YcaO) and *Methanopyrus kandleri* (*Mk*-YcaO) efficiently catalyzed thioamide installation on a synthetic 11-mer McrA substrate that contained five residues upstream and downstream of the modified Gly.[118] Nucleotide-bound crystal structures were obtained for *Mk*-YcaO (PDB: 6CI7), which displayed an overall architecture similar to LynD (azoline-forming YcaO; PDB: 4V1T) and *Ec*-YcaO (orphan YcaO; PDB: 4Q86) (section 3.4). While the nucleotide-binding residues are largely conserved across these proteins, the active site region of *Mk*-YcaO is different from the azoline-forming YcaOs, hinting towards a divergent substrate-binding site or reorganization upon substrate binding.[118] More recently, *Mj*-YcaO was co-crystallized with a synthetic 11-mer peptide substrate derived from the MCR α-subunit (*Mj*-McrA).[119] *Mj*-YcaO bound to *Mj*-McrA (PDB: 6PEU) (Fig. 34) represents the first reported structure of any YcaO protein bound to its peptide substrate and permitted definitive identification of residues involved in peptide binding. This study also revealed that when presented with an 11-mer peptide variant containing a Cys residue near the site of modification, *Mj*-YcaO was capable of forming a thiazoline.[119] Indeed, many of the active site residues identified in *Mj*-YcaO are highly conserved among divergent YcaO proteins, including members catalyzing azoline formation (section 3.4) and macrolactamidine formation (section 3.7), in addition to thioamide formation.[114,115,117–121] *Mj*-YcaO, however, lacks a basic residue for initial Cys deprotonation and cyclodehydration activity was observed only when a surrogate base was supplied in the assay. This cyclodehydration activity further supports the idea that all YcaO proteins modify their substrates *via* a shared mechanism and that it is the identity of the

nucleophile attacking the amide carbonyl carbon that determines the chemical outcome. For thioamidating YcaOs, the nucleophile derives from a yet unidentified source of sulfide, which attacks the target amide bond to yield a tetrahedral oxyanion intermediate (Fig. 33). Following attack of ATP and release of ADP, the resulting phosphorylated thiolate intermediate collapses to release the thioamidated product and phosphate as a byproduct. The role of TfuA-like proteins in thioamidation is presently unclear and possible roles include activation of YcaO, regulation of ATP usage by YcaO, and/or assisting in the delivery of sulfide equivalents.[131]

Evidence for the involvement of the YcaO/TfuA pair in RiPP thioamidation stems from a recent study on thiopeptides (section 3.2), another RiPP class that is known to feature thioamides; however, thioamidation of thiopeptides is a rare, secondary modification. During a recent bioinformatic expansion of the thiopeptide family, a novel thiopeptide, saalfelduracin, featuring a single thioamide was isolated and characterized.[132] Similar moieties have also been reported in Sch 18640 and thiopeptin; however, their biosynthetic origin was unknown. Genome sequencing of the native producers of these thiopeptides allowed identification of their putative BGCs, all of which encode YcaO-TfuA protein pairs, akin to the saalfelduracin and thioviridamide BGCs. Chromosomal insertion of *ycaO* and *tfuA* from the Sch 18640 BGC into a thiostrepton producer (lacks thioamides), resulted in the detection of a metabolite identical to Sch 18640. Thioamidation was dependent on the presence of TfuA and YcaO.[132] Recently, a new RiPP-mining tool, RIPPER (section 6.7) was employed to locate thioamidated RiPPs and revealed that YcaO-TfuA gene pairs are widespread among many uncharacterized BGCs in Actinobacteria.[14] Heterologous expression of a member of one such BGC enabled isolation and initial characterization of the thiovarsolins, presumed shunt metabolites from an enigmatic RiPP family that contain a single thioamide moiety installed in a (A/G)PR tripeptide that is repeated five times in the VarA precursor peptide from *Streptomyces varsoviensis*. Isolation of thioamidated GPR and APR peptides indicates that thioamidation occurs multiple times on a single precursor peptide. Deletion of the YcaO and TfuA encoding genes from the BGC abolished production of the thioamidated products, further corroborating their role in thioamide installation. Co-expression of the precursor peptide, YcaO and TfuA genes in *Streptomyces coelicolor* was sufficient to observe thioamidated peptides.[14]

3.6 Cyanobactin biosynthesis

Introduction and biosynthesis: Cyanobactins (Fig. 35) are diverse RiPP natural products produced by symbiotic and free-living cyanobacteria.[1] Although they were described earlier as N-to-C macrocyclized peptides, examples of linear cyanobactins have surfaced,[133] expanding the structural diversity of this family. Cyanobactin biosynthesis (Fig. 35) begins with the ribosomal generation of the precursor peptide, called the E peptide. In contrast to precursor peptides from most other RiPP classes that feature a single core peptide, cyanobactin precursor peptides are organized into multiple cassettes. Each cassette bears a core peptide that forms the mature cyanobactin flanked by highly conserved N-terminal and C-terminal recognition sequences (RSII and RSIII, respectively) that guide the biosynthetic enzymes. The core sequences in the precursor peptide are hypervariable and give rise to chemically diverse products. The order of post-translational tailoring has been established

for the patellamide (Fig. 35) and trunkamide pathways.[134] When present, a YcaO orthologous to the LAP cyclodehydratase recognizes RSI (present only in cyanobactin BGCs harboring YcaO) in the precursor peptide and converts Cys/Ser/Thr residues to azoline heterocycles (see section 3.4). The protease A then recognizes and cleaves C-terminal to RSII in the precursor peptide, liberating the LP. The protease/macrocyclase G identifies RSIII, cleaving N-terminal to this sequence, and in some examples, catalyzing N-to-C cyclization of the core peptide to form the mature cyanobactin. Other PTMs, such as oxidation of azolines, *N* and *O*-methylation, and prenylation, have been observed in cyanobactins (sections 5.8 and 5.9).[135] PatA homologs are the only biosynthetic enzymes common to all predicted cyanobactin BGCs, as exemplified by genome-mining studies.[133] This renders PatA and its orthologs as the class-defining enzyme for cyanobactins.

Class-defining enzyme: N-terminal protease, PatA: PatA is composed of an N-terminal protease domain and a C-terminal domain of unknown function. The crystal structures of the protease domains of PatA (PatA^pro; PDB: 4H6V) and a related ortholog, PagA (PagA^pro; PDB: 4H6W) have been determined.[136,137] Both PatA^pro and PagA^pro (Fig. 36) feature the classic subtilisin-like fold but lack the high affinity metal-binding site conserved across the subtilisin protease family that is necessary for activation of the propeptide. Although substrate-bound PatA^pro structures are not available, the GLEASVT motif comprising RSII has been modeled into PatA^pro by comparison to the structure of thermitase complexed with its substrate eglin-C in order to understand the substrate specificity determinants.[137] Based on sequence and structural alignment, the residues of the catalytic triad are Asp23-His58-Ser218 in PatA and Asp26-His61-Ser221 in PagA.[136] The imidazole ring of His58 in PatA points away from the active site due to a 19-residue loop pointed towards the active site (Fig. 36). As a result, His58 is not within hydrogen bonding distance from Asp23 and Ser218, suggesting that the active site is reorganized, possibly upon substrate binding or by the C-terminal DUF, for catalysis.[136] This loop, however, is only 12 residue long in PagA, providing an explanation as to why the catalytic triad is ideally positioned in PagA for catalysis (Fig. 36D).

3.7 Bottromycin biosynthesis

Introduction and biosynthesis: Bottromycins are peptide antibiotics recognized for their potent growth inhibitory activity against methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE).[1] They are relatively short peptides (8-mers) and feature an array of modifications including the class-defining macrolactamidine, a thiazole, Asp esterification, epimerization, decarboxylation, and β-methylation of Phe, Pro, and two of the three Val residues (Fig. 37). Their ribosomal origin and BGCs were identified by four groups in 2012 and are well conserved among several *Streptomyces* spp.[138–141] While biosynthetic studies have been conducted on several orthologous BGCs, this section will use the *Streptomyces bottropensis* gene nomenclature shown in Fig. 37A for simplicity. The bottromycin precursor peptides stand unique among other RiPP classes in that they exhibit an inverted RiPP paradigm, where the core peptide precedes a C-terminal follower peptide. Bottromycin BGCs encode two YcaO proteins, three radical SAM methyltransferases, an *O*-methyltransferase, an α/β hydrolase, an amidohydrolase, a cytochrome P450 enzyme, a leucyl-aminopeptidase, a transporter, and a

transcriptional regulator. Roles for each of these genes have been proposed.[138–141] Gene deletion studies conducted on various bottromycin-producing strains assigned the role of Asp methylesterification to the *O*-methyltransferase and β-methylation of Phe, Val, and Pro to the three class B radical SAM methyltransferases found in the BGC.[138,141] Biochemical studies showed that the leucyl-aminopeptidase BmbK removes the N-terminal Met[142,143] and confirmed that BmbB catalyzes *O*-methylation of Asp.[143] An untargeted metabolomics study carried out on mutants of the BGC in *Streptomyces scabies* proposed an order for the post-translational modifications in bottromycin biosynthesis as detailed in Fig. 37. This study implicated the YcaO proteins, BmbD and BmbE in thiazoline and macrolactamidine installation, respectively, which was subsequently confirmed via detailed biochemical studies.[143] The α/β hydrolase BmbG was shown to be responsible for the epimerization of the Asp residue (section 5.1.3).[144]

Class-defining enzyme: macrolactamidine-installing YcaO: The YcaO superfamily members BmbD and BmbE (alternative naming: BotC and BotCD, respectively) were expected to catalyze the ATP-dependent activation of the peptide (Fig. 37). However, these proteins are unique from other RiPP-modifying YcaOs in that they lack the N-terminal RRE domain implicated in precursor peptide recognition (section 4.1.1).[124] Intrigued by the nature of these stand-alone YcaOs, two groups simultaneously characterized the reactions catalyzed by BmbD and BmbE homologs *in vitro*.[27,28] BmbD orthologs were observed to catalyze the ATP-dependent loss of 18 Da from the precursor peptides, consistent with a dehydration event. A combination of high-resolution and tandem MS analysis,[120,121] mutagenesis, chemical labeling, and NMR spectroscopy[121] revealed that the BmbD orthologs install a thiazoline during bottromycin biosynthesis. A similar approach was taken to characterize the role of BmbE orthologs. Upon reaction with a precursor peptide variant that had the N-terminal Met removed, another ATP-dependent loss of 18 Da was observed. When the reaction product was analyzed by tandem MS, a fragmentation pattern characteristic of macrolactamidines was observed.[120] This product does not undergo amine-specific reductive amination with formaldehyde and borane, but undergoes thiol-specific alkylation with 2-bromoethylamine, as evidenced by MS.[121] Moreover, a precursor variant lacking Cys8 was processed by the BmbE ortholog and not the BmbD ortholog. Together, these studies established that BmbE orthologs alone are sufficient for macrolactamidine installation.

Macrolactamidine-forming YcaOs are the first YcaOs reported to form larger ring systems and use nitrogen nucleophiles.[120] The BmbE ortholog-catalyzed reaction was optimal at a pH of 9.5, where most of the N-terminus is deprotonated and available as a nucleophile for macrolactamidination, while also retaining enzymatic stability.[120] Prolonged reaction times led to opening of the macrolactamidine, which was dependent on the presence of the macrolactamidine-forming YcaO and ATP. This reversibility was explained by the finding that the *in vivo* reaction requires the presence of an additional protein, *i.e.* BmbG (alternative name BotAH).[143] Indeed, *in vitro* studies later showed that the BmbG ortholog acts as a gatekeeper during bottromycin biosynthesis by removing the follower peptide C-terminal to the thiazoline, essentially preventing reopening of the macrolactamidine.[145] Recently, the YcaO protein KlpD was shown to install a six-membered amidine ring, three thiazolines,

and one oxazoline during the maturation of a RiPP named klebsazolicin.[146] Therefore, KlpD is a rare example of a YcaO known to accept oxygen, sulfur, and nitrogen nucleophiles.

As macrolactamidine-forming YcaOs are not known to harbor RREs, studies then focused on understanding how these enzymes identify their substrates. Systematic C-terminal trimming of precursor peptides was performed, given that bottromycins use a follower peptide as opposed to a LP. These variants were assessed for stability in the presence of the YcaO by employing thermal shift assays and revealed that precursor peptide residues 30–39 are the most important for the peptide-protein interaction.[120] This conclusion is also supported by studies on an orthologous pathway, which identified residues 1–34 as the minimal substrate required for biosynthesis.[121] Macrolactamidine-forming YcaOs are generally tolerant to changes in the core region, *in vitro*. However, they strictly install the macrolactamidine on the fourth core residue as evidenced by the inability to alter ring size.[121] Macrolactamidine-forming YcaOs harbor the conserved ATP-binding motifs observed among other YcaOs that are essential for activity as evidenced by the lack of processing by Ala variants.[110,117,120,121] In contrast to the azoline-forming, E1-dependent YcaOs involved in LAP and cyanobactin biosynthesis (sections 3.4 and 3.6, respectively), macrolactamidine-forming YcaOs do not contain a Pro-rich C-terminus. The C-terminus is relatively basic and moderate truncations of the enzyme are tolerated as opposed to the azoline-forming YcaOs.[119,121] A bioinformatic survey of YcaO proteins found in GenBank predicted that macrolactamidine-forming stand-alone YcaOs are more prevalent than previously appreciated.[121]

3.8   Lasso peptide biosynthesis

Introduction and biosynthesis: Lasso peptides are RiPPs characterized by a unique [1]rotaxane conformation resembling that of a threaded lariat (Fig. 38)[1] with more than 70 family members isolated thus far. The lasso fold consists of a macrolactam bond between the N-terminus of the peptide and the side chain carboxylate of Asp/Glu at positions 7–9 of the core peptide.[1,147] The remaining C-terminal portion of the peptide is threaded through the macrolactam and is often held in position by bulky amino acid residues (termed steric lock or plug residues), by disulfide linkages, or sometimes by both. This conformation endows many lasso peptides with remarkable stability against proteases and heat,[1] although a few temperature-sensitive lasso peptides have been reported.[148–150] In addition to their stability, lasso peptides span a wide-range of potentially useful bioactivities including antimicrobial, anticancer, and antiviral activities.[151–153] Like other RiPPs, lasso peptide biosynthesis begins with the ribosomal synthesis of the precursor peptide (A) composed of leader and core regions. Lasso peptides are formed from a two-step sequence catalyzed by two enzymes, a cysteine protease homologous to transglutaminase (B protein), and a macrolactam synthetase (lasso cyclase) homologous to asparagine synthetase (C protein) that likely form a complex.[1] In approximately one-third of bioinformatically predicted lasso peptide BGCs,[154] the B protein is fused to the C-terminus of the RRE domain.[155] Although ATP has been reported to be required for processing by fused B proteins,[156] proteolysis by split B proteins does not require ATP.[157,158] The RRE domain-containing protein is referred to as the E or B1 protein, while the peptidase is termed the B or B2 protein. Either way, the RRE is responsible for binding the leader region of the precursor peptide[66,157,159–161] while

the peptidase performs LP cleavage.[157] The lasso cyclase then installs the macrolactam linkage when the C-terminal tail is threaded in an ATP-dependent manner.[156,157] Two studies independently reported *in vitro* reconstitution of the lasso peptide encoded in the *Thermobifida fusca* genome, termed fusilassin or fuscanodin.[150,158] In addition to the class-defining macrolactam, ancillary modifications such as phosphorylation (section 5.6), acetylation (section 5.9.1), methylation (section 5.3.7), deimination (section 5.5), hydroxylation (section 5.7.4.1), and epimerization (section 5.1.3) have been observed on lasso peptides.[152,154,162–164]

Class-defining enzyme: Lasso cyclase: Mutagenesis studies performed on lasso peptide precursors expressed in heterologous hosts have revealed precursor peptide-specific requisites for the biosynthetic enzymes. To discuss these requirements, standard RiPP nomenclature for residue numbering will be used (see Fig. 1).[1] All lasso cyclases studied thus far have a strict preference for the macrolactam acceptor residue.[147,156,158,165,166] Specifically, if the native precursor peptide possesses Asp at the acceptor position, changing it to Glu abolishes lasso peptide formation, and *vice versa*. However, the SviC cyclase, which catalyzes macrolactam formation between Cys1 and Asp9 in sviceucin constitutes an exception. SviC was able to substitute for McjC *in vitro* to efficiently ensure macrolactam closure between Gly1 and Glu8 in microcin J25.[167] Lasso cyclases also generally do not tolerate changes made to the size of the macrolactam. The only exceptions to this are the caulosegnin and fusilassin cyclases.[158,165] The caulosegnin BGC features three precursor peptides with acceptor residues at position 8 or 9, and each precursor is processed by the same cognate lasso cyclase.[165] The fusilassin/fuscanodin BGC features one precursor with a Glu acceptor at position 9 which forms the characteristic macrolactam. The corresponding cyclase tolerates both ring expansion and contraction, allowing changes from 7 to 10 residues in the macrolactam *in vitro*.[158] Thus far, most lasso cyclases investigated also do not tolerate changes made to the N-terminal residue of the core peptide, which is involved in macrolactam formation.[156,165,166,168] A notable exception is the fusilassin biosynthetic machinery that accepts all amino acids except Pro at position 1, *in vivo*. However, *in vitro* reconstitution showed that it was the protease and not the cyclase that did not tolerate Pro1.[158] The fusilassin precursor features Trp at position 1 and bulkier residues such as Tyr, Phe, Lys, and Leu at position 1 are processed more efficiently compared to smaller and charged residues. The fusilassin biosynthetic enzymes are the most robust lasso peptide biosynthetic enzymes characterized thus far and hold promise for lasso peptide engineering.

Until genome-mining was used to prioritize discovery efforts, all lasso peptides isolated possessed either Gly (Class II) or Cys (Class I) at position 1.[1] Recent discoveries have uncovered lasso peptides harboring Ala, Ser, Leu, Asp, Tyr, and Trp at position 1.[154,158,168–171] An extensive bioinformatic investigation of the lasso peptide biosynthetic space facilitated by the genome mining tool RODEO (section 6.2), identified ~3,000 lasso peptides in prokaryotes, as of August 2018.[154,158] The precursor peptides predicted in this study feature all canonical amino acids at position 1 except Pro. A majority of the bioinformatically predicted lasso peptides feature Gly at position 1, in line with its prevalence among known lasso peptides. Akin to many other RiPP classes, the RRE domain

governs interactions with the precursor peptide during lasso peptide biosynthesis (section 4.1.1).

3.9 Sactipeptide biosynthesis

Introduction and biosynthesis: Sactipeptides (Fig. 39) are RiPPs typified by sulfur-to-α-carbon thioether (i.e. sactionine) linkages between a donor Cys and an acceptor residue. Thus far, six sactipeptides, namely subtilosin A, thurincin H, thuricin CD (two peptide products), sporulation killing factor (SKF), and huazacin have been characterized from various *Bacillus* species, most of which exhibit narrow-spectrum growth inhibitory activity towards other Firmicutes.[1,43] After ribosomal synthesis of the sactipeptide precursor, sactionine linkage(s) are installed by a radical *S*-adenosylmethionine (rSAM) enzyme (InterPro family: IPR007197). The initial demonstration of this activity was with AlbA, which acts on the subtilosin precursor, SboA, in a LP-dependent manner.[172] The subtilosin BGC also encodes proteases and transporters, which are predicted to convert the thioether(s)-bearing precursor peptide into mature subtilosin.[172] The rSAM "sactisynthases" that install the class-defining thioether bridges belong to a large enzyme superfamily known to catalyze a multitude of difficult reactions in both primary and secondary metabolism. [173–175] Despite the wide range of reactions catalyzed, rSAM enzymes are unified by a common mechanism. rSAM enzymes house a [4Fe-4S] cluster in their active site where three of the four Fe atoms are coordinated by three Cys in a conserved CxxxCxxC (where x is any amino acid) motif.[173] The fourth "unique" Fe is ligated by the α-carboxylate and α-amine moieties of SAM. Under reducing conditions, the [4Fe-4S]$^+$ cluster transfers an electron to reductively cleave SAM to Met and a 5'-deoxyadenosine radical (5'-dA$^\bullet$). This 5'-dA$^\bullet$ then abstracts an unactivated hydrogen atom from the substrate which transforms to the product or initiates a reaction cascade depending on the type of rSAM enzyme.

Class-defining enzyme: sactionine-installing rSAM: Since the initial discovery of the involvement of AlbA in the installation of three sactionine linkages in subtilosin, other orthologous enzymes have also been shown to install thioethers in sactipeptides. For instance, SkfB installs one sactionine linkage during the maturation of the SKF, which is produced by *Bacillus subtilis* 168 under nutrient limiting conditions to delay sporulation.[176] In addition to the canonical [4Fe-4S] cluster, sactisynthases often display auxiliary iron-sulfur clusters (AISC) which are found in a C-terminal domain. When there are two additional [Fe-S] clusters, the domain has been called a SPASM domain (InterPro family: IPR023885, defined in section 2.14).[48] With the exception of anaerobic sulfatase-maturing enzyme,[177] the other founding members of 'SPASM' are RiPP maturases. Some sactisynthases, such as SkfB, feature a truncated SPASM domain, dubbed a "twitch" domain, which binds one auxiliary [Fe-S] cluster.[178] Numerous RiPP-related rSAM proteins contain AISC domains; however, these domains are not always retrieved by the SPASM/twitch model as the location and number of Cys is highly variable. Thus, we propose 'AISC domain' be used to encompass all auxiliary iron-sulfur cluster domains.

AlbA and SkfB have been reported to harbor two [4Fe-4S] clusters (including the canonical rSAM iron-sulfur cluster), as evidenced by UV-vis and electron paramagnetic resonance (EPR) spectroscopy;[172,176] however, a subsequent study showed a total of three [4Fe-4S]

clusters in AlbA.[179] The canonical [4Fe-4S] cluster involved in the reductive cleavage of SAM was corroborated by a lack of SAM cleavage activity by AlbA and SkfB variants lacking the Cys in the conserved CxxxCxxC motif. Changes made to Cys residues predicted (based on sequence alignments) to coordinate the auxiliary [4Fe-4S] cluster(s), prevented thioether formation in both the subtilosin and SKF pathways, despite retaining SAM cleavage activity.[172,176] These AlbA variants when complexed with the substrate SboA also failed to display the characteristic UV-vis absorption shift observed with wild-type AlbA and SboA, or a leaderless SboA variant, which the authors attribute to a direct interaction between the AISC and the core peptide of SboA.[172] Based on this, a radical mechanism for thioether installation by rSAM enzymes was proposed (Fig. 40). According to this mechanism, the 5'-dA• formed by the reductive cleavage of SAM abstracts a hydrogen atom from the α-carbon of the acceptor amino acid in the precursor peptide, thus generating a carbon-centered radical. This radical then forms the thioether bond with the thiyl radical generated by the transfer of an electron from the donor Cys to the AISC for which one of the sulfur ligands derives from the donor Cys. The now reduced AISC either transfers the electron to the oxidized primary [4Fe-4S] cluster or *via* an external agent to regenerate the enzyme for another round of catalysis.[172] A polar mechanism has also been put forth (Fig. 40), where the carbon-centered radical intermediate undergoes oxidation to form an *N*-acyliminium intermediate, while the electron is captured by the auxiliary [4Fe-4S] cluster. This *N*-acyliminium intermediate can then be attacked by the thiolate of the donor Cys to form the thioether.[179] Evidence for H-atom abstraction was provided by two independent studies on the subtilosin and SKF pathways. In one study, the authors used an SboA variant that contained residues 27–35 linked to residues 1–6 by an amide bond with the acceptor Phe deuterated uniformly. When this substrate was treated with AlbA, deuterium was incorporated into 5'-dA suggesting that the H-atom abstracted by 5'-dA• was from the acceptor Phe.[179] However, this observation did not prove that the abstracted H-atom was exclusively from the α-carbon of the acceptor. The first definitive evidence for this mechanism leveraged the substrate promiscuous nature of SkfB.[180] These researchers showed that upon reaction with SkfB, deuterium was transferred from the substrate SkfA into 5'-dA only when the acceptor Ala was labeled at both the α and β positions and not when Ala was labeled at the β position alone. Later studies used a radical clock (cyclopropylglycine) inserted in place of the acceptor Met in SkfA to show quenching of the generated substrate radical *via* ring opening in the presence of SkfB. A catalytically inactive variant of SkfB that lacks the twitch domain still catalyzed ring opening in the substrate analog, suggesting that the AISC was not essential for the initial abstraction of the hydrogen atom from SkfA.[181] This finding, along with studies using AlbA variants that lack the AISC, points towards a role in thioether installation, but the precise role played by the auxiliary clusters remains unclear.[172,176,179,181]

The only sactionine-forming rSAM enzyme that has been structurally characterized thus far is SkfB. SAM-bound SkfB (PDB: 6EFN) displays an overall modular architecture composed of a core rSAM domain flanked by an N-terminal RRE (section 4.1.1) and the C-terminal twitch domains (Fig. 41).[178] The rSAM domain is folded into a partial $(\beta/\alpha)_6$ triose phosphate isomerase (TIM) barrel, characteristic of rSAM enzymes where the β-sheets line the inside of the barrel and α-helices flank the exterior. The SAM-binding [4Fe-4S] cluster

resides in the loop region following the β1 strand in the core domain. The structure also revealed a combination of side chain and backbone interactions involved in orienting SAM in a catalytically active position.[178] Similar to that observed in other RiPP biosynthetic enzymes, the peptide-binding RRE domain is formed by a three-stranded antiparallel β-sheet followed by a triple helix, and is fused to the rSAM domain.[66,178] Although substrate-bound crystal structures of SkfB are not available, the sactisynthase involved in thurincin H biosynthesis lacking the N-terminal 89 residues (comprising the RRE) is incapable of forming sactionines despite exhibiting SAM cleavage activity.[182] The C-terminal AISC (twitch) domain of SkfB, formed by a three-stranded antiparallel β-sheet followed by two α-helices, coordinates a single [2Fe-2S] cluster, which was further confirmed by Mössbauer spectroscopy.[178] This finding was in contrast to an earlier study that suggested the AISC of SkfB was a [4Fe-4S] cluster.[176] An overlay of the conserved Cys within the SkfB twitch domain with that of BtrN, another rSAM-enzyme that uses an auxiliary [4Fe-4S] cluster, revealed that SkfB is capable of accommodating an [4Fe-4S] cluster.[178] Analysis of enzymatic activity in the context of Fe-S cluster content is expected to elucidate their role in catalysis.

3.10 Ranthipeptide biosynthesis

Introduction and biosynthesis: A bioinformatic investigation of the rSAM superfamily identified a group of Cys-rich peptides, primarily from the *Clostridium* genus, called SCIFFs (six Cys in forty-five residues).[42] These peptides were encoded next to a gene encoding a rSAM enzyme and thus were predicted to be substrates for post-translational modification. Although no mature SCIFF-derived natural product has ever been isolated, purified rSAM enzymes from predicted SCIFF-containing BGCs, CteB and Tte1186, installed a single thioether linkage between a donor Cys and an acceptor Thr on cognate precursor peptides, CteA and Tte1186a, *in vitro*.[183,184] A more recent bioinformatic analysis conducted on rSAM maturases predicted to install thioether linkages, including sactisynthases and SCIFF maturases, revealed that CteB (and Tte1186) is more closely related to QhpD (Interpro family: IPR023886) than to any sactisynthases.[43] QhpD is involved in the maturation of quinohemoprotein amino dehydrogenase (QHNDH), an enzyme that catalyzes the oxidative deamination of aliphatic and aromatic amines.[185] QhpD installs two β-thioethers and one γ-thioether linkage between Cys and Asp/Glu residues in the small subunit of QHNHD, QhpC (Interpro family: IPR015084).[185] In contrast to sactionines, which readily fragment under standard collision-induced dissociation (CID) conditions, no inter-ring fragmentation by CID was reported for the SCIFF-derived products,[183,184] which is reminiscent of lanthipeptide-like behavior. Quantum mechanical calculations performed on model, isomeric peptides that were linked by either a sactionine or a β-thioether revealed that the β-thioether linked isomer was more stable, providing a possible explanation for the differential behavior of SCIFF-derived products vs. sactipeptides under CID conditions.[43] Together, these data suggested that the thioethers formed on CteA and Tte1186a were not α-linked. Indeed, *in vivo* studies using a CteA variant labeled with deuterium at the α and β positions of Thr showed a mass loss of 2 Da upon co-expression with CteB, demonstrating that the modification yielded a γ-thioether.[43] Thus, thermocellin (modified CteA),[43,183] NxxC peptide (featuring one β-thioether between Cys and Asn),[44] and freyrasin (featuring 6 β-

thioethers between 6 Cys and 6 Asp residues)[43] now form a new class of RiPPs termed ranthipeptides (radical non-α thioether peptides) (Fig. 14 and 42). Ranthipeptides are distinguished from other thioether-containing RiPPs, such as lanthipeptides that display lanthionines (β-thioethers) installed by Michael-like nucleophilic addition (section 3.1), and sactipeptides that include sactionines installed by rSAM enzymes (section 3.9).[43,44]

Class-defining enzyme: rSAM enzyme installing non-α thioether linkages: All characterized ranthipeptide maturases [i.e. CteB, Tte1186, NxxcB (the NxxC peptide maturase, Fig. 14), and PapB (freyrasin maturase)] are bioinformatically predicted to be SPASM domain (InterPro family: IPR023885)-containing rSAM enzymes.[44,183,184,186] While Tte1186 and CteB are known to possess two AISCs,[178,184] NxxcB and PapB have been shown to harbor at least one AISC and they have additional conserved Cys residues, which suggests they possess two AISCs.[44,186] Two mechanisms have been proposed for the installation of β-thioethers in the NxxC peptide.[44] The proposed mechanism begins with the generation of a Cβ-centered radical by the 5'-dA• produced as a result of reductive cleavage of SAM by the primary $[4Fe-4S]^+$ cluster. This step is then followed by the attack of the generated substrate radical by the Cys donor activated by the auxiliary [4Fe-4S] cluster. The reduced AISC then transfers the electron to the oxidized primary $[4Fe-4S]^{2+}$ cluster either directly or *via* an external agent to return the enzyme to a catalytically active state. In the alternative heterolytic pathway, the 5'-dA• abstracts a hydrogen atom from either the Cα or the Cβ positions of the substrate Asn residue to generate a substrate radical. This generates a mildly acidic proton in the nearby β or α positions leading to the formation of an α, β-unsaturated amide. Subsequent conjugate addition of the α, β-unsaturated amide by the Cys thiolate generates the thioether linkage.[44] To distinguish between the possible mechanisms, different aspects of the pathways were tested. Upon reaction of the NxxcA precursor peptide with NxxcB, a decrease in absorbance was observed at 315 and 395 nm.[44] This observation is suggestive of ligation of the substrate Cys thiolate with the [4Fe-4S] cluster also observed in sactionine synthesis,[172] consistent with the proposed radical mechanism. When the reaction was carried out in deuterated water, deuterium was not incorporated into the product, suggesting that the polar mechanism is not likely operative. Although not conclusive, this study provides a working model for studying the mechanism of non-α thioether installation in ribosomal peptides.

CteB, originally proposed to be a sactisynthase, is the first ranthipeptide maturase and thioether-forming rSAM enzyme to be structurally characterized. The crystal structure of CteB (PDB: 5WGG) was obtained with bound SAM and a truncated version of the substrate CteA comprising residues 1–21 (CteA1–9 and 21 were resolved in the structure). This structure revealed three distinct domains characterized by the canonical rSAM domain flanked by an N-terminal RRE and a C-terminal AISC (SPASM) domain (Fig. 43).[183] The rSAM domain displays the classic $(\alpha/\beta)_6$-TIM barrel fold and features the common [4Fe-4S] and SAM-binding motifs. The RRE domain interacts with CteA in a manner similar to that observed in other substrate bound crystal structures of RiPP modifying enzymes (section 4.1.1).[49,66,115,183] Fittingly, a PapB variant lacking the RRE domain was incapable of installing thioethers on the precursor peptide PapA when heterologously expressed in *E. coli*.[186] The AISC domain of CteB houses two auxiliary [4Fe-4S] clusters.

One of the clusters (auxiliary cluster II) is coordinated by four cysteines in the SPASM domain, whereas auxiliary cluster I features an open coordination site which is bound to Cys21 of CteA.[183] The presence of an open coordination site on auxiliary cluster I and its proximity to CteA suggests that the auxiliary cluster may be involved in the activation of the donor Cys thiol. With a computational model of CteB bound to full-length CteA, the authors showed that the donor Cys ligated to the [Fe-S] cluster and the acceptor Thr are indeed in sufficient proximity for thioether formation.[183]

Substrate scope has been studied for two ranthipeptide maturases, NxxcB and PapB.[44,186] Since ranthipeptide maturases are believed to use a homolytic mechanism for non-α thioether installation, the acceptor residues could theoretically be any amino acid with a side chain. Indeed, replacement of Asn20 involved in β-thioether formation in NxxC peptide with Gln, Asp, Glu, and Ala resulted in thioether bearing peptides with varying yields, indicating the ability of these enzymes to accept non-natural acceptor residues.[44] However, PapB failed to install a β-thioether crosslink when the acceptor Asp was changed to Ala or Asn in a heterologous host.[186] PapB installed a γ-thioether crosslink when an acceptor Asp was changed to Glu, similar to QhpD which generates both β- and γ-thioethers in QhpC. [185,186] This observation also suggests that the carboxylate moiety in the acceptor residue may play a role in substrate recognition. PapB requires three intervening residues between the acceptor and donor residues for efficient thioether installation, but does not exhibit a preference for the identity of these residues. PapB also does not exhibit interdependency on ring-installation order.[186]

3.11   Biosynthesis of streptide and rotapeptides

Introduction and biosynthesis: Streptides are macrocyclic RiPPs characterized by C-C crosslinks between Lys and Trp residues, produced mainly by Streptococcal species (section 2.5).[188] They were initially identified as cyclic peptides in *Streptococcus thermophilus* LMD 9 culture supernatants at high cell densities in response to a novel quorum-sensing system involving the Rgg transcriptional regulator upon binding of a pheromone, SHP (<u>s</u>hort <u>h</u>ydrophobic <u>p</u>eptide).[189,190] The precise macrocyclic linkage found in streptide, a covalent bond between Cβ of Lys and the aromatic C7 of Trp on a 9-mer peptide (Fig. 44), was elucidated in 2015 using a combination of high-resolution MS/MS, and multidimensional NMR analyses.[188] A recent total chemical synthesis of streptide confirmed an *R* stereochemical configuration for the C3 position of Lys2.[191] A locally encoded rSAM enzyme, StrB, was shown to be essential for streptide maturation with subsequent *in vitro* studies showing that C-C formation activity of StrB was LP-dependent. The modified product is proposed to be processed by StrC, possibly in coordination with other proteases, to produce the mature streptide product.[188]

Class-defining enzyme: rSAM installing Lys-Trp C-C crosslink: The rSAM enzyme StrB is believed to utilize a radical mechanism to install the C-C Lys-Trp linkage in streptide. Similar to the rSAM enzymes that produce sactipeptides and ranthipeptides (sections 3.9 and 3.10), StrB and its orthologs contain a C-terminal SPASM domain.[172,183,188,192] UV-vis and EPR spectroscopic analyses originally suggested that StrB has two [4Fe-4S] clusters, one for SAM-binding and the other in the C-terminal domain.[188] However, investigation of

orthologous rSAM proteins from *Streptococcus suis* and *Streptococcus agalactiae* (SuiB and AgaB, respectively) pointed to the proteins having two AISCs.[192] This conclusion was later verified by X-ray crystal structures of SuiB bound to SAM and the SuiA precursor peptide (PDB: 5V1S and 5V1T).[193] Both radical addition and electrophilic aromatic substitution (EAS) mechanisms have been proposed for C-C bond formation in streptides (Fig. 45). [188,194] Each pathway begins with the abstraction of a H-atom from the β-methylene of Lys by 5'-dA$^\bullet$ to generate a substrate radical. In the radical addition mechanism (A, Fig. 45), this C-centered radical reacts with the indole side chain of Trp to generate an indolyl radical. Deprotonation, rearomatization, and reduction of the auxiliary [4Fe-4S] cluster completes the reaction. In the EAS mechanism, the lysyl radical undergoes deprotonation at the α-position, and electron transfer to the AISC, leading to the generation of an α, β-unsaturated amide.[194] A Michael-like addition from the indole onto the α, β-unsaturated amide and subsequent reprotonation generates the C-C crosslink. In both mechanisms, electron transfer from the AISC to the SAM-binding cluster, either directly or through an external redox partner, is expected to return the enzyme to a catalytically competent state.[188,194] In order to distinguish between the two mechanisms, the fate of the lysyl α-proton was followed using AgaA variants deuterated at the α and ε positions of Lys. When this substrate was treated with AgaB *in vitro*, loss of 2 Da was observed, inconsistent with the loss of the α-proton suggested by the EAS mechanism.[194] This observation provided evidence that the C-C crosslinking reaction follows a radical type mechanism.

Several crystal structures of SuiB were reported in 2017, which enhanced the understanding of streptide biosynthesis.[193] SuiB, like CteB and SkfB (sections 3.9 and 3.10), consists of an RRE-rSAM-SPASM tridomain architecture (Fig. 46). The N-terminal RRE domain adopts the wHTH-motif observed among other RiPP modifying enzymes to engender binding to their respective precursor peptides (section 4.1.1).[66,193] Unexpectedly, the SuiA-bound structure of SuiB revealed that the leader region of SuiA binds primarily through the bridging region that houses the first auxiliary [4Fe-4S] cluster rather than the RRE domain. These interactions are mediated by hydrogen bonding between the well-conserved LESS motif in the leader region of SuiA and the bridging region, which are expected to orient the core peptide in the active site for catalysis (section 4.1.1, Fig. 70).[193] Although it is possible that the RRE domains in SuiB could be vestigial, large scale conformational changes were observed in the RRE domain upon SuiA binding, which support interactions undetected in the crystal structure. The snapshot of the enzyme captured in the crystal structure plausibly represents a state where the RRE has released the precursor peptide upon reaching a certain stage of the catalytic cycle.[193]

Studies performed in the Sui and Aga pathways have revealed the promiscuous nature of the rSAM enzymes involved in streptide biosynthesis.[192] SuiB and AgaB accept both SuiA and AgaA as substrates, suggesting that small C-terminal extensions and deletions are tolerated. Changes made to the Lys2 and Trp6 residues involved in the crosslinking are not generally tolerated, however a substrate containing the Trp analog W6Bzt (3-benzothienyl-Ala) reacted with a ~4-fold reduction in rate. Changes made to the Asp in the conserved streptide motif "KGDGW" was also tolerated, with a 3-fold rate reduction. These studies revealed the tolerant nature of streptide synthases to accept natural and non-natural amino acids, which could be explored to generate unnatural streptide analogs.[192] Although the Cβ of Lys is

modified in streptide, removal of the ε-amino group of Lys is not tolerated, as evidenced by lack of modification on a norleucine variant. As a result, two roles were proposed for Lys2 in streptide biosynthesis. (1) Lys2 provides hydrogen bonding or ionic contacts to orient the substrate at the active site and, (2) Lys2 serves as a Brønsted base in the proposed catalytic mechanism.[192] These hypotheses were tested in a subsequent study using AgaA Lys2 analogs that varied either in the side chain length or the pK_a.[194] If the ε-amino group of Lys was important for binding, then changes to side chain length, while retaining the amine, would diminish turnover. Alternatively, if the Lys2 served as a Brønsted base, then replacement of the Lys ε-amino group with -OH and -SH, that vastly increase the pK_a yet retain H-bonding interactions, would negatively affect enzymatic activity. The enzymatic turnover was observed to be more dependent on the side chain length rather than the pK_a of the side chain, supporting an anchoring role. The increased turnover observed in the NH_2-group bearing analogs compared to the thiol- and hydroxy-bearing analogs suggest that the interaction may occur through salt-bridges.[194] The crystal structure of SuiB into which crosslinked SuiA was modeled revealed a potential base (Glu319) within 5 Å of SuiA-Trp(6) that could be involved in the deprotonation step of the proposed mechanism.[193] The E319A variant reduced k_{cat} by ~8-fold.[194] However, the role played by Glu319, whether a catalytic base or an aid in the relay of protons from the active site, remains to be elucidated.

A bioinformatic survey conducted in streptococcal genomes using rSAM enzymes that occur in the context of a Rgg/Shp quorum sensing system revealed several groups of short peptides each with conserved motifs.[24] *In vitro* treatment of a synthesized precursor peptide from one such group, termed the WGK cluster, with the cognate rSAM enzyme from *Streptococcus ferus*, produced a novel streptide featuring a tetrahydro[5,6]benzindole moiety generated through the installation of two C-C crosslinks between Lys and Trp residues (Fig. 14).[24] The mechanism employed by the corresponding rSAM enzyme, WgkB, to install two C-C linkages, is poorly understood.

3.12 Biosynthesis of proteusins and aeronamides

Introduction and biosynthesis: Proteusins are a family of mostly genome-predicted[195] bacterial peptides. Proteusin BGCs are noteworthy for their highly variable gene sets encoding maturation enzymes.

Until recently, the only known proteusins were the polytheonamides from the uncultivated sponge symbiont 'Entotheonella factor'. Polytheonamides are remarkably complex cytotoxic peptides carrying numerous modifications including D-amino acids, *C*-methylations, and *N*-methylations (Fig. 47) that induce the formation of a membrane-inserting β-helix pore. By heterologous expression, functions of all polytheonamide biosynthetic enzymes were characterized.[28,196] PoyD represents a new family of radical SAM epimerases (see section 5.1) and introduces 18 D-amino acid residues through irreversible L-to-D epimerization. Polytheonamide displays an alternating D/L pattern that is important for β-helix formation. The methyltransferase PoyE was shown to *N*-methylate eight Asn side chains.[197] The timing of this modification was studied at different intervals of coexpression in *E. coli*, revealing a complex pattern of largely C-to-N-terminal processing.[28] *N*-methylation occurs on epimerized Asn residues, but in *E. coli*, PoyE was also able to recognize L-Asn and Gln

units on non-natural peptide variants. For natural polytheonamides, *N*-methylated residues are arranged in a linear fashion on the β-helix and are connected by amide hydrogen bond bridges that stabilize the secondary structure.[198–200] Based on this pattern, extended artificial polytheonamide-based peptide variants were created with an inserted, Asn-containing repeat, which were *N*-methylated up to ten times.[28] Coexpression studies in *E. coli* assigned the putative Fe(II)-2-ketoglutarate-dependent enzyme PoyI as responsible for hydroxylation of Val and *N*-Me-Asn side chains (four in total), but it was also able to recognize His in core peptide variants.[28]

Seventeen additional modifications in polytheonamides are *C*-methylations that occur on unactivated sp^3 carbons of diverse amino acid residues within the PoyA core peptide. Likely candidates for catalyzing these methylations were PoyB and PoyC,[28] which are both putative class B rSAM methyltransferases (MTs) that are characterized by the presence of an additional N-terminal cobalamin (Cbl)-binding domain.[174,201] Indeed, confirmation of their role in PoyA polymethylation in heterologous expression experiments could only be achieved by switching from *E. coli* to a rhizobial host capable of producing Cbl (section 5.3.2).[28]

Molecular dynamics calculations were performed on polytheonamide variants suggesting that the extended hydrogen bond clamp formed by precisely aligned *N*-methylated Asn are of major importance for the stability of the β-helix.[200] Since six amino acid residues correspond to one helix turn, an NX$_5$N repeat in the core sequence is necessary to align multiple Asn residues on the polytheonamide nanotube. This insight was used in a genome mining strategy to identify further candidates for polytheonamide-like BGCs in sequenced genomes.[202] Searching for BGCs containing a gene combination for an epimerase, an *N*-methyltransferase, and a precursor with NX$_5$N core repeats identified orphan BGCs in diverse sources. These comprise another sponge metagenome (a gammaproteobacterium),[203] a marine single-cell genome (Verrucomicrobia), a deep-rock metagenome (alpha-proteobacteria), and the culturable beta-proteobacterium *Microvirgula aerodenitrificans* from a wastewater purification community.[202] For the latter organism, trials to identify a matching compound in cultures failed even after studies on a constructed reporter strain revealed conditions under which the biosynthetic genes are expressed. Products were ultimately accessed by introducing a His$_6$-tagged precursor variant into the producer, isolating the uncleaved modified precursor, and releasing the modified core peptide *in vitro* with the purified peptidase of the pathway. This strategy provided the new polytheonamide congener aeronamide A (Fig. 48A), a potent cytotoxin carrying one dehydration, 21 D-residues, five *N*-methylated Asn residues, and seven *C*-methylations, with only traces of side products. Core peptide switching experiments confirmed the remarkable efficiency of *M. aerodenitrificans* in generating hypermodified peptides, highlighting its potential as a synthetic biology chassis.[202] A core peptide from the deep-rock biome was converted to "polygeonamides" carrying up to 23 D-amino acids (the highest number observed to date) and multiple further modifications.

Polytheonamide-type BGCs represent only a small fraction of the architecturally diverse proteusin gene clusters detected in bacterial genomes.[195,204] Cyanobacteria are particularly enriched in proteusin BGCs, suggesting major potential for the discovery of structurally

unusual bioactive natural products. One example is landornamide (Fig. 48B; see section 5.4).

Class-defining feature: nitrile dehydratase-derived LP: Due to the lack of shared enzymology, the RiPP family definition of proteusins is based on a common precursor architecture comprising an unusually large leader peptide with homology to nitrile hydratases (the nitrile hydratase LPs, NHLP).

3.13 Epipeptide biosynthesis

Introduction and biosynthesis: Epipeptides were discovered based on work showing that a peptide assigned to the *yyd* RiPP BGC of *Bacillus subtilis* induces a two-component system that regulates stress response.[205] The *yyd* cluster (Fig. 49A) encodes, in addition to the precursor YydA, a single predicted maturase, YydG, with homology to rSAM enzymes of a previously unassigned family, but the nature of the modification remained unknown in the initial study. This function was recently identified *in vitro* using purified enzyme and a truncated version of the precursor peptide YydA.[29] A mixture of isobaric peptides was obtained that carried deuterium at an Ile and/or a Val site when conducting the assay in a D_2O-based medium. Further labeling experiments located the site of initial hydrogen abstraction as the α-carbon, and the nature of the conversion was identified as L-to-D-epimerization using synthetic peptide standards. The study also showed that replacement of a Cys residue in YydG by Ala resulted in an altered product profile with peptides containing ruptured backbone bonds at either side of the α-carbon. These and other data suggested the Cys as the source of the backside hydrogen introduced during epimerization of the substrate (Fig. 49B).

Class-defining enzyme: YydG-type radical SAM epimerase: YydG belongs to a rSAM family that differs from the previously reported PoyD-type proteusin epimerases (sections 3.12 and 5.1.1)[196] and contains as one of the distinguishing features a putative AISC domain[48]. Besides *Bacillus* spp., closer YydG homologs suggesting related functions were detected in several *Firmicutes* and *Actinomycetes*, including human gut-associated microbiota. For the family of epimerized peptides generated by YydG-like enzymes, the name "epipeptides" was proposed.

3.14 Spliceotide biosynthesis

Class-defining enzyme: radical SAM splicease: PlpX-type spliceases were discovered in genome studies aimed at characterizing the function of orphan rSAM genes present in several bacterial RiPP BGCs.[41] The *plp* cluster (Fig. 50A) produces an as-yet unknown natural product and is located in the genome of the cyanobacterium *Pleurocapsa*. It encodes, among other proteins, one proteusin-like (NHLP) and two Nif11-type precursor peptides (see section 4.4.1), a PoyD-like epimerase, and the protein pair PlpXY, of which PlpY is a small accessory protein with distant similarity to RREs (section 4.1.1) that is required for PlpX-mediated maturation. Coexpression of *plpXY* with either of the two Nif11 precursor genes (*plpA1* and *plpA2*; Fig. 50B) revealed an unusual modification resulting in an α-keto-β-amino residue (from hereon referred to as ketoamide) moiety, i.e., featuring a backbone

that is extended by one carbon unit. Comparison of the peptide with the precursor gene sequence suggested that loss rather than addition of core peptide atoms resulted in this difficult-to-rationalize modification. The biosynthetic origin was established by incorporation studies using isotopically labeled precursors. These experiments revealed for a Met-derived ketoamide of PlpA3 an unprecedented peptide backbone splicing reaction, in which the rSAM enzyme removes all atoms of a C-terminal Tyr unit except the amide carbonyl (Fig. 50C). Further experiments suggested considerable biotechnological potential of this transformation. It was shown that at least two ketoamide moieties can be introduced into the same core peptide, that codon exchange provided access to a range of β-ketoamides (Gly, Ala, Val, Leu, Ser, Pro, Gln), and that the full-length core peptide was not needed for modification (in the case of PlpA3, truncation to 11 residues was possible).[41]

3.15 Biosynthesis of graspetides including microviridins

Introduction and biosynthesis: Microviridins (Fig. 51) are compounds characterized by a cage-like structure, resulting from two lactone linkages between the side chain carboxyl group of Asp/Glu and the hydroxyl group of Ser/Thr, and a lactam linkage between the δ-carboxyl group of Glu and the ε-amino group of Lys. Microviridins inhibit serine proteases such as trypsin, chymotrypsin, subtilase, elastase, and the 20S proteasome, and have been recognized for their potential use in the treatment of pulmonary emphysema and some cancers.[1] Their biosynthesis was elucidated using *in vitro* and *in vivo* studies by two independent groups.[206,207] The lactones and lactams are sequentially installed on the precursor peptide by two dedicated ATP-grasp ligases, MvdD/MdnC and MvdC/MdnB (InterPro families: IPR026446 and IPR026439), that are homologous to the RimK ATP-grasp ligases involved in the maturation of the ribosomal protein S6.[206,207] The cyclized precursor is then processed by a yet-unidentified leader peptidase. The liberated cyclized core peptide is typically acetylated at the N-terminus by a locally encoded *N*-acetyltransferase (section 5.9.1) to yield the mature microviridin.[206,207] Aside from canonical microviridins, the structurally related peptide, marinostatin, consisting of two macrolactones in a microviridin-like core motif TxRxPSDxDE has also been identified in *Alteromonas* sp. B-10–31.[1]

Recently, the non-microviridin ATP-grasp-modified RiPPs plesiocin and thuringinin were produced *via* heterologous expression.[208,209] Plesiocin possesses four hairpin-like bicyclic repeats formed by two intramolecular ester linkages on a conserved TTxxxxEE (x is any amino acid) motif.[208] Thuringinin features three hairpin-like bicyclic motifs introduced by two ester linkages on a conserved TxxTxxxExxDxD core motif.[209] While plesiocin is a serine protease inhibitor akin to the microviridins, the bioactivity of thuringinin remains unknown.[1,208,209] Recent genome mining studies have revealed the existence of a plethora of topologically diverse RiPPs modified by ATP-grasp ligases and therefore have been described as omega-ester containing peptides (OEPs).[209–211] While the term OEP is suitable to describe microviridins, plesiocins, and thuringinins, all of which feature an ATP-grasp ligase mediated macrolactone linkage, they may not be appropriate for molecules lacking the macrolactone but exhibiting the macrolactam linkage (also installed by ATP-grasp ligases). A more appropriate name for this RiPP class would be "graspetides", which is reflective of the enzyme that installs the class-defining macrolactam and/or macrolactone modifications.

Therefore, we reclassify microviridins, plesiocins, and thuringinins as specific members of the newly formed graspetide family and recommend usage of graspetide to address ribosomal peptides that feature macrolactones and/or macrolactams installed by ATP-grasp ligases.

Class-defining enzyme: macrolact(one/am)-installing ATP-grasp ligase: The crystal structures of MdnB and MdnC (PDB: 5IG8 and 5IG9), involved in the biosynthesis of microviridin J have been determined, which aided in understanding the basis for precursor peptide recognition by these class of RiPP modifying enzymes.[212] MdnB and MdnC display highly similar structures overall, with the three characteristic domains observed across the ATP-grasp superfamily (Fig. 52). The lactone-forming MdnC was crystallized with bound MdnA precursor peptide (and variants). These structures revealed that the strictly conserved "PFFARFL" motif, previously shown to be important for biosynthesis through bioinformatic and mutational studies,[213,214] binds as an α-helix to the α7-helical region in the central domain of MdnC (section 4.1.3, Fig. 71).[212] Alterations to key residues on the MdnA precursor peptide and MdnC involved in the interactions abolished substrate binding, as shown by isothermal titration calorimetry and enzymatic processing assays. Residues N-terminal to the "PFFARFL" motif are not essential for binding to MdnB or MdnC. Structural comparison of the holo form of MdnC (in the open conformation) to the apo form of MdnB (in the closed conformation) revealed differences in the β9β10 hairpin which were 25 Å apart, implying large movement of the hairpin upon precursor binding. Based on the differences, the authors propose that binding of the LP in the α7-helical region induces a conformational change that opens up the interdomain space guarded by the β9β10 hairpins in the closed form. This then allows the core peptide to access the catalytic site between the central and C-terminal domains of the enzyme for macrocyclization.[212] The mechanism utilized by MdnC to bind MdnA represents a new precursor peptide recognition mechanism in RiPP biosynthesis, which for the majority of known prokaryotic RiPP maturases utilize an RRE-based strategy (section 4.1.1).[66] MdnC generates ADP upon reaction with MdnA, suggesting that the reaction proceeds *via* formation of an acylphosphate intermediate.[212] While MdnC uses the "PFFARFL" motif in the microviridin LP for recognition, plesiocin and thuringinin precursors, PsnA2 and TgnA, lack this motif.[208,209,212] Serial truncations of the precursor peptides, PsnA2 and TgnA revealed motifs "LFIx(D/E)L" and "KPYxxxYxE" to be essential for recognition by the cognate ATP-grasp ligases, PsnB and TgnB respectively.[209,210]

Studies on MvdC and MvdD (MdnB and MdnC orthologs) have revealed that both enzymes permit limited variation in the core peptide.[213] One pot reactions using constitutively activated MvdD and MvdC generated microviridin libraries targeted at serine proteases (section 7.2).[215] Recent bioinformatic analysis of 174 BGCs distributed across proteobacteria, cyanobacteria, and bacteroidetes revealed a far greater diversity in graspetide precursors than previously appreciated, thus holding promise for even more substrate tolerant pathways.[216] A distributive ATP-grasp ligase from *Anabaena*, *A*MdnC, for instance, processed three cores on the cognate class II precursor peptide, *A*MdnA, *in vitro*.[217] This enzyme also produced a doubly macrolactonized peptide as the only product upon reaction with the non-cognate precursor peptide, MdnA. Furthermore, *A*MdnC also processed

engineered variants of *A*MdnA containing up to four core peptides and installed up to eight macrolactones, highlighting the promiscuous nature of *A*MdnC and its potential use for the generation of graspetide analogs. The fourth "quasi" core peptide, obtained from the region between the first and second core peptide of *A*MdnA, was not always processed by *A*MdnC, and its role during the maturation process is unclear.[217] *A*MdnC follows an overall non-strict N-to-C directionality while possessing a strict order within each core peptide, installing the larger lactone first followed by the smaller lactone.[217] The cluster also harbors *A*MdnB, a homolog of MdnB, and whether or not it processes *A*MdnA and lactonized *A*MdnA, is yet to be seen. It remains undetermined if the mature natural product is an exceptionally large graspetide with multiple core-sequence repeats or if the final compound is cleaved into separate, smaller microviridin-type products.

The multi-core architecture of plesiocin has been leveraged to impart dual functionality to the mature product by generating a variant that inhibits both trypsin and chymotrypsin.[210] Leu3 in the TTLAIGEE core motif was identified to be the major determinant governing specificity to chymotrypsin which was then replaced with an Arg in the fourth core peptide to imbue anti-trypsin activity. TgnB, the thuringinin maturase, installs macrolactones in a distributive manner on TgnA.[209,217] However, unlike MdnC and *A*MdnC, TgnB installs the smaller inner lactone first followed by the outer lactone.[207,209,217] TgnB also exhibits selectivity for the acidic residues involved in crosslinking. The inner lactone requires a Glu while the outer lactone requires an Asp, which are also conserved among all predicted thuringinin precursor peptides.[209]

3.16   Borosin biosynthesis

<u>Class-defining enzyme: amide N-methyltransferase:</u> The borosin RiPP family is a group of cyclic peptides distinguished by the presence of an extensive number of α-N-methyl groups, which are introduced by SAM-dependent *N*-methyltransferases (*N*-MTs).[25,26,218] These borosin *N*-MTs are fused as N-terminal domains to their respective substrate core peptides and catalyze the iterative, autocatalytic *N*-methylation of peptide residues, representing the defining enzymatic feature of the borosin family. Additional amino acid residues are encoded in a follower region, located C-terminally of the core peptide (Fig. 53A) that is proposed to perform a similar role as LP sequences in directing recognition between PTM enzymes and their substrates.[26] It has been suggested that the covalent attachment of the substrate to the enzyme, also seen for the lyciumins (section 2.9), may increase the local concentration of the very hydrophobic (and thus insoluble) core peptide.[219]

The best-studied member of the borosins is omphalotin A (Fig. 7), which is produced by the basidiomycete fungus *Omphalotus olearius* and is a potent nematicide (LD$_{50}$ of 2 µg/mL) that is active against the plant pathogen *Meloidogyne incognita*.[221,222] Omphalotin A is derived from OphMA, which was discovered by two groups concurrently by mining the *O. olearius* genome for a gene candidate encoding the omphalotin peptide scaffold.[25,26] Electrospray ionization time-of-flight mass spectrometry (ESI-TOF MS) analysis of full-length OphMA expressed in *E. coli* resulted in the detection of a range of multiply methylated species, with up to 11 methylations reported. Such mass shifts were not detected

in a variant product lacking the C-terminal omphalotin-encoding region. Further tandem MS and electron-transfer dissociation (ETD) fragmentation analyses unambiguously localized nine methylation sites to nitrogens in omphalotin peptide bonds, with two-additional methylations located C-terminally to the core peptide.[25] Observed methylations extend from the N- to the C-terminus suggesting specific directionality for the MT activity. Similar experiments using a fungal heterologous expression host also detected an 11-fold methylated product, and co-expression with the associated protease, OphP, generated methylated products with up to nine methylations, consistent with the published omphalotin A structure. [26] Based on homology with other homodimeric SAM-dependent MTs, it was proposed that residues Tyr98 and Ser129 might be located within the OphMA SAM-binding pocket. Consistent with this hypothesis, the substitution of either residue with Ala abolished OphMA methylation activity. OphMA was shown to likely associate as a homodimer, raising the question of whether monomer automethylation is intra- or intermolecular. To distinguish between the two possibilities, inactive OphMA variants Y98A and S129A were transiently co-expressed with a catalytically active enzyme carrying a core peptide variant.[25] The mutants were shown to harbor up to ten α-*N*-methylations, supporting an intermolecular autocatalytic activity for OphMA.

In order to determine sequence requirements for methylation, OphMA variants were also examined *in vivo*. Removal of the C-terminal follower sequence still resulted in methylation, albeit incomplete, and introduction of a TEV protease cleavage site upstream of the core peptide sequence was also tolerated.[25] The activity of the catalytic domain of an OphA homolog from *Dendrothele bispora*, *db*OphMA, was also unaffected by the absence of the follower peptide sequence, for which it had no measurable affinity in fluorescence polarization experiments.[223] The *db*OphMA *N*-MT domain was shown not to modify free substrate peptide variants, suggesting *N*-methylation likely occurs because of the covalent linkage of the catalytic domain to its cognate substrate and homodimer formation. It is postulated that the follower peptide sequence functions instead as a recognition element for the subsequent action of the cluster-encoded peptidase that liberates the mature borosin product. The substitution of various *db*OphMA core peptide residues with Pro led to reduced or abolished methylation activity, suggesting OphMA homologs struggle to accept residues that are conformationally challenging to bind. However, replacing the OphMA and *db*OphMA core peptides with sequences resembling *N*-methylated peptides of non-ribosomal origin (e.g. cyclosporine A) did result in productive methyl transfer, albeit incompletely with respect to their natural product equivalents and with shifts in the native pattern of methylation.[25,223] This observed lack of substrate tolerance is thought to be due to steric hindrance at the nitrogen atom caused by the presence of non-native amino acids larger than Val/Thr in the core sequences tested. Together these results, and a subsequent study on core peptide variants that led to mixtures of products,[219] suggest limited substrate flexibility concerning both the core and flanking sequences among OphA homologs.

Recent crystallographic studies of truncated OphMA and *db*OphMA variants and active site mutants have revealed that OphMA forms a complex catenane structure in which homodimers intertwine to methylate each other's C-termini (Fig. 53B).[220,223] The *N*-MT domain is separated from the core sequence in each *cis* monomer by a 'clasp' domain that wraps around the adjacent subunit's *N*-MT domain to position the core peptide into the other

subunit's active site. Mutation of residues identified as being responsible for substrate peptide binding significantly reduced or abolished methylation activity, confirming their catalytic significance.[220] Combined with quantum-mechanical calculations and *in vitro* experiments, the current working mechanistic proposal for OphMA activity begins with deprotonation of the amide bond by a water molecule or enzyme base (Fig. 54). A tyrosine residue is suitably positioned for this function.[220,223] The deprotonated nitrogen atom of the resulting electrophilic imidate intermediate is then well-positioned for S_N2 attack on the SAM methyl group. *S*-adenosyl homocysteine (SAH) is produced as a byproduct of this reaction and is thought to then be displaced by another molecule of SAM to enable a subsequent amide methylation.[220,223] The side chains of the core peptide do not form specific interactions with the enzyme, possibly providing another explanation why the substrate is covalently attached to the protein.[220]

3.17 Dikaritin biosynthesis

Introduction and biosynthesis: Prior to 2014, fungal RiPPs were restricted to the amatoxins produced by Basidiomycetes (section 3.18). The discovery that ustiloxins are RiPPs provided the first example of RiPP biosynthesis in Ascomycetes.[224] The ustiloxin B biosynthetic gene cluster was identified based on the concurrent expression of contiguous genes in the genome of *Aspergillus flavus*, which had not been known to produce ustiloxins. Analysis of the BGC demonstrated a precursor peptide UstA with 16 repeats of a core peptide that corresponded to the sequence of ustiloxin B (Fig. 55A).[15] These core peptides are flanked by repeats that are likely recognition sequences, and UstA also contains a signal peptide that likely sends it to the endoplasmic reticulum and the Golgi apparatus, after which the peptide is thought to be processed by the endoproteinase Kex2 at the C-terminal side of a Lys-Arg sequence (Fig. 55B).[225] In addition to the precursor peptide, the BGC contains 14 genes (Fig. 55A). Gene disruption experiments supported the association of many of these genes with ustiloxin production, with the two proteins that have no characterized homologs, UstYa and UstYb (Protein family: PF11807; DUF3328; InterPro family: IPR021765), being required for production.[17,226] Sequence alignment of more than 200 UstY homologs that were all found in aspergilli suggested N-terminal transmembrane helices.[17]

Using an algorithm developed by the authors to detect highly repeated peptide sequences, other examples of genes encoding a repeated core peptide with an N-terminal signal peptide were detected in *Aspergillus* and *Fusarium* as well as the rice pathogen *Ustilaginoidea virens*, the producer of ustiloxins A and B.[227] Homologs of all genes except those encoding the peptidases UstP and UstH were observed in the BGC for the latter. The UstA precursor peptide in *U. virens* contains eight core peptide repeats of which five have the sequence YVIG and three have the sequence YAIG, consistent with observed production of both ustiloxins A and B.[227]

The bioinformatic analysis of fungal genomes also resulted in the discovery of new or proposed compounds.[17,228] Precursor peptides containing a signal peptide and repeated core peptides were observed frequently in the neighborhood of homologs of the UstYa and UstYb proteins and as many as 96 ustiloxin precursor peptide/UstY pairs were identified.[17] At least 38 different types of repeat sequences were identified that may produce a wide variety of

post-translationally modified products. One example from *A. flavus* was further characterized and the BGC consisting of just four genes (Fig. 55C) was shown to produce the new RiPP asperipin-2a, which contains a paracyclophane structure (Fig. 3).[17,18] Interestingly, the core peptides of asperipin-2a are flanked on both sides by Lys-Arg motifs that are believed to be processing sites for the Kex2 protease (Fig. 55D).

Class-defining enzymes: DUF3328-containing proteins: At present, homologs of the DUF3328-containing UstY proteins define the dikaritin RiPP class. The biosynthesis of ustiloxins has been investigated by detailed analysis of the products from gene deletion mutants and *in vitro* experiments.[229] Collectively, these studies enabled construction of a proposed biosynthetic pathway (Fig. 55E). The combined action of UstQ, UstYa and UstYb is believed to introduce the cyclic structure of *N*-desmethyl ustiloxin F. Disruption of these genes did not result in any detected products, but expression of these three genes with the UstA precursor in a non-producing *A. oryzae* strain resulted in production of *N*-desmethyl ustiloxin F. Whether UstQYaYb act before or after removal of the LP by the Kex2 protease is not known. The methyltransferase UstM then methylates the amino group and the P450 UstC oxidizes the Tyr ring and adds Cys (Fig. 55E). The class B flavin monooxygenase UstF1 was shown *in vitro* to oxidize the thioether to a sulfoxide and the monooxygenase UstF2 catalyzes an oxidative decarboxylation to the corresponding oxime, which is assumed to be converted to the corresponding aldehyde. The PLP-dependent UstD was demonstrated to add a C3 nucleophile formed from Asp to the aldehyde to generate ustiloxin B.[229] More recently, the biosynthesis of asperipin-2a was also investigated by heterologous production in *A. oryzae* via co-expression of *aprA*, *aprY*, *aprR*, and *aprT*.[18] The precursor peptide AprA contains eight repeats of the FYYTGY sequence (Fig. 55D) and mutation of either the third or the sixth Tyr to Phe aborted production indicating the importance of the phenol groups for oxidative cyclization. The authors noted the similarity in structure of asperipin 2a with plant paracyclophane natural products such as mauritine A, sanjoinin A, and ophiorrhisine A (Fig. 56A–C).[230] At present the biosynthetic origin of these compounds is not known but they might be RiPPs.

Other fungi produce several other groups of RiPPs that are structurally related to the ustiloxins such as the epichloëcyclins and the phomopsins. *Epichloë* endophytes of grasses produce cyclic peptides *in planta* from a ribosomal precursor GigA that, depending on the *Epichloë* species, has 1–8 repeats of a core peptide flanked by a Lys-Arg sequence.[231] At present, the structure of the epichloëcyclin products is not known but MS analysis indicates they are cyclic and contain dimethylated Lys. The cyclization was suggested to occur between a Tyr and an N-terminal Ile. The biosynthetic genes remain unreported. Phomopsins are a group of hexapeptide mycotoxins produced by the pathogenic Ascomycete *Phomopsis leptostromiformis* and are generated from a BGC that resembles that of the ustiloxins (Fig. 56D). They contain a similar macrocycle as the ustiloxins formed by crosslinking of former Tyr and Ile residues. In addition, the phomopsins contain several dehydro amino acids (Fig. 3). Phomopsins derive from a precursor peptide that contains multiple core repeats flanked by a Lys-Arg motif that are converted to the final product(s) (Fig. 56E).[16] The precursor peptide PhomA from *P. leptostromiformis* contains five copies that are converted to phomopsin A and three additional copies of a sequence that produces phomopsin P (Fig.

56E). The BGC also contains a tyrosinase (PhomQ), two S41 family proteases (PhomP1,P2), a SAM-dependent methyltransferase (PhomM), a zinc finger type regulator (PhomR), five homologs of the abovementioned UstY protein (PhomYa-e), and several proteins of unknown function (Fig. 56D). At present, the activities of the PhomY proteins are not known but they are likely involved in generation of the four dehydro amino acids and the formation of the macrocycle. The methyltransferase activity was investigated *in vitro* (see section 5.3.5).[16] The class-defining features of the dikaritins are the ether crosslinks introduced by the UstY homologs.

3.18 Amatoxin biosynthesis

Introduction, biosynthesis, and class-defining enzyme: Amatoxins such as α-amanitin are N-to-C cyclized peptides produced by mushrooms (Fig. 57). They also contain Cys-Trp crosslinks (tryptathionine) and various hydroxylations. Amatoxins are produced as a linear precursor peptide that contains a leader peptide, core peptide and C-terminal recognition sequence.[1] Several recent studies have provided new insights into the biosynthesis of the amatoxins (Fig. 57). Given that the core peptides for α-amanitin are flanked by Pro residues, the involvement of a prolyl oligopeptidase (POP; InterPro family: IPR001375, IPR002470) had been previously proposed in amatoxin biosynthesis, but cyclization had not been experimentally verified. *In vitro* activity of a POP from *Galerina marginata* showed the enzyme catalyzes two reactions during the biosynthesis of α-amanitin.[232] The enzyme was expressed in *Saccharomyces cerevisiae*, and the purified protein first hydrolyzed the 35-amino acid precursor peptide C-terminal to an internal Pro to release a 25-amino acid C-terminal peptide (Fig. 57). Subsequently, the enzyme performed a transpeptidation at a second Pro to generate a cyclic octamer. The two processes were not processive *in vitro* as the product of the first step was released. Furthermore, synthetic peptides corresponding to the 25-mer and analogs were cyclized. These experiments identified a minimum sequence required for proteolysis at the first Pro, and for cyclization upon proteolysis at the second Pro. Kinetic experiments showed that the enzyme does not have much preference of the full length peptide over the 25-mer. In a follow-up paper, the utility of *Gm*POPB was demonstrated by testing 127 novel peptide substrates, 100 of which were cyclized (see section 7.7.1).[233] The authors also demonstrated that the activity is specific for the POP investigated (termed POPB) as a second POP encoded in the genome (POPA) did not catalyze cyclization. POPA enzymes are present in all species of *Amanita* and *Galerina* whereas POPB was only associated with amatoxin producing species.

A detailed kinetic analysis of *Gm*POPB showed that product release is ordered with the cyclic peptide departing before the follower peptide.[234] The dissociation of the latter is slow, partially limiting the overall turnover rate. A subsequent crystallographic study provided insights into the various steps and explained why the product of the first step needs to be released prior to rebinding in a different conformation that enables cyclization.[235] These observations led to the design of optimized simpler substrates that may be beneficial for biotechnological applications. At present, the mechanisms of tryptathionine formation and side chain hydroxylation of Trp, Pro and Ile have not yet been elucidated. The combination of POP and the unidentified tryptathionine synthase is the class-defining feature of amatoxins.

3.19 Biosynthesis of N-to-C cyclized peptides including cyclotides and orbitides

Class-defining enzyme: cyclizing asparaginyl or serine endoprotease: Head-to-tail cyclized RiPPs include large peptides[236,237] and also many cyanobactins from cyanobacteria (section 3.6), the fungal amatoxins (section 3.18), and the plant-derived cyclotides and orbitides.[1] In recent years, several of the enzymes that catalyze the cyclization step have been experimentally characterized. The Pro oligopeptidase involved in amatoxin cyclization was discussed in section 3.18, and structures of the cyanobactin macrocylase PatG (section 3.6) were solved in 2012.[238] This section will discuss the newly discovered or newly characterized members of the plant asparaginyl endoprotease family (AEP, C13 protease family; InterPro family: IPR001096) including butelase 1[239] and *Oa*AEP1b,[240] a cyanobactin macrocyclase from *Oscillatoria* sp. PCC 6506 (OscG$_{mac}$),[241] an AEP from *Canavalia ensiformis* (jack bean, *Ce*AEP1) that cyclizes sunflower trypsin inhibitor (SFTI), [242] and the orbitide cyclase PCY1.[243]

AEPs are Cys proteases that cleave Asx (Asn/Asp)-Xaa bonds to generate an acyl-enzyme intermediate that can be captured intramolecularly leading to cyclization or intermolecularly leading to ligation. The SFTI-cyclizing AEP1 has modest *in vitro* cyclization activity leading mostly to hydrolysis. Butelase 1 on the other hand has relatively high cyclization activity. The enzyme was extracted from seeds of the tropical plant *Clitoria ternatea* and is naturally involved in cyclization of cyclotides. The enzyme can process a variety of peptides of 14 to 58 residues by cleaving the peptides after Asp/Asn in an Asx-His-Val motif and subsequently cyclizing them.[239] Butelase 1 shares high sequence homology with peptide cleaving proteases and much attention has been focused on the origins of the cyclization activity.[242] Recent structural investigations of both butelase 1 and homologs from the cyclic peptide-producing plants *Viola yedoensis* and *Viola canadensis* provided insights in the factors that control peptidase versus ligase/cyclization activities (i.e. interception of the acyl-enzyme intermediate by water or an amino terminus of a peptide, respectively).[244,245] Butelase 1 has comparable turnover rates to *Gm*POPB,[232,234] but both are higher than the catalytic activities of PCY1 (discussed below)[243] or PatG.[246]

*Oa*AEP was isolated from the cyclotide-producing plant *Oldenlandia affinis* and was recombinantly expressed in *E. coli*, providing the first example of an active cyclization AEP generated by heterologous expression.[240] It was demonstrated to cyclize a diverse array of peptides including native kalata substrate precursors, but unlike POPB (section 3.18) the enzyme did not catalyze the N-terminal cleavage step required for cyclization to take place, suggesting another protease may conduct this step. Use of two enzymes for removing the leader peptide and cyclization seems more common as it is also observed for the patellamides (PatA and PatG, section 3.6) and orbitides (see below). The catalytic parameters of *Oa*AEP are lower compared to those of butelase 1. Recently a group of more efficient enzymes that demonstrate cyclization activity at both acidic and neutral pH, termed canonical AEP ligases (to distinguish them from AEPs that have pH dependent ligation or hydrolysis activities), was reported.[247]

PatG (also called PatG$_{mac}$) is a subtilisin-type serine protease involved in macrocyclization of the cyanobactin patellamide (Fig. 35). Genome mining studies identified a putative

cyanobactin gene cluster in the genome of *Oscillatoria* sp. PCC 6506. Its macrocyclase OscG$_{mac}$ was expressed in *E. coli* and purified.[241] The enzyme showed higher substrate tolerance than PatG$_{mac}$ and was used to cyclize peptides of 6–30 amino acids, including D-amino acids.

Cyclization of the orbitide[1] segetalin A is catalyzed by a member of the S9A family of serine proteases, PCY1, isolated from the plant *Saponaria vaccaria*.[243] This family includes the prolyl oligopeptidases (see section 3.18) involved in head-to-tail cyclization of amatoxins, but PCY1 does not cleave adjacent to Pro residues. As noted above for *Oa*AEP1b, PCY1 also requires an additional protease (OLP1) to remove an N-terminal peptide before it can cyclize a peptide with a free amino terminus (Fig. 58).[243] Mutagenesis experiments demonstrated that substrate recognition is governed by an 11–16-residue follower peptide that is removed in the cyclization step.[243] The crystal structure of PCY1 (PDB: 5UW3) showed that the enzyme utilizes the cleaved C-terminal follower peptide of the substrate to attain a conformation that promotes macrocyclization.[248] This finding explained why the enzyme produces nine different orbitides of different sequence and ring size from substrates that have highly conserved follower sequences with especially high conservation in the C-terminal six residues that were visualized in the structure. Unlike the mostly hydrophobic interactions used for LP recognition in the biosynthesis of class I lanthipeptides, cyanobactins, lasso peptides and PQQ (see section 4.1.1), the follower peptide/recognition sequence binds to PCY1 via well-defined hydrogen bonds that result in closure of the active site with a large internal cavity that promotes macrocyclization and excludes water to prevent competing hydrolysis.[248]

One of the advantages of PCY1, despite slow turnover rates (~0.12 s^{-1} - 1 h^{-1}),[243,249] is the high substrate tolerance and the ability to produce small macrocycles (5–9 residues). A structure of an enzyme variant in which the active site Ser had been replaced by Ala showed electron density for part of the core peptide of pre-segetalin B1 in addition to the follower peptide. Additional binding analysis suggested that a shorter C-terminal tail might still result in sufficient affinity for catalysis. Therefore, a minimal substrate follower sequence of just three residues was designed and demonstrated to support macrocyclization.[249]

In contrast to the advances in the understanding of the cyclization processes of the amatoxins, cyclotides, orbitides, and cyanobactins, this step is still poorly understood for the circular bactiocins.[236,237] Recent genetic studies have investigated the importance of the leader peptide sequence and the potential involvement of specific genes,[250,251] but no definitive information regarding the molecular details have emerged. These studies do suggest that leader peptide removal and cyclization are two separate processes.

3.20   Biosynthesis of pheganomycin/guanidinotides

Four enzymes including a type III PKS are known to catalyze the formation of 2-(3,5-dihydroxyphenyl)-2-oxoacetic acid during the biosynthesis of vancomycin.[252] Reasoning that this compound is only a few putative steps away from the N-terminal structure of pheganomycin (Fig. 4A), a search for orthologs of these enzymes resulted in the identification of the pheganomycin BGC encoding the PGM9–11 proteins as well as an additional 18 genes nearby (Fig. 59A).[19] One of these genes encodes the novel peptide

ligase, PGM1, that was shown to catalyze amide bond formation between (*S*)-2-(3,5-dihydroxy-4-methoxyphenyl)-2-guanidinoacetic acid and a peptide derived from the precursor peptide encoded by *pgm2* (Fig. 59B). PGM1 is an ATP-grasp enzyme (defined in section 3.15) that connects a ribosomally synthesized peptide with the α–guanidino acid. The enzyme was demonstrated to be tolerant to changes in both the amino acid and the peptide allowing preparation of pheganomycin analogs. This substrate tolerance was analyzed by site-directed mutagenesis and structure determination of the enzyme (PDB: 3WVQ and 3WVR).[19] PGM4, PGM7, PGM8 and PGM12 were hypothesized to convert 2-(3,5-dihydroxyphenyl)-2-oxoacetic acid to the N-terminal guanidino acid, whereas PGM3, a rSAM methyltransferase, was proposed to *C*-methylate Val to *tert*-Leu (see section 5.3 for similar transformations). Finally, PGM14 may be involved in excision of the core peptide from the precursor PGM2. Thus, pheganomycin was shown to be the first example of a ribosomally synthesized peptide that is subsequently linked to a non-proteinogenic amino acid formed in part by a type III PKS. This discovery was later followed by the reports of other hybrid combinations of RiPP and non-RiPP pathways (section 3.1.5).

3.21 Biosynthesis of pyrroloquinoline quinone (PQQ) and mycofactocin

In recent years, much progress has been made in the understanding of the biosynthesis of the redox cofactor PQQ. Gene disruption studies demonstrated that five genes are required for PQQ production (Fig. 60A) with two other genes often but not always present in the operon.[253] In the first step, Glu and Tyr residues in the precursor peptide PqqA (Fig. 60B) are crosslinked by the rSAM protein PqqE in a reaction that requires the small protein PqqD (RRE domain, see section 4.1.1) to bind the LP of PqqA.[254,255] A two-component heterodimeric protease PqqFG from *Methylobacterium extorquens* AM1, a protein that is not always encoded in the PQQ BGC, was able to hydrolyze linear PqqA, preferentially hydrolyzing the peptide both N- and C-terminal to Ser residues.[256] Previously, a PqqF homolog from *Serratia* sp. FS14 had been crystallized demonstrating an HxxEH Zn-binding motif.[257] After PqqFG catalysis, trimming from the N- and C-termini of the initial products will be required by one or more additional unknown proteases to generate the crosslinked diamino acid that is the postulated substrate of PqqB (Fig. 60C). This protein has sequence homology with β-lactamases but was shown to functionally behave as an iron-dependent hydroxylase that oxidizes the phenol in a series of analogs of the crosslinked structure to a hydroxyl orthoquinone (Fig. 60C).[258,259] Subsequently, a cyclization step that is postulated to be spontaneous[258] provides the last intermediate that is oxidized by PqqC in an eight electron oxidation process that does not require any cofactors.[260] Thus, in recent years the enzymatic activities of PQQ biosynthesis have been elucidated, either with authentic substrates or substrate analogs.

Mycofactocin is another RiPP that has been suggested to be a redox cofactor. Its existence was first hypothesized based on a bioinformatic study that showed the co-occurrence of six genes in many bacteria, most notably *Mycobacterium* sp.[20] Furthermore, these genes were only present when members of three families of dehydrogenase genes were also in the genome, leading to the suggestion that the mycofactocin BGC might encode for a redox cofactor that is used by these dehydrogenases (e.g. MtfG, Fig. 61A).[20,261] However, the structure of the final product has not yet been determined. Several studies have provided

insights into the structure of the final product by investigating the functions of the six biosynthetic genes (*mftA-F*) (Fig. 61A). The rSAM protein MftC catalyzes the oxidative decarboxylation of the C-terminal Tyr of the precursor peptide MftA (Fig. 61B) in a reaction that also requires MftB for LP binding (RRE, section 4.1.1).[262,263] MftC then catalyzes a second reaction in which the penultimate Val is cyclized onto the initially formed tyramine (Fig. 61C).[264] MftE was recently shown to hydrolytically remove the LP generating 3-amino-5-[(*p*-hydroxyphenyl)-methyl]-4,4-dimethyl-2-pyrrolidinone (AHDP).[265] The amino group of AHDP is then oxidized by the FMN-dependent enzyme MftD, a member of the aldolase-TIM barrel fold family, to give pre-mycofactocin (Fig. 61C).[21] The molecule was able to oxidize NADH bound to carveol dehydrogenase from *M. smegmatis*, a known mycofactocin-dependent enzyme, and was competent to support turnover of carveol to carvone. Indeed, its redox properties are not unlike other known peptide-derived redox cofactors,[21] and several studies have supported a redox cofactor role for mycofactocin. [266–268] At present it is not known how the reduced pre-mycofactocin might be reoxidized for another turnover, but recent metabolomics studies detected both oxidized and reduced glycosylated mycofactocin derivatives in *Mycolicibacterium smegmatis*.[266] Mycofactocin represents another class of RiPP initially discovered bioinformatically (other examples are in sections 2.12–2.15, 3.14, and 3.24).

3.22   Biosynthesis of pantocin A

Pantocin A is a small tripeptide inhibitor of L-histidinol phosphate aminotransferase that originates from a Glu-Glu-Asp motif at the center of a 30 amino acid precursor peptide, PaaP. Its characterization was one of the earliest examples of using RiPP production in *E. coli* to obtain sufficient material for structure elucidation.[269] The peptide bears a characteristic bicyclic ring system (Fig. 62).[269,270] In addition to a gene involved in host self-immunity (*paaC*), the *paa* BGC contains only two biosynthetic genes, *paaA* which encodes an ATP-dependent enzyme of the ThiF/E1-superfamily, and *paaB*, encoding an α-ketoglutarate- and iron-dependent oxidase. *In vitro* reconstitution experiments using PaaA and synthetically prepared PaaP substrate revealed that PaaA catalyzes two dehydrations, a decarboxylation, and is responsible for generating the bicyclic ring system (Fig. 62). The PaaA-catalyzed transformation has been proposed to occur via one of two routes.[271] One route begins with condensation of the peptide backbone amide with the activated side chain of Glu16, followed by a Claisen-like condensation with an enolate on the side chain of Glu17. Alternatively, the Claisen-like condensation step between the side chains of the adjacent Glu residues could precede condensation with the backbone amide. Both routes would yield the same bicyclic core, which is subject to subsequent oxidative decarboxylation. The resulting intermediate enamine tautomers undergo an oxidative decarboxylation catalyzed by PaaA and/or PaaB, prior to cleavage of the mature product from the peptide backbone.

To probe the functional significance of the N-terminal leader and C-terminal follower sequences for PaaA activity, assays were performed using synthetic truncated PaaP variants. [271] While the N-terminal sequence was shown to be essential for PaaA catalysis, removal of the follower still allows the first condensation reaction to occur (by either route described previously). Structural studies have also been conducted for PaaA (PDB: 5FF5) and revealed

the presence of an RRE domain (section 4.1.1) that interacts with PaaP and is believed to direct the core peptide into the enzyme active site. More recently, mRNA display was employed to gain further insights into enzyme-substrate interactions, revealing broad enzyme promiscuity for PaaA outside of its core and predicted binding epitope.[272] This work highlights the potential of mRNA display-based techniques for studying RREs, in addition to creating new possibilities for introducing the indolizidinone moiety into synthetic peptide libraries. Critically, the technique also provided insights into the timing of modification, indicating that Glu16, rather than Glu17, is the preferred initial substrate residue, as illustrated in Fig. 62. We note that the term pantocin is given to natural products of diverse structures produced by *Pantoea agglomerans*, some of which may not be RiPPs. [270]

3.23 Methanobactin biosynthesis

Methanobactins form a family of copper-binding RiPPs that play a key role in copper homeostasis among methanotrophic bacteria. Common to the structures of all methanobactins are a pair of bidentate ligands, each comprising an oxazolone heterocycle adjacent to an enethiol (or thioamide tautomer), which mediate Cu(I) chelation (Fig. 63A). Although the BGCs encoding these Cu(I)-binding siderophores have been known for many years and are widespread among bacteria,[273] the enzymes responsible for installing these characteristic heterocycle-thioamides were only recently characterized from *Methylosinus trichosporium* OB3b.[274]

It was postulated that the installation of heterocycle-thioamide moieties would require a four-electron oxidation, suggesting the involvement of a redox cofactor. MbnB, a previously uncharacterized protein belonging to DUF692 encoded within methanobactin BGCs, was identified as a potential candidate for this transformation based on low sequence similarity to members of a TIM barrel family that include representatives bearing divalent metal cofactors.[275] Heterologous co-expression experiments revealed that MbnB forms a heterotrimeric complex with MbnC, a protein of unknown function, and the precursor peptide MbnA, indicating a role of MbnBC in biosynthesis. Spectroscopic studies further revealed the presence of a multinuclear Fe (di/tri) cofactor within MbnB,[274] consistent with the as-yet unpublished crystal structure from a homolog from *Haemophilus somnus* 129Pt (PDB: 3BWW) that possesses a diiron cluster for which no activity has yet been reported.

In vitro reconstitution experiments demonstrated that, in the presence of O_2, MbnBC reacts with MbnA to produce a product with a mass loss of 4 Da that absorbs strongly at 335 nm. This activity was shown to be dependent on the presence of the predicted multinuclear Fe cofactor, and substitution of the proposed iron ligands abolished MbnB activity. Subsequent MS/MS analysis allowed the mass loss to be localized to the N-terminal Cys21, which is the position of the oxazolone closest to the N-terminus of the final product. Consistent with this result, a C21S substitution in the substrate eradicated peptide modification. MbnBC does not contain any discernable RRE. Utilization of a truncated MbnA variant lacking the leader sequence led to diminished activity, suggesting an alternate mechanism of interaction with the LP. Taken together, these results suggest that the MbnBC homodimer is an oxidase that activates O_2 for the cleavage of the three aliphatic C-H bonds on both Cα and Cβ of Cys21

of MbnA, triggering an oxazolone-thiamide-forming four-electron oxidation (Fig. 63B). MbnA processing could be initiated by hydrogen atom abstraction from the Cys21 Cβ atom by a superoxo Fe(III) intermediate.[274] The formation of an oxazolone-thioamide moiety via such a metalloenzyme-mediated radical mechanism is unprecedented and presents a novel way of carrying out this chemistry. The mechanism by which MbnBC proceeds to the second residue (Cys27) for modification remains unclear. Another member of the DUF692 family is involved in an equally remarkable transformation involving Cys during pearlin biosynthesis (section 3.24).

3.24 Pearlin biosynthesis

During the maturation of lanthipeptides and thiopeptides, LanB enzymes catalyze the glutamylation of Ser and Thr residues via a glutamyl-tRNA-dependent mechanism (sections 3.1.1 and 3.2). Glutamate is subsequently eliminated to generate dehydroamino acid residues (Fig. 19B) that can be further modified.[49,71] As part of a bioinformatics survey of LanB-like enzymes, a number of homologs were identified that do not contain a canonical elimination domain, thus originally called small LanBs. One example, TglB, was identified in *Pseudomonas syringae* pv. *maculicola* ES4326 that is encoded near a gene encoding a 50-mer peptide (TglA; Fig. 64A).[50] Co-expression of these genes in *E. coli* resulted in the detection of a new TglA-related mass consistent with condensation with a Cys residue, rather than Glu. Furthermore, MS/MS analysis localized the addition of the Cys adduct to the C-terminal Ala of TglA, instead of a canonical ester linkage to Ser as anticipated from lanthipeptide and thiopeptide biosynthesis (sections 3.1.1 and 3.2). Subsequent *in vitro* reconstitution experiments using Cys, tRNA^{Cys}, Cys tRNA synthetase and ATP confirmed that TglB catalyzes the transfer of a Cys to the C-terminus of TglA in a tRNA- and ATP-dependent manner (Fig. 64B). This finding lead to the renaming of small LanBs to peptide aminoacyl-tRNA ligases (PEARLs). When the same experiment was repeated in a buffer containing H$_2$^{18}O, the resulting product contained only a single ^{18}O, and the addition of hydroxylamine to the reaction mixture permitted the trapping of activated TglA as the corresponding hydroxamate. Taken together, these observations indicated a mechanism for TglB in which the TglA C-terminal carboxylate is first activated by phosphorylation, with subsequent amide bond formation to the amino group of Cys-tRNA^{Cys} (Fig. 64B). tRNA^{Cys} is subsequently hydrolyzed to generate TglA-Cys. TglB contains a LP binding domain (RRE, section 4.1.1) and requires only the last 12 amino acids of TglA.[276]

Further *in vivo* and *in vitro* experimentation of other proteins encoded in the *tgl* BGC revealed that TglH, a DUF692-containing homolog of MbnBC (section 3.23), and TglI (RRE; section 4.1.1) catalyze a four-electron oxidative rearrangement that results in excision of the Cβ atom of the appended Cys residue (Fig. 64C).[50] TglF, a carboxy-SAM-dependent methyltransferase, subsequently catalyzes thiol carboxymethylation of the same residue, prior to TglG-mediated proteolytic cleavage to release thioglutamate. It is not clear whether this unstable compound is an intermediate or the final product of the pathway. Although TglA effectively remains unmodified following these transformations and the pearlins are therefore technically non-ribosomal in origin, a ribosomally synthesized peptide serves as a scaffold for their extension assembly using RRE domains present in TglB, TglI, and TglG,[50] and represents a new biosynthetic paradigm.

Class-defining enzyme: peptide aminoacyl-tRNA ligase: Examination of similar small LanB-like proteins encoded in the BGCs for the pyrroloquinoline alkaloids ammosamide and lymphostin revealed that these pathways employ a similar mechanism of peptide extension during biosynthesis. Previous work on these Trp-derived natural products indicated that they might be derived from a small precursor peptide bearing a C-terminal Trp.[51] However, when this Trp was replaced by Ser in the ammosamide precursor AmmA, or deleted altogether, ammosamides were still produced. In light of the TglB finding, AmmB2 was demonstrated to add a Trp residue to the C-terminus of a truncated AmmA peptide substrate in a tRNA[Trp]-dependent manner both *in vivo* and *in vitro*, explaining why ammosamides are produced when the C-terminal Trp was removed. PEARL enzyme-mediated peptide extension therefore represents a more general strategy in natural product biosynthesis. Furthermore, these findings illustrate that lymphostin is another example of the joining of a structure obtained by a RiPP biosynthetic pathway[277] with a structure obtained by PKS machinery.[278]

3.25 Glycocin biosynthesis

Glycocins are glycosylated peptides produced by various Firmicutes, exemplified by glycocin F from *Lactobacillus plantarum* and sublancin from *Bacillus subtilis* 168.[279] Sugar moieties are attached to Cys, Ser, and/or Thr generating *S*- or *O*-glycosides. In some cases, such as thurandacin and glycocin F, a single enzyme glycosylates both a Cys and a Ser.[279,280]

The NMR structure was solved for sublancin 168 revealing a compact structure consisting of two antiparallel α-helices connected by cystine bridges and hydrophic interactions,[281] providing a rationale for its proteolytic stability. The structure resembles that of the previously reported glycocin F.[279] Successful functional transfer of the sublancin biosynthetic gene cluster into *E. coli* permitted the rapid generation of sublancin core variants to explore structure-activity relationships.[282] These studies identified two residues in helix B as well as the *S*-glycosyl unit, as important for antibiotic activity. A similar conclusion was drawn regarding the importance of *S*-glycosylation in glycocin F using synthetic variants.[283,284] In addition, variants were tested, in which various different sugar units had been attached by exploiting the substrate tolerance of the *S*-glycosyl transferases SunS and EntS encoded in the sublancin and enterocin 96 BGCs, respectively.[285,286] This exchange of glycosyl moieties exerted unexpectedly little influence on the activity. Further experiments supported earlier evidence that sublancin might target the glucose uptake system.

Utilizing *E. coli* expression strategies, the function of orphan glycocin BGCs was investigated, motivated by the relatively small number (six) of previously known glycocins. Among 50 potential glycocin BGCs, four from various organisms including a thermophilic *Geobacillus* sp., an alkaliphilic *Bacillus* sp., and a *Listeria monocytogenes* strain yielded new peptides carrying glucose moieties including one, listeriocytocin, containing a diglucosylated Ser.[287] Two (mesophilic) *Bacillus* gene-derived products exhibited good activity against *Bacillus cereus*. In another study, the new glycocin pallidocin was generated in *E. coli* by expressing an orphan BGC from the thermophile *Aeribacillus pallidus*.[288]

Pallidocin, which is identical to the aforementioned glycocin from *Geobacillus* sp., features a glucosylated Cys and a predicted dihelical structure and is highly active against related thermophilic Firmicutes and some *Bacillus* species. Furthermore, co-expression in *E. coli* of the pallidocin *S*-glycosyltransferase and export protein with His$_6$-tagged leaderless core peptides that were identified in two other *Bacillus* genomes, provided two additional examples of antibacterial glycocins.[288]

Class-defining enzyme: combination of glycosyl transferase family 2 and peptidase C39: A recent bioinformatic survey using the Integrated Microbial Genomes-Atlas of Biosynthetic gene Clusters (section 6.9) for the combination of a SunS-like glycosyltransferase (Protein family PF00535) and a PCAT bifunctional peptidase-transporter (section 4.4.1)[289] suggests that the glycocins are more phylogenetically widespread and structurally more diverse than previously anticipated.[279]

4. Engagement and removal of leader peptides and recognition sequences

The modularity of RiPP biosynthesis and the associated plasticity and evolvability of their structures (see section 7) is accomplished in part through the bipartite nature of the precursor peptide. Typically, RiPP precursor peptides consist of two regions, an N-terminal LP, which serves as the recognition site for some of the biosynthetic enzymes, and a C-terminal core peptide, where the chemical modifications take place.[1] In the case of bottromycins and borosins, a peptide region providing substrate recognition is attached to the C-terminus of the core peptide and is thus termed a follower peptide (Fig. 1). Some RiPP pathways, such as pantocin and N-to-C cyclized peptides, have leader and follower peptides. The physical separation of substrate recognition from where the modifications are installed results in wide substrate tolerance for many RiPP biosynthetic enzymes. Since 2013, much new information has been obtained regarding the mechanisms of LP recognition, which will be discussed in this section.

As noted in section 1.1, the PTMs in some RiPPs require additional recognition sequences (RSs) beyond the LP that are often found flanking a core peptide. New information regarding the interaction of these often highly conserved RSs with their biosynthetic enzymes has been reported and will also be briefly discussed in this section.

4.1 Leader peptide recognition

4.1.1 The RiPP precursor recognition element (RRE)—A large fraction of class I lanthipeptide precursor peptides contain a highly conserved F-D/N-L-N/D motif in their LPs. The first co-crystal structure of a RiPP biosynthetic enzyme with a LP bound (PDB: 4WD9) revealed how NisB, the dehydratase in nisin biosynthesis, recognizes this motif within the NisA precursor peptide.[49] The structure showed clear electron density from Lys(−9) to Lys(−20) (negative numbering is used for LP sequences, Fig. 65). Recognition of the NisA LP is achieved through the formation of an antiparallel β-sheet with the β3 strand of a small domain on NisB that had been previously observed in the structure of TruD.[114] Specific binding interactions involved insertion of Phe(−18) and Leu(−16) of the FNLD

motif into a hydrophobic pocket formed by residues from α3 of the binding domain on NisB (Fig. 65). Covalent attachment of the NisA LP to the NisB binding site resulted in a catalytically competent complex sufficient for glutamylation and elimination (see section 3.1.1).[68]

Shortly after the publication of the NisA:NisB structure, the complex of LynD, the cyclodehydratase involved in the biosynthesis of the cyanobactin aestuaramide (see section 3.6), with a minimal substrate PatE' was reported.[115] Residues −18 to −4 of the LP of PatE' were observed in the structure, where residues Gln(−18) to Ser(−15) adopted a coiled conformation, Ser(−15) to Glu(−11) were involved in a helical turn, Ser(−9) to Ala(−6) formed a β-strand, and Leu(−5) to Gly(−4) adopted a coiled conformation (Fig. 66). The β-strand of the LP of PatE' again formed an antiparallel β-strand to β3 of the binding domain on LynD, and Leu(−13) and Leu(−10) inserted into hydrophobic pockets of α3. In addition, Glu(−11) and Glu(−8) made salt bridges and hydrogen bonds with LynD (Fig. 66).

Using a combination of crystallographic data from these co-crystal structures and bioinformatic approaches, it was demonstrated that biosynthetic pathways from many different RiPP classes, including cyanobactins, LAPs, class I lanthipeptides, thiopeptides, microcins, lasso peptides, sactipeptides, PQQ/mycofactocin, proteusins, and bottromycins use the same architectural domain to recognize the LP.[66] This RiPP precursor recognition element or RRE, consists of three α−helices (α1–3) and three β-sheets (β1–3) in a wHTH motif. Some RiPP biosynthetic pathways do not have the RRE domain embedded in a biosynthetic enzyme as discussed thus far, but instead encode a discrete RRE. For RiPP biosynthetic enzymes, this motif was first structuraly characterized in PqqD, a discrete RRE-containing protein involved in PQQ biosynthesis (section 3.21) (Fig. 67). PqqD was later shown to be responsible for binding PqqA, the PQQ precursor peptide,[255] and recently an NMR structure of the complex has been determined showing a similar interaction with the LP of PqqA.[290] The mode of LP recognition by the RRE has now been elucidated for multiple RiPP biosynthetic enzymes. For instance, biochemical analysis of BalhC and CurC involved in the biosynthesis of LAPs also suggested a central role of the α3/β3 cleft of the RRE,[66] and similar findings were reported for the discrete F proteins HcaF and TbtF involved in LAP and thiopeptide biosynthesis, respectively.[89,124] Although in most cases, similar binding poses are observed as those described for NisB, LynD, and PqqD, sometimes alternative binding conformations have been reported (see section 4.1.2).

In the case of lasso peptides, LP binding to an RRE-containing protein was first demonstrated using fluorescence polarization binding assays in the streptomonomicin pathway, where the LP of StmA (precursor peptide) bound to StmE (RRE).[66] This study also identified a subset of residues in StmE that mediate the LP interaction. Following this, the RRE from the lariatin biosynthetic pathway (LarB1) was also shown through bilayer interferometry assays to interact with the LP of LarA.[159] Photocrosslinking experiments suggested that the RRE may also bind the core region of LarA. A structural model of LarA-RRE binding generated using distance constraints obtained from the crosslinking experiments showed that the peptide bond between the leader and core peptides is solvent-exposed and possibly provides access to the leader peptidase.[159] Studies on the paeninodin biosynthetic pathway revealed that in addition to recognizing the PadeA LP, the RRE

delivers PadeA to the leader peptidase.[157] This conclusion was reached by the lack of cleavage activity on PadeA in the absence of the RRE or in the presence of RRE variants that bind poorly to PadeA. Hydrogen-deuterium exchange MS performed on LP-bound RRE showed decreased hydrogen-deuterium exchange at the α-helices and β3 strand, suggestive of an interaction with the LP. The β1 and β2 strands showed increased exchange consistent with flexibility/exposure after binding. These data, along with mutational studies, support a model for substrate recognition in line with that observed for other RREs, where the LP lies along the α3 helix and interacts with β3 to extend into a four-stranded antiparallel β-sheet. [66,157]

The recent crystal structures of discrete RRE proteins TfuB1 (also referred to as FusE) and close orthologs (PDB: 6JX3, 5V1V, and 5V1U) bound to cognate LPs support this model. [160,161] LP binding was shown to be primarily mediated by hydrophobic interactions with the RRE (Fig. 68). In addition, these structures revealed that Tyr(−17), Pro(−14), and Leu(−12) in a YxxPxL motif, conserved among precursors that harbor a discrete RRE[154,159] and shown to be important for substrate recognition by the RRE,[158,292,293] fit into hydrophobic pockets formed between the β3 strand and the α-helices.[160,161] The inability of RRE variants altered at residues that form these hydrophobic clefts to bind LPs further corroborate these findings.[161] Furthermore, insertion of a YxxPxLxxxG motif into the non-cognate precursor peptide to microcin J25, McjA, turned it into a competent substrate for TbiB2 while the wild-type precursor was not processed. The structure of the FusA LP bound to FusE revealed a hydrophobic patch formed by the LP and the RRE on the β-sheet and is predicted to provide an interaction surface for either the core peptide or leader peptidase for further processing.[160]

McbB involved in the biosynthesis of the LAP microcin B17 (Fig. 28, section 3.4) also engages its precursor peptide McbA using an RRE. The structure of the McbBCD complex bound to a McbA truncant revealed an unexpected stoichiometry and arrangement, where McbB, McbC, and McbD are present in a 2:1:1 ratio, and the McbB monomers are arranged in a head-to-tail conformation.[294] The asymmetric arrangement of McbB monomers allows for different functions of each subunit. The RRE of one of the McbB monomers interacts with the McbA LP by forming a four-stranded antiparallel β-sheet near the α3/β3 cleft similar to the interactions described thus far in this section (Fig. 69). Phe(−19) and Leu(−15) insert into a hydrophobic cavity in the cleft. Additional interactions were observed between Asp(−12) and Lys(−9) of McbA that interact with the second monomer of McbB by salt bridges.

Other RRE domain containing proteins that have been shown to interact with the LPs of their substrates include sactisynthases (section 3.9),[182,183] and RRE domains are also used for recognition of NHLPs. These long LPs (~90–100 residues) with partial homology to nitrile hydratases are used for the biosynthesis of a variety of RiPPs.[195,197] The epimerase OspD involved in proteusin biosynthesis (see section 5.1.1) contains a C-terminal RRE and mutational analysis of OspA implicated a stretch of amino acids near the N-terminus that are critical for catalysis.[295] This stretch is homologous to other RiPP precursor peptides including class I lanthipeptides, LAPs, and class II lanthipeptides even though the enzymes invoved in the biosynthesis of the latter do not contain RRE domains (see section 4.1.3).

4.1.2   RRE-containing proteins that engage substrate by alternative mechanisms—Although all examples discussed thus far display similar types of interactions between the LP and the corresponding RRE, exceptions have been reported. In the biosynthesis of streptide, the rSAM enzyme SuiB that introduces the Lys-Trp crosslink (section 3.11) contains an RRE, but surprisingly the SuiA LP does not bind at the α3-β3 interface. Instead, the LP binds in the catalytic barrel (Fig. 70A).[296] Rather than the extended β-strand secondary structure discussed in section 4.1.1, the SuiA LP adopts an α-helical structure and binding is stabilized through an extensive water-mediated, hydrogen bonding network via the LESS motif on the LP. The LP does make an electrostatic interaction between Glu(−5) and Arg27 of the RRE of SuiB (Fig. 70B). Further biochemical studies will need to be performed to confirm or refute if this unique binding mode is catalytically active or a crystallographic artifact. Another exception is the glutamylation domain TbtB involved in the biosynthesis of the thiopeptide thiomuracin (section 3.2). This enzyme contains an RRE but appears to only need recognition of and affinity for the previously post-translationally modified core peptide of its substrate for activity.[71]

4.1.3   Other leader peptide recognition mechanisms—The observation of RRE domains encoded in the BGCs of about half of the reported RiPP classes, regardless of the types of PTMs installed, suggests that substrate recognition in these systems is ancient with a common ancestor. It also requires that the other half of RiPP biosynthetic machineries must have alternative modes of substrate engagement. At present, no other common recognition mechanism has been found, but individual examples have been reported.

In the case of MdnC, an ATP-grasp enzyme that installs the first macrocycle in microviridin J (section 3.15), the LP is bound by a central domain in the protein.[212] LP recognition is mainly accomplished through electrostatic interactions involving a conserved Arg in a PFFARFL motif on the MdnA LP (Fig. 71).

In class II lanthipeptide synthetases (LanMs; section 3.1.2), hydrogen-deuterium exchange mass spectrometry, photocrosslinking studies, and fluorescence polarization measurements identified unstructured loops on the capping domain of the haloduracin β synthetase, HalM2, that may either directly bind to the HalA2 LP, or at least is necessary for HalM2 to enter a conformation to allow for precursor peptide binding (Fig. 72).[76,77] For the trifunctional class IV lanthipeptide synthetases (LanLs; section 3.1.4) composed of lyase, kinase, and cyclase domains, the kinase domain on SgbL is responsible for LP binding based on the available data. Binding and activity studies suggest that a predicted α-helical stretch on the N-terminal region of SgbA is important for SgbL recognition.[86,87] Similarly, NMR data, bioinformatics, and computational predictions suggest that an amphipathic α-helix formed by a conserved region of the leader peptide that positions branched hydrophobic amino acids on one face is also critical for recognition by class III lanthionine/labionin synthetases.[88] Structural information is not yet available for LanL enzymes or the related class III LanKC lanthipeptide synthetases (section 3.1.3).

Microcin C (McC, Fig. 73A) is an unusual RiPP because it lacks a LP on its precursor peptide. Therefore, biosynthetic enzymes must use an alternative method for substrate recognition. The *N*-formylated precursor peptide was shown to be a better substrate than the

desformyl analog for MccB, the adenylyltransferase responsible for forming the phosphoramidate linkage in McC.[297] Analysis of MccB in complex with *N*-formyl MccA depicted the *N*-formyl moiety in a pocket formed by two adjacent monomers of an MccB homodimer (Fig. 73B; PDB: 6OM4) explaining the importance of *N*-formylation.[298]

Whereas the heptapeptide microcin C from *E. coli* is biosynthesized from a precursor lacking a LP, related compounds are made from longer precursor peptides with an N-terminal extension that is released proteolytically. For instance, an 11-amino acid antimicrobial peptide that is modified with a C-terminal carboxymethylated cytosine that is also *O*-alkylated on the phosphoramidate linkage (Fig. 73C) is generated post-translationally from a 42-amino acid precursor peptide in *Yersinia pseudotuberculosis* IP32953.[299] Removal of the N-terminal peptide is performed by a TldDE-type protease that is also involved in the maturation of microcin B17 (see section 4.4.3). At present it is not clear whether the N-terminal peptide is a LP in the sense that it is recognized by the MccB-like PTM enzymes, or whether it functions mostly to keep the peptide-nucleotide antibiotic inactive inside the cell. MccB and its orthologs contain an RRE and thus recognition of the N-terminal peptide is likely.

4.2 Molecular interactions of recognition sequences

Compared to the advances in LP engagement by RiPP biosynthetic enzymes, the molecular details of interactions with RSs that flank core peptides (Fig. 1B) is not as well understood. Such RSs are present in the precursor peptides of a variety of RiPPs in bacteria (e.g. cyanobactins, graspetides, pheganomycin), fungi (e.g. amatoxins and dikaritins), and plants (e.g. orbitides, cyclotides, and lyciumins). The best understood RiPP enzymes in this respect are those that catalyze head-to-tail cyclizations in cyanobactin,[300–302] amatoxin, and orbitide biosynthesis (sections 3.6, 3.18, and 3.19, respectively). Recent crystal structures have been solved for the amatoxin cyclase POPB[235] and the orbitide cyclase PCY1.[248,249] For the latter, well-defined interactions were observed between the enzyme and the highly conserved C-terminal six amino acids (Fig. 74) that keep the follower peptide in the protein and prevent hydrolysis (by water) or another peptide entering the active site (for ligation), thus promoting intramolecular trapping of the acyl-enzyme intermediate to afford cyclized products. The N-to-C cyclization substrates for POPB and PCY1 contain single core peptides and the C-terminal extension are termed follower peptides, but these likely serve an analogous function to RSs in other N-to-C cyclization systems such as cyanobactins that have multiple core peptides (section 3.6). Although the molecular details of RS engagement for cyanobactin biosynthesis are not well understood on a molecular level, predictive rules that are governed by RSs have been successfully used for engineering purposes (see section 7).

4.3 Summary and outlook on substrate recognition

With the first co-crystal structures of biosynthetic enzymes and their substrates, important new insights have been obtained regarding LP recognition, and bioinformatic approaches have been able to extend these findings to much larger numbers of proteins. Aspects of substrate recognition that are still mostly unresolved include core peptide recognition as only a few structures are available in which electron density of all or part of the core peptide

is visible [*e.g.* the lanthipeptide dehydratase NisB (Fig. 20),[67] CteB in ranthipeptide biosynthesis,[183] the microcin B17 synthetase (Fig. 69B),[122] and the RiPP-related MCR-modifying YcaO that installs thioglycine[303]]. Furthermore, for biosynthetic pathways in which multiple enzymes act consecutively on a precursor peptide, it is not clear whether the RRE in one protein holds the substrate for other proteins to catalyze their reactions or whether RRE independent substrate recognition motifs are involved. In some cases, it is clear that a LP is not required for catalysis, especially for secondary PTMs. In contrast, in other examples, substrate recognition is mediated by PTMs that are introduced in the core peptide in earlier biosynthetic steps as exemplified by the strictly linear and ordered biosynthetic steps in thiopeptide biosynthesis (section 3.2).

4.4 Leader peptide removal

Removal of the LP is a critical step in RiPP biosynthesis and is often coupled to export of the mature compound. The LP cleaving enzyme varies between different RiPP classes, but common strategies have been recognized as discussed below.

4.4.1 AMS/PCAT bifunctional transporters—

Genes encoding peptidase-containing ATP-binding cassette (ABC) transporters [PCAT; also called ABC-transporter maturation and secretion (AMS) proteins] are often found clustered with the core biosynthetic genes in RiPP BGCs. This family of enzymes serves a dual function being responsible for coupling the hydrolysis of the LP through an N-terminal papain-like C39 peptidase domain (InterPro family: IPR005074) with export of the cleaved core peptide by the C-terminal ABC-type transporter (InterPro family: IPR027417). In most cases, the LP of the associated precursor peptide ends in a double Gly motif (typically GG, GS, or GA).[1] RiPP LPs that end in the double Gly motif include the NHLP and Nif11 families that have sequence homology with nitrile hydratase and a protein associated with nitrogen fixation, respectively.[195,304] The first structure of a PCAT was reported in 2015, illustrating how proteolysis is likely coupled to transport.[305] At present, the function of this transporter from *Clostridium thermocellum* identified by genome mining is unknown, but it is encoded near a gene for a putative 90-residue precursor peptide containing a LP with a double Gly motif. The homodimeric transporter consists of three domains, an N-terminal peptidase domain, a transmembrane domain (TMD), and a C-terminal nucleotide-binding domain (NBD) (Fig. 75A). In the absence of nucleotide, the protein adopts a conformation wherein the transmembrane helices form a tunnel that ends near the active site of the peptidase domain. Although the structure did not contain a peptide, this state likely represents the conformation in which the core peptide would be situated within the tunnel placing the double Gly sequence of the LP in the active site of the peptidase domain. The tunnel has a sufficient volume to accommodate a post-translationally modified peptide with multiple crosslinks. Nucleotide binding results in a rotation of the NBDs, which closes the transmembrane tunnel and displaces the peptidase domains.[305]

Investigation of the substrate specificity and recognition mechanism of the N-terminal peptidase domain of LahT (LahT150), the PCAT associated with a currently uncharacterized RiPP (section 5.3.7.1),[307] demonstrated tolerance to many substrates.[308] The key residues that are important for LP binding are Val(−4), Leu(−7), and Leu(−12), which are conserved

in many LPs ending in a double Gly motif. A co-crystal structure using an aldehyde-containing peptide analog showed that these key residues are located on a short α-helix and insert into a hydrophobic grove in LahT150 (Fig. 76).[308] A similar substrate recognition mechanism was more recently shown for a full length PCAT (Fig. 75B). C39-family cysteine proteases are not always encoded as N-terminal domains of transporters and sometimes are found as stand-alone proteins such as PoyH involved in polytheonamide biosynthesis (section 3.12). Like LahT150, this protease was shown to have broad substrate tolerance and was able to remove LPs from non-cognate RiPP classes.[309]

Similarly, bifunctional AMS proteins are found in all four classes of lanthipeptides,[62] but in some instances, the transport and proteolysis activities are encoded in two different polypeptides. To distinguish the two types of transporters (with and without a protease domain), LanT is used for ABC transporters that lack the protease domain and LanT$_p$ was introduced for transporters that contain the N-terminal C39 protease domain.[310]

4.4.2   Subtilisin-type Ser proteases—LP removal for many class I/II lanthipeptides (section 3.1) relies on a subtilisin-like serine protease LanP (peptidase S8 family; InterPro family: IPR008357). NisP,[311,312] ElxP,[76] LicP,[313] and CylA[314] responsible for LP removal for nisin, epilancin 15X, lichenicidin, and enterococcal cytolysin, respectively, have been characterized *in vitro*, and cleave both modified and unmodified precursor peptides. NisP (PDB: 4MZD),[315] EpiP (PDB: 3QFH),[316] and LicP (PDB: 4ZOQ)[313] have also been structurally characterized without bound substrate. Therefore, the mechanism by which substrate recognition is achieved remains incomplete. The efficiency of NisP activity has been investigated with NisA substrate analogs containing different numbers of (methyl)lanthionines.[317] These experiments revealed that NisP can cleave substrate without any rings but enzymatic activity is significantly increased following installation of the first ring. In the case of epilancin 15X, LP removal results in hydrolysis of the newly exposed N-terminal Dha residue to a ketone that is subsequently reduced by the dehydrogenase ElxO to yield the final product (section 5.9).[312] Unique substrate RSs for different LanP enzymes greatly expand the toolbox of specific proteases for use in biotechnology. Subtilisin-type Ser proteases are not only involved in LP removal for lanthipeptides, but also during cyanobactin biosynthesis where they are the class-defining enzymes (*e.g.* PatA and PatG, see section 3.6).

In addition to LP removal in bacterial peptides, subtilisin-like serine proteases are necessary for the production of the post-translationally modified (hydroxyPro) plant hormone IDA involved in the abscission process.[318] In fungi, the Kex2 Ser proteases (also members of the S8 family) are believed to be involved in processing of the dikaritins (section 3.17) but the timing is not known. Adding additional complexity, the Kex2 RSs are located at either the N-terminus or C-terminus or both termini of the core sequence, thus the exact nature of the proteolytic processes remains poorly understood.

4.4.3   TldD/E—TldD and TldE are metalloproteases (M103 family) common in bacteria, but their physiological function has been mostly elusive. One function of TldD/E is to cleave the LP of MccB17 (Fig. 28). TldD/E form a heterodimer (Fig. 77A), where TldD is responsible for Zn binding to catalyze the hydrolysis of unstructured peptides.[319] In the case

of MccB17, only the fully modified precursor is accepted as a substrate, suggesting that formation of the heterocycles causes the LP to become more exposed. TldD/E is remarkably substrate tolerant, as hydrogen bonding to the substrate is mediated only through backbone atoms (Fig. 77B). The unstructured substrate peptide is fed through a narrow channel and is progressively hydrolyzed until sufficient steric hindrance prevents further processing. A similar heterodimeric zinc-dependent protease was also implicated in the biosynthesis of PQQ (section 3.21)[256,257] and some pearlins (section 3.24).[277]

4.4.4 AplP-like proteases—Several RiPPs are produced as multiple congeners that have varying numbers of residues from the LP remaining, suggesting that for these compounds LP removal is not carried out by a single site-specific protease but instead, by stepwise degradation by non-specific aminopeptidase(s). Recently, the first enzyme that may perform this trimming of the LP was reported. A bifunctional Zn-dependent endo- and aminopeptidase, AplP, was demonstrated to perform full processing of class III lanthipeptides (section 3.1.3).[320] Orthologs of AplP (M1 protease family) are found in all organisms that encode class III lanthipeptides, but typically are not located in the RiPP BGC. AplP recognizes unmodified and modified precursors and initially hydrolyzes internal amide bonds C-terminally of a conserved E-I/L-L/Q motif in class III LPs; S-A-S/T motifs are additional cleavage sites for AplP. Extended reaction of modified AplA with AplP affords a fully liberated core peptide through an aminopeptidase mechanism. AplP-like proteases were demonstrated in multiple class III lanthipeptide BGCs to be responsible for LP removal. A similar mechanism is governing LP removal for class IV lanthipeptides,[85] lipolanthines,[88] and possibly other RiPPs.[321]

4.4.5 Pro oligopeptidases—In a subset of class III lanthipeptide BGCs, a conserved protein with homology to prolyl oligopeptidases (POPs), was identified.[322] FlaP, the POP associated with the flavipeptin gene cluster, cleaves at the conserved Pro–11 residue in class III lanthipeptide LPs. FlaP only cleaves modified FlaA, and specifically recognizes the C-terminal rings. After FlaP cleavage, an unknown aminopeptidase likely removes the remainder of the LP.

4.4.6 Other means of leader peptide removal—In some RiPP pathways, LP removal is an integral part of the core biosynthetic steps. For instance, as discussed in section 3.2 the LP can be ejected as part of a [4+2] cycloaddition process in thiopeptide biosynthesis (Fig. 24). Likewise, RiPPs that are N-to-C cyclized, such as amanitins, orbitides, and many cyclotides and cyanobactins require excision of the core peptide and cyclization of their termini, thus removing the LP and/or RS in the same process (section 3.18 and 3.19). Similarly, formation of the isopeptide bond between the N-terminal residue of lasso peptides and the side chain of Asp/Glu also first requires LP removal (section 3.8).

For the thiopeptide thiostrepton, the LP removal enzyme was shown to be TsrB (TsrI in an alternative nomenclature).[323] TsrB is a member of the epoxide hydrolases that belong to the α/β-hydrolase superfamily. The enzyme functions as a leader peptidase but also catalyzes the nucleophilic attack of the newly formed N-terminus of the core peptide onto an epoxide to form a second macrocyclic ring (see section 5.7.2).

5 Secondary PTMs: commonalities and differences in accessing molecular diversity

More than ten years ago, it was suggested that RiPPs might rival non-ribosomal peptides in terms of structural diversity.[324] Indeed, the past seven years have seen a tremendous expansion in the types of PTMs that are found in RiPPs. In addition to the primary PTMs covered in section 3 that define each RiPP class, many compounds undergo additional, compound-specific secondary PTMs (sometimes called tailoring reactions analogous to tailoring processes that take place after scaffold formation in other classes of natural products). These tailoring reactions often bestow on the corresponding RiPP higher affinity and selectivity for the target by additional molecular interactions.[3] In addition, they can increase environmental and/or metabolic stability, especially by modification of the N- and/or C-termini. In some cases, tailoring reactions can generate a group of congeners from an initially generated molecular scaffold. Such tailoring processes are often slower than the scaffold-forming reactions and a model has been suggested that such systems sacrifice catalytic efficiency for the ability to generate molecular diversity.[325] This diversity generating strategy in RiPP biosynthesis complements the alternative approach of hypervariability of core peptide sequences.[304,326–328] Both types of pathways result in high molecular diversity at the cost of catalytic efficiency.[78,325] This section discusses new tailoring reactions reported since 2013, the molecular mechanisms by which they take place, and highlights differences and commonalities in the various strategies used towards natural diversification of RiPPs. Therefore, the enzymatic processes are organized here by the type of chemical transformation.

5.1 Epimerization

5.1.1. Generation of D-amino acids involving PoyD-like rSAM epimerases—
Work on the polytheonamide biosynthetic pathway (section 3.12) revealed PoyD as a rSAM enzyme that installs multiple D-amino acids at alternating positions of the core peptide of its substrate by epimerization.[197] In further studies, genes encoding PoyD orthologs were also identified in a wider range of BGCs from cyanobacteria, rhizobia, and other bacteria.[196] Epimerase activity was confirmed for three proteins from cyanobacterial orphan BGCs using expression in *E. coli*. Unlike for PoyD that generates a dense epimerization pattern of alternating L- and D-amino acids, products of the cyanobacterial pathways contain 2–3 more widely spaced D-residues. Maturation is irreversible and clean, with substrates completely consumed and converted to single products in most cases.

Since epimerization is an isobaric modification, deuteration-based methods were developed to allow MS-based characterization. An initial method used a transaminase-deficient *E. coli* mutant to introduce deuterium labeled amino acids, which undergo exchange of deuterium with hydrogen at epimerized residues during catalysis. Deuterium loss was then localized by tandem MS.[196] An improved method, termed orthogonal D_2O-based induction system, does not require a transaminase mutant. It involves consecutive expression of the precursor and epimerase genes with a D_2O-based medium introduced between the induction of each component.[329] With a rapid analytical assay available, the substrate requirements for epimerization were studied more broadly in leader and core peptide isotope exchange

studies. The four tested epimerases OspD, PlpD, AvpD, and PoyD exhibited considerable substrate promiscuity and largely introduced related D-amino acid patterns into proteusin core peptides with the same sequence.[196,329] Thus, the cyanobacterial enzyme OspD that naturally installs two D-residues in its substrate, generated an alternating polytheonamide-type pattern on the PoyA core. Conversely, patterns were highly distinct for different core peptides epimerized with the same maturase, collectively suggesting that the core sequence largely dictates the product pattern.[329] Despite epimerase homologs exhibiting similar regioselectivities for a particular core, however, major differences existed regarding the order of epimerization. For example, PoyD epimerizes its core PoyA in a largely C-to-N-directional fashion, while PlpD converted an N-terminal region of PoyA first.[329] Correlations between the core sequence and the epimerization pattern, such as position, residue type, or motif, remain obscure.

The activity of proteusin epimerases was also reconstituted *in vitro*, permitting further mechanistic studies. For PoyD and OspD, a range of simplified precursor variants of the precursor peptide were converted to products, including leaderless versions.[330,331] OspD accepted a cyclic version of its core and linear peptides down to five amino acids in length with products carrying the same D-amino acid.[331] In these assays, the same directionality was observed as previously reported for *in vivo* conversions.[329] The results suggest significant potential for synthetic applications. Additional insights into the processivity of PoyD were gained by using partially epimerized peptides as test substrates.[330] Marked differences regarding reaction rates as well as product patterns were observed for different isomers, showing that initial epimerization events guide downstream reaction paths *in vitro*. Furthermore, D_2O-based labeling experiments and quantification of 5'-deoxyadenosine released by the rSAM enzyme showed that one equivalent of SAM was consumed per epimerized site.[330,331] For PoyD, Cys372 was identified as a candidate for donation of the backside hydrogen during epimerization, similar to the findings with YydG (see Fig. 49, section 3.13).[330]

5.1.2. Generation of D-Ala and D-aminobutyrate residues by LanJ dehydroamino acid reductases—Apart from direct L-to-D epimerization as described for proteusins and epipeptides (sections 3.12 and 3.13), the installation of D-amino acid residues can also occur via an alternate, indirect route during the maturation of some lanthipeptides (section 3.1). Key enzymes are LanJ dehydrogenases, which catalyze the hydrogenation of LanB-installed dehydro amino acids (section 3.1.1) in the core peptide (Fig. 78). Gene-deletion experiments led to the functional identification of the first LanJ member, LtnJ, which is a zinc-dependent dehydrogenase responsible for the conversion of Dha to D-Ala during lacticin 3147 biosynthesis.[332] A recent investigation of carnolysin identified CrnJ, which is distinct from LtnJ in that it is capable of catalyzing the asymmetric reduction of Dhb residues to rare D-aminobutyrate residues (in addition to converting Dha residues to D-Ala).[61] Since CrnJ belongs to a different enzyme superfamily, the flavin oxidoreductases,[333] LanJ enzymes are designated as being either LanJ$_A$ (zinc-dependent; InterPro family: IPR013149) or LanJ$_B$ (flavin oxidoreductase).[333] Furthermore, a luciferase-like enzyme (LanJ$_C$) has been recently implicated in the reduction of dehydro amino acids in the biosynthesis of both class II and class V lanthipeptides.[56,62]

The first *in vitro* characterization of a LanJ enzyme was conducted on NpnJ$_A$, which converts Dha residues to D-Ala in putative peptide substrates (NpnA1–3) of an orphan BGC in *Nostoc punctiformis*.[333] These substrates were predicted to yield linear peptide products as they do not contain Cys and because a lanthipeptide LanM homolog (NpnM) encoded in the BGC is missing several key residues necessary for cyclization activity (section 3.1.2). Reaction of NpnJ$_A$ with a range of NpnA3 variants dehydrated by NpnM revealed that NpnJ$_A$ is selective for the reduction of Dha residues but is capable of introducing D-Ala residues at non-native positions in a LP-independent manner.[333] The presence of an N-terminal flanking Asp residue impeded epimerization, consistent with a similar deactivating effect reported for charged flanking residues reported for LtnJ.[332] However, NpnJ$_A$ tolerated a large number of other flanking residues, demonstrating flexibility beyond the positional specificity of modified residues.[333] Successful *in vitro* reconstitution has also been achieved for the LanJ$_B$ homolog BsjJ$_B$ that installs multiple D-Ala residues and a single D-aminobutyrate residue during the maturation of the two-component class II lanthipeptide bicereucin from *B. cereu*s.[334]

5.1.3. Other epimerizations—An epimerized amino acid was also reported in a group of lasso peptides (section 3.8) that includes MS-271 (identical to siamycin I) and related compounds.[335–338] MS-271 is produced by *Streptomyces* sp. and comprises 21 residues including two disulfides as well as a C-terminal D-Trp. Genome sequencing identified the BGC, which includes genes for the precursor peptide, lasso cyclase, RRE, leader peptidase, two disulfide oxidoreductases, transcriptional regulators, ABC transporters, and a protein of unknown function (*mslH*).[339] Heterologous expression of the BGC resulted in the formation of MS-271 indicating that the epimerization activity resides within this group of enzymes. MslH appeared to be the only candidate for the epimerization activity, but the purified enzyme did not display any such activity with the linear core peptide. Thus, the authors hypothesized that the LP may be required or the lasso fold may be required for epimerization activity.

A D-Asp residue is present at position 7 in bottromycin (Fig. 37). Deletion of a P450 gene in the bottromycin BGC yielded an intermediate that was proposed to feature a C-terminal carboxylated thiazoline and an adjacent epimerized Asp.[143] Deuterium labelling experiments confirmed that this Asp could undergo non-enzymatic epimerization, which was hypothesized to occur due to the adjacent thiazoline, which lowers the pK$_a$ of the aspartate α-proton. Subsequent epimerization was proposed to be prevented by formation of the aromatic thiazole by the P450. However, more recently BotH (equivalent to BmbG), an enzyme in the α/β hydrolase family that lacks the usual catalytic residues, was shown to carry out the epimerization reaction.[144] The enzyme acts prior to oxidative decarboxylation that converts the thiazoline at position 8 to a thiazole and also prior to methylation of the side chain of Asp7. Several crystal structures of the enzyme were reported resulting in a proposed mechanism in which the side chain of Asp7 may act as the base that deprotonates at its own Cα.

Epimerized amino acids are also found in conopeptides and peptides from amphibians,[340] but the enzymes involved in their formation are currently not known. Similarly, the details of the origin of the D-amino acids in cacaoidin (Fig. 18A) is currently not known. Although its

BGC contains a LanJ$_B$ homolog that may reduce dehydro amino acids, at present the machinery that introduces those dehydro amino acids is not clear.[54]

5.2 NosL rearrangement during nosiheptide biosynthesis

The thiopeptide nosiheptide bears a distinctive secondary heterocycle that contains an indolic acid moiety derived from L-Trp (Fig. 79A). Mutational analyses identified that two members of the rSAM superfamily, encoded within the BGC, are critical for installing this structural feature. NosL catalyzes a complex rearrangement of L-Trp to 3-methyl-2-indolic acid (MIA), and NosN, which is described in section 5.3.6, is responsible for methylation of MIA and subsequent macrocyclization to close the secondary heterocycle of nosiheptide. Prior to NosN activity, NosIJK function to transfer MIA to a Cys residue on a linear pentathiazolyl nosiheptide intermediate.[341,342]

NosL belongs to the rSAM aromatic amino acid lyase family, which also includes CofH (F$_{420}$ cofactor biosynthesis), HydG (hydrogenase cluster maturation), and ThiH (thiamine biosynthesis). The latter three enzymes process L-Tyr to produce *p*-cresol and dehydroglycine (Dhg). NosL has a homolog in the nocathiacin biosynthetic pathway, a thiopeptide that features a similar indolic acid moiety.[343] Genetic complementation in addition to *in vitro* reconstitution experiments established that NosL is responsible for converting L-Trp to MIA.[344] In recent years, NosL has been extensively studied, revealing that the reaction involves a remarkable intramolecular migration of the L-Trp carboxylate to the C2 position of the indole ring, the removal of the Cα atom and the amino group, and leaving the former Cβ as a methyl group.[344–353]

The mechanism by which the enzyme achieves this challenging reaction has been extensively refined as work on NosL has progressed. At first, the prevalence of tryptophanyl and tyrosyl radicals in biology led to the proposal that following canonical homolytic cleavage of SAM, the resulting 5'-dA$^•$ abstracts a hydrogen atom from the indole nitrogen of L-Trp, rather than from a carbon center.[344] However, the determination of a crystal structure of the NosL-L-Trp complex contradicted this proposed H-atom abstraction site and rather suggested that NosL, as well as the tyrosine-lyases HydG and ThiH, would abstract a H-atom from the amino-nitrogen (Fig. 79B).[345] This conclusiuon was further supported by studies using various L-Trp and L-Tyr analogs.[346,349,354] By analogy with the tyrosine-lyases and based on the early detection of methylindole (MI), in addition to traces of both formaldehyde and glyoxylate as possible shunt products, a mechanistic hypothesis was proposed (Fig. 79C; mechanism A). Like HydG,[355] the resulting amino-centered radical was proposed to undergo Cα-Cβ bond scission to yield a methylene radical and Dhg. These two intermediates subsequently recombine to generate a ketyl radical **I** that undergoes a second β-scission to form 3-methyleneindoline-2-carboxylic acid, which isomerizes to MIA (Fig. 79C). The radical coproduct **II** may abstract a hydrogen atom from a suitable donor to produce an imine intermediate that is hydrolyzed to yield formaldehyde and ammonia. This mechanism was supported by a number of labelling experiments that allowed tracking of the key atoms in the product. Furthermore, the proposed shunt product 3-methylindole could be accessed by trapping of the methylene radical whereas glyoxylate would be formed as a hydrolysis product of Dhg. However, the subsequent trapping and characterization of the

3-(2-iminoethyl)indoline-2-carboxylic acid radical **III** as an intermediate of the reaction challenged this initial hypothesis and rather suggested a direct carboxyl radical migration from Cα to the C2 atom of the indole ring, (Fig. 79C, mechanism B).[352]

Recent biochemical experiments using additional L-Trp analogs further support the involvement of a formyl radical rather than a methylene radical intermediate and additionally demonstrate that cyanide is a coproduct of the NosL-catalyzed reaction, prompting a revision of the proposed mechanism.[353] Thus, the initial amino-centered radical undergoes a different β-scission to yield 2-indol-3-yl-ethan-1-imine and a transient carboxyl radical (Fig. 79C; mechanism B). This radical species then adds to the C2' of the indole to form a 3-(2-iminoethyl)indoline-2-carboxylic acid radical intermediate **III**, which was experimentally detected.[352] Recent structural characterization of NosL in complex with substrate or intermediate analogues, combined with theoretical calculations support this carboxyl migration is a two-step β-scission/recombination process.[356] The cyanide elimination step is likely heterolytic although the details are still unclear.[353,356] The resulting 3-methylindoline-2-carboxylic acid radical intermediate (or its aryl radical anion equivalent in brackets). transfers an electron to the NosL [4Fe-4S] cluster to produce a 3-methylindoline-2-carboxylic acid cation. Subsequent loss of either CO_2 or a proton yields the experimentally observed products 3-methylindole and MIA, respectively (Fig. 79C). The NosL active site arrangement is such that it is able to exquisitely control the production, orientation and recombination of the carboxyl radical intermediate.[356] The reason why *in vitro* NosL can undergo significant 3-methylindole production rather than MIA is unclear and likely depends on the nature of the reducing agent used to trigger the radical-based reaction. Furthermore, this new mechanism highlights the difference between NosL and tyrosine-lyases, in spite of sharing high sequence and structure similarities. However, the discovery that cyanide is a NosL coproduct unveils an unexpected link to [FeFe]-hydrogenase maturase HydG, a member of the tyrosine-lyase family.[353]

5.3 Methylation reactions

5.3.1. Class B rSAM methyltransferase TsrM in thiostrepton biosynthesis—In
this review we use the gene designations of Kelly *et al.* for thiostrepton biosynthetic proteins with the term used by Liu *et al.* provided in parentheses at first mentioning (for a comparison of the two nomenclatures, see[357]). TsrM (TsrT) is a member of the class B rSAM MTs,[201] and is one of a number of recently characterized rSAM enzymes that perform diverse transformations in the maturation of various thiopeptides (see also sections 5.3.3 and 5.3.6). *In vitro* experiments have shown that TsrM catalyzes C2 methylation of L-Trp to form 2-MeTrp (Fig. 80), the first dedicated step in an unusual ring expansion that introduces the quinaldic acid moiety present in thiostrepton (see Fig. 90 for the structure of thiostrepton).[358,359] Deuterium-labeling studies have shown that the transferred methyl group originates from SAM with SAH as a byproduct.[359,360] The net generation of 5'-deoxyadenosine (5'-dA) was not observed from this reaction, however, consistent with the finding that a TsrM variant lacking the Cys residues (replaced by Ala) necessary for [4Fe-4S] coordination does not form 2-MeTrp product, but is still capable of converting SAM to SAH.[360] Taken together, these observations indicate that the reductive cleavage of

SAM is not required for this transformation, a rare exception for rSAM enzymes, but that the [4Fe-4S] cluster plays a crucial role in methyl transfer to L-Trp.

More recent biophysical examination of TsrM has revealed further unusual features of this atypical rSAM enzyme. Analysis of TsrM by Mössbauer and hyperfine sublevel correlation (HYSCORE) spectroscopies confirmed the presence of the [4Fe-4S] cluster, but revealed that neither SAM, nor L-Trp directly coordinate to the cluster.[361] Previous work had shown methylcobalamin (MeCbl) to be the physiological cofactor of the enzyme,[360] but further spectroscopic analyses have subsequently detected a cob(II)alamin intermediate that is likely present in an uncharacteristic five-coordinate conformation.[361] In this instance, the dimethylbenzimidazole ligand to cobalt in cobalamin is replaced by a non-nitrogenous ligand, likely a water molecule.[361] These observations prompted an initial proposal for a mechanism in which the MeCbl Co-C bond undergoes homolytic cleavage to generate a methyl radical that subsequently attacks the sp^2 C2 of Trp, resulting in a Trp-based radical (Fig. 80A). Loss of an electron to the [4Fe-4S] cluster, followed by deprotonation, would result in 2-MeTrp. Finally, the [4Fe-4S] cluster could then reduce the cob(II)alamin intermediate to cob(I)alamin, a supernucleophilic species that might regenerate MeCbl by attack on the SAM methyl group, and would account for the accumulation of SAH.[360] Such a double-displacement mechanism is consistent with the net retention of stereochemistry observed during prior *in vivo* labeling experiments.[362]

While this hypothesis is in line with current knowledge of Met synthase and corrinoid/iron-sulfur protein function,[360,361] recent work utilizing Trp analogs has indicated a non-radical-based mechanism for TsrM (Fig. 80B).[363] This study discovered that the unmodified N1-amine group is crucial for turnover and that analogs substituted with a sulfur or oxygen at this position competitively inhibit methyl transfer. Furthermore, no formation of cob(II)alamin, nor of any substrate radicals, was detected during reactions with L-Trp or its analogs, which would argue against homolytic Co-C bond cleavage. Consequently, an alternate mechanism based on S_N2 chemistry was proposed in which the C2 of Trp is activated by N1 deprotonation, which induces the π electrons to attack the MeCbl methyl group, resulting in the production of cob(I)alamin and a methylated Trp intermediate. Subsequent C2 deprotonation and N1 reprotonation would generate the final product.[363] The question remains as to why a rSAM enzyme has evolved to catalyze a reaction that does not seem to require the reductive cleavage of SAM, but from a chemical reactivity viewpoint, heterolytic chemistry to methylate a nucleophilic position in an indole appears more logical than radical chemistry.

5.3.2. Class B rSAM MTs from polytheonamide biosynthesis

—Of the 48 total PTMs reported during the maturation of the polytheonamides (section 3.12), 17 are *C*-methylations that, unlike the methylation catalyzed by TsrM (section 5.3.1), occur on non-activated sp^3 carbon centers of diverse residues within the PoyA core peptide. Likely candidates for these methylations were PoyB and PoyC,[28] both putative class B rSAM MTs that are characterized by the presence of an additional N-terminal cobalamin (Cbl)-binding domain.[174,201] Indeed, confirmation of their role in PoyA polymethylation in heterologous expression experiments were only achieved by switching from *E. coli* to a rhizobial host capable of producing Cbl.[28] From these studies, 13 of the 17 expected *C*-methylations were

detected and localized. More recently, expression of polytheonamide core peptide variants in *Microvirgula aerodenitrificans* yielded products bearing up to ten *C*-methylations, of which six were localized by MS/MS analysis.[202] These methylations are likely installed by the PoyC homolog AerC, encoded in the *aer* BGC in the host genome, which installs seven *C*-methyl groups during the maturation of aeronamide A (for structure, see Fig. 48A).

The activity of PoyB and PoyC is determined by features within the PoyA core peptide, with PoyC acting on residues 1–21 and PoyB on residues 23–49. PoyC was demonstrated to also catalyze up to three of the previously proposed four methylations of an N-terminal Thr residue, which is dehydrated by the class II lanthipeptide dehydratase PoyF. Together, these modifications are necessary for establishing the polytheonamide N-terminal *tert*-butyl group (Fig. 47B) that enhances membrane insertion and bioactivity of these pore-forming cytotoxins.[28]

In vitro experiments using a synthetic truncated PoyA-1–15 peptide substrate variant have provided further insights into PoyC catalysis, resulting in the formation of a singly-methylated product at L-Val14, with SAH and 5'-dA detected as byproducts.[364] Conversion of this substrate residue to the D-Val configuration leads to unmethylated product, indicating that methylation precedes epimerization at this position during polytheonamide maturation. Substitution of the Cys residues present within a non-canonical CX_7CX_2C [4Fe-4S]-binding motif to Ala resulted in a PoyC variant incapable of substrate methylation, and SAH and 5'-dA byproducts were no longer detected. The AX_7AX_2A variant also lost the ability to load MeCbl, suggesting a critical role for the [4Fe-4S] cluster in Cbl methylation. Consistent with this observation, when the reaction was performed using CD_3-SAM, MeCbl was converted to CD_3-Cbl, indicating that PoyC-bound MeCbl is recycled from SAM during catalysis.[364] A mechanism has been proposed to explain the observations (Fig. 81).

Similar class B rSAM MTs are also involved in the bottromycin biosynthetic pathway (section 3.7), where mutagenesis experiments have confirmed their involvement in Cβ methylations on Pro2, Val4/5, and Phe6.[138,141,365] However, to date *in vitro* characterization studies have not yet been reported for these enzymes.

5.3.3. Class C rSAM MT in thiomuracin biosynthesis—Thiomuracin is another thiopeptide antibiotic that also undergoes a diverse array of modifications during maturation, one of which is the *C*-methylation of one of the six thiazole moieties (Fig. 24). *In vitro* reconstitution experiments confirmed that TbtI, a class C rSAM MT, is responsible for this activity.[366] Class C rSAM MTs are characterized by their homology to HemN/HemZ, which are mechanistically unrelated rSAM decarboxylases involved in heme biosynthesis.[174,201] A linear hexazole intermediate, but not a macrocyclic variant, was the substrate for TbtI, indicating that *C*-methylation must occurs prior to [4 + 2] cycloaddition (section 3.2).[71,89,97] TbtI functions in a presumably LP-independent manner, as it is capable of methylating a TbtA substrate variant with a severely truncated LP.[366] By constructing additional TbtA variants, TbtI was found to require a preceding Asn and at least one downstream thiazole moiety for regioselective *C*-methylation of thiazole 4, features that are also conserved in GE2270A, a structurally related thiopeptide produced by *Planobispora rosea*.[367]

To obtain further insights into the TbtI reaction, five Cys residues conserved among TbtI orthologs were replaced with Ala.[368] Only Ala variants of the three Cys residues that supply ligands for [4Fe-4S] cluster coordination resulted in inactive enzyme, whereas substitution of the remaining Cys residues had no adverse effects on TbtI activity. The observation that no additional Cys were required for activity precluded a class A-type rSAM MT reaction in which the SAM methyl group is first transferred to a protein Cys residue.[174] Experiments in which the enzyme was treated with $^{14}CH_3$-SAM provided further support against the possibility that the methyl group might be transferred to a different residue within the protein.

Further *in vitro* experimentation detected canonical rSAM reaction products, namely 5'-dA and SAH, at near-stoichiometric quantities to the methylated product, and these were formed at similar rates.[368] When TbtI was supplied with CD_3-SAM, ~90% of the 5'-dA produced contained a single deuterium, suggesting that the 5'-dA$^\bullet$ produced by the homolytic cleavage of SAM may abstract a hydrogen from a second molecule of SAM that serves as the methyl donor. Indeed, in a subsequent set of experiments utilizing CD_3-SAM, an ion was detected by MS that was consistent with the transfer of a CD_2H group to Thz4 in the TbtA hexazole peptide. Since the enzyme does not transfer a methyl group, the term methylase may be more appropriate than methyl transferase.

Based on the combined data, a mechanism was proposed (Fig. 82) that begins in a canonical fashion with the [4Fe-4S]-mediated reductive cleavage of SAM1 to generate 5'-dA$^\bullet$ and Met. 5'-dA$^\bullet$ then abstracts a hydrogen atom from the methyl group of SAM2 to generate a methylene radical intermediate. Such a SAM-derived radical is unprecedented in rSAM enzymology. This SAM-derived radical is proposed to add to the electrophilic Thz4 C=C bond to generate a resonance-stabilized substrate radical intermediate (**X**, Fig. 82), triggering subsequent deprotonation from the β-position by an active site base and the elimination of SAH. Glu105 has been suggested as a candidate active-site residue for deprotonation, because it is conserved in HemN (Glu145), and when substituted with Ala, resulted in a TbtI variant with severely reduced activity. Deprotonation would form a second resonance-stabilized radical intermediate (**Y**) with partial restoration of thiazole aromaticity. Reduction of **Y**, a possible additional function of the [4Fe-4S] cluster, would lead to formation of the resonance-stabilized anion **Z** (Fig. 82, mechanism a). Protonation of **Z** by the conjugate acid of an active site base, possibly, Glu105, would complete the transformation.

A plausible variation on the mechanism involves the abstraction of a hydrogen atom from a redox active amino acid (H-U) in the TbtI active site (mechanism b). The resulting amino acid would be subsequently reduced in preparation for another turnover. Alternatively, the allylic radical **Y** could abstract a hydrogen atom from the methyl group of 5'-dA (mechanism c), but *in vitro* experiments using SAM deuterated at the 5' position and methyl group effectively ruled out this possibility. Although additional biochemical and structural studies are required to further elucidate the TbtI mechanism, the data so far represent a fundamentally different use of SAM for this class of enzymes, reflecting their exceptional catalytic diversity.

5.3.4. Cysteine sulfur methylation by PtyS in polytheonamide biosynthesis—

'Entotheonella factor', the uncultivated sponge symbiont that is the source of the polytheonamides (see section 3.12), contains in its genome a second proteusin-type BGC (*pty* locus).[369] Coexpression studies using precursor peptide-maturase gene combinations and *E. coli* as host revealed that PtyS, a SAM-dependent methyltransferase, catalyzes *S*-methylation of up to four Cys residues as the modification type.[369] Prior to these studies, *S*-methylation was known in non-ribosomal peptide biosynthesis but not for RiPPs.[370,371] The structure of the final product is not yet known, since the *pty* BGC contains several additional unusual genes encoding potential maturases that so far remain uncharacterized.

5.3.5. α-*N*-Methylation in LAPs, linaridins, lanthipeptides, and phomopsins—

N-terminal methylation is a common modification among proteins, but few examples are known for RiPPs. Examples that have been investigated are the LAP plantazolicin[372–374] (section 3.4 and Fig. 83) and the linaridin cypemycin (section 3.3, Fig. 27),[375] with rare N^{α},N^{α}-dimethyl residues derived from Arg or Ala units, respectively, and the dikaritins ustiloxin and phomopsin that are monomethylated on their N-terminus (section 2.2, Fig. 3). The class V lanthipeptide cacaoidin (Fig. 18A) is also dimethylated on the N-terminus but its methyltransferase has not yet been investigated.[54] The divamides (Fig. 83), cinnamycin-like lanthipeptides produced by marine cyanobacteria, are trimethylated on their N-terminal amino group, currently a unique PTM in RiPPs. In each pathway, the methyl groups are attached by a single SAM-dependent methyltransferase in a final maturation step after proteolytic core peptide release. The dimethylation is functionally important for plantazolicin and cypemycin, since unmethylated peptide variants lack antibiotic activity. [372,376]

The methyltransferase for the LAP plantazolicin (section 3.4), termed BamL or PznL, as well as the ortholog BpumL from a related BGC encoded by *Bacillus pumilus*, were reconstituted *in vitro*. For a range of offered peptides with N-terminal Arg, but lacking heterocyclized moieties, both enzymes were highly selective and methylated only azole-bearing desmethyl-plantazolicin.[377] In contrast, a range of synthetic heterocyclized plantazolicin analogs with truncated C-termini were all accepted, including a minimalistic Arg-Cys-based dipeptide with one thiazole moiety.[378,379] The crystal structures of BamL and BpumL, which also included versions with bound truncated substrates (PDB: 4KVZ, 5DLY, 5DM0, 4KWC, and 5DM1), provided a rationale for this selectivity.[377] They revealed a plantazolicin-binding cleft with a hydrophobic tunnel harboring the azoles units. Constrictions in the narrow cleft provide an architecture that only allows access of heterocyclized substrates with planar azole moieties. The active-site pocket is sufficiently long to accommodate about the first five residues of the substrate. In agreement, K_M values showed a tendency to increase with decreasing peptide length for smaller peptides.

Unlike these LAP biosynthetic enzymes, a study on the pathway of the linaridin cypemycin[380] (section 3.3) showed that its methyltransferase CypM converted structurally diverse peptides that include open-chain as well as ring-containing molecules, such as the lanthipeptides nisin and haloduracin. Methylation occurred at the α-amino group of various amino acids as well as the ε-amino function of internal or C-terminal Lys units. The mononaridin MT MonM was shown to catalyze N-terminal alkylation reactions with SAM

analogs. The ability of MonM to catalyze allylation of nisin N-terminus allowed fluorescent labeling of nisin for a cell imaging study.[104]

An α-*N*-methylating enzyme, termed PhomM, was also reported for phomopsins, RiPP natural products of ascomycete fungi (section 3.17).[16] The enzyme, obtained from *E. coli* expressions, generated mono- and dimethylated products, with only the monomethylated version thus far found in nature.

Divamide A (Fig. 83) was isolated and characterized from the marine tunicate *Didemnum molle*,[381] and is structurally related to the class II lanthipeptide cinnamycin produced by *Streptomyces cinnamoneous*,[382] featuring three methyllanthionines, a lysinoalanine, and a β-hydroxy-Asp residue (Fig. 83). Additionally, divamide A features a rare *N*-trimethylated Glu residue and possesses anti-HIV activity.[381] The BGC was identified in the uncultivated symbiotic cyanobacterium *Prochloron didemni* by searching for candidate precursor-encoding sequences in the tunicate metagenome. The entire BGC was expressed heterologously in *E. coli* to yield an unmethylated precursor lacking the lysinoalanine residue, a feature subsequently introduced chemically by a previously established method. [383] The presence of the lysinoalanine (see section 5.10), was essential for the activity of DivMT, the MT responsible for catalyzing N-terminal trimethylation *in vitro*.[381]

5.3.6. Methylation and C-O bond formation: NosN in nosiheptide

biosynthesis—The class C rSAM MT NosN is required for the maturation of the thiopeptide nosiheptide (Fig. 79A) and, along with NosL (section 5.2), plays an important role in the formation of the characteristic secondary heterocycle, 3-methyl-2-indolic acid (MIA), present in the final product. NosN is unique in that it catalyzes C1 transfer, similar to the reaction catalyzed by TbtI (see section 5.3.3), and subsequent cyclization to form the secondary macrocycle.[384,385]

Initial *in vitro* experiments using NosN and a MIA thioester of *N*-acetylcysteamine (SNAC), a surrogate for MIA bound as a thioester to the acyl carrier protein NosJ, confirmed that the enzyme is responsible for indole methylation at C4.[342,385] When CD_3-SAM was supplied, only two deuterium atoms were transferred to the substrate, as reported for class C[368] and A rSAM MTs.[174] Thus, like TbtI (section 5.3.3), NosN also is not a methyl transferase but a methylase.[385] The third methyl deuterium from CD_3-SAM was incorporated into 5'-dA, a coproduct of the reaction.[385] An additional similarity between NosN and TbtI is the essentiality of only those Cys residues that are involved in coordination of the [4Fe-4S] cluster, which indicated that methyl transfer is not mediated by a protein Cys residue,[342] as it is for class A rSAM MTs.[174]

An additional intermediate believed to be 4-methylene-3-methylindolic acid-SNAC (MMIA-SNAC, see Fig. 84A) containing an electrophilic C4 methylene group has been detected in NosN reconstitution experiments.[385] 3,4-Dimethyl-2-indolic acid-SNAC (DMIA-SNAC, see Fig. 84A) was also observed at low intensity. Given that NosN was shown to only catalyze a single turnover at most with the MIA-SNAC substrate and that the resulting product MMIA-SNAC is slowly converted to DMIA-SNAC, it was proposed that MIA-NosJ might not be the natural enzyme substrate. Indeed, NosN was shown to catalyze formation of a

macrocyclic product when a synthetic pentathiazolyl substrate mimic was used spanning residues 42–46 of the precursor peptide NosM including the thioester linkage between Cys8 and MIA (Fig. 84B).[385] This result was later recapitulated using polyhistidine-tagged variants of the substrate NosM. Subsequent mutational analysis and labelling of the substrate confirmed that Glu6 of the pentathiazolyl substrate is responsible for trapping the exocyclic methylene intermediate generated by NosN to close the side-ring macrocycle through an ester bond.[385] The use of additional substrate mimics and the capture of NosN reaction intermediates have provided further information regarding the timing of NosN macrocyclization during nosiheptide maturation, showing that NosN acts prior to pyridine ring-formation by NosO and most likely also prior to NosD/E-catalyzed dehydrations of Ser/Thr residues (section 3.2).[386,387]

The described observations permitted a working hypothesis for the NosN mechanism (Fig. 84B) that initially proceeds in an analogous manner to that described for TbtI (section 5.3.3) with the [4Fe-4S]-mediated homolytic cleavage of SAM to produce Met and a 5'-dA• radical. The 5'-dA• abstracts a hydrogen from the methyl group of a second molecule of SAM to produce a methylene radical, which adds to C4 of MIA that has already been connected to Cys8 of the core peptide containing the thiazole groups. The resulting aryl radical intermediate is deprotonated at C4, triggering the elimination of SAH and the generation of a substrate radical intermediate bearing a C4 exocyclic methylene group. This species is oxidized by the [4Fe-4S] cluster to give the electrophilic MMIA species attached to Cys8, which is subsequently attacked by the Glu6 carboxyl group, resulting in ester bond formation and closure of the nosiheptide secondary heterocycle.[385]

An alternative mechanism (Fig. 84C) has been put forward in which 5'-methylthioadenosine (MTA, Fig. 84A) is the methyl donor, based on the detection of 5'-thioadenosine (5'-tA, Fig. 84A)[388] and on recent *in vitro* NosN experiments in which a pantetheinylated SAM substrate (MIA-pant) was incubated with allyl-SAM.[389] This approach permitted the trapping of 5'-dA• by the olefin moiety of a second allyl-SAM unit, consistent with the use of two molecules of SAM. Importantly, omission of MIA-pant from the reaction resulted in the production of 5'-allylthioadenosine (ATA, Fig. 84A), which is proposed to be generated in an analogous manner to 5'-tA from MTA, suggesting its involvement in the NosN mechanism. Consequently, a variation on the mechanism has been proposed in which binding of the MIA-containing substrate to the enzyme triggers the conversion of SAM to MTA (Fig. 84C). 5'-dA• generated by the reductive cleavage of a second SAM molecule then abstracts a hydrogen atom from MTA, generating a methylene radical that subsequently attacks the C4 position of the MIA moiety. 5'-tAH released as a coproduct is suggested to react with homoserine lactone to produce SAH, which has been identified as a NosN coproduct. This mechanism was supported by density functional theory calculations.[388,390] However, the production of 5'-tA has been questioned and the recent characterization of two on-pathway SAM adduct intermediates casts doubt on the involvement of MTA as an intermediate in the NosN-catalyzed reaction.[385,386] Further biochemical and structural investigations will be required to distinguish between the two mechanisms of methyl transfer.

5.3.7.   Carboxylate methyltransferases

5.3.7.1.   <u>Methylation of the C-terminal carboxylate:</u> Several *O*-methyltransferases have been reported to methylate the C-terminal carboxylate of peptides. The first protein performing methylation of the C-terminus of a RiPP was reported in 2013 with the discovery of aeruginosamide B, a linear cyanobactin (section 3.6) in which the N-terminus is prenylated and the C-terminus methylated (Fig. 85A).[391] Its BGC encodes a didomain protein AgeMTPT with prenyltransferase and methyl transferase domains (Fig. 85B). The enzyme was subsequently reconstituted and demonstrated to prenylate thiazoline-containing peptides.[392]

Lassomycin is an anti-mycobacterial lasso peptide (see section 3.8) with an *O*-methylated C-terminus.[393] Using the predicted MT within the lassomycin BGC as a BLAST query, a small number of lassomycin-like BGCs were identified in bacterial genomes,[394] of which the *stsp* cluster, located in a *Streptomyces* sp. genome, served as the source for *in vitro* MT studies. These experiments showed that StspM attaches a methyl group to the carboxyl moiety of the C-terminal Pro residue. The enzyme converted the full-length open-chain precursor peptide with a predicted 16 amino acid core peptide as well as N-terminally truncated variants down to eight residues, with decreasing efficiency for shorter peptides. Further mutational studies showed that the enzyme tolerates exchange of the terminal Pro to Ala and of more extended amino acid substitutions close to the modification site.

An MT that displays substrate tolerance was also encoded in a BGC of the human microbiome member of the *Lachnospiraceae* group (LahS$_B$; Fig. 85D). This enzyme was shown to methylate the C-terminus of a subset of precursor peptides (LahA2–5; Fig. 85E). Its activity was LP independent and a crystal structure was reported for the enzyme.[307] The final structures of the RiPPs produced by this BGC are currently not known.

In contrast to C-terminal carboxylate methylation, the carboxylate side chain of D-Asp in bottromycin is methylated by BmbA (Fig. 37).[143] *In vitro* assays using the *S. scabies* ortholog of this protein indicated that this is the final step in bottromycin biosynthesis.

5.3.7.2.   <u>Cryptic methylation: MT-mediated β-amino acid incorporation:</u> Previous reports identified a family of *O*-methyltransferases that are commonly found encoded in actinobacterial class I lanthipeptide BGCs.[33,395] Indeed, members of this family, referred to as LanS$_A$ enzymes, represent the third most abundant enzymes associated with such BGCs after the core biosynthetic enzymes LanB and LanC (section 3.1.1).[62] LanS$_A$ enzymes share low homology with protein L-isoaspartate (D-aspartate) *O*-methyltransferases (PIMTs). Consistent with a role in PTM of Asp, associated LanA substrates all possess a conserved Asp residue in the core peptide region. Recently, a representative enzyme encoded in the *olv* BGC from *S. olivaceus* was studied both *in vivo* and *in vitro*, revealing that methylation of this conserved Asp residue (Asp6) sets the stage for a remarkable transformation that results in the incorporation of a β-amino acid residue (Fig. 86).[70]

Heterologous co-expression of His$_6$-OlvA, which contains Thr, four Ser and four Cys residues, with the dehydratase OlvB and cyclase OlvC in the presence or absence of OlvS$_A$, resulted in a mass consistent with a 4-fold dehydrated product. However, despite having

identical masses, the 4-fold dehydrated products of the two experiments possessed different retention times during RP-HPLC analysis, suggesting structurally different products. Furthermore, a second minor product corresponding to a 5-fold dehydrated peptide was detected exclusively in the presence of OlvS$_A$. This product disappeared on extended sample incubation to leave only the 4-fold dehydrated product, hinting that the 5-fold dehydrated peptide might represent an intermediate in the reaction. Thiol derivatization experiments provided strong support that all four Cys residues in the core peptide are involved in the formation of (methyl)lanthionine crosslinks, which prevented informative tandem MS analyses.

To elucidate the structure of OlvS$_A$-generated products and the nature of the transformation catalyzed, NMR analyses were performed and solution structures were obtained.[70] Critically, following reactions in the presence of OlvS$_A$, strong NOE signals were observed indicative of a β-peptide linkage between the side chain carboxylate of Asp6 and the amino group of Gly7. This conversion of Asp to isoAsp introduces an additional methylene group into the peptide backbone, and an unusual carboxyl side chain, explaining the shift in retention time observed during RP-HPLC analysis. To probe the possible reaction mechanism of OlvS$_A$, its activity was reconstituted *in vitro* using 4-fold cyclized His$_6$-OlvA. In time course experiments, SAM-dependent methylation was observed. Subsequently, 5-fold dehydrated product consistent with the formation of succinimide was detected, concomitant with the appearance of a 4-fold dehydrated product (Fig. 86). In addition to the NMR structure of the final product with an isoAsp residue, complementary *in vitro* hydrazine trapping and ^{18}O-labeling experiments provided further evidence of likely succinimide formation during the transformation. ^{18}O-labeling experiments further indicated that multiple cycles of methylation occur via the succinimide intermediate, and that OlvS$_A$ is also able to accept isoAsp containing cyclic peptides. This latter observation suggests that the electrophilic succinimide might be the intended product, and further experimentation will be required to explore this possibility.

5.3.8   Tyrosine methylation in cittilins—Cittilin A, a member of a recently discovered RiPP class, contains a methylated Tyr residue (Fig. 18C).[58] Methylation is a secondary rather than class-defining PTM since the native host produces both cittilin A and a demethyl congener (cittilin B). The methyltransferase CitC encoded in the BGC was recombinantly expressed and shown to methylate cittilin B indicating it is not leader peptide dependent and likely acts last in the biosynthetic pathay.

5.4.   Arginine to ornithine conversion during landornamide biosynthesis

Landornamide A (Fig. 87B) represents the most recent addition to the proteusins, and is distinct from other, polytheonamide-type[197,202] family members (section 3.12) in that it is a bicyclic peptide rather than forming a beta-helix, and because it possesses ornithine residues as a novel PTM.[204] Landornamide A is the product of the *osp* (renamed *osp1*) BGC encoded in *Kamptonema* (*Oscillatoria*) sp. The BGC (Fig. 87A) features genes encoding OspD, a previously characterized rSAM epimerase (section 5.1.1) that installs two D-amino residues into the OspA precursor core peptide,[196,329,331] a class II lanthionine synthetase (OspM), and OspR, an initially hypothetical protein. OspR does not resemble any previously

characterized maturase enzymes, but weak homology to arginases suggested it might be the enzyme responsible for the hydrolysis of two L-Arg residues in the OspA core peptide to L-Orn.

To access the final product of the pathway and to characterize the individual maturation steps, the *ospAMDR* genes were cloned and expressed in *E. coli* as a multi-gene unit retaining native intergenic regions, with *ospA* modified to introduce an N-terminal His$_6$-tag. Subsequent purification, proteolytic digestion and LCMS analysis of an OspA core fragment revealed an overall loss of 120 Da relative to an unmodified peptide, corresponding to two dehydrations and the loss of two urea equivalents, which was consistent with the predicted activities of OspM and OspR, respectively. Expression of pathway variants containing single-point mutations within PTM enzyme loci were performed in order to probe the function and timing of each of these enzymes during biosynthesis. Mutation of the predicted OspR manganese-binding motif resulted in a product bearing two lanthionine bridges and two D-amino acid residues at the expected positions, but lacking Orn residues in place of Arg8 and Arg15, confirming the role of the enzyme in Arg-to-Orn conversion. In all instances in which the native *ospR* coding sequence was retained, complete conversion of both Arg8 and Arg15 to Orn was observed, indicating that *osp* PTM enzymes function in a promiscuous manner and can perform catalysis irrespective of other PTMs.

Based on a proposed mechanism for rat liver arginase derived from structural data,[396] OspR catalysis likely begins with the initial nucleophilic attack on the guanidinium group of Arg by an active site metal-bridging hydroxide ion, resulting in the formation of a metastable tetrahedral intermediate (Fig. 88). Subsequent proton transfer, possibly mediated via Asp39, to the amine results in collapse of the tetrahedral intermediate to yield L-Orn. The subsequent addition of a water molecule to the manganese cluster facilitates the departure of urea.

5.5 Arginine to citrulline conversion during lasso peptide biosynthesis

Another recently characterized PTM involving Arg was found in the lasso peptide citrulassin. Arg9 in this compound is hydrolyzed to citrulline and the Arg involved is conserved in all 55 homologs of the precursor peptide.[154] An obvious peptidylarginine deiminase is not encoded in the BGC, and therefore the origin of the citrulline is currently unknown.

5.6 Phosphorylation during paeninodin biosynthesis

During efforts to expand the lasso peptide family (section 3.8) beyond members isolated and characterized from either proteobacteria or actinobacteria, a recent study focused on a family of BGCs found among firmicutes. Heterologous expression of a BGC from *Paenibacillus dendritiformis* led to the isolation of paeninodin, a lasso peptide bearing a phosphorylated C-terminal Ser residue.[162] Indeed, a unique feature conserved among the BGCs of firmicutes studied is a gene encoding a putative HPr kinase (InterPro family: IPR011104), which are typically involved in sugar uptake processes. Deletion of the HPr-related kinase gene *padeK* from the expression plasmid abolished production of phosphorylated paeninodin, which was recovered by *in trans* expression of an additional vector carrying *padeK*. *In vitro* experiments

confirmed that PadeK modifies the C-terminal Ser of the precursor peptide. A PadeK homolog from *Thermobacillus composti* (ThcoK) was shown to be exchangeable for PadeK both *in vivo* and *in vitro* and exhibited much higher phosphorylation activity.

HPr kinases share a conserved active-site motif consisting of one His, one Lys, and two Asp residues (Fig. 89). Stabilized by hydrogen bonding with His123, the conjugate base of Asp179 deprotonates the Ser46 side chain of HPr for subsequent attack on the γ-phosphate group from ATP. Lys161 is responsible for ATP binding and Asp178 participates in Ca^{2+} coordination. Single and quadruple Ala substitutions for the corresponding residues, in addition to double Asp-to-Ala substitutions, in both PadeK and ThcoK abolished phosphorylation activity. These lasso peptide tailoring kinases have the ability to transfer multiple phosphate groups onto the precursor peptides, depending on the phosphate donor and the precursor sequence leading to polyphosphorylated lasso peptides.[397] More recently, a second example of a lasso peptide with a phosphorylated tail was reported for pseudomycoidin.[398] The authors reported that after phosphorylation, the phosphate group is diglycosylated, a unique PTM not previously reported. The BGC for this lasso peptide from *Bacillus pseudomycoides* resembles that of paeninodin and does not contain any obvious glycosyltransferases. Genetic experiments suggest that the nucleotidyltransferase PsmN may be responsible for glycosylation.

A wide range of substrates varying in both length and amino acid composition were assayed to explore ThcoK substrate specificity. Remarkably, it was shown that even a variant comprising only the last five residues of the peptide, is modified albeit to a small extent. Substitution of the C-terminal Ser residue abolished phosphorylation activity, even when replaced with residues bearing a hydroxyl group side chain, and phosphorylation was also not detected following the substitution of core residues for Ser at several alternate locations. These findings indicate that ThcoK phosphorylation proceeds in a leader- and core-independent fashion and that the C-terminal Ser is essential for activity. Finally, both PadeK and ThcoK were unable to modify the mature paeninodin lasso peptide, suggesting that the lasso fold impedes access of the kinase to the C-terminal Ser and that phosphorylation likely precedes lasso fold formation.

Though phosphorylation was localized to the C-terminal Ser residue, the modification could occur on either the side chain or the C-terminus. To distinguish between the two possibilities, NMR analysis comparing synthetic and enzymatically phosphorylated PadeA 11-mer variants definitively demonstrated that phosphorylation occurs at the Ser side chain. [162]

5.7 Hydroxylation and halogenation

5.7.1 Oxidation strategies—Although hydroxylation and halogenation tailoring processes are relatively common in RiPP and non-RiPP natural products, relatively few *in vitro* characterized examples of the PTM enzymes have been reported. Despite the paucity of *in vitro* studies, a plethora of genetic studies have implicated the role of specific open reading frames necessary for hydroxylation or halogenation. The following sections will discuss the current knowledge of these transformations in RiPP biosynthetic pathways. We

will not discuss examples of oxidations of RiPPs for which the BGCs are currently not known.

5.7.2 Cytochrome P450-catalyzed hydroxylation and epoxidation of thiopeptides—Genetic characterization of the biosynthesis of the thiopeptide GE2270 (Fig. 90A) was carried out through heterologous expression of the *ptb* BGC from *Planobispora rosea* in *Nonomuraea* sp.[367] Genetic deletion of *ptbO*, a cytochrome P450 monooxygenase, resulted in the production of a GE2270 derivative lacking the hydroxyl moiety on the β-carbon of Phe8 implicating this enzyme in the hydroxylation process.

To generate thiostrepton derivatives (Fig. 90B), *Streptomyces laurentii* tsrM (also called *tsrT*), which cannot form quinaldic acid,[399] was fed with 7' or 8'-fluorinated quinaldic acid analogs.[400] Rather than identifying thiostrepton analogs, only a truncated product was found in which the macrocycle containing the quinaldic acid was lacking. These findings suggested that epoxidation of the quinaldic acid moiety is required prior to LP removal and subsequent cyclization by attack of the liberated amino group of Ile1 onto the epoxide (Fig. 90B). TsrI (also called TsrP) and TsrK (also called TsrR) are homologous to cytochrome P450 enzymes (InterPro family: IPR001128) and are predicted to perform the bishydroxylation of Ile10 and epoxidation of the quinaldic acid. Genetic deletion of *tsrI* yielded an intermediate that shares the same structure as the product identified with the fluorinated analogs, suggesting that the epoxidation reaction is performed by TsrI. Deletion of *tsrK* resulted in the loss of product formation, suggesting that dihydroxylation of Ile10 is perhaps an early checkpoint during thiostrepton biosynthesis.[400]

Nosiheptide contains two hydroxyl groups in the macrocyclic scaffold (Fig. 90A). Genetic and biochemical characterization of *nosB* and *nosC* predicted to encode P450 monooxygenases revealed their role in nosiheptide maturation.[401] Deletion of *nosB* from *Streptomyces actuosus*, resulted in production of a compound where the hydroxylation at the γ-carbon of Glu6 was missing. Subsequent *in vitro* expression of NosB and incubation with des-hydroxy nosiheptide yielded mature nosiheptide. Deletion of *nosC* resulted in an intermediate that lacked the hydroxyl on the pyridine ring, but also contained a bis-Dha tail, and recombinant NosC hydroxylated this intermediate on the pyridine ring.[401]

A cytochrome P450 enzyme is also believed to be responsible for the hydroxylation of a Pro residue in the biosynthesis of the lanthipeptide NAI-107,[402,403] but this activity has not yet been reconstituted *in vitro*. P450-catalyzed hydroxylation of Phe has also been proposed in the biosynthesis of the thioamitide thioalbamide[11] and gene deletions in the thiovarsolin BGC suggest that VarO, a heme oxygenase (InterPro family: IPR016084), is involved in dehydrogenation of the arginine side chain.[14]

5.7.3 Flavoprotein-catalyzed oxidation and halogenation

5.7.3.1 Formation of the quinaldic acid of thiostrepton: Like nosiheptide, the thiopeptide thiostrepton features two macrocycles (Fig. 90A and B). One macrocycle is formed by the class-defining [4+2]-cycloaddition reaction forming a six-membered, nitrogen-containing heterocycle (section 3.2). The second macrocycle is specific to the nosiheptide and thiostrepton sub-families of thiopeptides. In both cases, part of second

macrocycle is fashioned from L-Trp. For nosiheptide, MIA formation and macrocyclization involves two rSAM proteins discussed in sections 5.2 and 5.3.6. For thiostrepton, the quinaldic acid moiety (Fig. 90B) is also believed to be derived from L-Trp by a different rSAM-catalyzed process. Genetic studies suggested that *tsrM (*also called *tsrT), tsrV (*also called *tsrA*), and *tsrQ* (also called *tsrE*) are required for quinaldic acid biosynthesis.[399] TsrM was characterized as a rSAM methyltransferase to produce 2-methyl-L-Trp (Fig. 80, section 5.3.1). To determine the roles of *tsrV* and *tsrQ*, the corresponding enzymes were produced in *E. coli* and the bacteria were provided with 2-methyl-DL-Trp.[399] Production of a quinolone ketone was only observed when both enzymes were expressed. Purified TsrV catalyzed the pyridoxyl-5'-phosphate dependent transformation of 2-methyl-L-Trp to indolylpyruvate using a variety of ammonia acceptor co-substrates (Fig. 91). Furthermore, reconstitution of TsrQ with FAD, NADPH, O_2, and a flavin reductase resulted in the conversion of indolylpyruvate to the corresponding quinolone ketone.[399] At lower temperatures, selective hydroxylation at the 3'-position of indolylpyruvate was detected. The TsrQ product is highly reactive and can readily hydrate to the unstable 2,3-dihydroxy-pyrroline (Fig. 91). This intermediate can undergo ring expansion by first breaking the N1-C2 bond, followed by condensation of the amine onto the ketone and subsequent dehydration-rearomatization to generate the quinoline ketone (Fig. 91).

5.7.3.2   Oxime Formation in Azolemycins: Azolemycins are a family of LAPs (section 3.4) produced by *Streptomyces* sp.[404] The azolemycins contain unique oxime moieties installed on the N-terminal amine of Val1 with either the *E* or *Z* stereochemistry (Fig. 92). Subsequent experiments using Marfey's reagent permitted the configuration of all stereocenters in azolemycin A to be elucidated. In addition to genes encoding the canonical apparatus necessary for the introduction of the characteristic azoles in the biosynthesis of other LAPs (section 3.4), the BGC encodes an SAM-dependent MT (AzmE), and a flavin-dependent monooxygenase (AzmF, InterPro family: IPR036661).[404] Subsitution of the *azmF* gene with a selection marker in *Streptomyces* sp. lead to abolishment of azolemycin A-D production. Instead, compounds were isolated comprising an amino group in place of the oxime moiety or lacking the N-terminal Val residue altogether. These observations are consistent with a role for AzmF in oxime formation, a modification not previously documented in the final structure of a RiPP, but which has been seen previously as an intermediate in ustiloxin maturation where it is installed by the flavin monooxygenase UstF2 (section 3.17).[229] A survey of AzmF homologs in actinomycetes revealed that the majority are found in putative BGCs for non-ribosomal peptides and that only a single other example is found in a putative LAP pathway (encoded by *Actinomadura oligospora*).

5.7.3.3   2-Aminovinylcysteine formation by oxidative decarboxylation: AviCys and the related avionin structures are found in several RiPPs including class I and class II lanthipeptides, thioamides (Fig. 2), lipolanthines (Fig. 11), lanthidins (Fig. 18A), and linaridins (Fig. 27). Recent studies have explored the biosynthetic LanD flavoenzymes (InterPro family: IPR003382) involved in the oxidative decarboxylation of the C-terminal Cys for various RiPPs. NAI-107 is a class I lanthipeptide containing a C-terminal AviCys that is installed by MibD, a flavin-dependent decarboxylase. Recombinant MibD displayed decarboxylation activity of the terminal Cys residue in both full length MibA as well as in

the MibA core peptide. Thus, the enzyme does not require the LP nor do the thioether rings need to be installed first. However, MibD did not display the large substrate tolerance previously described in early studies of the lanthipeptide decarboxylase EpiD,[405] and instead tolerates a more limited sequence motif. The oxidative decarboxylation of the linaridin cypemycin is catalyzed by CypD,[406] whose crystal structure was solved (PDB: 6JDD). The enzyme is structurally similar to previously characterized lanthipeptide LanD proteins despite low sequence similarity. Investigation of AviCys formation for the lanthipeptide mutacin 1140 showed that a lanthionine was formed in the absence of the MutD decarboxylase,[407] suggesting that oxidative decarboxylation is not required for ring formation. Co-expression of TvaA, the precursor peptide to thioviridamide, with the decarboxylase TvaF in *E. coli* led to the production of a C-terminal thioenol, consistent with observations for AviCys biosynthesis in lanthipeptides. TvaF can modify both the full length TvaA and a mutated core peptide, TvaA$_{S8A(2-13)}$, albeit at a significantly lower rate, indicating that the leader peptide is not strictly required but likely assists with substrate recognition by TvaF.[129] The biosynthesis of the lanthidin cacaoidin has not yet been investigated but its BGC contains a LanD-like decarboxylase (Fig. 18B).[54]

For lipolanthines, the LanD decarboxylase MicD was shown to work in concert with the MicKC labionin synthetase, with the activity of both greatly affected by the presence of its partner.[88]

5.7.3.4 Chlorination of NAI-107 and ammosamide A:
All known Trp halogenases (InterPro family: IPR006905) prior to 2013 used L-Trp as the substrate. Recently, two enzymes have been identified that act on Trp imbedded in a peptide. The lanthipeptide NAI-107 contains a 5-chloro-Trp residue that is generated by a FADH$_2$-dependent halogenase, MibH. MibH collaborates with MibS, the cognate NADH-dependent flavin reductase.[408] MibH exhibits unusual substrate specificity, because the enzyme was incapable of chlorinating free Trp, Trp in a linear peptide, and Trp in mutacin 1140, which has a similar set of rings as NAI-107. Therefore, MibH seemingly recognizes the overall structure of NAI-107, including the amino acid sequence of the C-terminal rings. Structural characterization of MibH showed a large substrate binding cleft afforded by subtle amino acid changes compared to previously characterized Trp halogenases explaining the selectivity for a macrocyclic substrate.[408] Although the enzyme is very selective for its peptide substrate, it is tolerant to using other halides as brominated variants of NAI-107 were obtained by growing producing organisms from either *Actinoallomurus* or *Microbispora* in media supplemented with KBr.[409]

Ammosamide A (Fig. 16) belongs to a group of RiPPs known as the pearlins (see section 2.15). Ammosamide A and its congeners are produced by marine *Streptomyces* sp. The BGC of the ammosamides contains a Trp halogenase, *amm3* that is homologous to MibH. Genetic deletion of *amm3* resulted in complete loss of product formation,[51] suggesting that chlorination of the indole ring occurs early in the biosynthesis. Chemical complementation with 6-Cl-Trp did not restore ammosamide production, further supporting the hypothesis that the chlorination event occurs on a specific Trp in a peptidic substrate.

5.7.3.5   Thioether oxidation: The terminal methyllanthionine in the lanthipeptide actagardine is oxidized to a sulfoxide by a dedicated oxidase, GarO. The enzyme is homologous to luciferase-like monooxygenases. Co-expression of the substrate GarA, the lanthipeptide synthetase GarM (section 3.1.2), and GarO in *E. coli* resulted in the production of the cyclic, sulfoxide-containing product.[410] Purified GarO selectively oxidized the terminal thioether ring of cyclized GarA in the presence of FMN and NADH. GarO did not require the LP to catalyze thioether oxidation, and likely recognizes the terminal methyllanthionine in the macrocycle.

Thioether oxidation is also found in the fungal RiPP α-amanitin (Fig. 57, section 3.18), but the enzyme involved in the oxidation the Cys-Trp crosslink to the sulfoxide is not yet identified. In contrast, the class B flavin monooxygenase UstF1 was shown *in vitro* to oxidize the thioether of an advanced intermediate to a sulfoxide (Fig. 55, section 3.17).[229]

5.7.4.   Non-heme iron-dependent oxidation

5.7.4.1   Asp hydroxylation in the lanthipeptide duramycin and lasso peptide canucin A: Duramycin, a lanthipeptide that binds phosphatidylethanolamine, contains an *erythro*-3-hydroxy-aspartic acid residue that is also found in the structurally similar divamides (Fig. 83). The hydroxy-Asp is installed by an α-ketoglutarate/iron(II)-dependent hydroxylase, DurX.[411] Mutational analysis of the DurA precursor peptide determined that the glycine immediately C-terminal to the Asp residue is necessary for DurX activity. Additionally, DurX prefers cyclized substrate over linear peptide. Interestingly, the hydroxylation of the highly conserved Asp is required for the next PTM,[412] the installation of a lysinoalanine crosslink that is characteristic for this group of lanthipeptides (see section 5.10).

Asp hydroxylation was also reported for the lasso peptide canucin A. *In vitro* the α-ketoglutarate/iron(II)-dependent hydroxylase CanE oxidized the linear precursor peptide CanA prior to lasso formation in a reaction that was facilitated by the stand-alone RRE protein CanB1.[164]

5.7.4.2   β-Hydroxylation of Val and Asn in polytheonamides: β-Hydroxylation of polytheonamides occurs at Val and Asn residues (Fig. 47). Co-expression studies confirmed that PoyI, a putative α-ketoglutarate/iron(II)-dependent enzyme, catalyzes the selective hydroxylation of Val32, Asn38, and Val24.[28] The β-hydroxylation events seem to be both regioselective and side chain specific. Some mutations in PoyA such as V31L and N38H were tolerated and afforded the hydroxylated products, whereas N38Q and V31H did not appear to be substrates for PoyI.

5.7.5.   Pyridoxal phosphate (PLP)-dependent oxidations—PLP-dependent oxidation of the N-terminal amino group has been documented for several RiPPs. These include the MftD-catalyzed reaction shown in Fig. 61C (section 3.21) and the aminotransferase MbnN that catalyzes the transamination of the N-terminal Leu to the ketone during the biosynthesis of methanobactins (Fig. 63A; section 3.23).[413]

5.7.6   Uncharacterized oxidation enzymes: hydroxylation of dikaritins—
Biosynthesis of ustiloxin B requires at least two hydroxylation events, one at the β-carbon

and one at the aromatic ring of Tyr (Fig. 3). Three enzymes in the biosynthetic gene cluster have been implicated to work together to perform these transformations. UstQ, a tyrosinase, UstYa, a DUF3328-containing protein (section 3.17), and UstYb, a second DUF3328 containing protein, are necessary for the formation of the core scaffold, desmethylustiloxin F (Fig. 55E).[229] UstQ, UstYa, and UstYb needed to be co-expressed together with the precursor UstA to observe product formation. Expression of UstA with UstQ, UstYa, or UstYb alone, or in pairs was not sufficient for production. The molecular mechanism by which these proteins oxidize the substrate remains to be elucidated as they belong to a family of proteins for which no other members have been previously characterized.

Likewise, two other characterized dikaritins, phomopsin A and asperipin-2a (Fig. 3), contain a similar pattern of aromatic hydroxylation. Phomopsin A contains β-hydroxy-3',4'-dihydroxy-Phe, which is possibly formed by the homologous PhomQ, PhomYa, and PhomYb proteins encoded in the phomopsin BGC.[16] In asperipin-2a, it has been hypothesized that AprY, a DUF3328 containing protein, is responsible for α-hydroxylation–dehydration to yield an imine intermediate that can hydrolyze to the ketone, which may serve as a substrate for the reductase AprR to yield the β-hydroxy residue.[414] However, more study is required to validate this hypothesis.

5.8 Prenylation

Cyanobactin prenyltransferases (PTases) increase the structural diversity of this natural product family through the *O*-prenylation of Tyr, Thr and Ser residues in the forward or reverse prenyl orientation.[326,415,416] Cyanobactins (section 3.6) bearing reverse *O*-prenylated Tyr can undergo a further Claisen rearrangement to yield forward *C*-prenylated Tyr.[326,415] Prenylation of Trp residues has also been documented, both at the N-1[417,418] or C-3[419–421] positions of the indole ring, in addition to *N*-prenylation of the amino terminus of some linear cyanobactins.[391] Recently, the biosynthesis of the bis-prenylated linear peptide alkaloids muscoride A and B was described, which feature unusual prenyl groups that protect both amino- (reverse prenyl on α-nitrogen of Val) and carboxy- (forward prenyl on carboxy group of terminal methyloxazole) termini.[422,423] These enzymes (InterPro family: IPR031037) therefore significantly expand the cyanobactin structural diversity and also represent promising tools for biocatalysis. Although the enzymology of cyanobactin prenylation has been reviewed previously,[1] more recent structural, biochemical and molecular dynamics studies have shed further light on the basis of broad substrate tolerance of the TruF family of PTases and are summarized here.

Co-crystal structures of the Tyr *O*-prenylating enzyme PagF from the prenylagaramide biosynthetic pathway from *Oscillatoria agardhii* in complex with linear (PDB: 5TU4 and 5TU5) and macrocyclic (PDB: 5TU6) peptide substrates have highlighted a number of key features that explain the high substrate promiscuity of TruF-type PTases, despite the absence of obvious recognition sequences.[416] Structural data revealed that PagF (PDB: 5TTY) comprises an α/β PT barrel fold like those observed in bacterial ABBA enzymes and fungal indole PTases.[424] However, in PagF, the barrel fold is truncated, resulting in a solvent-exposed channel that must be occluded by the peptide substrate to prevent nonproductive quenching of the dimethylallyl pyrophosphate-derived carbocation intermediate, a role

performed by structural elements in characterized small-molecule PTases. Binding of peptide substrates in PagF create a deep, encapsulated hydrophobic cavity that effectively shields the allylic carbocation from solvent, as observed in cocrystal structures with a dimethylallyl *S*-thiolodiphosphate analog.[416] A series of hydrophobic residues line the circumference of the active-site tunnel that further protect reactive intermediates.

In addition to solvent exclusion from the PagF active site, peptide binding also serves to orient the Tyr hydroxyl group for prenylation in the vicinity of the prenyl donor for direct electrophilic attack on the Tyr oxygen. Superposition of cocrystal structures with either cyclic or linear peptide substrates resulted in the almost identical placement of the isoprene-accepting Tyr residue.[416] This observation suggested that PagF can modify Tyr residues in any substrate, provided the geometric and orientation constraints imposed by the active sites can be satisfied. A minimal *N*-Tyr-ψ-R (ψ = any aliphatic/aromatic residue) motif was hypothesized, consistent with molecular dynamics simulations, and was validated biochemically using non-physiological substrates that were monitored for *O*-prenylation *in vitro*.[416]

Though the vast majority of RiPP PTases catalyze the regioselective transfer of C5 dimethylallyl donors to their cognate peptide substrates, reconstitution of the activity of PirF from piricyclamide in *Microcystis aeruginosa* confirmed its Tyr *O*-geranylation activity. [425,426] *In vitro* reconstitution experiments elucidated that PirF specifically geranylates Tyr residues when presented with Ser, Thr, Trp, or Tyr derivatives as substrates.[425] Experiments with further small molecule substrates revealed a broad substrate scope for PirF, which is able to geranylate L- and D-Tyr, in addition to a selection of small phenolic compounds, though larger Tyr-containing peptide substrates are favored to small amino acids. A Tyr-Tyr-Tyr tripeptide substrate was a particularly favored substrate and was used to explore isoprenoid specificity using C_5-C_{20} donors and PirF was found to selectively utilize the C_{10} donor GPP. Competition assays with GPP and C_5-C_{20} donors showed that the alternative donors did not compete significantly with GPP and had little effect on final yields of geranylated Tyr-Tyr-Tyr.[425] In order to determine the basis for C_{10} donor utilization, the crystal structure of PirF was elucidated and uncovered a single amino acid mutation in the vicinity of the isoprene binding pocket that is distinct from C_5-utilizing homologs such as PagF.[426] In PagF, Phe222 represents one of the hydrophobic residues mentioned previously that serve to stabilize the allylic carbocation against solvent quenching. In PirF, the equivalent residue is a Gly, which results in an enlargement of the active site pocket to accommodate GPP. Consistent with the role of this residue in governing isoprene donor substrates, PagF-F222G and F222A variants both showed robust geranyltransferase activity, concomitant with a 10 to 20-fold loss of C_5 isoprene activity that rules out a simple gain of function mutation.[426] The Gly222 variant displayed greater catalytic efficiency than the Ala variant, likely due to greater steric hindrance caused by the Ala side chain. Subsequent co-crystallization of the F222A variant with GPP and $MgCl_2$ permitted the visualization of GPP extension into the active site space created by the F222A substitution.

Aside from cyanobactin biosynthesis, prenylation is also a critical step in the maturation of the RiPP ComX,[1] a quorum sensing pheromone from *Bacillus* species that involves geranylation or farnesylation at the indolic C-3 position of a Trp residue in the core peptide.

[427] Recent mutational analyses have revealed the essential nature of an Asp residue that is necessary for preComX-binding by the prenyl transferase ComQ, in addition to residues that determine specificity for either C_{10} or C_{15} donor substrates.[428] Reconstitution of ComQ$_{natto}$, responsible for farnesylation of a Trp residue in the ComX$_{natto}$ core peptide from *B. subtilis* subsp. *natto*, demonstrated broad peptide substrate tolerance for the enzyme.[429] Remarkably, ComQ$_{natto}$ accepted a range of N- and or C-terminally truncated ComX$_{natto}$ analogs, in addition to even a single Trp substrate, suggesting a leader sequence is not necessary for substrate recognition.

5.9 Additional modifications of N- and C-termini

The N- and C-termini of peptides are vulnerable to exopeptidase degradation. Therefore, many RiPP BGCs encode enzymes that modify these termini, either during the primary scaffold installation (e.g. via macrocyclization) or by secondary tailoring processes. Methylation (section 5.3.7.1) and prenylation (section 5.8) of N- and C-termini, respectively, were discussed in previous sections as well as oxidation of the N-terminus to an oxime (section 5.7.3.2) and oxidative decarboxylation of Cys at the C-terminus (section 5.7.3.3). Several other strategies have emerged that are briefly discussed in this section.

Dehydration of Ser/Thr in the first position of the core peptide results in Dha/Dhb residues, which upon proteolytic removal of the LP tautomerize to the corresponding α-keto amides (Fig. 93A). In some cases, such as the polytheonamides (Fig. 47; section 3.12), this structure is further methylated by rSAM enzymes (section 5.3.1), whereas for other compounds the ketone is reduced to the corresponding alcohol, either by a dehydrogenase in the BGC, or by an unknown enzyme (e.g. Fig. 2). In the case of the biosynthesis of the lanthipeptide epilancin 15X the reduction is catalyzed by the NADH-dependent oxidoreductase ElxO encoded in the BGC and has been reconstituted *in vitro*.[312] Modification of C-termini has also been reported to involve dehydration of a Ser in the biosynthesis of the thiopeptide nosiheptide (Fig. 90A).[430–432] Incubation of a biosynthetic intermediate containing a C-terminal Dha with recombinant NosA resulted in enamide hydrolysis to afford a C-terminal amide (Fig. 93B). A crystal structure of the enzyme (PDB: 4ZA1) provided insights into the mechanism of amide formation.[431] NosA analogs are encoded in the BGCs of a number of other amidated thiopeptides such as nocathiacin,[433] GE2270A,[367] and berninamycin[434] suggesting a common mechanism of C-terminal amide formation.

The chemistry leading to amidation of thiostrepton is different. Genetic studies showed that its C-terminus first undergoes a cryptic methylation by an unknown enzyme, possibly to facilitate dehydration of the C-terminal Ser.[435] *In vitro* experiments showed that the resulting methyl ester is then hydrolyzed to the carboxylate by TsrB, and gene inactivation studies indicated that the Asn-synthetase-like amidotransferase TsrC subsequently converts the carboxylate to the corresponding carboxamide.

Another modification of the C-terminus is found in the thiopeptide micrococcin P1. Genetic studies suggest the short chain dehydrogenase TclP performs an oxidative decarboxylation of the C-terminal Thr to the corresponding 2-oxopropylamine. This ketone is subsequently reduced to the alcohol by TclS.[90,436] Genetic evidence also implicates C-terminal oxidative decarboxylation in bottromycin biosynthesis by a cytochrome P450 enzyme.[143]

5.9.1 N-terminal acylation—Several RiPPs are acylated on their N-termini after leader peptide removal. Some acylations are formed by linking ribosomal peptides to fatty acids such as in the lipolanthines (section 3.5), whereas other N-terminal acyl groups are the result of post-translational processing of an N-terminal amino acid (*e.g.* polytheonamide A, Fig. 47B, and lanthipeptides, Fig. 93A) or acylation with a small acyl group (*e.g.* thioamitides, Fig. 32; section 3.5).

Other RiPPs are N-terminally acetylated such as the LAP goadsporin (Fig. 97), the lasso peptide albusnodin (section 3.8), and many microviridins/graspetides (section 3.15). For goadsporin, the GCN5-related N-acetyltransferase (GNAT) family member GodH catalyzes the acetylation.[437] Similarly, the N-terminal acetylation of albusnodin is catalyzed by a GNAT protein.[163] For microviridins, the protoype MdnE is also a GNAT acetyl transferase that acetylates the N-terminus.[206] The gene encoding such an acetyltransferase is sometimes missing from microviridin BGCs,[438] but at present it is unclear if this leads to a non-acetylated product or whether the acetyltransferase is encoded outside of the gene cluster.

5.10 Lysinoalanine crosslink formation

Many RiPPs feature macrocycles that introduce conformational restraints that facilitate target binding and reduce proteolytic susceptibility. Section 3 discussed nature's strategies for macrocyclization that introduce the crosslinks that distinguish different RiPP classes. Sometimes, additional crosslinks are formed resulting in secondary macrocycles. Examples already discussed include the compound-specific second macrocycles found in the thiostrepton and nosiheptide groups (Fig. 90A and B) of thiopeptides. Another example is a group of class II lanthipeptides (section 3.1.2) including cinnamycin, duramycin and the divamides that contain a lysinoalanine crosslink (Fig. 83). A small protein encoded in the BGCs of these compounds was recently shown to form the crosslink by catalyzing the addition of a Lys to a Dha.[412] For duramycin the crystal structure of this protein (DurN) bound to its product or biosynthetic intermediates (PDB: 6C0G, 6C0H, 6C0Y) demonstrated that the enzyme does not seem to make any contacts with the substrate near the site of the chemical reaction. Instead the enzyme binds the substrate to hold it in a reactive conformation and a hydroxylated Asp in the substrate appears to act as the base that deprotonates the Lys nucleophile. Biochemical and structural studies showed that the hydroxylation of this Asp is critical for lysinoalanine formation.[412] Thus, prior PTM of an Asp in the substrate, as discussed in section 5.7.4.1, is required for the formation of the next PTM. Such a strict order of PTMs is not uncommon in RiPP biosynthesis, but the substrate-assisted nature of lysinoalanine formation is at present unique. Recently, substrate assistance was also proposed for Asp epimerization during bottromycin biosynthesis (section 5.1.3).[144]

5.11 RiPP glycosylation

The glycocins are RiPPs for which glycosylation is the class-defining PTM (section 3.25). Surprisingly, very few other glycosylations have been reported of members of other RiPP classes, unlike the ubiquitous glycosylated natural products from non-RiPP biosynthetic pathways.[439,440] Several glycosylated thiopeptides are known in series *e*[441] such as glycothiohexide α, philipimycin, and nocathiacin I, but although the BGC of the latter has been determined,[433] the glycosylation steps have not yet been investigated. Two examples of

glycosylated lanthipeptides have been reported. The class III lanthipeptide NAI-112 (section 3.1.3; Fig. 22) is glycosylated on the indole nitrogen of Trp.[84] Like the glycocins listeriocytocin and enterocin 96,[287] the class V lanthipeptide cacaoidin is a diglycosylated RiPP. However, unlike these glycocins that are diglucosylated on Ser, cacaoidin carries a 6-deoxygulopyranosyl-(rhamnopyranose) disaccharide on Tyr.[54] Several glycosyl transferases as well as enzymes involved in rhamnose biosynthesis are encoded in the cacaoidin BGC (Fig. 18B). Finally, the lasso peptide pseudomycoidin is glycosylated on a C-terminal phosphorylated Ser residue (section 5.6).[398]

6 RiPP Genome-mining tools

6.1 BAGEL

BActeriocin GEnome mining tool, BAGEL (http://bagel4.molgenrug.nl/) was the first web-based tool that enabled users to screen genetic information to find RiPP BGCs. Originally reported in 2006, BAGEL has undergone periodic updates.[442–445] Next to RiPPs, BAGEL also predicts genetically encoded non-post translationally modified bacteriocins. BAGEL detects specific RiPP classes based on defined properties of the modification enzymes (for instance a LanB and a LanC enzyme for class I lanthipeptides, section 3.1.1) and based on specific properties required for the core peptide (e.g. contains Cys and Thr/Ser). BAGEL requires prokaryotic nucleotide sequence (FASTA format) as input. The workflow of BAGEL4[445] is as follows: first, the program performs a six-frame translation. Second, the hypothetical proteins are screened for the presence of motifs found in modification enzymes for the defined RiPP classes. The third step entails defining the so-called areas of interest in the genome, based on the hits of step 2. In the final step, these areas are analyzed in detail, i.e. first genes are called using GLIMMER[446] and annotated based on Basic Local Alignment Search Tool (BLAST)[447] with the UniRef90 database. Modification enzymes are annotated based on protein domains they entail. Subsequently, all possible small open reading frames (ORFs) are called up to a set maximum size. The core peptide is either detected based on homology to known core peptides or filtered based on set properties expected for core peptides of the given class. A new feature in BAGEL4 is the option to upload RNA expression data that can be visualized along with the BGC to inform whether the RiPP is expressed in the tested condition. Additionally, BAGEL4 offers an indication of the modifications taking place in the core peptide based on homology to known modified peptides. This data is downloaded from UnitProt directly and visualized based on homology, giving a fast overview of the similarity to known RiPPs and expected modifications.

BAGEL is widely used as a quick and easy way to check the RiPP/bacteriocin potential in genomes. It is used to improve annotations of genomes and to discover new BGCs. For instance, BAGEL was used to discover almost 400 new potential head-to-tail cyclized peptides of which many were found in the genus of *Bacillus*.[448] BAGEL was also used to characterize the RiPP expression potential of strains with plant-growth promoting properties[449] and also of lactic acid bacteria with desired properties for starter cultures.[450]

6.2 RODEO

Rapid ORF Description & Evaluation Online, RODEO (http://rodeo.scs.illinois.edu/), a genome-mining tool reported in 2017, was the first to use machine learning to predict RiPP precursor peptides.[154] The workflow of RODEO is as follows: when a protein or a list of proteins are used as input queries, the algorithm retrieves the relevant genomic records from GenBank. RODEO then uses profile Hidden Markov Model (pHMM)-based analysis to annotate the function of genes flanking the query protein(s). To do so, RODEO utilizes the HMMER toolkit[451] and compares proteins to Pfam, TIGRFAM, or customized HMM databases.[452,453] Since RiPP precursor peptides are often small and hypervariable, they frequently are not predicted as protein-coding sequences. Therefore, RODEO performs a six-frame nucleotide translation of the intergenic regions in search for possible precursor peptides. These translated reads are then analyzed using a scoring function, specific to a chosen RiPP class, which combines heuristic scoring, motif analysis, and supervised machine learning. The output is an annotated BGC with a list of scored, predicted precursor peptides, provided in both graphical (html) and tabular (csv) formats. The current version, RODEO 2.0, supports precursor peptide prediction for lasso peptides, class I-IV lanthipeptides, thiopeptides, and sactipeptides with the latter sufficient to also identify ranthipeptides.[43,62,132,154,454] The predictive capabilities of RODEO were incorporated into antiSMASH4.0 (and later versions), a secondary metabolite BGC prediction software that performs analysis on single genome inputs (section 6.9).[454] RODEO is available to the user in both webtool and command-line formats (recommended for large jobs, >1,000 queries).

RODEO's utility was first demonstrated by the broad-scale investigation of lasso peptides, revealing more than 1,400 lasso peptide BGCs, a 10-fold expansion over what was previously appreciated.[154] The predictive capabilities of RODEO were further bolstered by the isolation and characterization of new lasso peptides (section 3.8), such as LP2006, citrulassin, and lagmycin,[154] prioritized based on predicted structural novelty. RODEO has been used to perform in-depth mining of four other RiPP classes: the sactipeptides and ranthipeptides,[43] the thiopeptides,[132] and class I-IV lanthipeptides.[62] These studies highlight the utility of RODEO in performing in-depth, high-throughput analyses of a specific RiPP class. RODEO-enabled analysis of multiple inputs in a single query also allows for the quick generation of large, reliable data sets that can be leveraged to glean new bioinformatic insights into a RiPP family. For instance, studies on the lasso peptide family revealed the "YxxP" motif in the LP region which was predicted to be important for recognition by the RRE (section 4.1.1).[154] These predictions were corroborated by biochemical characterization in several studies.[158,160,161,292,293] Very little information exists regarding how RiPP biosynthetic complexes are formed and regulated, and data sets that are sufficiently large can be leveraged to predict protein-protein interaction surfaces that mediate RiPP biosynthesis.[455] As new compounds of a RiPP class are described, the scoring modules can continually be improved and used to update the RiPP family of interest, as recently demonstrated for the lasso peptides[158] and lanthipeptides.[62] New scoring modules could also be developed to aid in the analysis of newer RiPP classes by adjusting the scoring metrics. Although RODEO was originally developed as a RiPP genome-mining tool, it could be utilized to analyze non-RiPP BGCs by using custom configuration files and pHMMs.

Similar to other genome mining tools,[456,457] the capabilities of RODEO are reliant to a certain extent on the user's knowledge of a RiPP class.

6.3 RiPPER

RiPP Precursor Peptide Enhanced Recognition (RiPPER; https://github.com/streptomyces/ripper) is a tool meant for the class-independent discovery of RiPPs.[14] RiPPER leverages RODEO to fetch nucleotide data corresponding to a query protein(s) and its local genomic neighborhood. Unlike RODEO that performs translation on all six frames in the intergenic regions of the query,[154] RiPPER employs a modified version of Prodigal (PROkaryotic Dynamic programming Gene-finding Algorithm) to identify candidate precursor peptides (20–120 amino acids).[14] Prodigal is an algorithm that uses features such as ribosomal binding sites, GC content and codon bias to identify bacterial coding sequences.[458] Since RiPP precursors tend to be in the same direction as that of the tailoring enzymes, Prodigal scores are enhanced if the identified precursor peptide is encoded as such. The top three high-scoring gene products within 8 kb from the gene encoding the query protein, along with additional genes scoring beyond a threshold Prodigal score, are listed in a text file with associated information such as conserved domains and Prodigal score, among others.[14] Multiple peptides are retrieved per query, which may not all be plausible precursor peptides as shown by test analyses on lasso peptides, graspetides, and thiopeptides. Therefore, peptide similarity networks and BGC analysis must be done on multiple queries in parallel to identify possible precursors. This approach was employed to analyze 229 TfuA-containing BGCs in Actinobacteria (section 3.5), revealing the diversity of thioamidated RiPPs. This dataset was leveraged to isolate thioamidated tripeptides, termed thiovarsolins, from *Streptomyces varsoviensis via* heterologous expression.[14] Thiovarsolins A-D derive from one precursor peptide VarA, which features repeats in the core peptide. The BGC also encodes an ATP-grasp ligase and amidinotransferase that are conserved among homologous BGC but are not functional under the conditions expressed; therefore, thiovarsolins have been suggested to be shunt products.[14] Unlike RODEO, antiSMASH, and RiPP-PRISM that are available as webtools, RiPPER is currently available only in the command-line format.

6.4 NeuRiPP

NeuRiPP is another addition to the suite of tools for RiPP precursor peptide prediction (https://github.com/emzodls/neuripp). Aimed at tailoring enzyme-independent prediction of RiPP precursor peptides, NeuRiPP employs deep neural networks trained on experimentally validated RiPPs, and precursors predicted with a high degree of confidence by existing RiPP genome-mining tools.[459] In addition to identifying precursor peptides predicted by RODEO and RiPPER on the test set, NeuRiPP identifies additional precursor peptides, most of which hit HMMs developed for precursor peptides of known RiPP classes.[459] NeuRiPP awaits validation as new compounds are yet to be isolated from NeuRiPP-predicted precursor peptides. Like RiPPER, NeuRiPP also lacks a web-based interface and thus is currently restricted to users comfortable with a command-line interface.

6.5 RiPPMiner

RiPPMiner is an online resource (http://www.nii.ac.in/rippminer.html) that offers tools, based on a curated database,[460] allowing users to assess if a protein sequence is RiPP-related

and to which known class it belongs. Additionally, RiPPMiner attempts to predict the LP cleavage site for lanthipeptides, cyanobactins, lasso peptides, and thiopeptides. The curated database of RiPPs was generated from previously published databases and currently entails 513 records. This database was used for machine learning to generate a support vector machine able to discriminate RiPPs from other small proteins. To predict LP cleavage sites, a random-forest approach is employed. RiPPMiner also predicts cross-links within RiPP structures based on a support vector machine classification. Recently a genome search option was added that allows the user to upload genomic data (FASTA format) to mine for RiPP BGCs.

6.6   RiPPQuest

RiPPQuest is an online program (https://gnps.ucsd.edu/) that matches tandem MS data to RiPP BGCs encoded by a particular organism.[461] The search space is limited to the vicinity of the encoded RiPP biosynthesis genes identified in the genome. The generated database for the proteomic search includes an extensive number of peptide modifications to enable RiPP discovery. Although it is desirable to couple genetic potential with experimental validation, this also means that detection depends on finding the producing culture conditions and sample preparation. This platform can help to further automate RiPP discovery and enables researchers to go beyond genome-based identification in a more automated way.

6.7   RiPP-PRISM

PRediction Informatics for Secondary Metabolomes (PRISM) was originally developed to enable identification of non-ribosomal peptide and polyketide BGCs and predict structures of the associated natural products.[462] In a recent version, PRISM 3 (http://grid.adapsyn.com/prism/#!/prism), the functionality was expanded to include BGC identification and structure prediction for RiPPs, among other classes of natural products.[456] RiPP-PRISM identifies RiPP BGCs in an input query using a set of rules that includes comparison of genes to a library of 154 Hidden Markov Models (HMMs) associated with 21 RiPP classes.[463] The precursor peptides in the BGC, recognized using a combination of heuristic scoring and HMM analyses, are further subjected to motif analysis using a collection of 54 RiPP-associated motifs to identify potential LP/follower peptide cleavage sites. Tailoring reactions based on domains identified in the BGC are then virtually performed on potential sites in the predicted core peptide, to generate a combinatorial library of hypothetical structures for each identified RiPP BGC.[456,463] One caveat, also common to many other RiPP genome mining tools,[154,454,457] is that all predictions are based on homology to proteins associated with known RiPP classes. As a result, RiPP-PRISM cannot identify novel RiPP families and also cannot predict novel PTMs. Nevertheless, RiPP-PRISM is unique among other RiPP genome mining tools by facilitating comprehensive analysis of genomes, beginning with the identification of potential RiPP BGCs and providing a library of possible structures, thus enhancing the prospects of RiPP discovery.[456,463] RiPP-PRISM was used to perform a global analysis on 65,421 prokaryotic genomes in the database of the National Center for Biotechnology Information, which predicted 30,261 RiPP BGCs that would encode 2,231 potentially unique RiPP products.[463] This study underscored the global prevalence of RiPP BGCs across prokaryotes, highlighting several bacterial phyla previously underappreciated as RiPP producers, such as Thermotogae, Fusobacteria, Dictoglomi, and others. Structural

predictions generated by RiPP-PRISM were used in tandem with automated LC-MS/MS searches using the GNP (Genomes to Natural Products) platform to isolate and characterize a novel RiPP, aurantizolicin, from *Streptomyces aurantiacus* JA 450 extracts.[463,464] Aurantizolicin belongs to a small family of RiPPs termed YM-216391 that are characterized by an azole-rich macrocycle.[1,465,466] The compounds are structurally similar to head-to-tail cyclized cyanobactins, but are produced by actinobacteria rather than cyanobacteria. Only two representative BGCs in the genomes were identified during the study. This highlights the utility of RiPP-PRISM to be used in combination with other natural product discovery platforms in expediting the targeted discovery of RiPPs.

6.8 AntiSMASH

AntiSMASH (Antibiotics & Secondary Metabolite Analysis Shell) is an online program (https://antismash.secondarymetabolites.org/) that was originally published in 2011[467] and has since undergone frequent updates and enhancements.[454,468–470] In addition to its use for RiPP discovery, it also supports the mining of non-ribosomally encoded compounds. It supports the input of prokaryotic and eukaryotic DNA. As other tools, it integrated previously described homology models for the identification of core peptides. Recently, the RODEO program has been integrated into the pipeline (antiSMASH 4.0 and later). In the most recent version (antiSMASH 5.0), more non-RiPP classes have been added, the run times have been improved, and the output has been adapted to a format (JSON) that enables automated downstream processing of the generated data. The user-friendly interface combined with the many classes of compounds it can mine for have made this the most highly cited genome mining tool for natural product identification.

6.9 IMG-ABC

Integrated Microbial Genomes-Atlas of Biosynthetic gene Clusters, IMG-ABC (https://img.jgi.doe.gov/cgi-bin/abc/main.cgi), is a publicly available database of predicted and experimentally verified natural product BGCs and their associated products.[289,471,472] IMG-ABC utilizes ClusterMine360,[473] DoBiscuit,[474] antiSMASH,[454,470,475,476] PubChem Compound,[477] and MeSH library[478] to curate characterized natural products and their associated BGCs. It uses ClusterFinder[479] and antiSMASH[454,470,475,476] to predict and annotate putative BGCs in genomic and metagenomic data in IMG.[480] An update performed in 2016 integrated a tool called ClusterScout with IMG-ABC, allowing for targeted identification of custom BGCs.[472] The latest update, IMG-ABC v5,[289] uses antiSMASH 5.0,[470] expanding its predictive capabilities to additional BGC types including several classes of RiPPs. IMG-ABC v5 (as of September 2019) contains a total of 330,884 verified and predicted BGCs in 42,892 publicly available genomes and 4,944 metagenome-derived scaffolds.[289] Searches on IMG-ABC can be performed using attributes associated with the secondary metabolite or the BGC of interest. Alternatively, IMG-ABC can also be browsed for secondary metabolites and BGCs by taxonomy, ecosystem, natural product/BGC type, gene count, and Pfam information for functional assignment of neighboring genes. IMG-ABC provides the most comprehensive information on secondary metabolites and BGCs in genomic and metagenomic data in IMG, with links to external databases and tools within IMG allowing users to perform large-scale analyses with any desired level of detail. [289,471,472]

6.10 DeepRiPP

DeepRiPP (http://deepripp.magarveylab.ca/) is a recent addition to the genome mining tools specific for RiPPs, and similar to RODEO, the tool employs a machine learning based approach.[481] DeepRiPP consists of three intergrated algorithms: NLPPrecursor to identify RiPP precursor peptides in a class-independent fashion, BARLEY, to aid in the cheminformatic identification of potentially novel compounds, and CLAMS, to match genomic information with comparative metabolomic data. DeepRiPP was used to analyze more than 10,000 extracts from nearly 500 bacterial strains. These efforts led to the discuss of three novel RiPPs: deepstreptin (a lasso peptide, section 3.8), and deepflavo and deepginsen (lanthipeptides, section 3.1).

6.11 RRE-Finder

RRE-Finder (http://rodeo.scs.illinois.edu/), another recent addition to the RiPP genome mining toolkit, facilitates detection of RRE domains (section 4.1.1) in known and potentially novel RRE-dependent RiPP classes.[482] The tool is available to the users in two modes of operation: precision mode and exploratory mode. Precision mode utilizes 35 custom HMMs built using RRE domains from largely known RiPP classes but includes a few high-confidence RREs from predicted new RiPP classes. The intent is for precision mode to enable class-dependent discovery of RRE domain-containing proteins. Exploratory mode uses a truncated version of the HHPred[483] workflow and a custom database of ~2,400 sequence-divergent RREs to facilitate discovery of novel RRE-dependent RiPP classes. Using RRE-Finder working in precision mode, ~35,000 RRE domain-containing proteins were identified in the UniProtKB protein database,[484] revealing many novel, yet-to-be explored, RRE-dependent RiPP classes. RRE-Finder is available to the user as a downloadable command-line tool. The precision mode of RRE-Finder has been integrated into RODEO (section 6.2) and will be integrated into the future release of anti-SMASH (section 6.8).

6.12 decRiPPter

DecRiPPter (https://github.com/Alexamk/decRiPPter) is yet another recent addition to the growing list of class-independent RiPP genome-mining tools.[56] This algorithm also utilizes machine learning, specifically, a support vector approach, in combination with a pan-genomic analysis to identify genes associated with RiPP biosynthesis within operon-like contexts. Two unique features consider whether these genes are distinct from the core genome (*i.e.* part of the accessory genome) and whether they encode sequences that overlap with known biosynthetic proteins already in the antiSMASH and MIBiG databases. Together, these filters reduce retrieval of primary metabolic pathways and previously described RiPP classes. When visualizing the results from the genus *Streptomyces* using sequence similarity networking, 42 new candidate RiPP families were found with experimental data supporting the identification of a novel class V lanthipeptide (section 2.17).

7 Engineering, screening, and production of RiPP variants

The great expansion of knowledge regarding RiPP biosynthesis in the last two decades has catalyzed a large engineering effort. The manipulation of leader and core peptides as well as PTM enzymes through single and multiple point mutations has allowed the assessment of substrate tolerance of the biosynthetic enzymes. Initial demonstration of the versatility of the enzymes to accept core peptides attached to their cognate LP prompted the development of RiPP modular systems, where the PTM enzymes, the LP and the core peptide are considered as separate modules. The lanthipeptide nisin (section 3.1.1) served as the first example of RiPP-inspired modular design in *Lactococcus lactis*,[485] but many other examples have since been reported and are reviewed here. Since RiPP engineering was not covered in the previous RiPP community-wide review,[1] this section of the current review also includes studies predating 2013. However, we will not cover the very large volume of site-directed mutagenesis studies on the core peptide, which has greatly aided understanding RiPP biosynthesis and structure-activity relationships.[151,486,487] Instead, we focus on new technologies and novel strategies to make RiPP analogs.

Manipulation of core peptides to challenge the PTM enzymes and to study their specificity, binding motifs, mechanism, and processivity has been common in RiPP research. More recently, different engineering approaches have been applied to access completely novel chemical entities, yielding different new functions. We here discuss efforts and successes in modifying rings of macrocyclic RiPPs, the incorporation of non-canonical amino acids (ncAAs), the development of various *in vitro* engineering systems, and the use of high throughput screening and display systems that have been of particular interest and fruitfulness in the last seven years.

7.1 RiPP variants and hybrids: novel combinations of known functional moieties

RiPP structural genes commonly encode a peptide consisting of minimally a leader and a core peptide. Research conducted in the last years demonstrated that these sequences often have motifs with concrete functions. Sequences have been identified that correspond to recognition elements for PTM enzymes, spacers to allow the correct positioning of the core peptide in the enzyme's active site, LP cleavage sequences, or structural motifs within the core peptide that specifically interact with the enzymes. With this continuously expanding repository of functional sequences, the combinatorial assembly of moieties with a well-defined function, originating from different RiPPs, unmodified peptides or synthetic compounds, together with selected PTM enzymes, offers the prospect of biosynthesizing a vast array of new-to-nature bioactive compounds (Fig. 94).

Precursor peptides containing multiple core sequences have some distinctive advantages in RiPP engineering. The most straightforward application is the use of multiple core peptides to increase yield: the recombinant yield of lyciumins (section 2.9) in tobacco was improved by 5- to 10-fold by including 5 or 10 repeats of the same core peptide in a single precursor peptide.[32] However, such increases in yield are not found with all pathways/substrates and need to be empirically determined.[302] Another potential advantage is in engineering of novel RiPPs.[488] Some core peptides have slightly different sequence selectivity and post-translational modification requirements,[217] such that a desired modification that fails at one

core peptide may work at another. The spacing between enzyme recognition sequences and core peptides may be more flexible in precursors containing multiple core peptides, enabling synthesis of hybrid products using enzymes from more than one biosynthetic pathway.[489,490] Finally, another as-yet unexplored benefit might be the design or high-throughput synthesis of synergistically acting products. With careful design, it may be possible to generate these products in the desired ratio. For example, in peptides with two different core sequences, sometimes compounds are generated from each core with equal stoichiometry.[302]

7.2 RiPP analogs accessed by leader peptide engineering

The role of the LP in RiPP biosynthesis was discussed in section 4.1. For many RiPP classes, the RRE[66] mediates the interaction between the biosynthetic proteins and the peptide substrate. This LP does not necessarily need to be covalently attached to the core peptide to achieve enzyme activation. Complementation *in cis* (covalent linkage of the LP to its cognate PTM enzyme, *e.g.* the lanthipeptide synthetase LctM,[491] cyanobactin heterocyclases PatD,[489] LynD,[115] and TruD,[302,392] and microviridin cyclases MvdCD)[215] or *in trans* (i.e. addition of the LP *in vitro*,[492] or coexpression of the LP and the core peptide as separate molecules)[493] results in core peptide modification. This observation simplifies core peptide design and reduces the precursor peptide size, which facilitates chemical synthesis of peptides or libraries for *in vitro* modification.[494,495] For instance, the complete synthesis of the linear cyanobactin-like RiPP aeruginosamide (Fig. 85) was reconstructed *in vitro* using the heterocyclase TruD attached to its LP.[392] This platform facilitated the characterization of the order of *N*- and *C*-alkylation by the enzyme AgeMTPT, which prenylates the N- and C-terminus (section 5.3.7.1).[392] Similarly, MvdD and MvdC covalently fused to the LP or with added LP, allowed the reconstruction of the complete microviridin biosynthesis pathway (section 3.15) in a LP-independent fashion.[215] This strategy was used for *in vitro* screening of microviridin libraries for protease inhibition (section 7.7.1).

LP engineering has allowed the design of new-to-nature RiPP hybrids in *E. coli* that are derived from the combination of known pathways.[496] In this strategy, recognition motifs of different LPs are fused to structural elements that chosen enzymes are able to modify in their native system. As an example, a LAP (section 3.4) and class I lanthipeptide hybrid precursor peptide (section 3.1.1) was designed (Fig. 95) that contained the RS for the cyclodehydratase HcaDF (section 3.4), the key FNLD motif of the nisin LP for recognition by the dehydratase NisB and the cyclase NisC (section 3.1.1), and a hybrid core peptide with pieces of their respective cognate core peptides. This design added a second function to the nisin LP as a spacer sequence between the HcaDF recognition motif and its substrate sequence GGRCG. Similarly, the C-terminal residues behind the FNLD motif and the GGRCG in the core peptide served as a spacer between the FNLD motif and the amino acids to be modified by NisBC. Upon co-expression of the designed peptide with HcaDF and NisBC, a peptide containing the desired thiazoline, dehydrobutyrine, lanthionine, and methyllanthionine was the main product (Fig. 95).[496]

A second hybrid class was formed by the combination of HcaDF with the subtilosin rSAM enzyme AlbA (section 3.9) to produce thiazoline-containing sactipeptides. A similar

precursor peptide architecture was designed with the RS of HcaDF, the LP of subtilosin, and a hybrid core peptide consisting mainly of the subtilosin precursor with replacement of ACLVD by RCGGC. Upon co-expression of this chimeric peptide with HcaDF and AlbA, two thiazolines and two sactionines were present in the product.[496] Since engineering enzyme-enzyme interactions (for a review, readers are referred to reference[93]) in such a way that the partially modified core peptide is acted on by different enzymes in the right order is an (almost) impossible task, point mutations that favor/hamper one enzyme over the other were used to manipulate the modification order.[496]

E. coli was also transformed with a combination of genes encoding HcaDF and the class II lanthipeptide synthetase ProcM (section 3.1.2).[497] In the previous two examples, the enzymes used contained RRE motifs (section 4.1.1), but this is not the case for ProcM. A hybrid LP was constructed with the minimal binding motifs for the heterocyclase HcaDF and ProcM. Point mutations in the prochlorosin-derived core peptide introduced residues that provided a sequence amenable for HcaDF modification. Since the core peptides were natural substrates of ProcM, initially no thiazoline could be installed indicating outcompetition of HcaDF by ProcM for Cys modification. This problem was solved by reducing the ProcM expression level. Thus, a peptide containing both thiazoline and lanthionine was produced albeit as a mixture with a peptide without thiazoline. These and other experiments demonstrated that core peptide design and fine-tuning expression levels are pivotal to achieve the desired modification pattern.[496]

LP combinations to use different biosynthesis pathways concomitantly have also been used in flexible *in vitro* translation systems. This approach has allowed the reconstitution of thiopeptide biosynthesis with a set of enzymes from diverse RiPP enzymes in one pot (section 7.3).[490]

The addition of tailoring enzymes from different BGCs to existing pathways has also been accomplished by combining dehydro amino acid reductases (section 5.1.2) or C-terminal decarboxylases (section 5.7.3.3) with the nisin biosynthetic machinery to form hybrids *in vivo*.[498] These additional secondary post-translational tailoring modifications do not rely on LP recognition. Similarly, HcaDF-ProcM modified peptides were expressed together with either the dehydrogenase NpnJ (InterPro IPR013149) or the decarboxylase MibD (InterPro family: IPR003382) in *E. coli*.[496] Further modification using other LP-independent enzymes or PTM enzymes activated by covalently attached cognate LPs *(vide supra)* might further enlarge the repertoire of available PTMs in the future.

A different approach to producing non-cognate RiPPs uses chimeric substrates composed of leader and core peptides from different members of a certain class. This approach was first demonstrated for chimeras of the LP of the class I lanthipeptide subtilin and core peptides made up of nisin and subtilin fragments.[499,500] More recently, a set of more than 60 putative lanthipeptides was detected *in silico*, several of which were produced by attaching the bioinformatically identified non-cognate core peptides to the NisA LP and using the nisin biosynthetic machinery.[501,502] Similarly, the *tru* biosynthetic enzymes served as a production platform in *E. coli* for the products of cyanobactin core peptides (section 3.6) detected *in silico* that were inserted into peptides containing the TruE LP and RSs.[503] A

chimeric approach was also taken with the LP of the class II lanthipeptide prochlorosin 2.8 and the core peptide of the unrelated lanthipeptide lacticin 481. The class II lanthipeptide synthetase ProcM converted this chimeric substrate into a product with the correct lacticin 481 ring pattern.[504] The same strategy has also been used for lasso peptides (section 3.8). For instance, the fusilassin/fuscanodin biosynthetic machinery was used to make the non-cognate citrulassin and cellulonodin-1 *in vitro*.[150,158] Notably, whereas fusilassin/fuscanodin contains a Trp1-Glu9 macrolactam, citrulassin possesses a Leu1-Asp8 macrolactam and a core peptide that is three residues shorter than that of fusilassin/fuscanodin, and cellulonodin and fusilassin/fuscanodin share identity in the core peptide at only 8 of 19 positions. These examples illustrate the power of using appropriate enzymatic systems to access natural products that may be difficult to obtain from the native organisms.

7.3 *In vitro* translation and post-translational modification

The systems discussed in section 7.2 highlight both the opportunities but also the difficulties of producing each PTM enzyme in the right amount, at the right time, and with all the necessary cofactors *in vivo*. This challenge can be avoided when the PTM enzymes are purified and fully characterized, so that all the necessary cofactors will be present during the reaction *in vitro*. In addition, tolerance of the PTM for non-cognate peptides can increase due to the option to use longer reaction times and artificially increased enzyme:substrate ratios. Coupling *in vitro* translation systems with the appropriate PTM enzymes can aid with expression timing and competition of different enzymes for the same amino acid to insert different PTMs, thereby improving the homogeneity of the final product. *In vitro* biosynthesis can also simplify the incorporation of non-proteinogenic amino acids.

The main limitation of this strategy is that the enzyme needs to be (heterologously) expressed and purified and a thorough knowledge of the cofactors, tolerance of reaction conditions, and (minimal) RSs is required in order to provide optimal conditions. *In vitro* translation technology has drastically evolved in the last decades, as the required cellular components are better understood and the addition of PTM enzymes can be achieved with less interference on the reaction mixture (for a review see[505]). The fact that no living cells are involved also solves potential problems that novel RiPPs can pose for heterologous expression systems when the novel products exhibit antimicrobial activity. A great advance is the development of flexizymes and flexible *in vitro* translation (FIT) systems, which allow not only RiPP biosynthesis but also enable genetic code reprogramming.[506,507] Flexizymes are acylation ribozymes that can acylate tRNA using many acyl-donors (e.g. amino acids with non-proteinogenic side chains, *N*-alkylated, *N*-acylated, β-, and D-amino acids, and even non-amino acids) without the requirement for structural similarity as in the case of conventional amino acyl-tRNA synthetases. This flexibility is extended to the tRNAs they can accept via recognition of the 3' end of the tRNA molecule. Compatibility with the ribosome and the translation machinery is the main limitation for this system.

The cyclodehydratase PatD involved in the biosynthesis of the cyanobactin patellamide (section 3.6; Fig. 35) has been used in the FIT system to investigate leader and core peptide tolerance in a simplified manner.[489] A structural gene was designed encoding the patellamide LP, RSs, core peptide, and C-terminal extension. When the core peptide was that

of patellamide, the expected product containing four azolines was obtained. The FIT system was then used to determine the minimal size of the substrate for PatD.[489] Thus, it was shown that the sequence between the LP and the core sequence is merely a spacer that is not required for PatD although it serves as the RS for the protease PatA. Indeed, replacing this sequence by a different protease cleavage sequence still allowed PatD modification.[508] In addition, only the C-terminal six residues of the LP were required for recognition and modification. *In trans* supplementation with the LP suggests that it activates the enzyme as a *trans*-acting chaperone and not as an essential *in cis* element. In addition to interrogation of the LP and RSs, extensive mutagenesis of core peptides was performed with the FIT system.[489] PatD modified even a 36-amino acid core peptide in a context-independent fashion, with a preference for Cys over Ser and Thr. This substrate tolerance is not shared *in vitro* or *in vivo* by similar cyclodehydratases from other LAP systems despite belonging to similar families.[108,509]

In addition, PatD has been used to create novel heterocycles using the FIT system. Threonine analogs with arylated or alkylated β-carbons were correctly processed into substituted azolines with PatD activity requiring the 2-*S* configuration (Fig. 96, panel II). In addition to its use to form substituted heterocycles, PatD accepted an amino group as a nucleophile in the β-position to yield imidazoline, as well as either amino or thiol groups at the γ-carbon. In the latter cases, a mass loss consistent with heterocyclization was observed, but the structure of the heterocycle was not determined (Fig. 96, panel IV).[510]

The FIT system has also been used for the reconstitution of goadsporin biosynthesis, aiding in the determination of the order of the enzymatic modifications and the tolerance towards variations in the core peptide.[414] Goadsporin is a LAP (section 3.4) but also contains dehydro amino acids introduced by a split lanthipeptide dehydratase (section 3.2; Fig. 97). Experimental difficulties necessitated using a PTM enzyme from a different BGC. Thus, the enzymes GodDEFH were expressed in *E. coli*, whereas the glutamate elimination enzyme GodG was replaced by LazF originating from the lactazole biosynthesis pathway (lactazole is a thiopeptide, section 3.2).[511] Sequential addition of PTM enzymes to the reaction showed that first GodD and GodE are required for full cyclodehydration of the core peptide. In the absence of the oxidase GodE, GodD installed a variable number of azolines, indicating that azoline oxidation is required for complete heterocyclization. Serine dehydration via GodF-catalyzed glutamylation required azoles to be installed, but only one residue was glutamylated. When the azole-containing peptide was incubated with GodF and LazF, both Ser residues were dehydrated to Dha. This reaction proceeded with N- to C-directionality, indicating that the first dehydration is essential for the second one to take place. After proteolytic removal of the LP, GodH (section 5.9.1) acetylated the fully modified core peptide. Different deletions in the core peptide and mutations of a minimal core peptide identified an X-T/S/C-Y motif for cyclodehydration activity, where X is a small uncharged amino acid and Y a non-acidic amino acid.[437]

The analogous function of enzymes from different RiPP families was also exploited with the FIT system for the synthesis of thiopeptides (Fig. 98).[490] Instead of reconstituting the canonical pathway, enzymes with an analogous function were borrowed from alternative soluble and well-established *in vitro* systems. In addition, the incorporation of the ncAA

phenylselenocysteine (SecPh) by codon reprogramming allowed orthogonal chemical oxidation to yield Dha without needing the two proteins of a dehydratase (section 3.2). Compared to *in vitro* thiopeptide biosynthesis accomplished previously using six canonical enzymes purified from heterologous hosts,[71,89] using this engineered system minimizes the number of PTM enzymes required to three. In this strategy the cyanobactin cyclodehydratase LynD produces azolines that are oxidized to azoles by the thiopeptide dehydrogenase TbtE. Chemical oxidation of selenocysteine derivatives produces the dehydroalanines that serve as a substrate for pyridine formation catalyzed by TclM (InterPro family: IPR023809) from the thiocillin gene cluster (section 3.2). FIT also was used to test different arrangements of the LP recognition motifs for LynD and TclM in order to obtain the correct PTMs.[490]

More recently, the FIT system has been also combined with recombinantly produced lactazole biosynthetic enzymes, achieving *in vitro* biosynthesis of the thiopeptide lactazole A and its analogs.[512] Stepwise addition of the enzymes to the precursor peptide resulted in either under- or overdehydrated thiopeptides while selective production of the native lactazole A occurred only when the full enzyme set was present from the beginning, implying orchestrated actions of the enzymes during cooperative maturation of the thiopeptide. Intensive mutagenesis of the precursor using this system has revealed remarkable substrate tolerance of the biosynthetic enzymes and demonstrated production of diverse designer lactazole analogs with 10 consecutive mutations, 14- to 62-membered macrocycles, and 18 amino acid-long tail regions, as well as hybrid thiopeptides containing multiple non-canonical amino acids (see section 7.4.3).[512]

Very recently, a cell-free protein synthesis (CFPS) system was also used for the preparation of variants of the lanthipeptide nisin.[513] The levels of purified dehydratase NisB and cyclase NisC (section 3.1.1) were first optimized with the sequence of the precursor peptide encoding nisin Z. Then available genomes were searched for natural nisin analogs, and the 18 core peptide variants thus identified were fused to the nisin Z leader peptide. The CFPS system was then used to produce the nisin variants, with four peptides displaying antimicrobial activities, which were then produced in larger amounts using heterologous expression in *E. coli*. A library of an additonal 3,000 variants made by CFPS was screened for activity against *E. coli* and two nisin analogs were identified with improved Gram-negative activity compared to nisin Z.

In vitro translation systems can also be engineered in an enzyme-free fashion to create RiPPs. A screening system for functional lanthipeptides (section 3.1) was constructed in which 10^{11} genes were simultaneously screened by crosslinking the lanthipeptide to its coding mRNA during translation.[514] The *in vitro* translation system substituted lysine with the structural homolog 4-selenalysine (SeLys), which in the presence of hydrogen peroxide was converted into Dha. This Dha was attacked non-enzymatically under alkaline conditions by a neighboring cysteine rendering a lanthionine, although the stereochemistry was not controlled. The chemical attachment of the coding mRNA to its lanthipeptide was achieved using a puromycin-tagged short oligonucleotide that partly annealed to the 3' end of the mRNA. This approach induces formation of a covalent bond between peptide and mRNA by the ribosome, and therefore phenotype and genotype are linked. A library encoding a hypervariable xxK'xxCxxxx sequence (with K' = SeLys) was synthesized. After

transcription, puromycin-labeled mRNA was generated and translated. Upon purification of the translated library and reverse transcription, about 10^{13} molecules of peptide-mRNA conjugate were produced, providing 24-fold coverage of the library. This library was tested for binding to staphylococcal sortase A as a drug target using five selection rounds that provided 42 clones in which hydrophobic residues were the most abundant, especially Trp. Chemically synthesized positive hits, including all the possible stereochemical variants, were tested for affinity *in vitro* providing five candidates with micromolar affinity for sortase A.[514]

Collectively, these studies demonstrate the versatility of *in vitro* translation systems for analysis of full biosynthetic routes, albeit at small scale. Mixing biosynthetic routes, expanding the chemical diversity with ncAAs, and using large gene libraries that do not rely on transformation efficiencies of the heterologous host for full coverage, will drastically enlarge the analytical possibilities of the FIT system.

7.4 Engineering RiPPs containing non-canonical amino acids

The structural diversity of RiPPs brought about by PTM enzymes constitutes a great advantage over unmodified peptides in terms of bioactivity and stability. An even higher level of chemical diversity has been introduced using non-canonical amino acids (ncAAs) that can confer attractive properties. The presence of certain ncAAs can increase the stability of the peptide by reducing the accessibility to and recognition by proteases (*e.g.* by use of D-amino acid, β-amino acids, and *N*-alkylamino acids). Some ncAAs such as fluorinated amino acids can enhance the half-life and bioavailability of a peptide *in vivo*.[515] Moreover, ncAAs open a wide spectrum of bio-orthogonal chemistry that affords conjugation opportunities in a context-independent manner. These ncAAs can be coupled to diverse probes by standard bio-orthogonal chemical reactions, such as copper-catalyzed alkyne-azide cycloadditions (CuAAC or click-chemistry), olefin metathesis, and metalloporphyrin-catalyzed alkylation.[516] Click-based examples in peptide chemistry include the coupling of peptides to polyethylene glycols to increase their solubility and half-life, to fluorophores in order to monitor the distribution or mode of action of a compound, and to sugars or any other chemical moiety to alter the activity spectrum.[517] ncAAs have been incorporated into RiPPs through three main routes, (1) by chemical synthesis of the linear precursor peptide containing the ncAAs in the desired locations for further *in vitro* modification, (2) by supplementation-based incorporation or (3) by codon reprogramming.

7.4.1. ncAA incorporation by using synthetic precursor peptides—The first route can be applied when the PTM enzymes of a certain biosynthetic gene cluster have been isolated for use *in vitro* and when their specificity and requirements are well-known. As a first reported example, the class II lanthipeptide synthetase LctM (section 3.1.2) was isolated and then used to modify variants of its cognate peptide LctA, which were synthesized with three different ncAA types (D-amino acids, β-amino acids, and *N*-alkylglycine).[494] These residues were located at different positions in the core peptide that were known to be amenable to mutations with no deleterious effect on LctM activity. In this case, the LP was fused to the core peptide by CuAAC and this non-natural peptide was recognized and modified by the enzyme even when several ncAAs were simultaneously

inserted. Although ncAAs were not well tolerated in the N-terminal linear region, ring C was amenable and provided two variants (Phe23Homophenylalanine and Trp19Naphthylalanine) with slightly improved antimicrobial activity when compared to the parent lacticin 481.[494]

LctM was also exploited to modify synthetic lacticin 481 precursor peptides with *ortho*-nitro-phenylglycine derivatives at position 1. This ncAA allowed photocleavage of the LP with good yields in a context-independent manner, thereby obviating the use of leader peptidases and allowing the activation of the fully modified (antimicrobial) RiPP *in situ*.[518] A further step to improve this methodology is represented by a PTM enzyme activated with its cognate LP fused (section 7.2), which avoids the necessity of removing the LP. Using this approach, lacticin 481 variants containing ncAAs were produced that outperformed the native compound.[491]

Similarly, the macrocyclase PatG (section 3.19, InterPro family IPR034056) has been used *in vitro* with synthetic peptides containing ncAAs (e.g. diamino propionate, ornithine, and aminohexanoic acid) including the N-terminal residue that forms the lactam. Although the reaction is slow,[519] diverse circular peptides could be produced. Furthermore, full reconstruction of the cyanobactin pathway has been accomplished.[301] Trimming the essential RSs allowed a drastic reduction of the structural peptide to approximately one third of the original length. Sequential addition of the enzymes showed a specific order for the system where the cyclodehydratase ThcD, leader peptidase PatA, macrocyclase PatG and prenyltransferase TruF (InterPro family: IPR031037) worked step-wise to completely transform and decorate the core peptide. Moreover, tailoring enzymes were exchanged to alter the modification pattern. For instance, the prenyltransferase PagF prenylated tyrosine instead of serine and threonine that were modified by TruF.[301] It is noteworthy that the full route involved PTM enzymes from three different cyanobactin BGCs, which still allowed conversion of 95% of the synthetic peptide into the final product. One-pot synthesis was demonstrated as well, highlighting the proteases PatA and PatG as critical points. When PatA is present in high amounts and cleaves the LP, heterocyclization is almost abolished because the recognition by the heterocyclase PatD disappears. A solution for this drawback was the use of a different protease and cleavage site (e.g. TEV site) instead of PatA and its canonical sequence. In this way the distance between the cyclodehydratase recognition sequence and the modifiable residues was maintained.[508]

The use of synthetic peptides allowed increasing the ring size up to 22 amino acids using PatG.[301] In future studies, substrate tolerant macrocyclases such as butelase-1 or other asparaginyl endopeptidases from the cyclotide pathway (section 3.19),[239,240] prolyl oligopeptidases from the amatoxin cluster (section 3.18),[235] or PCY1 from the orbitide biosynthesis route (section 3.19),[248] might facilitate the overall process as a replacement for PatG, since their structure and recognition elements are now very well understood. These enzymes display faster kinetics than PatG, and were used to cyclize larger peptides such as head-to-tail cyclized bacteriocins.[520]

The increased interest in peptide cyclization has driven the *in vitro* characterization of macrocyclase requirements. The necessity for proline or thiazole as P1 residue for cyanobactin cyclases (e.g. PatG) has been challenged using triazole or vicinal cysteine

disulfide bonds, which are readily introduced during peptide synthesis prior to enzymatic cyclization.[521,522] In addition, several triazoles, polyethylene glycol, amino benzoic acid or amino *n*-alkyl acids (up to 8-amino octanoic acid) were inserted in the peptide backbone and still cyclized by PatG.[523] Moreover, cyanobactin macrocyclases (section 3.6) with increased substrate tolerance have been used to increase ring sizes, incorporate D-amino acids, and process peptides with Cys- and Ser-pseudoproline at the P1 position.[241]

Butelase-1 involved in cyclotide biosynthesis (section 3.19) is currently the fastest cyclase and has proven to have broad substrate tolerance in terms of peptide size (up to 200 residues). This enzyme requires Asn at position P1 and His-Val at P1' and P2', respectively. Residues in P1" and P2" also affect cyclization with Pro at P1" unfavorable and Ile, Leu, Val, Cys the preferred residues at P2";[239] Gly at P1" allows the use of virtually any amino acid at P2", thus enabling a broader designer freedom.[524] Butelase promiscuity affords the cyclization of peptides containing D-amino acids even at the P1" and P2" positions or even all D-amino acid-containing peptides (except for the P1, P1' and P2' positions) and has been used for the preparation of conotoxins, θ–defensin or SFTI.[524]

Thiopeptides have been prepared using a semisynthetic route. In this strategy, a synthetic thiocillin core peptide containing thiazole rings was fused to its LP using native chemical ligation (section 3.2).[94] Trimming the LP using this approach facilitated peptide synthesis and identified key residues for correct processing by TclM.[95] This strategy opens possibilities to test this enzyme for further efforts including incorporation of ncAAs or variants with different ring sizes.[525]

In summary, the approach using purified PTM enzymes and synthetic peptides, referred to as *in vitro* mutasynthesis,[494] offers a powerful platform to explore at an analytical level the tolerance and the effect of the ncAAS. The main limitations are the availability of well-characterized enzymes that are active *in vitro* (i.e. that can be expressed and purified in an active soluble form), the reduced amounts of material that can be produced, and sometimes slow kinetics of the PTM enzymes.

7.4.2. Selective pressure incorporation of ncAAs—*In vivo* approaches have also proven successful to introduce ncAAs into RiPPs. Auxotrophic strains[526] can be used to incorporate ncAAs in expressed peptides and proteins, an approach called selective pressure incorporation (SPI).[527,528] This strategy relies on the capability of aminoacyl-tRNA synthetases to mischarge their cognate tRNA with structurally similar amino acid analogs, albeit typically with reduced efficiency.[529] Once charged to the tRNA, the ncAA will be incorporated during ribosomal synthesis when the mischarged tRNA recognizes the proteinogenic amino acid codon. The presence of proteinogenic amino acids sometimes can outcompete incorporation of the analog. Therefore, auxotrophic strains are often used that are unable to synthesize the cognate canonical amino acid in combination with chemically defined media lacking this amino acid.

The SPI method has been used to incorporate a variety of analogs into different RiPPs. Using a range of auxotrophic *E. coli* strains, Met, Pro, and Trp analogs were incorporated into the class II lanthipeptide lichenicidin (see section 3.1.2 for general biosynthetic

pathway).[530] The most successful incorporation was that of the Met analogs homopropargylglycine, azidohomoalanine, norleucine, and ethionine. The first two analogs served as a basis for further bio-orthogonal CuAAC. All the Met variants were incorporated and rendered compounds with antimicrobial activity close to that of the wild-type lanthipeptide. CuAAC was performed and showed successful addition of a glucopyranoside and fluorescein as a proof of concept for bio-orthogonal conjugation.[530]

The use of SPI for RiPP production faces two major hurdles. First, the incorporation of the ncAA into host proteins (including PTM enzymes) can result in the production of inactive proteins, which causes host stress. Secondly, usually slower tRNA acylation kinetics are associated with mischarging tRNAs with ncAAs. In order to solve the first issue, control over the timing of enzyme(s) and structural gene expression using different promoters can provide a cleaner production system. This method has been tested using Trp analogs with fluorine, methyl, or hydroxyl groups at position 5 of the indole to access ncAA-containing variants of the class I lanthipeptide nisin (section 3.1.1) in *L. lactis*. In this approach, a nisin inducible promoter was first induced to express the dehydratase, cyclase and transporter (NisB, NisC, NisT) prior to the zinc-controlled expression of nisin precursor peptide mutants containing Trp analogs at position 1, 4, 17 or 32. The slower tRNA acylation was compensated by including an additional copy of the tryptophanyl-tRNA-synthetase that was expressed at the same time as the *nisA* structural gene.[531] With these experimental improvements, incorporation efficiency ranged between 69% and 97%, with production levels up to 50% when compared to typical nisin production. Yields varied greatly with the selected ncAA and the position of incorporation. Consistently, 5-methyl-Trp was incorporated with a reduced yield in all locations tested and mutants in position 4 and 32 favored the production of partly dehydrated nisin. Dehydration efficiency of Ser and Thr was affected in some of the variants, when they were positioned close to ncAAs.

In addition to lanthipeptides, the lasso peptide capistruin (section 3.8) has been produced in a methionine auxotrophic *E. coli* strain using SPI. Ring, loop and tail amino acids were individually replaced by azidohomoalanine and homopropargylglycine albeit in low yields, particularly when the ring amino acid was mutated.[529] However, all analog-carrying lasso peptides that were produced in quantifiable amounts were shown to have the lasso structure. This result shows compatibility of the capistruin modification machinery with the non-natural side chains present in the ncAA-containing peptides. This paper also describes achieving similar features by using the stop-codon suppression method (section 7.4.3), which typically increases the production yields.

7.4.3   Stop codon suppression incorporation of ncAAs—Stop codon suppression (SCS) is the most exploited strategy for the incorporation of ncAAs into RiPPs. The SCS method employs a stop codon, typically the amber stop codon, to encode incorporation of a specific ncAA.[532,533] To achieve this, an additional orthogonal tRNA synthetase and tRNA pair is introduced into the producer cell. The orthogonal tRNA recognizes the amber UAG codon such that the stop codon is "suppressed" and the ncAA charged to the tRNA is incorporated and protein synthesis can continue.

Amber codon suppression has been tested with diverse archaea-derived orthogonal amino acyl-tRNA synthetases and their respective tRNAs in both Gram-positive and Gram-negative hosts to produce several RiPP classes. The most broadly used orthogonal pairs are pyrrolysyl-tRNA synthetase (PylRS) and tRNA[Pyl] from *Methanosarcina barkeri* or *Methanosarcina mazei* as well as *O*-methyltyrosine-tRNA synthethase and tRNA[O-Me-Tyr] from *Methanococcus jannaschii*, and the most commonly used host is *E. coli*. Expression of RiPP pathways in *E. coli* was achieved early on for cyanobactins[534] and lanthipeptides,[535] and hence the first examples of SCS were reported for these compounds.[503,536]

The class II lanthipeptide synthetases ProcM, NukM, HalM1 and HalM2 (section 3.1.2), and the class I machinery of nisin (section 3.1.1) were heterologously expressed with their respective substrates in *E. coli* and shown to be fully active. The relaxed substrate specificity of ProcM[497] was used for the proof-of-concept *in vivo* incorporation of ncAAs in ProcA3.2. The simultaneous expression of ProcM, ProcA3.2 and an orthogonal tRNA/amino acyl-tRNA synthetase pair allowed the incorporation of the photo-crosslinking residue *p*-benzoyl-L-phenylalanine.[536] Subsequently, similar class II lanthipeptide production systems have been engineered using the lacticin 481 and nukacin ISK-1 systems. Variants containing hydroxy acid derivatives of Lys, Phe, and Tyr in the first position of the core peptide resulted in an ester bond connecting LP and core peptide, thus allowing cleavage of the LP by simple hydrolysis.[537] In addition, substitutions of Trp19 and Phe21 of lacticin 481, which were shown with synthetic peptides to lead to improved variants (section 7.4.1), were produced using SCS technology.[538] The range of lanthipeptide producing strains that can incorporate ncAAs has also been extended. Recently, the incorporation of Boc-Lys in the class I lanthipeptide nisin was achieved with the pyrrolysyl pair in *E. coli* for screening purposes and then transferred to *L. lactis*.[539] The constitutive expression of *pylRS* greatly simplified the number and/or size of vectors required, thereby making the expression chassis more stable and with faster growth. Additionally, constitutive expression of amino acyl-tRNA synthetases increased the final yield.[539]

An improvement in ncAA incorporation in class I lanthipeptides in *E. coli* has been the supplementation of tRNA[Glu],[538,540] required by NisB to glutamylate the Ser/Thr residues prior to dehydration (section 3.1.1).[49] Thus, Ser5 could be replaced by keto-, azide or acetylene containing amino acids with yields up to 5 mg/L providing sufficient material for downstream orthogonal chemistry.[540] With increased product homogeneity, remodeling nisin's ring structure was also accomplished. The typical lanthionine thioether crosslink was replaced using *p*-chloroacetamide phenylalanine that can react non-enzymatically with cysteine. Although the antimicrobial activity of nisin was lost, this study established proof-of-principle for ring chemistry alteration *in vivo*.[540] Other improvements for the use of SCS with the nisin system involved fine-tuning the expression levels of the biosynthetic enzymes and the ncAA incorporation machinery, and the use of an expression host lacking endogenous amber stop codons (for more discussion of this strain, see below).[538] Although successful, production yields decreased by 50–100-fold compared to production of nisin in *E. coli* without ncAA incorporation.

The class II lanthipeptide cinnamycin (see sections 3.1.2 and 5.10) has been produced with ncAAs using amber suppression with the *pylRS* pair in the Gram-positive heterologous host

Streptomyces albus.[541] In this case, the complete cinnamycin biosynthetic cluster (similar in structure to duramycin and the divamides, Fig. 83), including tailoring enzymes was expressed together with a TAG-encoding core peptide. Notably, Asp hydroxylation by CinX was not complete and therefore CinX was eliminated from the production system to gain homogeneity in the final product and increase the production yield 5-fold. Considering that non-hydroxylated cinnamycin is less bioactive than the fully modified peptide, this observation could indicate that the immunity determinants are not fully functional in the heterologous host. Thus, full modification of the core peptide in heterologous hosts might not be advisable if a high titer is desired. Strategies that may increase the yield include production of the fully modified peptide with the LP still attached for *in vitro* activation. [535,536,542–544]

In addition to lanthipeptides, other RiPP families have been produced *in vivo* using codon reprogramming. The complete cyanobactin pathway (section 3.6) leading to the cyanobactin trunkamide was reconstituted in *E. coli* as the first example of a multistep RiPP assembly platform with ncAA incorporation.[503] Cyanobactin structural genes often contain two core peptides. Thus, mutating the second core peptide to introduce the amber codon, while keeping the first cognate core peptide intact, provided an internal control of production. This work demonstrated broad substrate tolerance of the cyanobactin modification machinery. Also, it showed that highly mutated core sequences linked to the LP and flanked by RSs were modified, provided the last amino acid in the core peptide is a cysteine that is subsequently heterocyclized.[503] A thorough adjustment of the plasmid system and expression timing of the different enzymes was required for the production of compounds with the right modification pattern.[503,545] Tuning of expression was also required for the amino acyl-tRNA synthetase for ncAA incorporation. In this system, constitutive expression of the amino acyl-tRNA synthetase rendered the highest yield of ncAA-containing cyanobactins.

A systematically optimized production system for ncAA-containing thiopeptides (section 3.2) has been constructed in *B. cereus.*[546] Several DNA-regulating sequences (promoter, terminator and Shine-Dalgarno sequence) were assayed to control expression of tRNA^{Pyl} and a codon optimized tRNA^{Pyl} synthetase using a TAG-containing GFP reporter. Thus, increased fluorescence was paired to optimal promoter combinations for each member of the orthogonal pair. The production of thiocillin variants containing an amber codon at different positions together with a chromosomally integrated *tclABCDI* cluster under the control of native regulatory systems, allowed the expression of ncAA-containing thiocillin variants albeit with reduced production yields and antimicrobial activity. Interestingly, an alkyne functionalized Lys derivative was used to orthogonally incorporate a biotin attached to a photo-reactive diazirine. This thiocillin derivative was used as a photocrosslinking probe to determine the natural target of thiocillin, showing binding to protein L11 of the 50S ribosome.[546]

A sactipeptide production system containing the radical SAM enzyme AlbA responsible for the sulfur-to-α-carbon (sactionine) linkages in subtilosin A (section 3.9) has been heterologously expressed with an *O*-methyl tyrosine-tRNA synthetase pair[547] in a recombinant TAG-codon deprived *E. coli* strain.[548] The use of such strains can, in principle,

reduce the synthesis of large aberrant proteins encoded in the chromosome (*vide infra*). Notably, the heterologous expression system could better tolerate mutations in the Phe residues involved in sactionines than the native system in *B. subtilis*, although the stereochemistry of the variants has not yet been determined. Similar *E. coli* expression systems for the lasso peptides microcin J25 and capistruin (section 3.8; Fig. 38) have been developed.[529,549] Whereas the amber codon in the lasso tail reduced capistruin production, mutations of microcin J25 ring, loop and lock residues to Phe derivatives allowed production of the engineered compounds. The production yield was more dependent on the chemical structure of the ncAA than on the position, as has been observed also with other RiPP classes. The presence of ncAAs decreased the antimicrobial activity of the variants to a variable degree depending on the position and the structure of the ncAA. The ability to incorporate *p*-bromophenylalanine into microcin J25 was critical to the solution of the crystal structure of the RNA polymerase-microcin J25 complex.[550]

Engineering approaches using peptides and proteins containing ncAAs obtained by SCS offers opportunities for improved protein production. In this sense, the ability of macrocyclases to stabilize peptides and proteins and the combination with click-chemistry represents a robust and potent route to improve potential peptidic pharmaceuticals. As an example, the remarkable promiscuity of butelase-1 as a macrocyclase (section 3.19) and its tolerance to ncAAs (see section 7.4.1) has been exploited on dihydrofolate reductase (DHFR).[551] Expression in *E. coli* of DHFR containing ncAA that display alkyne groups and a C-terminal extension with the Asn-His-Val recognition sequence for butelase-1 allowed the production of a cyclic DHFR variant. Next, CuAAC was used to conjugate either biotin or a cell-penetrating peptide to the cyclic DHFR for enzyme inmobilization or intracellular delivery, respectively. The cyclized enzyme survival time inside cells was longer than that of linear counterparts.

Like SPI, the SCS method has specific limitations. The orthogonal tRNA that recognizes the stop codon is competing with release factor-1 (RF1). The function of RF1 is to recognize the amber stop codon and, by binding to it, to facilitate the termination of translation. When this happens, the protein is truncated at the site at which the ncAA was intended to be incorporated.[552] Several methods have been described where the competition between ncAA incorporation and RF1 binding was improved towards the former *e.g.* by engineering of the orthogonal tRNA[553] or directed evolution of its tRNA-synthetase.[552] In one study, the authors replaced all 321 amber stop codons in an *E. coli* expression strain with ochre stop codons, allowing complete deletion of RF1 from the genome, whilst keeping the resulting C321.Δ1 strain viable.[548] In essence, the UAG codon was completely repurposed. C321.Δ1 showed improved applicability for incorporation of ncAAs, without reducing fitness and has been used for ncAA incorporation in RiPPs.[538,547] A second problem is that near-cognate tRNAs, with anti-codons strongly resembling that of the amber stop codon, can mismatch and incorporate their canonical amino acid instead of the ncAA.[554] This problem especially arises when RF1 is deleted.[555] As these near-cognate tRNAs are essential, the problem can hardly be circumvented in living cells.

Both of the aforementioned SCS limitations are addressed in cell-free CFPS systems. CFPS encompasses a range of protein biosynthesis methods that employ biological machinery

without using intact, living cells. Hence, essential cellular mechanisms that hamper ncAA incorporation can be removed without consequence. A typical CFPS setup involves a cell lysate, containing the necessary protein synthesis machinery, supplemented with a range of compounds or enzymes to support or modify the production effort. Using this method, the aforementioned problem of near-cognate tRNAs competing with orthogonal tRNAs can be addressed. For instance, near cognate tRNAs for the amber stop codon in the synthesis mixture have been inactivated by adding antisense oligonucleotides, which led to a 5-fold decrease in near cognate suppression without impairing normal protein expression.[555]

While the previously described advancements have not been widely implemented in the CFPS production of ncAA-containing RiPPs, this approach has recently received more attention. C321. 1 has been used as a basis for the CFPS system, allowing for cell-free synthesis without RF1.[556] When taking the recent advancements into account, a logical next step is the incorporation of ncAAs in RiPPs, using one of the improved SCS methods by CFPS. Recently, the FIT system (section 7.3; Fig. 96), in which multiple sense codons originally encoding proteinogenic amino acids can be simultaneously reprogrammed to designated ncAAs, has allowed *in vitro* production of ncAA-containing RiPPs. The combination of FIT-mediated genetic code reprogramming with RiPP biosynthetic enzymes has been demonstrated for *in vitro* production, not only of peptides with novel azoline derivatives as previously described[510] (Fig. 96A), but also of hybrid thiopeptides with a variety of ncAAs such as *N*-methylated amino acids, D-amino acids, β-amino acids, and hydroxy acids.[512]

In summary, proof-of-concept has been achieved for ncAA incorporation into diverse RiPP classes and heterologous hosts. Mutasynthesis for analytical approaches, when the PTM enzymes are available and the ncAAs are compatible (section 7.4.1), using peptide synthesis can provide a suitable starting point for screening. *In vivo* technologies, in particular stop-codon suppression, are being optimized for higher production yields and increased homogeneity in the final product. Special attention should be paid to requirements such as cofactors or maturation conditions[540,547] that each enzyme in the biosynthesis route might have, as well as compartmentalization and expression timing of the different enzymes in complex pathways.[557] Optimization of growth conditions, promoters, Shine-Dalgarno sequences and cluster arrangement can influence the success or failure in RiPP engineering. Thus far, constitutive expression of the tRNA synthetase and inducible expression of precursor peptides, tRNA and biosynthetic enzymes have been the most successful strategies. Last, design of the biosynthesis of non-cognate peptides must also consider sensitivity of the heterologous host to the new RiPP analog, which can be detrimental for high yield production.

7.5 RiPP mutasynthesis and engineering strategies based on growth conditions

An alternative means of accessing RiPP analogs is feeding non-natural building blocks or applying alterations of the growth medium and fermentation conditions. Growing microbisporicin-producing streptomycetes in the presence of NaBr was sufficient to change the typical chlorinated tryptophan in this class I lanthipeptide (section 3.1.1) into the brominated form, which was more active than the parent compound.[409] Considering that

microbisporicin is undergoing clinical evaluation, this is an important achievement. Similarly, reconstruction of the quinaldic acid pathway for the thiopeptide thiostrepton in *Streptomyces laurentii* (sections 3.2 and 5.7.3.1) showed that indolic ring rearrangement involves the formation of an intermediate ketone 4-acetylquinoline-2-carboxylic acid (Fig. 90) that can be externally supplied. The stereospecific oxidoreductase acting on this ketone can use a 6-fluorinated variant that serves as a substrate for the downstream processing enzymes, resulting in a fluorinated thiostrepton analog that was 4-fold more active than the original compound.[558] Similarly, fluorinated Trp was used for the fluoroindolic acid ring closure of nosiheptide by NosL (section 5.2).[344] Halogenated indole supplementation provides a certain flexibility in the ring closure of some thiopeptides, and may avoid side effects caused by forced feeding using Trp-derived ncAAs. Notably, studies with the cyanobactin pathway showed that changes in the growth media and conditions can be crucial to increase yields (up to 30,000-fold) due to alteration of the metabolic routes in the heterologous host.[325]

Expression of BGCs in the cyanobacterium *Nostoc punctiforme* was shown to be greatly upregulated by high density fermentation conditions involving high concentrations of bicarbonate.[321] These conditions resulted in expression of four RiPP gene clusters including the *mvd* BGC, which led to the discovery of a new microviridin (section 3.15) that is not acylated at its N-terminus but instead is extended with different numbers of amino acids originating from the leader peptide.[321] In addition to finding conditions that allowed isolation of previously uncharacterized compounds, these findings also suggest that leader peptide removal may be a stepwise aminopeptidase process similar to that discussed in section 4.4.4.

7.6   Accessing bioactive scaffolds by rational design using RiPP biosynthetic enzymes

As discussed in section 3.14, rSAM enzymes convert α-amino acid dipeptide sequences into β-peptide structures (Fig. 50). In addition to the extended backbone as a new feature, the introduced carbonyl group is also of interest as a handle for further manipulation. Ketoamides are known pharmacophores of non-ribosomal and synthetic peptides that inhibit Ser and Cys proteases, with the ketone functional group important in mechanism-based inhibition. Examples of therapeutic relevance are the drugs boceprevir and telaprevir, peptidomimetics used for hepatitis C treatment that were developed from synthetic peptide leads. Exploring the promiscuity of the splicease, six amino acids around the splice site of its substrate were modified to mimic the boceprevir lead sequence, resulting in successful conversion.[41] The keto group could also be modified via hydrazone formation to access conjugates, exemplified by a fluorescent moiety that was attached to the spliced core peptide. Thus, diverse applications of spliceases might be envisaged.

Similarly, the dehydrogenase NpnJ$_A$ that reduces Dha to D-Ala residues during lanthipeptide biosynthesis (section 5.1.2) modified a variety of non-lanthipeptide substrates. The enzyme was used to generate an analog of the heptapeptide dermorphin, a μ-opioid receptor agonist produced by South American frogs.[334] These results highlight the substrate tolerant nature of this enzyme and its potential for bioengineering.

Integrin binders can inhibit angiogenesis during tumor development, thereby reducing tumor growth, which makes them interesting molecules for drug discovery and development. In proof-of-principle studies, the lasso peptide microcin J25 (section 3.8) was used as scaffold for epitope grafting employing the RGD-integrin-binding motif.[559,560] The integrin binding motif was also inserted in ProcA2.8 at three different positions providing bicyclic compounds with nanomolar binding affinity upon reaction with the class II lanthipeptide synthetase ProcM (section 3.1.2). Cyclization improved the inhibition capacity by one order of magnitude compared to the linear counterpart and provided proteolytic resistance against trypsin.[561]

7.7 RiPP library generation and peptide display methods

7.7.1 High-throughput screening for new-to-nature RiPP discovery and new biological activity—In RiPP research, the analysis of natural point mutants provides valuable information on the tolerance of PTM enzymes, on essential motifs in the LP, on enzyme processing and kinetics, and on the impact on biological activity. However, these studies involve only a local alteration of the sequence, the effect of which may be only modest compared to larger sequence variation. DNA synthesis technologies provide a powerful and inexpensive way to access large sequence variations, saturating each position with all the amino acids or only a subset of them depending on the degenerate codons used. The main challenge of such studies is the identification of a suitable host and screening methodology to produce libraries and test the outcome, respectively. Different hosts, designs and screening methods have been developed in recent years using diverse RiPP biosynthesis machineries.

An NNT codon library coding for 15 possible amino acids was used to simultaneously replace three positions in the lasso peptide microcin J25 (section 3.8), providing 3375 different clones.[562] For screening purposes, an *E. coli* host expressing the structural gene library, immunity protein and PTM enzymes under the control of three different promoters was used. In this construction, the gene library expression was controlled by IPTG, the enzymes were constitutively expressed and immunity was induced by arabinose. Thus, the library was replicated on three plates, one containing IPTG and glucose, the second IPTG and arabinose, and the third with no inducer. Clones that were unable to grow with IPTG and glucose were used in a second screen using supernatants of cultures grown with IPTG and arabinose for antimicrobial activity against *Salmonella* serotype Newport and *E. coli*. Twelve new improved variants of microcin J25, against one or both strains, with up to three simultaneous mutations, were isolated.[562] In another approach, the lasso peptide astexin-1 has been proposed as a suitable candidate for library screening (including surface exposed libraries, *vide infra*) owing to the demonstration of high flexibility in the C-terminal region of its precursor peptide. Fusions of the precursor with GFP or leucine zipper protein A1 were still modified, indicating that a bulky C-terminal protein domain does not abolish production.[563]

Macrocyclic peptide libraries have been developed using the fungal machinery of the cyclic hexapeptide cycloamanide in *E. coli*.[233] The POPB catalyzing the cyclization reaction (section 3.18; InterPro family: IPR002470) was used with a set of substrate variants with

different lengths fused to the maltose binding protein (MBP), and peptides up to 16 amino acids were cyclized *in vitro*. An NNK library randomizing three positions in the core peptide maintained key residues for cyclization, including the important C-terminal Pro in the LP. Random selection of transformants identified a large diversity in the sequences. For faster production screening, groups of eight colonies were grown together. After *in vitro* removal of MBP and cyclization, MS analyses confirmed that most peptides were cyclized, except for those with charged residues or Tyr at position 1.

An extended screening method for circular RiPPs including heterocyclization and prenylation, was developed with the cyanobactin pathway in *E. coli* (section 3.6).[503] Trunkamide was taken as a scaffold and a Pro was maintained in position 3 and a Cys as the last amino acid of the core peptide since a heterocycle is mandatory at this position. Single, double, triple and quadrupole mutant libraries were synthesized in which any codon was introduced. Therefore, stop codons were detected as well as frameshift mutations. Manual replication of the clones in growth media, extraction and mass-spectrometry coupled to DNA sequencing, demonstrated that sequences unrelated to trunkamide were processed, although some amino acid residues were never present at certain positions and some others, such as basic residues, were unfavorable. This study provided an extensive evaluation of the substrate tolerance towards heterocyclization and prenylation.[488]

In vivo thiopeptide expression (section 3.2) has been optimized (30-fold yield improvement) using modified *Streptomyces coelicolor*, in which the BGCs coding natural products had been previously deleted.[564] In this strain, a vector containing the entire cluster with the structural gene inactivated was complemented with an *E. coli-Streptomyces* shuttle vector harboring a library of structural gene variants. Saturation mutagenesis with NNK degenerate primers allowed the creation of seven libraries, six with randomized positions in the macrocycle and one outside of it. Screening of the library for antimicrobial activity was done by assays in solid media. In addition to obtaining valuable information about the impact of mutations on PTM installation, a variant with improved activity was isolated with this methodology. Similarly, a site-saturation library was generated varying each position in the precursor peptide that is incorporated into the macrocycle of the thiopeptide thiocillin. Expression in *B. cereus* and antimicrobial screening resulted in eight variants with improved activity.[565]

A microviridin library and screening system was developed to isolate specific protease inhibitors (see section 7.2).[566] Simultaneous mutation of five residues was achieved based on previous single point mutant analyses. Thus, three amino acids were used for positions 1, 2, 3 and 15, and ten possibilities were created for position 5. A previously developed heterologous production platform in *E. coli* was applied.[214] In this platform, essential RiPP-regulatory sequences were identified and used, as well as a minimal LP sequence. Several clones produced a compound with low inhibitory concentration against at least one of the proteases tested. Position 5 was pivotal in protease selectivity, thus saturation mutagenesis on this position was performed and the products screened in a colorimetric assay for protease specificity. Subsequently, a *p*-nitroanilide fused to peptides specifically targeted by one protease were mixed with culture supernatants of the producer cells to assay directly for

protease inhibition. Eventually, variants F5L, F5V and F5K were obtained as subtilisin-specific inhibitors with no activity on chymotrypsin or thrombin.

An alternative method that does not require peptide purification from *E. coli* fermentations, and can test partly modified microviridins has also been developed. A LP covalently bound on the ATP-grasp ligases MvdD and MvdC (section 3.15), together with the leader independent *N*-acetyl transferase MvdB were used for one-pot *in vitro* synthesis of microviridins.[215] Two core peptide libraries containing any amino acid at position 5 of either microviridin K or microviridin B were synthesized and processed with the three enzymes, and partially or fully modified peptides were tested. In addition to determining unfavorable amino acids at this position that prevented correct cyclization, the libraries were evaluated for subtilisin and trypsin inhibition with the colorimetric assay previously mentioned.[566] Protease-specific inhibitors with potencies in the low micromolar or nanomolar range were identified, highlighting the effect of each ring and acetylation on activity.[215]

Several studies have performed extensive library screening of lanthipeptides (section 3.1) with *in situ* activation of candidate peptides by LP removal coupled to antimicrobial activity detection. In one set of studies, the class I lanthipeptide nisin inspired the architecture of the variants.[567] In one approach, the NisA LP was fixed and the cognate core peptide was divided in different sections corresponding to functional domains: a lipid II binding domain, a hinge region, and a membrane insertion/pore forming domain. Each of these sections was diversified with modules originating from twelve lanthipeptides, both class I and class II, for which the structure and mechanism of action was (partly) known, connected by designed linkers that confer flexibility resembling the hinge region of nisin. Although the N-terminus was limited to conserved sequences from nisin and gallidermin to keep a proper cleavage site for the protease NisP (InterPro family: IPR008357)[311] and to facilitate NisBC modification (section 3.1.1),[501] the remaining regions were designed with larger variability. [567] A library encoding all possible combinations of these modules was assembled by controlled pore glass synthesis combined with a mix-and-split approach (ca. 6,000 possible genes). The library was cloned and maintained in *E. coli* and used to transform *L. lactis* expressing NisBCT but not the protease NisP. External NisP addition resulted in activation by LP removal and the library was screened using a miniaturized Fleming assay that was termed nano-Fleming. In this screening platform, the producer cells were resuspended together with the sensor strain in an alginate solution and encapsulated by dropping the alginate cell suspension in a $CaCl_2$ solution. By manipulating dropping speed and vibration, the particle size of the alginate beads was set to an approximate diameter of 0.5 mm and volume of 65 nL. These dimensions ensured an average of 0.3 producer and 150 sensor cells per alginate bead, effectively converting every bead into a typical Petri dish for antimicrobial activity testing. The beads remained isolated from the environment by incubation in a hydrophobic phase, preventing crosstalk between the beads. As the producer and sensor strains were labeled with red and green fluorescence markers, respectively, beads that produced an active compound after NisP cleavage, could be selected based on their fluorescence emission. A particle sorting device efficiently selected beads where the green fluorescence was low, indicating that an active lanthipeptide was produced. These beads were used for further isolation of the producer strain and sequencing for the identification of the lanthipeptide gene sequence. This system allowed the screening of 3.2×10^5 nL reactors

(ensuring full coverage of the library) from which 839 clones were isolated. A secondary assay using the 205 unique peptide sequences retrieved showed that even active peptides produced in low yield were identified during particle sorting indicating high sensitivity of the method. Purification of the lanthipeptide and MS characterization showed that even peptides with every position occupied by a module from a different lanthipeptide were present in the positive hits. Although the production yield and heterogeneity in dehydration patterns are areas for improvement, this strategy allowed the identification of novel hybrid lanthipeptides with low MIC values against several Gram-positive pathogens, including strains resistant against nisin.[567] The screening platform shows great versatility and potential for further development with other RiPP families or indicator strains for targeted antimicrobial discovery.

A second lanthipeptide screening platform was recently reported using class II lanthipeptide synthetases in *E. coli* (section 3.1.2).[568] Spatial separation of the leader peptidase and the precursor modification machinery was used as in the previous system to ensure high production of the modified precursor before activation and antimicrobial activity screening. In this strategy, the leader peptidase LicP from the lichenicidin gene cluster[313,569] was fused to the OmpA secretion signal leading to accumulation of the protease in the periplasm of *E. coli*. The PTM enzyme and a library of precursor peptides were co-expressed in the cytoplasm. Last, the producer organism was engineered to induce autolysis involving phage λ SRRz under the control of a temperature-regulated promoter. Thus, increasing the incubation temperature induced cell lysis, removing the physical barrier between the leader peptidase in the periplasm and the fully modified core peptides in the cytoplasm. Lysis thus results in core peptide release and diffusion around the producer colony causing inhibition of the sensor strain if the mutant is active. This in-colony activation system has been used with the Halβ peptide from the two-component lanthipeptide haloduracin, where the LP was modified to include a LicP cleavage sequence. An NNK saturation library was used for each residue that is not essential for ring formation, and after induction, lysis and addition of Halα for full activity, halo sizes and modification extent of the compounds were analyzed. This approach allowed the creation of an activity-based heat-map for each position and each amino acid. Although the controls indicated that lysis and/or compartmentalization are not completely tight, and the activity can be affected by activation rate, diffusion, host protease activity and production level (as with most heterologous systems discussed in section 7), the system constitutes a versatile platform for screening.[568]

In addition to manipulating their native bioactivities, RiPPs have also been used as a scaffold for completely new functions. Lanthionine rings introduce stable thioether bonds that encompass a variable number of amino acids. Pioneering work was performed using NisBC from the BGC of the class I lanthipeptide nisin (section 3.1.1) to stabilize the peptide hormone angiotensin, replacing the natural disulfide bridge by an engineered lanthionine.[570] This structural change rendered a more potent and stable molecule with promising clinical applications.[571] Class II lanthipeptide synthetases (section 3.1.2) have also been tested for such purpose. ProcM displayed high tolerance to sequence variability in the ring sequences of one of its substrates, ProcA2.8, as well as the linker region connecting the two rings naturally present in this molecule. Several point mutations, deletions and insertions in the first ring were tolerated, although the second ring was not amenable for insertions.[561]

In addition to grafting protein-binding motifs on a RiPP scaffold (section 7.6), development of bioactive peptides that can disrupt protein-protein interactions could have interesting medical applications. Reverse two-hybrid systems provide a robust screening platform for such inhibitors.[572] NWY codons were used for randomizing the positions within the two rings of the class II lanthipeptide prochlorosin 2.8 (section 3.1.2). This codon usage results in eight different amino acids at each position and avoids both stop codons as well as Ser, Thr and Cys that might interfere with the canonical ring formation and create aberrant rings. A variant library of 10^9 members was used to transform *E. coli*, resulting in a reduction of the library size to 10^6 due to limited transformation efficiency. This library was used with a previously established reverse two-hybrid bacterial system involving the p6-UEV interaction. P6 is an HIV protein that interacts with the TSG101 human protein at the ubiquitin E2 variant domain (UEV). If this interaction is blocked, viral egress can no longer take place. Briefly, in the reverse two-hybrid system, p6 was translationally fused to P22 and UEV to 422, forming a P22–422 transcriptional repressor complex when p6 and UEV interact. The repressor prevents transcription of *HIS3*, kanamycin resistance gene and *lacZ* leading to a strong growth defect. When the p6-UEV interaction is blocked by a member of the RiPP library the repressor is released and transcription is enabled.[573] Using this system, faster growing colonies were selected from the library and false positives were removed. Additional controls involved testing initial hits in a different reverse two-hybrid system to rule out non-specific inhibition.[572] Out of 80 initial hits, one passed the three selection rounds and was purified. Notably, its sequence was unrelated to known inhibitors of the p6-UEV interaction. Thus, this large randomization effort gave access to a novel binding inhibition motif, highlighting the advantages of an unbiased screening process for the identification of new therapeutic targets. After LP removal the protein-protein inhibitory activity *in vitro* was potentiated to low micromolar concentrations and binding to UEV was dependent on lanthionine ring formation. Since the size of this compound compromised its cell permeability, it was fused to a Tat-peptide for transport inside eukaryotic cells where viral assembly was inhibited at low concentrations.[572] This system can be further optimized by reducing plasmid size to increase transformation efficiency.

7.7.2.   RiPP surface display for screening—Surface display technologies facilitate identification of surface anchored peptides that bind to a protein or receptor of interest. This interaction can be traced back to the genotype to identify the sequence of the positive hit. The technology enables evaluation of large combinatorial libraries. Bacterial, yeast and phage display technologies have been implemented with RiPP biosynthesis machineries providing examples that can serve as a starting point for different discovery platforms. Examples of epitope grafting and discovery of high-affinity binders or disruptors of protein-protein interactions have been reported.

A bacterial surface display system for lanthionine-containing peptides modified by the class I lanthipeptide biosynthetic machinery of nisin (section 3.1.1) was developed using *L. lactis* as an expression host.[574] The nisin precursor peptide was fused to a sortase recognition motif and co-expressed with NisBC. Sortases catalyze peptide bond formation between an LPXTG sequence in a secreted peptide and a short peptide on the peptidoglycan. The display system produced nisin anchored to the cell wall as demonstrated by adding trypsin to

the culture, thus releasing active nisin that inhibited a sensor strain in co-culture. Next, a library of a randomized 3-mer sequence using the NNS codon flanked by Ser and Cys was successfully dehydrated by NisB and cyclized by NisC. The library of 8,000 possible sequences was screened using magnetic beads coated with streptavidin yielding a potent binder with the sequence SMNVC that was correctly cyclized.[574] More recently, the system was used to screen NisB variants that are capable of dehydrating precursor peptides that are not good substrates for wild-type NisB.[575]

Another RiPP display system targeting neuropilin-1 and neuropilin-2 (involved in angiogenesis and possible anticancer targets[576]) has been developed in *E. coli*.[577] This system was inspired by cyclotides (section 3.19), macrocyclic peptides from plants (for a review of peptide grafting using circular plant peptides, see reference[578]). Since surface display requires a covalent bond between the RiPP and the surface protein, macrocyclization of the N- and C-termini is not feasible. Thus, the lactam forming step was removed from the expression system relying on cystine-knot formation for cyclization. Cyclotides have shown great sequence tolerance as long as the knotted disulfide bonds are correctly positioned. Kalata B1 was fused to the circularly permutated OmpX outer membrane protein.[579] Loop 6 in kalata B1 was randomized to generate a library of 6×10^9 possible sequences that was tested for neuropilin-1 receptor binding through successive rounds of cell sorting. The best candidate was used to construct a second library randomizing additional positions in loop 5. The best three hits bound the neuropilin-1 receptor with a K_D of 40–60 nM, which was 200-fold better than the best hit after randomizing only loop 6. Chemical synthesis of acyclic and cyclic derivatives of the hits showed that the cyclic peptides displayed increased protease resistance against most of the proteases tested and more potent inhibition of cell migration during *in vitro* testing.[577]

More recently, phage display of class II lanthipeptides (section 3.1.2) has been achieved using the ProcM enzyme in *E. coli* as a host to screen for two novel biological activities.[580] N- and C-terminal fusions or the prochlorosin precursor ProcA3.3 to the pIII protein of the M13 phage were tested. The unusual and less commonly used C-terminal fusion provided improved expression and cyclization due to longer residence time in the cytoplasm, where ProcM was expressed. Conversely, the N-terminal fusions did not result in modification. Thus, the expression systems used consisted of the pIII coat protein followed by a linker and the leader and core peptides. A C-terminal His-tag was added for convenience. Whereas most of the expression systems used in RiPP engineering use high-copy number vectors and express the PTM enzymes from strong inducible promoters, low constitutive expression provided the best results for this system.[580] Three libraries based on the topology of prochlorosins 1.1, 2.8 and 2.11 were synthesized. In these constructs, the Cys and Ser/Thr residues were kept at their original position and the other residues in the core peptides were varied resulting in 10^9 sequences for each library. The phages pooled after expression of the substrate libraries with ProcM were evolved for streptavidin or urokinase-type plasminogen activator (uPA) binding during three rounds of selection. The streptavidin selection provided 82 hits corresponding to two unrelated sequences. One was dehydrated but linear, whereas the other contained one essential lanthionine ring. Screening on the more relevant biological target uPA, involved in cancer development and many other pathologies,[581] provided a total of 368 clones from the three libraries that shared common motifs.[582] Purification of selected

variants demonstrated that the peptides were modified and bound to uPA, inhibiting its catalytic activity. Analysis of the identified hits also showed some heterogeneity in the modification state of the displayed peptides, which can hamper the identification of the best binder.

A second lanthipeptide phage display system using the modification machinery of class I lanthipeptides (section 3.1.1) and N-terminal fusions of the precursor peptide to protein III was also reported.[583] Since phage assembly takes place in the periplasm and the Sec-mediated transport cannot translocate structured proteins easily, Tat-mediated transport was chosen. The fully modified nisin precursor peptide containing a Tat export signal was detected in the periplasm of *E. coli* upon modification by NisBC expressed in the cytoplasm. Thus, for phage display a gene was constructed encoding the Tat signal peptide followed by a His-tagged nisin LP that was attached to a library of nisin core peptide variants that was fused to a truncated pIII. The library randomized the five residues in rings A and B of nisin with an NNK-codon (3.2×10^6 possible clones). Co-expression with NisBC and helper plasmid encoding wild-type pIII resulted in phage displaying the modified nisin variants. Expression of the library was followed by digestion with externally added leader peptidase NisP to remove the LP (section 4.4.2), thus uncapping the N-terminal rings A and B of the nisin analogs that bind lipid II. The phages were incubated with biotinylated lipid II and binders were recovered for *E. coli* infection and genetic identification of the successful clones. Four clones were enriched in the selection. One of them was expressed yielding a correctly modified peptide. Surprisingly, this variant lacked antimicrobial activity due to binding to lipid II in a different way than nisin.[583]

The first RiPP-inspired yeast display system was developed using the cyclotide scaffold (section 3.19) to produce libraries of cystine-knot peptide (knottins)[584] that could bind to the integrin αvβ3. The sequence of the cystine-knot peptide AgRP was fused to the yeast surface agglutinin Aga2. Aga2 is attached to Aga1 by disulfide bonds and the latter is covalently anchored to the yeast surface. The RGD integrin-binding sequence was fixed at positions 3–5 in AgRP loop 4, whereas the surrounding six amino acids were randomized providing a library of 5×10^6 clones. After three selection rounds using cell sorting several clones were isolated. Usually a Gly was located in front of the RGD sequence followed by hydrophilic/charged amino acids. These peptides bound integrin with nanomolar affinity. Next, loops 1–3 of the best integrin-binder were randomized for new yeast display selection, in order to increase the affinity. Although the affinity was not increased, selectivity for αvβ3 over other isoforms was achieved.[584]

The first successful yeast display of RiPPs has been recently reported.[583] C-terminal fusions of a class II lanthipeptide-based library to Aga2 were explored using the precursor peptide of lacticin 481, LctA, expressed with the synthetase LctM in *S. cerevisiae*. In these conditions LctA was fully modified and the rings correctly formed. Similar results were obtained using the class II lanthipeptide system of HalA2 and HalM2 indicating that the N-terminal Aga2 domain does not hamper enzymatic modification, similar to the findings in the case of MBP or the pIII coat protein for phage display (see above).[580] In order to allow PTM and correct surface display, the design in the yeast platform required appropriate compartmentalization signals for the enzymes and the combinatorial peptides. A strep-tag added on LctA/HalA2

allowed the detection of the peptide on the surface and tandem MS analysis demonstrated their correct modification. αvβ3 integrin binders were selected with a library in which the 12 amino acids of the lacticin 481 ring C were mutated using an NDT-codon library (3×10^6 possibilities). This library ensured that the epitope RGD would be present. Two rounds of fluorescence activated cell sorting provided a fast and sensitive screening method for integrin binders. Nearly 95% of the isolated interactions contained the RGD motif. Expression of the positive hits and structural analysis showed they had the right ring pattern and could bind integrin in the nanomolar range.[583]

8. Outlook

Just seven years after the first comprehensive review of RiPP biosynthesis, the field has exploded in terms of discovery of new compound classes, discovery of new compounds within each class, new genome mining tools specifically designed for RiPPs, and a multitude of engineering tools that take full advantage of the genetically encoded precursor peptides. Moreover, the enzymology of RiPP biosynthesis has continued to reveal unprecented biochemical reactions and substrate recognition is now well established for many systems.

With the new advances have also come new questions and challenges. While individual enzymes are increasingly understood at the molecular level, the mechanisms of communication between biosynthetic enzymes and the structures of enzyme complexes are still mostly unresolved.[93] Similarly, although the interaction of enzymes with their leader peptides, follower peptides, and recognition sequences is now understood for a subset of RiPP biosynthetic pathways, the interactions with the core peptides are much less well established, especially for enzymes that operate iteratively on substrates that are changing in structure with each successive reaction.

RiPPs are currently also still underdeveloped in terms of commercial usage, but the advances in discovery and engineering should aid in future applications. A particularly interesting observation is that RiPPs appear to be highly abundant in microbiomes, and several compounds have been linked to human disease and disease prevention.[585,586] At present the RiPP field is defined largely based upon the chemistry of microbial metabolism, with a few exceptions in animals and plants.[587] In the longer term, it will be worth exploring commonalities with human and animal hormones and signaling peptides. These peptides seem to occupy the domain of primary metabolism from the anthrocentric perspective, but in comparison to bacteria, higher animals occupy a small branch on the evolutionary tree, and their products are also quite specialized to a relatively narrow taxonomic branch in comparison to the much larger web of life.

Other areas that will likely see new developments are structure prediction based on the make-up of the BGC, improved understanding of the mode of action of RiPPs, and further exploration of the many exciting engineering approaches described in this review. Thus, the future holds tremendous potential.

Acknowledgments

Biographical description

The authors of this community review are a multidisciplinary and multinational group of scientists that are all working on the biosynthesis, discovery, and engineering of RiPPs. Oscar Kuipers, Wilfred van der Donk, Jörn Piel, Douglas Mitchell and members of their laboratories were the coordinating authors of the review. Manolo Montalban, Auke van Heel, Jakob Viel and Oscar Kuipers (top row, left-to-right) have investigated RiPP biosynthesis in bacteria with a focus on the microbiology and engineering of lanthipeptides. Thomas Scott and Jörn Piel (second row, 1st and 2nd) work on the discovery and biosynthesis of chemically distinct, bioactive RiPPs. Sangeetha Ramesh and Douglas Mitchell (second row, 3rd and 4th) focus on the enzymology and discovery of new RiPP classes and develop new bioinformatic tools. Imran Rahman and Wilfred van der Donk (bottom row, left to right) investigate the enzymology, discovery and engineering of RiPPs.

References

1. Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian K-D, Fischbach MA, Garavelli JS, Göransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Müller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJT, Rebuffat S, Ross RP, Sahl H-G, Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Süssmuth RD, Tagg JR, Tang G-L, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM and van der Donk WA, Nat. Prod. Rep, 2013, 30, 108–160. [PubMed: 23165928]

2. Li Y and Rebuffat S, J Biol Chem, 2020, 295, 34–54. [PubMed: 31784450]

3. Funk MA and van der Donk WA, Acc. Chem. Res, 2017, 50, 1577–1586. [PubMed: 28682627]

4. Yang X and van der Donk WA, Chemistry – A European Journal, 2013, 19, 7662–7677.

5. Plat A, Kuipers A, Rink R and Moll GN, Current protein & peptide science, 2013, 14, 85–96. [PubMed: 23441895]

6. Schmidt EW and Donia MS, Methods Enzymol, 2009, 458, 575–596. [PubMed: 19374999]

7. Demerec M, Adelberg EA, Clark AJ and Hartman PE, Genetics, 1966, 54, 61–76. [PubMed: 5961488]

8. Hayakawa Y, Sasaki K, Adachi H, Furihata K, Nagai K and Shin-ya K, J Antibiot (Tokyo), 2006, 59, 1–5. [PubMed: 16568712]

9. Izumikawa M, Kozone I, Hashimoto J, Kagaya N, Takagi M, Koiwai H, Komatsu M, Fujie M, Satoh N, Ikeda H and Shin-ya K, J. Antibiot, 2015, 68, 533–6.

10. Izawa M, Kawasaki T and Hayakawa Y, Appl Environ Microbiol, 2013, 79, 7110–3. [PubMed: 23995943]

11. Frattaruolo L, Lacret R, Cappello AR and Truman AW, ACS Chem. Biol, 2017, 12, 2815–2822. [PubMed: 28968491]

12. Kjaerulff L, Sikandar A, Zaburannyi N, Adam S, Herrmann J, Koehnke J and Müller R, ACS Chem. Biol, 2017, 12, 2837–2841. [PubMed: 28981254]

13. Kawahara T, Izumikawa M, Kozone I, Hashimoto J, Kagaya N, Koiwai H, Komatsu M, Fujie M, Sato N, Ikeda H and Shin-Ya K, J. Nat. Prod, 2018, 81, 264–269. [PubMed: 29381067]

14. Santos-Aberturas J, Chandra G, Frattaruolo L, Lacret R, Pham TH, Vior NM, Eyles TH and Truman AW, Nucleic Acids Res, 2019, 47, 4624–4637. [PubMed: 30916321]

15. Umemura M, Nagano N, Koike H, Kawano J, Ishii T, Miyamura Y, Kikuchi M, Tamano K, Yu J, Shin-ya K and Machida M, Fungal Genet Biol, 2014, 68, 23–30. [PubMed: 24841822]

16. Ding W, Liu WQ, Jia Y, Li Y, van der Donk WA and Zhang Q, Proc Natl Acad Sci U S A, 2016, 113, 3521–6. [PubMed: 26979951]

17. Nagano N, Umemura M, Izumikawa M, Kawano J, Ishii T, Kikuchi M, Tomii K, Kumagai T, Yoshimi A, Machida M, Abe K, Shin-Ya K and Asai K, Fungal Genet Biol, 2016, 86, 58–70. [PubMed: 26703898]

18. Ye Y, Ozaki T, Umemura M, Liu C, Minami A and Oikawa H, Organic & biomolecular chemistry, 2019, 17, 39–43.

19. Noike M, Matsui T, Ooya K, Sasaki I, Ohtaki S, Hamano Y, Maruyama C, Ishikawa J, Satoh Y, Ito H, Morita H and Dairi T, Nat Chem Biol, 2015, 11, 71–6. [PubMed: 25402768]

20. Haft DH, BMC Genomics, 2011, 12, 21. [PubMed: 21223593]

21. Ayikpoe RS and Latham JA, J Am Chem Soc, 2019, 141, 13582–13591. [PubMed: 31381312]

22. Peña-Ortiz L, Graça AP, Guo H, Braga D, Köllner TG, Regestein L, Beemelmanns C and Lackner G, Chem. Sci, 2020, DOI: 10.1039/d0sc01172j.

23. Ibrahim M, Guillot A, Wessner F, Algaron F, Besset C, Courtin P, Gardan R and Monnet V, J Bacteriol, 2007, 189, 8844–54. [PubMed: 17921293]

24. Bushin LB, Clark KA, Pelczer I and Seyedsayamdost MR, J. Am. Chem. Soc, 2018, 140, 17674–17684. [PubMed: 30398325]

25. van der Velden NS, Kälin N, Helf MJ, Piel J, Freeman MF and Künzler M, Nature Chemical Biology, 2017, 13, 833–835. [PubMed: 28581484]

26. Ramm S, Krawczyk B, Mühlenweg A, Poch A, Mösker E and Süssmuth RD, Angewandte Chemie International Edition, 2017, 56, 9994–9997. [PubMed: 28715095]

27. Viehrig K, Surup F, Volz C, Herrmann J, Abou Fayad A, Adam S, Köhnke J, Trauner D and Müller R, Angewandte Chemie International Edition, 2017, 56, 7407–7410. [PubMed: 28544148]

28. Freeman MF, Helf MJ, Bhushan A, Morinaka BI and Piel J, Nat. Chem, 2017, 9, 387–395. [PubMed: 28338684]

29. Benjdia A, Guillot A, Ruffie P, Leprince J and Berteau O, Nat. Chem, 2017, 9, 698–707. [PubMed: 28644475]

30. Yahara S, Shigeyama C, Ura T, Wakamatsu K, Yasuhara T and Nohara T, Chem Pharm Bull (Tokyo), 1993, 41, 703–9. [PubMed: 8508472]

31. Hattori J, Boutilier KA, van Lookeren Campagne MM and Miki BL, Molecular & general genetics : MGG, 1998, 259, 424–8. [PubMed: 9790599]

32. Kersten RD and Weng J-K, PNAS, 2018, 115, E10961–E10969. [PubMed: 30373830]

33. Zhang Q, Doroghazi JR, Zhao X, Walker MC and van der Donk WA, Applied and environmental microbiology, 2015, 81, 4339–50. [PubMed: 25888176]

34. Wiebach V, Mainz A, Siegert M-AJ, Jungmann NA, Lesquame G, Tirat S, Dreux-Zigha A, Aszodi J, Beller DL and Süssmuth RD, Nature Chemical Biology, 2018, 14, 652. [PubMed: 29915235]

35. Luu DD, Joe A, Chen Y, Parys K, Bahar O, Pruitt R, Chan LJG, Petzold CJ, Long K, Adamchak C, Stewart V, Belkhadir Y and Ronald PC, Proc Natl Acad Sci U S A, 2019, 116, 8525–8534. [PubMed: 30948631]

36. Pruitt RN, Joe A, Zhang W, Feng W, Stewart V, Schwessinger B, Dinneny JR and Ronald PC, The New phytologist, 2017, 215, 725–736. [PubMed: 28556915]

37. Ronald P and Joe A, Annals of botany, 2018, 121, 17–23. [PubMed: 29182721]

38. Amano Y, Tsubouchi H, Shinohara H, Ogawa M and Matsubayashi Y, Proc Natl Acad Sci U S A, 2007, 104, 18333–8. [PubMed: 17989228]

39. Wei T, Chern M, Liu F and Ronald PC, Molecular plant pathology, 2016, 17, 1493–1498. [PubMed: 26765864]

40. Baba H and Ishibashi T, Adv Exp Med Biol, 2019, 1190, 165–179. [PubMed: 31760644]

41. Morinaka BI, Lakis E, Verest M, Helf MJ, Scalvenzi T, Vagstad AL, Sims J, Sunagawa S, Gugger M and Piel J, Science, 2018, 359, 779–782. [PubMed: 29449488]

42. Haft DH and Basu MK, J. Bacteriol, 2011, 193, 2745–2755. [PubMed: 21478363]

43. Hudson GA, Burkhart BJ, DiCaprio AJ, Schwalen CJ, Kille B, Pogorelov TV and Mitchell DA, J Am Chem Soc, 2019, 141, 8228–8238. [PubMed: 31059252]

44. Caruso A, Bushin LB, Clark KA, Martinie RJ and Seyedsayamdost MR, J. Am. Chem. Soc, 2019, 141, 990–997. [PubMed: 30521328]

45. Caruso A, Martinie RJ, Bushin LB and Seyedsayamdost MR, J Am Chem Soc, 2019, 141, 16610–16614. [PubMed: 31596076]

46. Clark KA, Bushin LB and Seyedsayamdost MR, J. Am. Chem. Soc, 2019, 141, 10610–10615. [PubMed: 31246011]

47. Imai Y, Meyer KJ, Iinishi A, Favre-Godal Q, Green R, Manuse S, Caboni M, Mori M, Niles S, Ghiglieri M, Honrao C, Ma X, Guo J, Makriyannis A, Linares-Otoya L, Bohringer N, Wuisan ZG, Kaur H, Wu R, Mateus A, Typas A, Savitski MM, Espinoza JL, O'Rourke A, Nelson KE, Hiller S, Noinaj N, Schaberle TF, D'Onofrio A and Lewis K, Nature, 2019, 576, 459–464. [PubMed: 31747680]

48. Grell TAJ, Goldman PJ and Drennan CL, J. Biol. Chem, 2015, 290, 3964–3971. [PubMed: 25477505]

49. Ortega MA, Hao Y, Zhang Q, Walker MC, van der Donk WA and Nair SK, Nature, 2015, 517, 509–512. [PubMed: 25363770]

50. Ting CP, Funk MA, Halaby SL, Zhang Z, Gonen T and van der Donk WA, Science, 2019, 365, 280–284. [PubMed: 31320540]

51. Jordan PA and Moore BS, Cell Chemical Biology, 2016, 23, 1504–1514. [PubMed: 27866908]

52. Wyche TP, Ruzzini AC, Schwab L, Currie CR and Clardy J, Journal of the American Chemical Society, 2017, 139, 12899–12902. [PubMed: 28853867]

53. Reisberg SH, Gao Y, Walker AS, Helfrich EJN, Clardy J and Baran PS, Science (New York, N.Y.), 2020, 367, 458–463.

54. Ortíz-López FJ, Carretero-Molina D, Sánchez-Hidalgo M, Martin J, Gonzalez I, Roman-Hurtado F, de la Cruz M, Garcia-Fernandez S, Reyes F, Deisinger JP, Muller A, Schneider T and Genilloud O, Angew Chem Int Ed Engl, , DOI:10.1002/anie.202005187.

55. Román-Hurtado F, Sánchez-Hidalgo M, Martín J, Ortíz-López FJ and Genilloud O, bioRxiv, 2020, 2020.05.20.105809.

56. Kloosterman AM, Cimermancic P, Elsayed SS, Du C, Hadjithomas M, Donia MS, Fischbach MA, van Wezel GP and Medema MH, bioRxiv, 2020, 2020.05.19.104752.

57. Tao M, Xu M, Zhang F, Cheng Z, Bashiri G, Wang J, Hong J, Wang Y, Xu L, Chen X, Huang S-X, Lin S and Deng Z, Angewandte Chemie International Edition, , DOI:10.1002/anie.202008035.

58. Hug JJ, Dastbaz J, Adam S, Revermann O, Koehnke J, Krug D and Müller R, ACS Chem Biol, , DOI:10.1021/acschembio.0c00430.

59. Tang W and van der Donk WA, Nature chemical biology, 2013, 9, 157–9. [PubMed: 23314913]

60. Tang W, Jimenez-Oses G, Houk KN and van der Donk WA, Nature chemistry, 2015, 7, 57–64.

61. Lohans CT, Li JL and Vederas JC, Journal of the American Chemical Society, 2014, 136, 13150–3. [PubMed: 25207953]

62. Walker MC, Eslami SM, Hetrick KJ, Ackenhusen SE, Mitchell DA and van der Donk WA, BMC Genomics, 2020, 21, 387. [PubMed: 32493223]

63. Mohr KI, Volz C, Jansen R, Wray V, Hoffmann J, Bernecker S, Wink J, Gerth K, Stadler M and Müller R, Angewandte Chemie (International ed. in English), 2015, 54, 11254–11258. [PubMed: 26211520]

64. Caetano T, van der Donk W and Mendo S, Microbiol Res, 2020, 235, 126441. [PubMed: 32109689]

65. Garg N, Salazar-Ocampo LM and van der Donk WA, Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7258–63. [PubMed: 23589847]

66. Burkhart BJ, Hudson GA, Dunbar KL and Mitchell DA, Nat. Chem. Biol, 2015, 11, 564–570. [PubMed: 26167873]

67. Bothwell IR, Cogan DP, Kim T, Reinhardt CJ, van der Donk WA and Nair SK, Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17245–17250. [PubMed: 31409709]

68. Repka LM, Hetrick KJ, Chee SH and van der Donk WA, Journal of the American Chemical Society, 2018, 140, 4200–4203. [PubMed: 29537838]

69. Ortega MA, Hao Y, Walker MC, Donadio S, Sosio M, Nair SK and van der Donk WA, Cell chemical biology, 2016, 23, 370–80. [PubMed: 26877024]

70. Acedo JZ, Bothwell IR, An L, Trouth A, Frazier C and van der Donk WA, J. Am. Chem. Soc, 2019, 141, 16790–16801. [PubMed: 31568727]

71. Hudson GA, Zhang Z, Tietz JI, Mitchell DA and van der Donk WA, J. Am. Chem. Soc, 2015, 137, 16012–16015. [PubMed: 26675417]

72. Yang X and van der Donk WA, ACS chemical biology, 2015, 10, 1234–8. [PubMed: 25723375]

73. Abts A, Montalbán-Lopez M, Kuipers OP, Smits SH and Schmitt L, Biochemistry, 2013, 52, 5387–95. [PubMed: 23869662]

74. Reiners J, Abts A, Clemens R, Smits SH and Schmitt L, Scientific reports, 2017, 7, 42163. [PubMed: 28169337]

75. Dong SH, Tang W, Lukk T, Yu Y, Nair SK and van der Donk WA, eLife, 2015, 4, e07607.

76. Habibi Y, Uggowitzer KA, Issak H and Thibodeaux CJ, J. Am. Chem. Soc, 2019, 141, 14661–14672. [PubMed: 31449409]

77. Rahman IR, Acedo JZ, Liu XR, Zhu L, Arrington J, Gross ML and van der Donk WA, ACS Chem Biol, 2020, 15, 1473–1486. [PubMed: 32293871]

78. Thibodeaux CJ, Ha T and van der Donk WA, Journal of the American Chemical Society, 2014, 136, 17513–29. [PubMed: 25409537]

79. Thibodeaux CJ, Wagoner J, Yu Y and van der Donk WA, Journal of the American Chemical Society, 2016, 138, 6436–44. [PubMed: 27123925]

80. Tang W, Thibodeaux GN and van der Donk WA, ACS chemical biology, 2016, 11, 2438–46. [PubMed: 27348535]

81. Yu Y, Zhang Q and van der Donk WA, Protein Science, 2013, 22, 1478–1489. [PubMed: 24038659]

82. Bobeica SC, Zhu L, Acedo JZ, Tang W and van der Donk WA, Chem. Sci, 2020, DOI: 10.1039/D0SC01651A.

83. Jungmann NA, Krawczyk B, Tietzmann M, Ensle P and Süssmuth RD, Journal of the American Chemical Society, 2014, 136, 15222–8. [PubMed: 25291240]

84. Iorio M, Sasso O, Maffioli SI, Bertorelli R, Monciardini P, Sosio M, Bonezzi F, Summa M, Brunati C, Bordoni R, Corti G, Tarozzo G, Piomelli D, Reggiani A and Donadio S, ACS chemical biology, 2014, 9, 398–404. [PubMed: 24191663]

85. Ren H, Shi C, Bothwell IR, van der Donk WA and Zhao H, ACS Chem Biol, 2020, 15, 1642–1649. [PubMed: 32356655]

86. Hegemann JD and van der Donk WA, J. Am. Chem. Soc, 2018, 140, 5743–5754. [PubMed: 29633842]

87. Hegemann JD, Shi L, Gross ML and van der Donk WA, ACS Chem. Biol, 2019, 14, 1583–1592. [PubMed: 31243957]

88. Wiebach V, Mainz A, Schnegotzki R, Siegert M-AJ, Hügelland M, Pliszka N and Süssmuth R, Angew Chem Int Ed Engl, , DOI:10.1002/anie.202003804.

89. Zhang Z, Hudson GA, Mahanta N, Tietz JI, van der Donk WA and Mitchell DA, J. Am. Chem. Soc, 2016, 138, 15511–15514. [PubMed: 27700071]

90. Bewley KD, Bennallack PR, Burlingame MA, Robison RA, Griffitts JS and Miller SM, Proc Natl Acad Sci U S A, 2016, 113, 12450–12455. [PubMed: 27791142]

91. Ozaki T, Kurokawa Y, Hayashi S, Oku N, Asamizu S, Igarashi Y and Onaka H, ChemBioChem, 2016, 17, 218–223. [PubMed: 26630235]

92. Du Y, Qiu Y, Meng X, Feng J, Tao J and Liu W, J Am Chem Soc, 2020, 142, 8454–8463. [PubMed: 32293883]

93. Sikandar A and Koehnke J, Nat. Prod. Rep, 2019, 36, 1576–1588. [PubMed: 30920567]

94. Wever WJ, Bogart JW, Baccile JA, Chan AN, Schroeder FC and Bowers AA, Journal of the American Chemical Society, 2015, 137, 3494–7. [PubMed: 25742119]

95. Wever WJ, Bogart JW and Bowers AA, J. Am. Chem. Soc, 2016, 138, 13461–13464. [PubMed: 27575591]

96. Bogart JW and Bowers AA, J. Am. Chem. Soc, 2019, 141, 1842–1846. [PubMed: 30653303]

97. Cogan DP, Hudson GA, Zhang Z, Pogorelov TV, van der Donk WA, Mitchell DA and Nair SK, PNAS, 2017, 114, 12928–12933. [PubMed: 29158402]

98. Bogart JW, Kramer NJ, Turlik A, Bleich RM, Catlin DS, Schroeder FC, Nair SK, Williamson RT, Houk KN and Bowers AA, J Am Chem Soc, , DOI:10.1021/jacs.0c05639.

99. Ma S and Zhang Q, Nat Prod Rep, 2020, doi: 10.1039/c9np00074g.

100. Claesen J and Bibb M, Proceedings of the National Academy of Sciences, 2010, 107, 16297–16302.

101. Claesen J and Bibb MJ, Journal of Bacteriology, 2011, 193, 2510–2516. [PubMed: 21421760]

102. Rateb ME, Zhai Y, Ehrner E, Rath CM, Wang X, Tabudravu J, Ebel R, Bibb M, Kyeremeh K, Dorrestein PC, Hong K, Jaspars M and Deng H, Org. Biomol. Chem, 2015, 13, 9585–9592. [PubMed: 26256511]

103. Shang Z, Winter JM, Kauffman CA, Yang I and Fenical W, ACS Chem. Biol, 2019, 14, 415–425. [PubMed: 30753052]

104. Fangting Wang, Wanqing Wei, Junfeng Zhao, Tianlu Mo, Xin Wang, Xuedong Huang, Suze Ma, Shu Wang, Zixin Deng, Wei Ding, Yong Liang and Qi Zhang, CCS Chemistry, , DOI:10.31635/ccschem.020.202000247.

105. Mo T, Liu W-Q, Ji W, Zhao J, Chen T, Ding W, Yu S and Zhang Q, ACS Chem. Biol, 2017, 12, 1484–1488. [PubMed: 28452467]

106. Li Y-M, Milne JC, Madison LL, Kolter R and Walsh CT, Science, 1996, 274, 1188–1193. [PubMed: 8895467]

107. Cox CL, Doroghazi JR and Mitchell DA, BMC Genomics, 2015, 16, 778. [PubMed: 26462797]

108. Deane CD, Burkhart BJ, Blair PM, Tietz JI, Lin A and Mitchell DA, ACS Chem. Biol, 2016, 11, 2232–2243. [PubMed: 27248686]

109. Igarashi Y, Kan Y, Fujii K, Fujita T, Harada K, Naoki H, Tabata H, Onaka H and Furumai T, J. Antibiot, 2001, 54, 1045–1053.

110. Burkhart BJ, Schwalen CJ, Mann G, Naismith JH and Mitchell DA, Chem. Rev, 2017, 117, 5389–5456. [PubMed: 28256131]

111. Melby JO, Dunbar KL, Trinh NQ and Mitchell DA, J. Am. Chem. Soc, 2012, 134, 5309–5316. [PubMed: 22401305]

112. Dunbar KL, Melby JO and Mitchell DA, Nat Chem Biol, 2012, 8, 569–575. [PubMed: 22522320]

113. Dunbar KL and Mitchell DA, J. Am. Chem. Soc, 2013, 135, 8692–8701. [PubMed: 23721104]

114. Koehnke J, Bent AF, Zollman D, Smith K, Houssen WE, Zhu X, Mann G, Lebl T, Scharff R, Shirran S, Botting CH, Jaspars M, Schwarz-Linek U and Naismith JH, Angew. Chem. Int. Ed, 2013, 52, 13991–13996.

115. Koehnke J, Mann G, Bent AF, Ludewig H, Shirran S, Botting C, Lebl T, Houssen WE, Jaspars M and Naismith JH, Nature chemical biology, 2015, 11, 558–563. [PubMed: 26098679]

116. Ge Y, Czekster CM, Miller OK, Botting CH, Schwarz-Linek U and Naismith JH, Biochemistry, 2019, 58, 2125–2132. [PubMed: 30912640]

117. Dunbar KL, Chekan JR, Cox CL, Burkhart BJ, Nair SK and Mitchell DA, Nat Chem Biol, 2014, 10, 823–829. [PubMed: 25129028]

118. Mahanta N, Liu A, Dong S, Nair SK and Mitchell DA, PNAS, 2018, 115, 3030–3035. [PubMed: 29507203]

119. Dong S-H, Liu A, Mahanta N, Mitchell DA and Nair SK, ACS Cent. Sci, 2019, 5, 842–851. [PubMed: 31139720]

120. Franz L, Adam S, Santos-Aberturas J, Truman AW and Koehnke J, J. Am. Chem. Soc, 2017, 139, 18158–18161. [PubMed: 29206037]

121. Schwalen CJ, Hudson GA, Kosol S, Mahanta N, Challis GL and Mitchell DA, J. Am. Chem. Soc, 2017, 139, 18154–18157. [PubMed: 29200283]

122. Ghilarov D, Stevenson CEM, Travin DY, Piskunova J, Serebryakova M, Maxwell A, Lawson DM and Severinov K, Molecular Cell, 2019, 73, 749–762.e5. [PubMed: 30661981]

123. Mitchell DA, Lee SW, Pence MA, Markley AL, Limm JD, Nizet V and Dixon JE, J. Biol. Chem, 2009, 284, 13004–13012. [PubMed: 19286651]

124. Dunbar KL, Tietz JI, Cox CL, Burkhart BJ and Mitchell DA, J. Am. Chem. Soc, 2015, 137, 7672–7677. [PubMed: 26024319]

125. Melby JO, Li X and Mitchell DA, Biochemistry, 2014, 53, 413–422. [PubMed: 24364559]

126. Hayakawa Y, Sasaki K, Adachi H, Furihata K, Nagai K and Shin-ya K, J. Antibiot, 2006, 59, 1–5.

127. Izawa M, Nagamine S, Aoki H and Hayakawa Y, J Gen Appl Microbiol, 2018, 64, 50–53. [PubMed: 29311496]

128. Izawa M, Kawasaki T and Hayakawa Y, Appl. Environ. Microbiol, 2013, 79, 7110–7113. [PubMed: 23995943]

129. Lu J, Li J, Wu Y, Fang X, Zhu J and Wang H, Organic letters, 2019, 21, 4676–4679. [PubMed: 31184189]

130. Nayak DD, Mahanta N, Mitchell DA and Metcalf WW, eLife, 2017, 6, e29218. [PubMed: 28880150]

131. Mahanta N, Szantai-Kis DM, Petersson EJ and Mitchell DA, ACS Chem. Biol, 2019, 14, 142–163. [PubMed: 30698414]

132. Schwalen CJ, Hudson GA, Kille B and Mitchell DA, Journal of the American Chemical Society, 2018, 140, 9494–9501. [PubMed: 29983054]

133. Leikoski N, Liu L, Jokela J, Wahlsten M, Gugger M, Calteau A, Permi P, Kerfeld CA, Sivonen K and Fewer DP, Chemistry & Biology, 2013, 20, 1033–1043. [PubMed: 23911585]

134. Martins J and Vasconcelos V, Marine Drugs, 2015, 13, 6910–46. [PubMed: 26580631]

135. Gu W, Dong SH, Sarkar S, Nair SK and Schmidt EW, Methods in enzymology, 2018, 604, 113–163. [PubMed: 29779651]

136. Agarwal V, Pierce E, McIntosh J, Schmidt EW and Nair SK, Chem. Biol, 2012, 19, 1411–1422. [PubMed: 23177196]

137. Houssen WE, Koehnke J, Zollman D, Vendome J, Raab A, Smith MCM, Naismith JH and Jaspars M, ChemBioChem, 2012, 13, 2683–2689. [PubMed: 23169461]

138. Huo L, Rachid S, Stadler M, Wenzel SC and Müller R, Chem. Biol, 2012, 19, 1278–87. [PubMed: 23021914]

139. Gomez-Escribano JP, Song L, Bibb MJ and Challis GL, Chemical Science, 2012, 3, 3522.

140. Hou Y, Tianero Ma. D. B., Kwan JC, Wyche TP, Michel CR, Ellis GA, Vazquez-Rivera E, Braun DR, Rose WE, Schmidt EW and Bugni TS, Organic Letters, 2012, 14, 5050–5053. [PubMed: 22984777]

141. Crone WJK, Leeper FJ and Truman AW, Chemical Science, 2012, 3, 3516.

142. Mann G, Huo L, Adam S, Nardone B, Vendome J, Westwood NJ, Müller R and Koehnke J, ChemBioChem, 2016, 17, 2286–2292. [PubMed: 27653442]

143. Crone WJK, Vior NM, Santos-Aberturas J, Schmitz LG, Leeper FJ and Truman AW, Angewandte Chemie International Edition, 2016, 55, 9639–9643. [PubMed: 27374993]

144. Sikandar A, Franz L, Adam S, Santos-Aberturas J, Horbal L, Luzhetskyy A, Truman AW, Kalinina OV and Koehnke J, Nat Chem Biol, , DOI:10.1038/s41589-020-0569-y.

145. Sikandar A, Franz L, Melse O, Antes I and Koehnke J, J. Am. Chem. Soc, 2019, 141, 9748–9752. [PubMed: 31192589]

146. Travin DY, Metelev M, Serebryakova M, Komarova ES, Osterman IA, Ghilarov D and Severinov K, J. Am. Chem. Soc, 2018, 140, 5625–5633. [PubMed: 29601195]

147. Hegemann JD, Zimmermann M, Zhu S, Steuber H, Harms K, Xie X and Marahiel MA, Angew. Chem. Int. Ed, 2014, 53, 2230–2234.

148. Hegemann JD, Fage CD, Zhu S, Harms K, Di Leva FS, Novellino E, Marinelli L and Marahiel MA, Molecular bioSystems, 2016, 12, 1106–1109. [PubMed: 26863937]

149. Allen CD, Chen MY, Trick AY, Le DT, Ferguson AL and Link AJ, ACS Chem. Biol, 2016, 11, 3043–3051. [PubMed: 27588549]

150. Koos JD and Link AJ, Journal of the American Chemical Society, 2019, 141, 928–935. [PubMed: 30532970]

151. Maksimov MO, Pan SJ and Link AJ, Nat. Prod. Rep, 2012, 29, 996–1006. [PubMed: 22833149]

152. Hegemann JD, Zimmermann M, Xie X and Marahiel MA, Accounts of chemical research, 2015, 48, 1909–19. [PubMed: 26079760]

153. Li Y, Zirah S and Rebuffat S, Lasso Peptides. Bacterial Strategies to Make and Maintain Bioactive Entangled Scaffolds, Springer-Verlag, New-York, 2015.

154. Tietz JI, Schwalen CJ, Patel PS, Maxson T, Blair PM, Tai H-C, Zakai UI and Mitchell DA, Nature Chemical Biology, 2017, 13, 470–478. [PubMed: 28244986]

155. Maksimov MO and Link AJ, Journal of the American Chemical Society, 2013, 135, 12038–12047. [PubMed: 23862624]

156. Yan K-P, Li Y, Zirah S, Goulard C, Knappe TA, Marahiel MA and Rebuffat S, ChemBioChem, 2012, 13, 1046–1052. [PubMed: 22488892]

157. Zhu S, Fage CD, Hegemann JD, Mielcarek A, Yan D, Linne U and Marahiel MA, Sci Rep, 2016, 6, 35604. [PubMed: 27752134]

158. DiCaprio AJ, Firouzbakht A, Hudson GA and Mitchell DA, J. Am. Chem. Soc, 2019, 141, 290–297. [PubMed: 30589265]

159. Cheung WL, Chen MY, Maksimov MO and Link AJ, ACS Cent. Sci, 2016, 2, 702–709. [PubMed: 27800552]

160. Sumida T, Dubiley S, Wilcox B, Severinov K and Tagami S, ACS Chem. Biol, 2019, 14, 1619–1627. [PubMed: 31188556]

161. Chekan JR, Ongpipattanakul C and Nair SK, Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24049–24055. [PubMed: 31719203]

162. Zhu S, Hegemann JD, Fage CD, Zimmermann M, Xie X, Linne U and Marahiel MA, J. Biol. Chem, 2016, 291, 13662–78. [PubMed: 27151214]

163. Zong C, Cheung-Lee WL, Elashal HE, Raj M and Link AJ, Chem. Commun, 2018, 54, 1339–1342.

164. Zhang C and Seyedsayamdost MR, ACS chemical biology, 2020, 15, 890–894.

165. Hegemann JD, Zimmermann M, Xie X and Marahiel MA, J. Am. Chem. Soc, 2013, 135, 210–222. [PubMed: 23214991]

166. Zimmermann M, Hegemann JD, Xie X and Marahiel MA, Chemistry & Biology, 2013, 20, 558–569. [PubMed: 23601645]

167. Li Y, Ducasse R, Zirah S, Blond A, Goulard C, Lescop E, Giraud C, Hartke A, Guittet E, Pernodet JL and Rebuffat S, ACS chemical biology, 2015, 10, 2641–2649. [PubMed: 26343290]

168. Zimmermann M, Hegemann JD, Xie X and Marahiel MA, Chem. Sci, 2014, 5, 4032–4043.

169. Mevaere J, Goulard C, Schneider O, Sekurova ON, Ma H, Zirah S, Afonso C, Rebuffat S, Zotchev SB and Li Y, Sci Rep, 2018, 8, 8232. [PubMed: 29844351]

170. Metelev M, Tietz JI, Melby JO, Blair PM, Zhu L, Livnat I, Severinov K and Mitchell DA, Chemistry & Biology, 2015, 22, 241–250. [PubMed: 25601074]

171. Kodani S, Hemmi H, Miyake Y, Kaweewan I and Nakagawa H, J Ind Microbiol Biotechnol, 2018, 45, 983–992. [PubMed: 30191430]

172. Flühe L, Knappe TA, Gattner MJ, Schäfer A, Burghaus O, Linne U and Marahiel MA, Nat Chem Biol, 2012, 8, 350–357. [PubMed: 22366720]

173. Broderick JB, Duffus BR, Duschene KS and Shepard EM, Chemical reviews, 2014, 114, 4229–317. [PubMed: 24476342]

174. Bauerle MR, Schwalm EL and Booker SJ, J Biol Chem, 2015, 290, 3995–4002. [PubMed: 25477520]

175. Mehta AP, Abdelwahed SH, Mahanta N, Fedoseyenko D, Philmus B, Cooper LE, Liu Y, Jhulki I, Ealick SE and Begley TP, J Biol Chem, 2015, 290, 3980–6. [PubMed: 25477515]

176. Flühe L, Burghaus O, Wieckowski BM, Giessen TW, Linne U and Marahiel MA, J. Am. Chem. Soc, 2013, 135, 959–962. [PubMed: 23282011]

177. Berteau O, Guillot A, Benjdia A and Rabot S, J. Biol. Chem, 2006, 281, 22464–22470. [PubMed: 16766528]

178. Grell TAJ, Kincannon WM, Bruender NA, Blaesi EJ, Krebs C, Bandarian V and Drennan CL, J. Biol. Chem, 2018, 293, 17349–17361. [PubMed: 30217813]

179. Benjdia A, Guillot A, Lefranc B, Vaudry H, Leprince J and Berteau O, Chem. Commun, 2016, 52, 6249–6252.

180. Bruender NA and Bandarian V, Biochemistry, 2016, 55, 4131–4134. [PubMed: 27410522]

181. Kincannon WM, Bruender NA and Bandarian V, Biochemistry, 2018, 57, 4816–4823. [PubMed: 29965747]

182. Wieckowski BM, Hegemann JD, Mielcarek A, Boss L, Burghaus O and Marahiel MA, FEBS Letters, 2015, 589, 1802–1806. [PubMed: 26026269]

183. Grove TL, Himes PM, Hwang S, Yumerefendi H, Bonanno JB, Kuhlman B, Almo SC and Bowers AA, J. Am. Chem. Soc, 2017, 139, 11734–11744. [PubMed: 28704043]

184. Bruender NA, Wilcoxen J, Britt RD and Bandarian V, Biochemistry, 2016, 55, 2122–2134. [PubMed: 27007615]

185. Nakai T, Ito H, Kobayashi K, Takahashi Y, Hori H, Tsubaki M, Tanizawa K and Okajima T, J. Biol. Chem, 2015, 290, 11144–11166. [PubMed: 25778402]

186. Precord TW, Mahanta N and Mitchell DA, ACS Chem. Biol, 2019, 14, 1981–1989. [PubMed: 31449382]

187. Grove TL, Himes PM, Hwang S, Yumerefendi H, Bonanno JB, Kuhlman B, Almo SC and Bowers AA, J. Am. Chem. Soc, 2017, 139, 11734–11744. [PubMed: 28704043]

188. Schramma KR, Bushin LB and Seyedsayamdost MR, Nat. Chem, 2015, 7, 431–437. [PubMed: 25901822]

189. Ibrahim M, Guillot A, Wessner F, Algaron F, Besset C, Courtin P, Gardan R and Monnet V, Journal of Bacteriology, 2007, 189, 8844–8854. [PubMed: 17921293]

190. Fleuchot B, Gitton C, Guillot A, Vidic J, Nicolas P, Besset C, Fontaine L, Hols P, Leblond-Bourget N, Monnet V and Gardan R, Molecular Microbiology, 2011, 80, 1102–1119. [PubMed: 21435032]

191. Isley NA, Endo Y, Wu Z-C, Covington BC, Bushin LB, Seyedsayamdost MR and Boger DL, J. Am. Chem. Soc, 2019, 141, 17361–17369. [PubMed: 31577142]

192. Schramma KR and Seyedsayamdost MR, ACS Chem. Biol, 2017, 12, 922–927. [PubMed: 28191919]

193. Davis KM, Schramma KR, Hansen WA, Bacik JP, Khare SD, Seyedsayamdost MR and Ando N, Proc Natl Acad Sci USA, 2017, 114, 10420–10425. [PubMed: 28893989]

194. Schramma KR, Forneris CC, Caruso A and Seyedsayamdost MR, Biochemistry, 2018, 57, 461–468. [PubMed: 29320164]

195. Haft DH, Basu MK and Mitchell DA, BMC Biol., 2010, 8, 70. [PubMed: 20500830]

196. Morinaka BI, Vagstad AL, Helf MJ, Gugger M, Kegler C, Freeman MF, Bode HB and Piel J, Angew Chem Int Ed Engl, 2014, 53, 8503–7. [PubMed: 24943072]

197. Freeman MF, Gurgui C, Helf MJ, Morinaka BI, Uria AR, Oldham NJ, Sahl HG, Matsunaga S and Piel J, Science, 2012, 338, 387–90. [PubMed: 22983711]

198. Hamada T, Matsunaga S, Yano G and Fusetani N, J. Am. Chem. Soc, 2005, 127, 110–8. [PubMed: 15631460]

199. Hamada T, Matsunaga S, Fujiwara M, Fujita K, Hirota H, Schmucki R, Guntert P and Fusetani N, J. Am. Chem. Soc, 2010, 132, 12941–5. [PubMed: 20795624]

200. Renevey A and Riniker S, Eur. Biophys. J, 2017, 46, 363–374. [PubMed: 27744521]

201. Zhang Q, van der Donk WA and Liu W, Acc. Chem. Res, 2012, 45, 555–64. [PubMed: 22097883]

202. Bhushan A, Egli PJ, Peters EE, Freeman MF and Piel J, Nature chemistry, 2019, 11, 931–939.

203. Rust M, Helfrich EJN, Freeman MF, Nanudorn P, Field CM, Rückert C, Kündig T, Page MJ, Webb VL, Kalinowski J, Sunagawa S and Piel J, Proc. Natl. Acad. Sci. U. S. A, 2020, in press.

204. Bosch N, Mariana B, Greczmiel U, Morinaka B, Gugger M, Oxenius A, Vagstad AL and Piel J, Angewandte Chemie (International ed. in English), 2020, 10.1002/anie.201916321.

205. Butcher BG, Lin YP and Helmann JD, Journal of bacteriology, 2007, 189, 8616–25. [PubMed: 17921301]

206. Ziemert N, Ishida K, Liaimer A, Hertweck C and Dittmann E, Angewandte Chemie International Edition, 2008, 47, 7756–7759. [PubMed: 18683268]

207. Philmus B, Christiansen G, Yoshida WY and Hemscheidt TK, ChemBioChem, 2008, 9, 3066–3073. [PubMed: 19035375]

208. Lee H, Park Y and Kim S, Biochemistry, 2017, 56, 4927–4930. [PubMed: 28841794]

209. Roh H, Han Y, Lee H and Kim S, ChemBioChem, 2019, 20, 1051–1059. [PubMed: 30576039]

210. Lee C, Lee H, Park J-U and Kim S, Biochemistry, 2020, 59, 285–289. [PubMed: 31644266]

211. Lee H, Choi M, Park J-U, Roh H and Kim S, J. Am. Chem. Soc, 2020, 142, 3013–3023. [PubMed: 31961152]

212. Li K, Condurso HL, Li G, Ding Y and Bruner SD, Nature Chemical Biology, 2016, 12, 973–979. [PubMed: 27669417]

213. Philmus B, Guerrette JP and Hemscheidt TK, ACS Chemical Biology, 2009, 4, 429–434. [PubMed: 19445532]

214. Weiz AR, Ishida K, Makower K, Ziemert N, Hertweck C and Dittmann E, Chemistry & Biology, 2011, 18, 1413–1421. [PubMed: 22118675]

215. Reyna-González E, Schmid B, Petras D, Süssmuth RD and Dittmann E, Angew. Chem. Int. Ed, 2016, 55, 9398–9401.

216. Ahmed MN, Reyna-González E, Schmid B, Wiebach V, Süssmuth RD, Dittmann E and Fewer DP, ACS Chemical Biology, 2017, 12, 1538–1546. [PubMed: 28406289]

217. Zhang Y, Li K, Yang G, McBride JL, Bruner SD and Ding Y, Nature Communications, 2018, 9, 1780.

218. Quijano MR, Zach C, Miller FS, Lee AR, Imani AS, Künzler M and Freeman MF, J. Am. Chem. Soc, 2019, 141, 9637–9644. [PubMed: 31117659]

219. Song H, Fahrig-Kamarauskaitè JR, Matabaro E, Kaspar H, Shirran SL, Zach C, Pace A, Stefanov B-A, Naismith JH and Künzler M, ACS Chem Biol, 2020, 10.1021/acschembio.0c00237.

220. Song H, van der Velden NS, Shiran SL, Bleiziffer P, Zach C, Sieber R, Imani AS, Krausbeck F, Aebi M, Freeman MF, Riniker S, Künzler M and Naismith JH, Science Advances, 2018, 4, eaat2720. [PubMed: 30151425]

221. Sterner O, Etzel W, Mayer A and Anke H, Nat Prod Lett, 1997, 10, 33–38.

222. Mayer A, Anke H and Sterner O, Nat Prod Lett, 1997, 10, 25–32.

223. Ongpipattanakul C and Nair SK, ACS Chem. Biol, 2018, 13, 2989–2999. [PubMed: 30204409]

224. Umemura M, Koike H, Nagano N, Ishii T, Kawano J, Yamane N, Kozone I, Horimoto K, Shin-ya K, Asai K, Yu J, Bennett JW and Machida M, PloS one, 2013, 8, e84028. [PubMed: 24391870]

225. Yoshimi A, Umemura M, Nagano N, Koike H, Machida M and Abe K, AMB Express, 2016, 6, 9. [PubMed: 26842395]

226. Umemura M, Nagano N, Koike H, Kawano J, Ishii T, Miyamura Y, Kikuchi M, Tamano K, Yu J, Shin-ya K and Machida M, Fungal genetics and biology : FG & B, 2014, 68, 23–30. [PubMed: 24841822]

227. Tsukui T, Nagano N, Umemura M, Kumagai T, Terai G, Machida M and Asai K, Bioinformatics (Oxford, England), 2015, 31, 981–5.

228. Vignolle GA, Mach RL, Mach-Aigner AR and Derntl C, BMC Genomics, 2020, 21, 258. [PubMed: 32216757]

229. Ye Y, Minami A, Igarashi Y, Izumikawa M, Umemura M, Nagano N, Machida M, Kawahara T, Shin-ya K, Gomi K and Oikawa H, Angewandte Chemie International Edition, 2016, 55, 8072–8075. [PubMed: 27166860]

230. Gournelis DC, Laskaris GG and Verpoorte R, in Progress in the Chemistry of Organic Natural Products, eds. Herz W, Falk H, Kirby GW, Moore RE and Tamm CH, Springer-Verlag/Wein, New York, 1998, vol. 75, pp. 1–179. [PubMed: 9739622]

231. Johnson RD, Lane GA, Koulman A, Cao M, Fraser K, Fleetwood DJ, Voisey CR, Dyer JM, Pratt J, Christensen M, Simpson WR, Bryan GT and Johnson LJ, Fungal genetics and biology : FG & B, 2015, 85, 14–24. [PubMed: 26519220]

232. Luo H, Hong SY, Sgambelluri RM, Angelos E, Li X and Walton JD, Chemistry & biology, 2014, 21, 1610–7. [PubMed: 25484237]

233. Sgambelluri RM, Smith MO and Walton JD, ACS synthetic biology, 2018, 7, 145–152. [PubMed: 28866879]

234. Czekster CM and Naismith JH, Biochemistry, 2017, 56, 2086–2095. [PubMed: 28332820]

235. Czekster CM, Ludewig H, McMahon SA and Naismith JH, Nature communications, 2017, 8, 1045.

236. Gabrielsen C, Brede DA, Nes IF and Diep DB, Appl Environ Microbiol, 2014, 80, 6854–6862. [PubMed: 25172850]

237. Perez RH, Zendo T and Sonomoto K, Front Microbiol, 2018, 9, 2085. [PubMed: 30233551]

238. Koehnke J, Bent AF, Houssen WE, Mann G, Jaspars M and Naismith JH, Curr. Opin. Struct. Biol, 2014, 29, 112–121. [PubMed: 25460274]

239. Nguyen GK, Wang S, Qiu Y, Hemu X, Lian Y and Tam JP, Nature chemical biology, 2014, 10, 732–8. [PubMed: 25038786]

240. Harris KS, Durek T, Kaas Q, Poth AG, Gilding EK, Conlan BF, Saska I, Daly NL, van der Weerden NL, Craik DJ and Anderson MA, Nature communications, 2015, 6, 10199.

241. Alexandru-Crivac CN, Umeobika C, Leikoski N, Jokela J, Rickaby KA, Grilo AM, Sjo P, Plowright AT, Idress M, Siebs E, Nneoyi-Egbe A, Wahlsten M, Sivonen K, Jaspars M, Trembleau L, Fewer DP and Houssen WE, Chemical communications (Cambridge, England), 2017, 53, 10656–10659.

242. Bernath-Levin K, Nelson C, Elliott AG, Jayasena AS, Millar AH, Craik DJ and Mylne JS, Chemistry & biology, 2015, 22, 571–82. [PubMed: 25960260]

243. Barber CJ, Pujara PT, Reed DW, Chiwocha S, Zhang H and Covello PS, The Journal of biological chemistry, 2013, 288, 12500–10. [PubMed: 23486480]

244. Hemu X, El Sahili A, Hu S, Wong K, Chen Y, Wong YH, Zhang X, Serra A, Goh BC, Darwis DA, Chen MW, Sze SK, Liu C-F, Lescar J and Tam JP, Proc. Natl. Acad. Sci. USA, 2019, 116, 11737–11746. [PubMed: 31123145]

245. James AM, Haywood J, Leroux J, Ignasiak K, Elliott AG, Schmidberger JW, Fisher MF, Nonis SG, Fenske R, Bond CS and Mylne JS, The Plant journal : for cell and molecular biology, 2019, 98, 988–999. [PubMed: 30790358]

246. Lee J, McIntosh J, Hathaway BJ and Schmidt EW, J. Am. Chem. Soc, 2009, 131, 2122–4. [PubMed: 19166292]

247. Harris KS, Guarino RF, Dissanayake RS, Quimbar P, McCorkelle OC, Poon S, Kaas Q, Durek T, Gilding EK, Jackson MA, Craik DJ, van der Weerden NL, Anders RF and Anderson MA, Scientific reports, 2019, 9, 10820. [PubMed: 31346249]

248. Chekan JR, Estrada P, Covello PS and Nair SK, Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 6551–6556. [PubMed: 28584123]

249. Ludewig H, Czekster CM, Oueis E, Munday ES, Arshad M, Synowsky SA, Bent AF and Naismith JH, ACS chemical biology, 2018, 13, 801–811. [PubMed: 29377663]

250. Gabrielsen C, Brede DA, Salehian Z, Nes IF and Diep DB, J Bacteriol, 2014, 196, 911–919. [PubMed: 24336941]

251. Perez RH, Sugino H, Ishibashi N, Zendo T, Wilaipun P, Leelawatcharamas V, Nakayama J and Sonomoto K, Microbiology, 2017, 163, 431–441. [PubMed: 28113050]

252. Chen H, Tseng CC, Hubbard BK and Walsh CT, Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 14901–6. [PubMed: 11752437]

253. Klinman JP and Bonnot F, Chemical Reviews, 2014, 114, 4343–4365. [PubMed: 24350630]

254. Barr I, Latham JA, Iavarone AT, Chantarojsiri T, Hwang JD and Klinman JP, J. Biol. Chem, 2016, 291, 8877–8884. [PubMed: 26961875]

255. Latham JA, Iavarone AT, Barr I, Juthani PV and Klinman JP, J. Biol. Chem, 2015, 290, 12908–12918. [PubMed: 25817994]

256. Martins AM, Latham JA, Martel PJ, Barr I, Iavarone AT and Klinman JP, The Journal of biological chemistry, 2019, 294, 15025–15036. [PubMed: 31427437]

257. Wei Q, Ran T, Ma C, He J, Xu D and Wang W, The Journal of biological chemistry, 2016, 291, 15575–87. [PubMed: 27231346]

258. Koehn EM, Latham JA, Armand T, Evans RL 3rd, Tu X, Wilmot CM, Iavarone AT and Klinman JP, Journal of the American Chemical Society, 2019, 141, 4398–4405. [PubMed: 30811189]

259. Tu X, Latham JA, Klema VJ, Evans RL 3rd, Li C, Klinman JP and Wilmot CM, J. Biol.Inorg. Chem, 2017, 22, 1089–1097. [PubMed: 28825148]

260. Bonnot F, Iavarone AT and Klinman JP, Biochemistry, 2013, 52, 4667–75. [PubMed: 23718207]

261. Haft DH, Pierce PG, Mayclin SJ, Sullivan A, Gardberg AS, Abendroth J, Begley DW, Phan IQ, Staker BL, Myler PJ, Marathias VM, Lorimer DD and Edwards TE, Scientific reports, 2017, 7, 41074. [PubMed: 28120876]

262. Khaliullin B, Aggarwal P, Bubas M, Eaton GR, Eaton SS and Latham JA, FEBS Lett., 2016, 590, 2538–2548. [PubMed: 27312813]

263. Bruender NA and Bandarian V, Biochemistry, 2016, 55, 2813–2816. [PubMed: 27158836]

264. Khaliullin B, Ayikpoe R, Tuttle M and Latham JA, J Biol Chem, 2017, 292, 13022–13033. [PubMed: 28634235]

265. Ayikpoe R, Salazar J, Majestic B and Latham JA, Biochemistry, 2018, 57, 5379–5383. [PubMed: 30183269]

266. Peña-Ortiz L, Graça AP, Guo H, Braga D, Köllner TG, Regestein L, Beemelmanns C and Lackner G, bioRxiv, 2019, 821413.

267. Krishnamoorthy G, Kaiser P, Lozza L, Hahnke K, Mollenkopf H-J and Kaufmann SHE, mBio, 2019, 10, e00190–19. [PubMed: 31113891]

268. Dubey AA and Jain V, Biochemical and Biophysical Research Communications, 2019, 516, 1073–1077. [PubMed: 31279528]

269. Jin M, Wright SA, Beer SV and Clardy J, Angew. Chem. Int. Ed, 2003, 42, 2902–5.

270. Jin M, Liu L, Wright SA, Beer SV and Clardy J, Angew. Chem. Int. Ed, 2003, 42, 2898–901.

271. Ghodge SV, Biernat KA, Bassett SJ, Redinbo MR and Bowers AA, J. Am. Chem. Soc, 2016, 138, 5487–90. [PubMed: 27088303]

272. Fleming SR, Himes PM, Ghodge SV, Goto Y, Suga H and Bowers AA, Journal of the American Chemical Society, 2020, 142, 5024–5028. [PubMed: 32109054]

273. Kenney GE and Rosenzweig AC, BMC Biol, 2013, 11, 17. [PubMed: 23442874]

274. Kenney GE, Dassama LMK, Pandelia ME, Gizzi AS, Martinie RJ, Gao P, DeHart CJ, Schachner LF, Skinner OS, Ro SY, Zhu X, Sadek M, Thomas PM, Almo SC, Bollinger JM Jr., Krebs C, Kelleher NL and Rosenzweig AC, Science, 2018, 359, 1411–1416. [PubMed: 29567715]

275. Nagano N, Orengo CA and Thornton JM, J. Mol. Biol, 2002, 321, 741–65. [PubMed: 12206759]

276. Zhang Z and van der Donk WA, Journal of the American Chemical Society, 2019, 141, 19625–19633. [PubMed: 31751505]

277. Ting CP, Funk MA, Halaby SL, Zhang Z, Gonen T and van der Donk WA, Science, 2019, 365, 280–284. [PubMed: 31320540]

278. Miyanaga A, Janso JE, McDonald L, He M, Liu H, Barbieri L, Eustaquio AS, Fielding EN, Carter GT, Jensen PR, Feng X, Leighton M, Koehn FE and Moore BS, Journal of the American Chemical Society, 2011, 133, 13311–3. [PubMed: 21815669]

279. Norris GE and Patchett ML, Current opinion in structural biology, 2016, 40, 112–119. [PubMed: 27662231]

280. Wang H, Oman TJ, Zhang R, Garcia De Gonzalo CV, Zhang Q and van der Donk WA, Journal of the American Chemical Society, 2014, 136, 84–7. [PubMed: 24325644]

281. Garcia De Gonzalo CV, Zhu L, Oman TJ and van der Donk WA, ACS chemical biology, 2014, 9, 796–801. [PubMed: 24405370]

282. Biswas S, Garcia De Gonzalo CV, Repka LM and van der Donk WA, ACS chemical biology, 2017, 12, 2965–2969. [PubMed: 29112373]

283. Amso Z, Bisset SW, Yang SH, Harris PWR, Wright TH, Navo CD, Patchett ML, Norris GE and Brimble MA, Chemical science, 2018, 9, 1686–1691. [PubMed: 29675216]

284. Bisset SW, Yang SH, Amso Z, Harris PWR, Patchett ML, Brimble MA and Norris GE, ACS chemical biology, 2018, 13, 1270–1278. [PubMed: 29701461]

285. Wu C, Biswas S, Garcia De Gonzalo CV and van der Donk WA, ACS Infect. Dis, 2019, 5, 454–459. [PubMed: 30582697]

286. Nagar R and Rao A, Methods in molecular biology (Clifton, N.J.), 2019, 1954, 279–296.

287. Ren H, Biswas S, Ho S, van der Donk WA and Zhao H, ACS chemical biology, 2018, 13, 2966–2972. [PubMed: 30183259]

288. Kaunietis A, Buivydas A, Citavicius DJ and Kuipers OP, Nature communications, 2019, 10, 1115.

289. Palaniappan K, Chen IA, Chu K, Ratner A, Seshadri R, Kyrpides NC, Ivanova NN and Mouncey NJ, Nucleic acids research, 2020, 48, D422–d430.

290. Evans RL 3rd, Latham JA, Xia Y, Klinman JP and Wilmot CM, Biochemistry, 2017, 56, 2735–2746. [PubMed: 28481092]

291. Tsai TY, Yang CY, Shih HL, Wang AH and Chou SH, Proteins, 2009, 76, 1042–8. [PubMed: 19475705]

292. Martin-Gómez H, Linne U, Albericio F, Tulla-Puche J and Hegemann JD, J. Nat. Prod, 2018, 81, 2050–2056. [PubMed: 30178995]

293. Hegemann JD, Schwalen CJ, Mitchell DA and van der Donk WA, Chem. Commun, 2018, 54, 9007–9010.

294. Ghilarov D, Stevenson CEM, Travin DY, Piskunova J, Serebryakova M, Maxwell A, Lawson DM and Severinov K, Molecular Cell, 2019, 73, 749–762.e5. [PubMed: 30661981]

295. Fuchs SW, Lackner G, Morinaka BI, Morishita Y, Asai T, Riniker S and Piel J, Angewandte Chemie (International ed. in English), 2016, 55, 12330–3. [PubMed: 27584723]

296. Davis KM, Schramma KR, Hansen WA, Bacik JP, Khare SD, Seyedsayamdost MR and Ando N, Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10420–10425. [PubMed: 28893989]

297. Zukher I, Pavlov M, Tsibulskaya D, Kulikovsky A, Zyubko T, Bikmetov D, Serebryakova M, Nair SK, Ehrenberg M, Dubiley S and Severinov K, mBio, 2019, 10, e00768–19. [PubMed: 31040244]

298. Dong SH, Kulikovsky A, Zukher I, Estrada P, Dubiley S, Severinov K and Nair SK, Chem. Sci, 2019, 10, 2391–2395. [PubMed: 30881667]

299. Tsibulskaya D, Mokina O, Kulikovsky A, Piskunova J, Severinov K, Serebryakova M and Dubiley S, Journal of the American Chemical Society, 2017, 139, 16178–16187. [PubMed: 29045133]

300. Sardar D, Pierce E, McIntosh JA and Schmidt EW, ACS Synth. Biol, 2015, 4, 167–176. [PubMed: 24625112]

301. Sardar D, Lin Z and Schmidt EW, Chemistry & biology, 2015, 22, 907–16. [PubMed: 26165156]

302. Gu W, Sardar D, Pierce E and Schmidt EW, Journal of the American Chemical Society, 2018, 140, 16213–16221. [PubMed: 30387998]

303. Nayak DD, Liu A, Agrawal N, Rodriguez-Carerro R, Dong SH, Mitchell DA, Nair SK and Metcalf WW, PLoS biology, 2020, 18, e3000507. [PubMed: 32092071]

304. Li B, Sher D, Kelly L, Shi Y, Huang K, Knerr PJ, Joewono I, Rusch D, Chisholm SW and van der Donk WA, PNAS, 2010, 107, 10430–10435. [PubMed: 20479271]

305. Lin DY, Huang S and Chen J, Nature, 2015, 523, 425–30. [PubMed: 26201595]

306. Kieuvongngam V, Olinares PDB, Palillo A, Oldham ML, Chait BT and Chen J, eLife, 2020, 9, e51492. [PubMed: 31934861]

307. Huo L, Zhao X, Acedo JZ, Estrada P, Nair SK and van der Donk WA, ChemBioChem, 2020, 21, 190–199. [PubMed: 31532570]

308. Bobeica SC, Dong SH, Huo L, Mazo N, McLaughlin MI, Jimenéz-Osés G, Nair SK and van der Donk WA, eLife, 2019, 8, e42305. [PubMed: 30638446]

309. Helf MJ, Freeman MF and Piel J, J Ind Microbiol Biotechnol, 2019, 46, 551–563. [PubMed: 30627933]

310. Repka LM, Chekan JR, Nair SK and van der Donk WA, Chem. Rev, 2017, 117, 5457–5520. [PubMed: 28135077]

311. Montalbán-López M, Deng J, van Heel AJ and Kuipers OP, Front. Microbiol, 2018, 9, 160. [PubMed: 29479343]

312. Ortega MA, Velasquez JE, Garg N, Zhang Q, Joyce RE, Nair SK and van der Donk WA, ACS chemical biology, 2014, 9, 1718–25. [PubMed: 24866416]

313. Tang W, Dong S-H, Repka LM, He C, Nair SK and van der Donk WA, Chem. Sci, 2015, 6, 6270–6279. [PubMed: 30090246]

314. Tang W, Bobeica SC, Wang L and van der Donk WA, J Ind Microbiol Biotechnol, 2019, 46, 537–549. [PubMed: 30484123]

315. Xu Y, Li X, Li R, Li S, Ni H, Wang H, Xu H, Zhou W, Saris PE, Yang W, Qiao M and Rao Z, Acta crystallographica. Section D, Biological crystallography, 2014, 70, 1499–505. [PubMed: 24914961]

316. Kuhn ML, Prachi P, Minasov G, Shuvalova L, Ruan J, Dubrovska I, Winsor J, Giraldi M, Biagini M, Liberatori S, Savino S, Bagnoli F, Anderson WF and Grandi G, FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2014, 28, 1780–93. [PubMed: 24421400]

317. Lagedroste M, Smits SHJ and Schmitt L, Biochemistry, 2017, 56, 4005–4014. [PubMed: 28675292]

318. Schardon K, Hohl M, Graff L, Pfannstiel J, Schulze W, Stintzi A and Schaller A, Science, 2016, 354, 1594–1597. [PubMed: 27940581]

319. Ghilarov D, Serebryakova M, Stevenson CEM, Hearnshaw SJ, Volkov DS, Maxwell A, Lawson DM and Severinov K, Structure, 2017, 25, 1549–1561.e5. [PubMed: 28943336]

320. Chen S, Xu B, Chen E, Wang J, Lu J, Donadio S, Ge H and Wang H, Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2533–2538. [PubMed: 30679276]

321. Dehm D, Krumbholz J, Baunach M, Wiebach V, Hinrichs K, Guljamow A, Tabuchi T, Jenke-Kodama H, Süssmuth RD and Dittmann E, ACS Chem Biol, 2019, 14, 1271–1279. [PubMed: 31091070]

322. Völler GH, Krawczyk B, Ensle P and Süssmuth RD, Journal of the American Chemical Society, 2013, 135, 7426–9. [PubMed: 23651048]

323. Zheng Q, Wang S, Duan P, Liao R, Chen D and Liu W, Proceedings of the National Academy of Sciences, 2016, 113, 14318–14323.

324. McIntosh JA, Donia MS and Schmidt EW, Nat. Prod. Rep, 2009, 26, 537–559. [PubMed: 19642421]

325. Tianero MD, Pierce E, Raghuraman S, Sardar D, McIntosh JA, Heemstra JR, Schonrock Z, Covington BC, Maschek JA, Cox JE, Bachmann BO, Olivera BM, Ruffner DE and Schmidt EW, Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1772–7. [PubMed: 26831074]

326. McIntosh JA, Lin Z, Tianero MD and Schmidt EW, ACS Chem. Biol, 2013, 8, 877–83. [PubMed: 23411099]

327. Sardar D, Tianero MD and Schmidt EW, Methods in enzymology, 2016, 575, 1–20. [PubMed: 27417922]

328. Cubillos-Ruiz A, Berta-Thompson JW, Becker JW, van der Donk WA and Chisholm SW, Proc Natl Acad Sci U S A, 2017, 114, E5424–E5433. [PubMed: 28630351]

329. Morinaka BI, Verest M, Freeman MF, Gugger M and Piel J, Angew. Chem., Int. Ed, 2017, 56, 762–766.

330. Parent A, Benjdia A, Guillot A, Kubiak X, Balty C, Lefranc B, Leprince J and Berteau O, Journal of the American Chemical Society, 2018, 140, 2469–2477. [PubMed: 29253341]

331. Vagstad AL, Kuranaga T, Puntener S, Pattabiraman VR, Bode JW and Piel J, Angew. Chem. Int. Ed, 2019, 58, 2246–2250.

332. Cotter PD, O'Connor PM, Draper LA, Lawton EM, Deegan LH, Hill C and Ross RP, Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18584–9. [PubMed: 16339304]

333. Yang X and van der Donk WA, Journal of the American Chemical Society, 2015, 137, 12426–9. [PubMed: 26361061]

334. Huo L and van der Donk WA, Journal of the American Chemical Society, 2016, 138, 5254–7. [PubMed: 27074593]

335. Helynck G, Dubertret C, Mayaux JF and Leboul J, The Journal of antibiotics, 1993, 46, 1756–7. [PubMed: 8270499]

336. Fréchet D, Guitton JD, Herman F, Faucher D, Helynck G, Monegier du Sorbier B, Ridoux JP, James-Surcouf E and Vuilhorgne M, Biochemistry, 1994, 33, 42–50. [PubMed: 8286361]

337. Yano K, Toki S, Nakanishi S, Ochiai K, Ando K, Yoshida M, Matsuda Y and Yamasaki M, Bioorganic & medicinal chemistry, 1996, 4, 115–20. [PubMed: 8689231]

338. Tsunakawa M, Hu SL, Hoshino Y, Detlefson DJ, Hill SE, Furumai T, White RJ, Nishio M, Kawano K, Yamamoto S and et al., The Journal of antibiotics, 1995, 48, 433–4. [PubMed: 7797448]

339. Feng Z, Ogasawara Y, Nomura S and Dairi T, ChemBioChem, 2018, 19, 2045–2048. [PubMed: 29974638]

340. Kreil G, J Biol Chem, 1994, 269, 10967–10970. [PubMed: 8157620]

341. Badding ED, Grove TL, Gadsby LK, LaMattina JW, Boal AK and Booker SJ, J. Am. Chem. Soc, 2017, 139, 5896–5905. [PubMed: 28343381]

342. Ding W, Ji W, Wu Y, Wu R, Liu WQ, Mo T, Zhao J, Ma X, Zhang W, Xu P, Deng Z, Tang B, Yu Y and Zhang Q, Nat. Commun, 2017, 8, 437. [PubMed: 28874663]

343. Zhang Q and Liu W, Nat. Prod. Rep, 2013, 30, 218–226. [PubMed: 23250571]

344. Zhang Q, Li Y, Chen D, Yu Y, Duan L, Shen B and Liu W, Nat. Chem. Biol, 2011, 7, 154–60. [PubMed: 21240261]

345. Nicolet Y, Zeppieri L, Amara P and Fontecilla-Camps JC, Angew. Chem., Int. Ed, 2014, 53, 11840–11844.

346. Bhandari DM, Xu H, Nicolet Y, Fontecilla-Camps JC and Begley TP, Biochemistry, 2015, 54, 4767–4769. [PubMed: 26204056]

347. Ji X, Li Y, Ding W and Zhang Q, Angew. Chem., Int. Ed, 2015, 54, 9021–9024.

348. Bhandari DM, Fedoseyenko D and Begley TP, J. Am. Chem. Soc, 2016, 138, 16184–16187. [PubMed: 27998091]

349. Ji X, Li Y, Jia Y, Ding W and Zhang Q, Angew. Chem., Int. Ed, 2016, 55, 3334–3337.

350. Ji X, Liu W-Q, Yuan S, Yin Y, Ding W and Zhang Q, Chem. Commun. (Cambridge, U. K.), 2016, 52, 10555–10558.

351. Ji X, Li Y, Xie L, Lu H, Ding W and Zhang Q, Angew. Chem., Int. Ed, 2016, 55, 11845–11848.

352. Sicoli G, Mouesca J-M, Zeppieri L, Amara P, Martin L, Barra A-L, Fontecilla-Camps JC, Gambarelli S and Nicolet Y, Science (Washington, DC, U. S.), 2016, 351, 1320–1323.

353. Bhandari DM, Fedoseyenko D and Begley TP, J. Am. Chem. Soc, 2018, 140, 542–545. [PubMed: 29232124]

354. Sayler RI, Stich TA, Joshi S, Cooper N, Shaw JT, Begley TP, Tantillo DJ and Britt RD, ACS Cent Sci, 2019, 5, 1777–1785. [PubMed: 31807679]

355. Kuchenreuther JM, Myers WK, Stich TA, George SJ, Nejatyjahromy Y, Swartz JR and Britt RD, Science, 2013, 342, 472–475. [PubMed: 24159045]

356. Amara P, Mouesca JM, Bella M, Martin L, Saragaglia C, Gambarelli S and Nicolet Y, J. Am. Chem. Soc, 2018, 140, 16661–16668. [PubMed: 30418774]

357. Li C and Kelly WL, Natural product reports, 2010, 27, 153–64. [PubMed: 20111801]

358. Kelly WL, Pan L and Li CX, J Am Chem Soc, 2009, 131, 4327–4334. [PubMed: 19265401]

359. Pierre S, Guillot A, Benjdia A, Sandstrom C, Langella P and Berteau O, Nat Chem Biol, 2012, 8, 957–959. [PubMed: 23064318]

360. Benjdia A, Pierre S, Gherasim C, Guillot A, Carmona M, Amara P, Banerjee R and Berteau O, Nat. Commun, 2015, 6, 8377. [PubMed: 26456915]

361. Blaszczyk AJ, Silakov A, Zhang B, Maiocco SJ, Lanz ND, Kelly WL, Elliott SJ, Krebs C and Booker SJ, J. Am. Chem. Soc, 2016, 138, 3416–3426. [PubMed: 26841310]

362. Zhou P, O'Hagan D, Mocek U, Zeng Z, Yuen LD, Frenzel T, Unkefer CJ, Beale JM and Floss HG, J. Am. Chem. Soc, 1989, 111, 7274–7276.

363. Blaszczyk AJ, Wang B, Silakov A, Ho JV and Booker SJ, J. Biol. Chem, 2017, 292, 15456–15467. [PubMed: 28747433]

364. Parent A, Guillot A, Benjdia A, Chartier G, Leprince J and Berteau O, J. Am. Chem. Soc, 2016, 138, 15515–15518. [PubMed: 27934015]

365. Gomez-Escribano JP, Song L, Bibb MJ and Challis GL, Chem. Sci, 2012, 3, 3522–3525.

366. Mahanta N, Zhang Z, Hudson GA, van der Donk WA and Mitchell DA, Journal of the American Chemical Society, 2017, 139, 4310–4313. [PubMed: 28301141]

367. Tocchetti A, Maffioli S, Iorio M, Alt S, Mazzei E, Brunati C, Sosio M and Donadio S, Chemistry & biology, 2013, 20, 1067–77. [PubMed: 23932526]

368. Zhang Z, Mahanta N, Hudson GA, Mitchell DA and van der Donk WA, J. Am. Chem. Soc, 2017, 139, 18623–18631. [PubMed: 29190095]

369. Helf MJ, Jud A and Piel J, ChemBioChem, 2017, 18, 444–450. [PubMed: 27966282]

370. Hotta K, Keegan RM, Ranganathan S, Fang M, Bibby J, Winn MD, Sato M, Lian M, Watanabe K, Rigden DJ and Kim CY, Angewandte Chemie (International ed. in English), 2014, 53, 824–8. [PubMed: 24302672]

371. Al-Mestarihi AH, Villamizar G, Fernandez J, Zolova OE, Lombo F and Garneau-Tsodikova S, Journal of the American Chemical Society, 2014, 136, 17350–4. [PubMed: 25409494]

372. Molohon KJ, Melby JO, Lee J, Evans BS, Dunbar KL, Bumpus SB, Kelleher NL and Mitchell DA, ACS Chem. Biol, 2011, 6, 1307–13. [PubMed: 21950656]

373. Scholz R, Molohon KJ, Nachtigall J, Vater J, Markley AL, Sussmuth RD, Mitchell DA and Borriss R, Journal of bacteriology, 2011, 193, 215–24. [PubMed: 20971906]

374. Kalyon B, Helaly SE, Scholz R, Nachtigall J, Vater J, Borriss R and Süssmuth RD, Org. Lett, 2011, 13, 2996–2999. [PubMed: 21568297]

375. Komiyama K, Otoguro K, Segawa T, Shiomi K, Yang H, Takahashi Y, Hayashi M, Otani T and Omura S, J. Antibiot, 1993, 46, 1666–71.

376. Claesen J and Bibb M, Proc. Natl. Acad. Sci. U. S. A, 2010, 107, 16297–302. [PubMed: 20805503]

377. Lee J, Hao Y, Blair PM, Melby JO, Agarwal V, Burkhart BJ, Nair SK and Mitchell DA, Proc. Natl. Acad. Sci. U. S. A, 2013, 110, 12954–9. [PubMed: 23878226]

378. Piwowarska NA, Banala S, Overkleeft HS and Sussmuth RD, Chem Commun (Camb), 2013, 49, 10703–5. [PubMed: 24100616]

379. Sharma A, Blair PM and Mitchell DA, Org. Lett, 2013, 15, 5076–9. [PubMed: 24063702]

380. Zhang Q and van der Donk WA, FEBS Lett., 2012, 586, 3391–3397. [PubMed: 22841713]

381. Smith TE, Pond CD, Pierce E, Harmer ZP, Kwan J, Zachariah MM, Harper MK, Wyche TP, Matainaho TK, Bugni TS, Barrows LR, Ireland CM and Schmidt EW, Nature chemical biology, 2018, 14, 179–185. [PubMed: 29291350]

382. Widdick DA, Dodd HM, Barraille P, White J, Stein TH, Chater KF, Gasson MJ and Bibb MJ, Proc. Natl. Acad. Sci. USA, 2003, 100, 4316–21. [PubMed: 12642677]

383. Ökesli A, Cooper LE, Fogle EJ and van der Donk WA, J. Am. Chem. Soc, 2011, 133, 13753–60. [PubMed: 21770392]

384. Yu Y, Duan L, Zhang Q, Liao R, Ding Y, Pan H, Wendt-Pienkowski E, Tang G, Shen B and Liu W, ACS Chem. Biol, 2009, 4, 855–64. [PubMed: 19678698]

385. LaMattina JW, Wang B, Badding ED, Gadsby LK, Grove TL and Booker SJ, J. Am. Chem. Soc, 2017, 139, 17438–17445. [PubMed: 29039940]

386. Wang B, LaMattina JW, Marshall SL and Booker SJ, J. Am. Chem. Soc, 2019, 141, 5788–5797. [PubMed: 30865439]

387. Qiu Y, Du Y, Wang S, Zhou S, Guo Y and Liu W, Org. Lett, 2019, 21, 1502–1505. [PubMed: 30785762]

388. Ding W, Li Y, Zhao J, Ji X, Mo T, Qianzhu H, Tu T, Deng Z, Yu Y, Chen F and Zhang Q, Angew Chem Int Ed Engl, 2017, 56, 3857–3861. [PubMed: 28112859]

389. Ji X, Mandalapu D, Cheng J, Ding W and Zhang Q, Angew. Chem. Int. Ed, 2018, 57, 6601–6604.

390. Ding W, Wu Y, Ji X, Qianzhu H, Chen F, Deng Z, Yu Y and Zhang Q, Chem. Commun. (Cambridge, U. K.), 2017, 53, 5235–5238.

391. Leikoski N, Liu LW, Jokela J, Wahlsten M, Gugger M, Calteau A, Permi P, Kerfeld CA, Sivonen K and Fewer DP, Chemistry & Biology, 2013, 20, 1033–1043. [PubMed: 23911585]

392. Sardar D, Hao Y, Lin Z, Morita M, Nair SK and Schmidt EW, Journal of the American Chemical Society, 2017, 139, 2884–2887. [PubMed: 28195477]

393. Gavrish E, Sit CS, Cao S, Kandror O, Spoering A, Peoples A, Ling L, Fetterman A, Hughes D, Bissell A, Torrey H, Akopian T, Mueller A, Epstein S, Goldberg A, Clardy J and Lewis K, Chem Biol, 2014, 21, 509–518. [PubMed: 24684906]

394. Su Y, Han M, Meng X, Feng Y, Luo S, Yu C, Zheng G and Zhu S, Appl. Microbiol. Biotechnol, 2019, 103, 2649–2664. [PubMed: 30707253]

395. Marsh AJ, O'Sullivan O, Ross RP, Cotter PD and Hill C, BMC Genomics, 2010, 11, 679. [PubMed: 21118552]

396. Kanyo ZF, Scolnick LR, Ash DE and Christianson DW, Nature, 1996, 383, 554–7. [PubMed: 8849731]

397. Zhu S, Fage CD, Hegemann JD, Yan D and Marahiel MA, FEBS Lett, 2016, 590, 3323–3334. [PubMed: 27585551]

398. Zyubko T, Serebryakova M, Andreeva J, Metelev M, Lippens G, Dubiley S and Severinov K, Chemical science, 2019, 10, 9699–9707. [PubMed: 32055339]

399. Lin Z, Ji J, Zhou S, Zhang F, Wu J, Guo Y and Liu W, Journal of the American Chemical Society, 2017, 139, 12105–12108. [PubMed: 28820583]

400. Zheng Q, Wang S, Liao R and Liu W, ACS Chem. Biol, 2016, 11, 2673–2678. [PubMed: 27560135]

401. Liu W, Xue Y, Ma M, Wang S, Liu N and Chen Y, ChemBioChem, 2013, 14, 1544–1547. [PubMed: 23939763]

402. Maffioli SI, Iorio M, Sosio M, Monciardini P, Gaspari E and Donadio S, Journal of natural products, 2014, 77, 79–84. [PubMed: 24422756]

403. Sosio M, Gallo G, Pozzi R, Serina S, Monciardini P, Bera A, Stegmann E and Weber T, Genome announcements, 2014, 2, e01198–13.

404. Liu N, Song L, Liu M, Shang F, Anderson Z, Fox DJ, Challis GL and Huang Y, Chem. Sci, 2016, 7, 482–488. [PubMed: 28791101]

405. Kupke T, Kempter C, Jung G and Götz F, J. Biol. Chem, 1995, 270, 11282–9. [PubMed: 7744764]

406. Mo T, Yuan H, Wang F, Ma S, Wang J, Li T, Liu G, Yu S, Tan X, Ding W and Zhang Q, FEBS Lett., 2019, 593, 573–580. [PubMed: 30771247]

407. Escano J, Ravichandran A, Salamat B and Smith L, Applied and environmental microbiology, 2017, 83, e00668–17. [PubMed: 28500042]

408. Ortega MA, Cogan DP, Mukherjee S, Garg N, Li B, Thibodeaux GN, Maffioli SI, Donadio S, Sosio M, Escano J, Smith L, Nair SK and van der Donk WA, ACS chemical biology, 2017, 12, 548–557. [PubMed: 28032983]

409. Cruz JC, Iorio M, Monciardini P, Simone M, Brunati C, Gaspari E, Maffioli SI, Wellington E, Sosio M and Donadio S, Journal of natural products, 2015, 78, 2642–7. [PubMed: 26512731]

410. Shi Y, Bueno A and van der Donk WA, Chem. Commun, 2012, 48, 10966–8.

411. Huo L, Ökesli A, Zhao M and van der Donk WA, Appl. Environ. Microbiol, 2017, 83, e02698–16. [PubMed: 27864176]

412. An L, Cogan DP, Navo CD, Jiménez-Osés G, Nair SK and van der Donk WA, Nature chemical biology, 2018, 14, 928–933. [PubMed: 30177849]

413. Park YJ, Kenney GE, Schachner LF, Kelleher NL and Rosenzweig AC, Biochemistry, 2018, 57, 3515–3523. [PubMed: 29694778]

414. Ye Y, Ozaki T, Umemura M, Liu C, Minami A and Oikawa H, Organic & biomolecular chemistry, 2019, 17, 39–43.

415. McIntosh JA, Donia MS, Nair SK and Schmidt EW, J. Am. Chem. Soc, 2011, 133, 13698–705. [PubMed: 21766822]

416. Hao Y, Pierce E, Roe D, Morita M, McIntosh JA, Agarwal V, Cheatham TE, Schmidt EW and Nair SK, Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14037–14042. [PubMed: 27872314]

417. Dalponte L, Parajuli A, Younger E, Mattila A, Jokela J, Wahlsten M, Leikoski N, Sivonen K, Jarmusch SA, Houssen WE and Fewer DP, Biochemistry, 2018, 57, 6860–6867. [PubMed: 30452235]

418. Iwasaki K, Iwasaki A, Sumimoto S, Sano T, Hitomi Y, Ohno O and Suenaga K, Tetrahedron Lett, 2018, 59, 3806–3809.

419. Okada M, Sugita T, Akita K, Nakashima Y, Tian T, Li C, Mori T and Abe I, Org. Biomol. Chem, 2016, 14, 9639–9644. [PubMed: 27714214]

420. Sano T and Kaya K, Tetrahedron Lett, 1996, 37, 6873–6876.

421. Parajuli A, Kwak DH, Dalponte L, Leikoski N, Galica T, Umeobika U, Trembleau L, Bent A, Sivonen K, Wahlsten M, Wang H, Rizzi E, De Bellis G, Naismith J, Jaspars M, Liu X, Houssen W and Fewer DP, Angew. Chem. Int. Ed, 2016, 55, 3596–9.

422. Nagatsu A, Kajitani H and Sakakibara J, Tetrahedron Lett, 1995, 36, 4097–4100.

423. Mattila A, Andsten RM, Jumppanen M, Assante M, Jokela J, Wahlsten M, Mikula KM, Sigindere C, Kwak DH, Gugger M, Koskela H, Sivonen K, Liu X, Yli-Kauhaluoma J, Iwai H and Fewer DP, ACS Chem. Biol, 2019, 14, 2683–2690. [PubMed: 31674754]

424. Metzger U, Schall C, Zocher G, Unsold I, Stec E, Li SM, Heide L and Stehle T, Proc. Natl. Acad. Sci. U. S. A, 2009, 106, 14309–14. [PubMed: 19706516]

425. Morita M, Hao Y, Jokela JK, Sardar D, Lin Z, Sivonen K, Nair SK and Schmidt EW, J. Am. Chem. Soc, 2018, 140, 6044–6048. [PubMed: 29701961]

426. Estrada P, Morita M, Hao Y, Schmidt EW and Nair SK, J. Am. Chem. Soc, 2018, 140, 8124–8127. [PubMed: 29924593]

427. Okada M, Sato I, Cho SJ, Iwata H, Nishio T, Dubnau D and Sakagami Y, Nat. Chem. Biol, 2005, 1, 23–4. [PubMed: 16407988]

428. Hirooka K, Shioda S and Okada M, Biosci. Biotechnol. Biochem, 2020, 84, 347–357. [PubMed: 31670609]

429. Sugita T, Okada M, Nakashima Y, Tian T and Abe I, Chembiochem, 2018, 19, 1396–1399. [PubMed: 29665236]

430. Liu W, Ma M, Xue Y, Liu N, Wang S and Chen Y, ChemBioChem, 2013, 14, 573–6. [PubMed: 23440918]

431. Liu S, Guo H, Zhang T, Han L, Yao P, Zhang Y, Rong N, Yu Y, Lan W, Wang C, Ding J, Wang R, Liu W and Cao C, Sci. Rep, 2015, 5, 12744. [PubMed: 26244829]

432. Wang Y, Liu S, Yao P, Yu Y, Zhang Y, Lan W, Wang C, Ding J, Liu W and Cao C, Acta crystallographica. Section F, Structural biology communications, 2015, 71, 1033–7. [PubMed: 26249695]

433. Ding Y, Yu Y, Pan H, Guo H, Li Y and Liu W, Molecular bioSystems, 2010, 6, 1180–5. [PubMed: 20473441]

434. Malcolmson SJ, Young TS, Ruby JG, Skewes-Cox P and Walsh CT, Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8483–8. [PubMed: 23650400]

435. Liao R and Liu W, J. Am. Chem. Soc, 2011, 133, 2852–5. [PubMed: 21323347]

436. Bennallack PR, Bewley KD, Burlingame MA, Robison RA, Miller SM and Griffitts JS, Journal of Bacteriology, 2016, 198, 2431–2438. [PubMed: 27381911]

437. Ozaki T, Yamashita K, Goto Y, Shimomura M, Hayashi S, Asamizu S, Sugai Y, Ikeda H, Suga H and Onaka H, Nature communications, 2017, 8, 14207.

438. Unno K, Kaweewan I, Nakagawa H and Kodani S, Appl Microbiol Biotechnol, 2020, 104, 5293–5302. [PubMed: 32300852]

439. Liang DM, Liu JH, Wu H, Wang BB, Zhu HJ and Qiao JJ, Chemical Society reviews, 2015, 44, 8350–74. [PubMed: 26330279]

440. Elshahawi SI, Shaaban KA, Kharel MK and Thorson JS, Chemical Society reviews, 2015, 44, 7591–697. [PubMed: 25735878]

441. Bagley MC, Dale JW, Merritt EA and Xiong X, Chem. Rev, 2005, 105, 685–714. [PubMed: 15700961]

442. de Jong A, van Hijum SAFT, Bijlsma JJE, Kok J and Kuipers OP, Nucleic Acids Res., 2006, 34, W273–279. [PubMed: 16845009]

443. de Jong A, van Heel AJ, Kok J and Kuipers OP, Nucleic Acids Res., 2010, 38, W647–651. [PubMed: 20462861]

444. van Heel AJ, de Jong A, Montalbán-López M, Kok J and Kuipers OP, Nucleic Acids Res., 2013, 41, W448–453. [PubMed: 23677608]

445. van Heel AJ, de Jong A, Song C, Viel JH, Kok J and Kuipers OP, Nucleic Acids Research, 2018, 46, W278–W281. [PubMed: 29788290]

446. Delcher AL, Bratke KA, Powers EC and Salzberg SL, Bioinformatics, 2007, 23, 673–679. [PubMed: 17237039]

447. Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ, Journal of molecular biology, 1990, 215, 403–10. [PubMed: 2231712]

448. van Heel AJ, Montalban-Lopez M, Oliveau Q and Kuipers OP, Microb Genom, 2017, 3, e000134. [PubMed: 29177092]

449. Wu H, Gu Q, Xie Y, Lou Z, Xue P, Fang L, Yu C, Jia D, Huang G, Zhu B, Schneider A, Blom J, Lasch P, Borriss R and Gao X, Environmental microbiology, 2019, 21, 3505–3526.

450. Markusková B, Lichvariková A, Szemes T, Kore ová J, Kuchta T and Drahovská H, FEMS Microbiol. Lett, 2018, 365, fny257.

451. Finn RD, Clements J, Arndt W, Miller BL, Wheeler TJ, Schreiber F, Bateman A and Eddy SR, Nucleic Acids Res, 2015, 43, W30–W38. [PubMed: 25943547]

452. Finn RD, Coggill P, Eberhardt RY, Eddy SR, Mistry J, Mitchell AL, Potter SC, Punta M, Qureshi M, Sangrador-Vegas A, Salazar GA, Tate J and Bateman A, Nucleic Acids Res., 2016, 44, D279–285. [PubMed: 26673716]

453. Haft DH, Selengut JD, Richter RA, Harkins D, Basu MK and Beck E, Nucleic Acids Res, 2013, 41, D387–D395. [PubMed: 23197656]

454. Blin K, Wolf T, Chevrette MG, Lu X, Schwalen CJ, Kautsar SA, Suarez Duran HG, de los Santos ELC, Kim HU, Nave M, Dickschat JS, Mitchell DA, Shelest E, Breitling R, Takano E, Lee SY, Weber T and Medema MH, Nucleic Acids Research, 2017, 45, W36–W41. [PubMed: 28460038]

455. Ovchinnikov S, Kamisetty H and Baker D, eLife, 2014, 3, e02030. [PubMed: 24842992]

456. Skinnider MA, Merwin NJ, Johnston CW and Magarvey NA, Nucleic Acids Research, 2017, 45, W49–W54. [PubMed: 28460067]

457. van Heel AJ, de Jong A, Song C, Viel JH, Kok J and Kuipers OP, Nucleic Acids Res., 2018, 46, W278–W281. [PubMed: 29788290]

458. Hyatt D, Chen G-L, LoCascio PF, Land ML, Larimer FW and Hauser LJ, BMC Bioinformatics, 2010, 11, 119. [PubMed: 20211023]

459. de los Santos ELC, Sci Rep, 2019, 9, 13406. [PubMed: 31527713]

460. Agrawal P, Khater S, Gupta M, Sain N and Mohanty D, Nucleic Acids Research, 2017, 45, W80–W88. [PubMed: 28499008]

461. Mohimani H, Kersten RD, Liu W-T, Wang M, Purvine SO, Wu S, Brewer HM, Pasa-Tolic L, Bandeira N, Moore BS, Pevzner PA and Dorrestein PC, ACS Chemical Biology, 2014, 9, 1545–1551. [PubMed: 24802639]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

462. Skinnider MA, Dejong CA, Rees PN, Johnston CW, Li H, Webster AL, Wyatt MA and Magarvey NA, Nucleic acids research, 2015, 43, 9645–9662. [PubMed: 26442528]

463. Skinnider MA, Johnston CW, Edgar RE, Dejong CA, Merwin NJ, Rees PN and Magarvey NA, Proceedings of the National Academy of Sciences, 2016, 113, E6343–E6351.

464. Johnston CW, Skinnider MA, Wyatt MA, Li X, Ranieri MRM, Yang L, Zechel DL, Ma B and Magarvey NA, Nat Commun, 2015, 6, 8421. [PubMed: 26412281]

465. Pei Z-F, Yang M-J, Li L, Jian X-H, Yin Y, Li D, Pan H-X, Lu Y, Jiang W and Tang G-L, Org Biomol Chem, 2018, 16, 9373–9376. [PubMed: 30516779]

466. Kaweewan I, Komaki H, Hemmi H, Hoshino K, Hosaka T, Isokawa G, Oyoshi T and Kodani S, J Antibiot (Tokyo), 2019, 72, 1–7. [PubMed: 30310179]

467. Medema MH, Blin K, Cimermancic P, de Jager V, Zakrzewski P, Fischbach MA, Weber T, Takano E and Breitling R, Nucleic Acids Res., 2011, 39, W339–346. [PubMed: 21672958]

468. Blin K, Medema MH, Kazempour D, Fischbach MA, Breitling R, Takano E and Weber T, Nucleic Acids Res., 2013, 41, W204–212. [PubMed: 23737449]

469. Weber T, Blin K, Duddela S, Krug D, Kim HU, Bruccoleri R, Lee SY, Fischbach MA, Muller R, Wohlleben W, Breitling R, Takano E and Medema MH, Nucleic acids research, 2015, 43, W237–W243. [PubMed: 25948579]

470. Blin K, Shaw S, Steinke K, Villebro R, Ziemert N, Lee SY, Medema MH and Weber T, Nucleic Acids Research, 2019, 47, W81–W87. [PubMed: 31032519]

471. Hadjithomas M, Chen I-MA, Chu K, Ratner A, Palaniappan K, Szeto E, Huang J, Reddy TBK, Cimerman i P, Fischbach MA, Ivanova NN, Markowitz VM, Kyrpides NC and Pati A, mBio, 2015, 6, e00932–15. [PubMed: 26173699]

472. Hadjithomas M, Chen I-MA, Chu K, Huang J, Ratner A, Palaniappan K, Andersen E, Markowitz V, Kyrpides NC and Ivanova NN, Nucleic Acids Res, 2017, 45, D560–D565. [PubMed: 27903896]

473. Conway KR and Boddy CN, Nucleic Acids Research, 2012, 41, D402–D407. [PubMed: 23104377]

474. Ichikawa N, Sasagawa M, Yamamoto M, Komaki H, Yoshida Y, Yamazaki S and Fujita N, Nucleic acids research, 2013, 41, D408–D414. [PubMed: 23185043]

475. Blin K, Medema MH, Kazempour D, Fischbach MA, Breitling R, Takano E and Weber T, Nucleic Acids Res, 2013, 41, W204–12. [PubMed: 23737449]

476. Blin K, Medema MH, Kottmann R, Lee SY and Weber T, Nucleic acids research, 2016, 45, D555–D559. [PubMed: 27924032]

477. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J and Bryant SH, Nucleic Acids Research, 2009, 37, W623–W633. [PubMed: 19498078]

478. Rogers FB, Bull Med Libr Assoc, 1963, 51, 114–116. [PubMed: 13982385]

479. Cimermancic P, Medema MH, Claesen J, Kurita K, Wieland Brown LC, Mavrommatis K, Pati A, Godfrey PA, Koehrsen M, Clardy J, Birren BW, Takano E, Sali A, Linington RG and Fischbach MA, Cell, 2014, 158, 412–421. [PubMed: 25036635]

480. Markowitz VM, Chen IM, Chu K, Szeto E, Palaniappan K, Pillay M, Ratner A, Huang J, Pagani I, Tringe S, Huntemann M, Billis K, Varghese N, Tennessen K, Mavromatis K, Pati A, Ivanova NN and Kyrpides NC, Nucleic acids research, 2014, 42, D568–73. [PubMed: 24136997]

481. Merwin NJ, Mousa WK, Dejong CA, Skinnider MA, Cannon MJ, Li H, Dial K, Gunabalasingam M, Johnston C and Magarvey NA, Proc Natl Acad Sci USA, 2020, 117, 371. [PubMed: 31871149]

482. Kloosterman AM, Shelton KE, van Wezel GP, Medema MH and Mitchell DA, bioRxiv, 2020, 2020.03.14.992123.

483. Soding J, Biegert A and Lupas AN, Nucleic Acids Research, 2005, 33, W244–W248. [PubMed: 15980461]

484. UniProt C, Nucleic acids research, 2015, 43, D204–D212. [PubMed: 25348405]

485. Lubelski J, Rink R, Khusainov R, Moll GN and Kuipers OP, Cell. Mol. Life Sci, 2008, 65, 455–476. [PubMed: 17965835]

486. Kuipers OP, Bierbaum G, Ottenwälder B, Dodd HM, Horn N, Metzger J, Kupke T, Gnau V, Bongers R, van den Bogaard P, Kosters H, Rollema HS, de Vos WM, Siezen RJ, Jung G, Götz F, Sahl HG and Gasson MJ, Antonie van Leeuwenhoek, 1996, 69, 161–169. [PubMed: 8775976]

487. Cortés J, Appleyard AN and Dawson MJ, Methods Enzymol., 2009, 458, 559–74. [PubMed: 19374998]

488. Ruffner DE, Schmidt EW and Heemstra JR, ACS synthetic biology, 2015, 4, 482–92. [PubMed: 25140729]

489. Goto Y, Ito Y, Kato Y, Tsunoda S and Suga H, Chemistry & biology, 2014, 21, 766–774. [PubMed: 24856821]

490. Fleming SR, Bartges TE, Vinogradov AA, Kirkpatrick CL, Goto Y, Suga H, Hicks LM and Bowers AA, J. Am. Chem. Soc, 2019, 141, 758–762. [PubMed: 30602112]

491. Oman TJ, Knerr PJ, Bindman NA, Vélasquez JE and van der Donk WA, J. Am. Chem. Soc, 2012, 134, 6952–6955. [PubMed: 22480178]

492. Levengood MR, Patton GC and van der Donk WA, J. Am. Chem. Soc, 2007, 129, 10314–15. [PubMed: 17676843]

493. Khusainov R and Kuipers OP, ChemBioChem, 2012, 2433–2438. [PubMed: 23070977]

494. Levengood MR, Knerr PJ, Oman TJ and van der Donk WA, J. Am. Chem. Soc, 2009, 131, 12024–5. [PubMed: 19655738]

495. Knerr PJ, Oman TJ, Garcia De Gonzalo CV, Lupoli TJ, Walker S and van der Donk WA, ACS Chem Biol, 2012, 7, 1791–1795. [PubMed: 22920239]

496. Burkhart BJ, Kakkar N, Hudson GA, van der Donk WA and Mitchell DA, ACS Cent. Sci, 2017, 3, 629–638. [PubMed: 28691075]

497. Mukherjee S and van der Donk WA, Journal of the American Chemical Society, 2014, 136, 10450–9. [PubMed: 24972336]

498. van Heel AJ, Mu D, Montalban-Lopez M, Hendriks D and Kuipers OP, ACS synthetic biology, 2013, 2, 397–404. [PubMed: 23654279]

499. Kuipers OP, Rollema HS, de Vos WM and Siezen RJ, FEBS Lett., 1993, 330, 23–27. [PubMed: 8370453]

500. Chakicherla A and Hansen JN, J. Biol. Chem, 1995, 270, 23533–9. [PubMed: 7559517]

501. van Heel AJ, Kloosterman TG, Montalban-Lopez M, Deng J, Plat A, Baudu B, Hendriks D, Moll GN and Kuipers OP, ACS synthetic biology, 2016, 5, 1146–1154. [PubMed: 27294279]

502. Majchrzykiewicz JA, Lubelski J, Moll GN, Kuipers A, Bijlsma JJ, Kuipers OP and Rink R, Antimicrob. Agents Chemother, 2010, 54, 1498–505. [PubMed: 20100873]

503. Tianero MD, Donia MS, Young TS, Schultz PG and Schmidt EW, J. Am. Chem. Soc, 2012, 134, 418–25. [PubMed: 22107593]

504. Zhang Q, Yu Y, Velásquez JE and van der Donk WA, Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18361–6. [PubMed: 23071302]

505. Dopp JL, Tamiev DD and Reuel NF, Biotechnol. Adv, 2019, 37, 246–258. [PubMed: 30572024]

506. Goto Y, Katoh T and Suga H, Nature protocols, 2011, 6, 779–90. [PubMed: 21637198]

507. Goto Y and Suga H, Current opinion in chemical biology, 2018, 46, 82–90. [PubMed: 29957445]

508. Houssen WE, Bent AF, McEwan AR, Pieiller N, Tabudravu J, Koehnke J, Mann G, Adaba RI, Thomas L, Hawas UW, Liu H, Schwarz-Linek U, Smith MC, Naismith JH and Jaspars M, Angewandte Chemie (International ed. in English), 2014, 53, 14171–4. [PubMed: 25331823]

509. Deane CD, Melby JO, Molohon KJ, Susarrey AR and Mitchell DA, ACS chemical biology, 2013, 8, 1998–2008. [PubMed: 23823732]

510. Goto Y and Suga H, ChemBioChem, 2020, 21, 84–87. [PubMed: 31523895]

511. Hayashi S, Ozaki T, Asamizu S, Ikeda H, Omura S, Oku N, Igarashi Y, Tomoda H and Onaka H, Chemistry & biology, 2014, 21, 679–88. [PubMed: 24768308]

512. Vinogradov AA, Shimomura M, Goto Y, Ozaki T, Asamizu S, Sugai Y, Suga H and Onaka H, Nature communications, 2020, 11, 2272.

513. Liu R, Zhang Y, Zhai G, Fu S, Xia Y, Hu B, Cai X, Zhang Y, Li Y, Deng Z and Liu T, Advanced Science, 2020, n/a, 2001616.

514. Hofmann FT, Szostak JW and Seebeck FP, Journal of the American Chemical Society, 2012, 134, 8038–41. [PubMed: 22545861]

515. Buer BC and Marsh EN, Protein science : a publication of the Protein Society, 2012, 21, 453–62. [PubMed: 22274989]

516. Maaskant RV and Roelfes G, ChemBioChem, 2019, 20, 57–61. [PubMed: 30246492]

517. Li H, Aneja R and Chaiken I, Molecules, 2013, 18, 9797–9817. [PubMed: 23959192]

518. Bindman N, Merkx R, Koehler R, Herrman N and van der Donk WA, Chem. Commun, 2010, 46, 8935–7.

519. McIntosh JA, Robertson CR, Agarwal V, Nair SK, Bulaj GW and Schmidt EW, Journal of the American Chemical Society, 2010, 132, 15499–501. [PubMed: 20961047]

520. Hemu X, Qiu Y, Nguyen GK and Tam JP, Journal of the American Chemical Society, 2016, 138, 6968–71. [PubMed: 27206099]

521. Oueis E, Jaspars M, Westwood NJ and Naismith JH, Angew. Chem. Int. Ed, 2016, 55, 5842–5845.

522. Oueis E, Stevenson H, Jaspars M, Westwood NJ and Naismith JH, Chemical communications (Cambridge, England), 2017, 53, 12274–12277.

523. Oueis E, Nardone B, Jaspars M, Westwood NJ and Naismith JH, ChemistryOpen, 2017, 6, 11–14. [PubMed: 28168143]

524. Nguyen GK, Hemu X, Quek JP and Tam JP, Angewandte Chemie (International ed. in English), 2016, 55, 12802–6. [PubMed: 27624217]

525. Bowers AA, Acker MG, Young TS and Walsh CT, Journal of the American Chemical Society, 2012, 134, 10313–6. [PubMed: 22686940]

526. Wong JT, Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 6303–6. [PubMed: 6413975]

527. van Hest JC and Tirrell DA, FEBS Lett, 1998, 428, 68–70. [PubMed: 9645477]

528. Budisa N, Minks C, Medrano FJ, Lutz J, Huber R and Moroder L, Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 455–9. [PubMed: 9435213]

529. Al Toma RS, Kuthning A, Exner MP, Denisiuk A, Ziegler J, Budisa N and Sussmuth RD, ChemBioChem, 2015, 16, 503–509. [PubMed: 25504932]

530. Oldach F, Al Toma R, Kuthning A, Caetano T, Mendo S, Budisa N and Süssmuth RD, Angew. Chem. Int. Ed, 2012, 51, 415–418.

531. Zhou L, Shao J, Li Q, van Heel AJ, de Vries MP, Broos J and Kuipers OP, Amino acids, 2016, 48, 1309–18. [PubMed: 26872656]

532. Wang L, Brock A, Herberich B and Schultz PG, Science, 2001, 292, 498–500. [PubMed: 11313494]

533. Chin JW, Martin AB, King DS, Wang L and Schultz PG, P Natl Acad Sci USA, 2002, 99, 11020–11024.

534. Schmidt EW, Nelson JT, Rasko DA, Sudek S, Eisen JA, Haygood MG and Ravel J, Proc. Natl. Acad. Sci. U.S.A, 2005, 102, 7315–20. [PubMed: 15883371]

535. Nagao J, Harada Y, Shioya K, Aso Y, Zendo T, Nakayama J and Sonomoto K, Biochem. Biophys. Res. Commun, 2005, 336, 507–13. [PubMed: 16143300]

536. Shi Y, Yang X, Garg N and van der Donk WA, J. Am. Chem. Soc, 2011, 133, 2338–41. [PubMed: 21114289]

537. Bindman NA, Bobeica SC, Liu WR and van der Donk WA, Journal of the American Chemical Society, 2015, 137, 6975–8. [PubMed: 26006047]

538. Kakkar N, Perez JG, Liu WR, Jewett MC and van der Donk WA, ACS chemical biology, 2018, 13, 951–957. [PubMed: 29439566]

539. Bartholomae M, Baumann T, Nickling JH, Peterhoff D, Wagner R, Budisa N and Kuipers OP, Frontiers in microbiology, 2018, 9, 657. [PubMed: 29681891]

540. Zambaldo C, Luo X, Mehta AP and Schultz PG, J. Am. Chem. Soc, 2017, 139, 11646–11649. [PubMed: 28809560]

541. Lopatniuk M, Myronovskyi M and Luzhetskyy A, ACS chemical biology, 2017, 12, 2362–2370. [PubMed: 28758722]

542. Lin Y, Teng K, Huan L and Zhong J, Microbiol. Res, 2011, 166, 146–54. [PubMed: 20630724]

543. Valsesia G, Medaglia G, Held M, Minas W and Panke S, Appl. Environ. Microbiol, 2007, 73, 1635–1645. [PubMed: 17194841]

544. Singh M, Chaudhary S and Sareen D, Mol Microbiol, 2020, 113, 326–337. [PubMed: 31696567]

545. Donia MS, Ruffner DE, Cao S and Schmidt EW, ChemBioChem, 2011, 12, 1230–6. [PubMed: 21542088]

546. Luo X, Zambaldo C, Liu T, Zhang Y, Xuan W, Wang C, Reed SA, Yang PY, Wang RE, Javahishvili T, Schultz PG and Young TS, Proc. Natl. Acad. Sci. USA, 2016, 113, 3615–20. [PubMed: 26976568]

547. Himes PM, Allen SE, Hwang S and Bowers AA, ACS chemical biology, 2016, 11, 1737–44. [PubMed: 27019323]

548. Lajoie MJ, Rovner AJ, Goodman DB, Aerni HR, Haimovich AD, Kuznetsov G, Mercer JA, Wang HH, Carr PA, Mosberg JA, Rohland N, Schultz PG, Jacobson JM, Rinehart J, Church GM and Isaacs FJ, Science (New York, N.Y.), 2013, 342, 357–60.

549. Piscotta FJ, Tharp JM, Liu WR and Link AJ, Chemical communications (Cambridge, England), 2015, 51, 409–12.

550. Braffman NR, Piscotta FJ, Hauver J, Campbell EA, Link AJ and Darst SA, Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1273–1278. [PubMed: 30626643]

551. Bi X, Yin J, Hemu X, Rao C, Tam JP and Liu C-F, Bioconj. Chem, 2018, 29, 2170–2175.

552. Owens AE, Grasso KT, Ziegler CA and Fasan R, ChemBioChem, 2017, 18, 1109–1116. [PubMed: 28383180]

553. Guo J, Melancon CE 3rd, Lee HS, Groff D and Schultz PG, Angew. Chem. Int. Ed. Engl, 2009, 48, 9148–51. [PubMed: 19856359]

554. Venkat S, Chen H, Gan Q and Fan C, Front. Pharmacol, 2019, 10, 248. [PubMed: 30949051]

555. Gan Q and Fan C, Biochimica et biophysica acta. General subjects, 2017, 1861, 3047–3052. [PubMed: 27919800]

556. Martin RW, Des Soye BJ, Kwon YC, Kay J, Davis RG, Thomas PM, Majewska NI, Chen CX, Marcum RD, Weiss MG, Stoddart AE, Amiram M, Ranji Charna AK, Patel JR, Isaacs FJ, Kelleher NL, Hong SH and Jewett MC, Nature communications, 2018, 9, 1203.

557. Medema MH, Breitling R, Bovenberg R and Takano E, Nature reviews. Microbiology, 2011, 9, 131–7. [PubMed: 21189477]

558. Duan L, Wang S, Liao R and Liu W, Chemistry & biology, 2012, 19, 443–8. [PubMed: 22520750]

559. Knappe TA, Manzenrieder F, Mas-Moruno C, Linne U, Sasse F, Kessler H, Xie X and Marahiel MA, Angew. Chem. Int. Ed, 2011, 50, 8714–7.

560. Hegemann JD, De Simone M, Zimmermann M, Knappe TA, Xie X, Di Leva FS, Marinelli L, Novellino E, Zahler S, Kessler H and Marahiel MA, J. Med. Chem, 2014, 57, 5829–5834. [PubMed: 24949551]

561. Hegemann JD, Bobeica SC, Walker MC, Bothwell IR and van der Donk WA, ACS Synth. Biol, 2019, 8, 1204–1214. [PubMed: 31042373]

562. Pan SJ and Link AJ, J. Am. Chem. Soc, 2011, 133, 5016–23. [PubMed: 21391585]

563. Zong C, Maksimov MO and Link AJ, ACS chemical biology, 2016, 11, 61–68. [PubMed: 26492187]

564. Young TS, Dorrestein PC and Walsh CT, Chemistry & biology, 2012, 19, 1600–10. [PubMed: 23261603]

565. Tran HL, Lexa KW, Julien O, Young TS, Walsh CT, Jacobson MP and Wells JA, J Am Chem Soc, 2017, 139, 2541–2544. [PubMed: 28170244]

566. Weiz AR, Ishida K, Quitterer F, Meyer S, Kehr J-C, Müller KM, Groll M, Hertweck C and Dittmann E, Angew. Chem. Int. Ed, 2014, 53, 3735–3738.

567. Schmitt S, Montalbán-López M, Peterhoff D, Deng J, Wagner R, Held M, Kuipers OP and Panke S, Nat. Chem. Biol, 2019, 15, 437–443. [PubMed: 30936500]

568. Si T, Tian Q, Min Y, Zhang L, Sweedler JV, van der Donk WA and Zhao H, Journal of the American Chemical Society, 2018, 140, 11884–11888. [PubMed: 30183279]

569. Caetano T, Krawczyk JM, Mosker E, Süssmuth RD and Mendo S, Chem. Biol, 2011, 18, 90–100. [PubMed: 21276942]

570. Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN and Haas M, J. Pharmacol. Exp. Ther, 2009, 328, 849–54. [PubMed: 19038778]

571. Kuipers A, Moll GN, Wagner E and Franklin R, Peptides, 2019, 112, 78–84. [PubMed: 30529303]

572. Yang X, Lennard KR, He C, Walker MC, Ball AT, Doigneaux C, Tavassoli A and van der Donk WA, Nature Chemical Biology, 2018, 14, 375–380. [PubMed: 29507389]

573. Tavassoli A, Lu Q, Gam J, Pan H, Benkovic SJ and Cohen SN, ACS Chem. Biol, 2008, 3, 757–64. [PubMed: 19053244]

574. Bosma T, Kuipers A, Bulten E, de Vries L, Rink R and Moll GN, Applied and environmental microbiology, 2011, 77, 6794–801. [PubMed: 21821759]

575. Zhao X, Cebrián R, Fu Y, Rink R, Bosma T, Moll GN and Kuipers OP, ACS Synth Biol, 2020, 9, 1468–1478. [PubMed: 32374981]

576. Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, Bogler O, Mikkelsen T, Hirose T, Nishikawa R and Cheng SY, Oncogene, 2007, 26, 5577–5586. [PubMed: 17369861]

577. Getz JA, Cheneval O, Craik DJ and Daugherty PS, ACS chemical biology, 2013, 8, 1147–54. [PubMed: 23537207]

578. Wang CK and Craik DJ, Nature chemical biology, 2018, 14, 417–427. [PubMed: 29662187]

579. Rice JJ and Daugherty PS, Protein engineering, design & selection : PEDS, 2008, 21, 435–42.

580. Urban JH, Moosmeier MA, Aumüller T, Thein M, Bosma T, Rink R, Groth K, Zulley M, Siegers K, Tissot K, Moll GN and Prassler J, Nature Communications, 2017, 8, 1500.

581. Mahmood N, Mihalcioiu C and Rabbani SA, Frontiers in oncology, 2018, 8, 24. [PubMed: 29484286]

582. Chen S, Rentero Rebollo I, Buth SA, Morales-Sanfrutos J, Touati J, Leiman PG and Heinis C, Journal of the American Chemical Society, 2013, 135, 6562–9. [PubMed: 23560397]

583. Hetrick KJ, Walker MC and van der Donk WA, ACS Cent. Sci, 2018, 4, 458–467. [PubMed: 29721528]

584. Silverman AP, Levin AM, Lahti JL and Cochran JR, J. Mol. Biol, 2009, 385, 1064–75. [PubMed: 19038268]

585. Kim SG, Becattini S, Moody TU, Shliaha PV, Littmann ER, Seok R, Gjonbalaj M, Eaton V, Fontana E, Amoretti L, Wright R, Caballero S, Wang Z-MX, Jung H-J, Morjaria SM, Leiner IM, Qin W, Ramos RJJF, Cross JR, Narushima S, Honda K, Peled JU, Hendrickson RC, Taur Y, van den Brink MRM and Pamer EG, Nature, 2019, 572, 665–669. [PubMed: 31435014]

586. Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J, Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R, Hutmacher F, Lee S, Ventura-Cots M, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr., Vargas V, Altamirano J, Caballeria J, Shawcross DL, Ho SB, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Tu XM, Eckmann L, van der Donk WA, Young R, Lawley TD, Starkel P, Pride D, Fouts DE and Schnabl B, Nature, 2019, 575, 505–511. [PubMed: 31723265]

587. Luo S and Dong S-H, Molecules, 2019, 24, 1541.

Fig. 1.
Generic representation of RiPP biosynthesis. A. Most precursor peptides for RiPPs have two parts, a leader region and a core region. In some cases, a follower peptide is present. The core peptide is post-translationally modified to generate the mature RiPP, which at some stage requires leader/follower peptide removal. B. For some RiPP classes, the core peptide is flanked on one or both sides by short recognition sequences (RSs) that are important for post-translational modification. These systems often, but not always, have multiple copies of the core peptides, which can be highly diverse in sequence and lead to a group of different RiPP products.

Fig. 2.
Structure of JBIR-140. Primary PTMs are highlighted in yellow and secondary PTMs are highlighted in cyan. The stereochemistry has been determined for some of the stereocenters. 9

Fig. 3.
Structures of representative dikaritins. A. Ustiloxin B. B. Phomopsin A. C. Asperipin-2a; the stereochemistry is proposed based on NMR data.[18] Primary PTMs are highlighted in yellow and secondary PTMs are highlighted in cyan.

A. Structure of pheganomycin and its congeners. Primary PTMs are highlighted in yellow and secondary PTMs are highlighted in cyan. B. Sequence of the precursor peptide of the pheganomycins. The two core sequences are underlined.

Fig. 4.

pre-mycofactocin

Fig. 5.
Structure of pre-mycofactocin (see section 3.21). Further PTMs such as oligoglycosylation of the phenol that are currently not completely elucidated take place to furnish the final structure.[22]

Fig. 6.
Structures of A. Streptide, and B. Streptide-like RiPP with an additional crosslink; LP = leader peptide.

omphalotin A

Fig. 7.
Structure of omphalotin A illustrating the class-defining *N*-methylations and head-to-tail cyclization in yellow.

A. Structure of crocagin A. **B.** BGC for crocagin A. **C.** Sequence of the precursor peptide

Fig. 8.
A. Structure of crocagin A. B. BGC for crocagin A. C. Sequence of the precursor peptide
with the core peptide in red. In the absence of other characterized crocagins, all PTMs that
form the heterocyclic central structure are currently class-defining and are shown in yellow.
The secondary modification (i.e. N-terminal methylation) is shown in cyan.

Fig. 9.
Structure of an epimerized peptide from *B. subtilis*. Yellow indicates the class-defining, epimerization. Note on the peptide representation in this review: a free N-terminus is depicted as H- and a free carboxyl terminus as -OH.

Fig. 10.
A. Structure of lyciumin A. The class-defining modifications are in yellow. B. Precursor peptide with core peptides underlined and colored according to unique core peptide sequences. The C-terminal bold sequence indicates the BURP domain.

Fig. 11.
Structure of microvionin. The avionin (decarboxylated labionin) is highlighted on the right, and together with N-terminal lipidation forms the class-defining PTM for lipolanthines; the lipid structure (cyan) can vary and is not class-defining.

Fig. 12.
A. Structure of bacterial RaxX. B. BGC for RaxX production. C. Structure of the plant peptide PSY1. The arabinose chain is attached to (4*R*)-hydroxyPro. A second hydroxylated Pro is indicated as Pro-OH (the C-terminal OH reflects a free carboxylic acid; see Fig. 9). Tyr sulfation (yellow) is the class-defining PTM for sulfatyrotides.

Fig. 13.
Example of a splicease reaction. The class-defining α-oxoamide backbone bond is shown in yellow. Stereochemistry at the preceding Leu α-carbon has not yet been defined. See section 3.14 for further details.

Fig. 14.
A. Structure of ranthionine in thermocellin (shown is most likely a biosynthetically immature structure).[43] B. Ranthipeptide featuring a Cys-Asn crosslink.[44] H- denotes a free N-terminus and -OH a free carboxylic acid C-terminus. The unifying feature of ranthipeptides is a thioether linkage formed from a Cys thiol to a non-α-carbon of another amino acid (yellow) in a radical-mediated process.

Fig. 15. Structures of bacterial peptides that are macrocyclized by radical SAM proteins.
A. Arg-Tyr crosslink in ryptides. B. Thr-Gln crosslink in rotapeptides. C. Lys-Trp and Trp-Trp crosslinks in darobactin.

Fig. 16.
Structures of two pearlins made by post-translational modification of scaffold peptides. The class-defining PTM of pearlins is initial aminoacyl-tRNA-dependent extension of a ribosomal peptide. The appended amino acid is then further modified, and in the last biosynthetic step, the initially generated peptide bond undergoes peptidolysis. Thus, all PTMs in the final structure are secondary modifications (cyan).

Fig. 17.
A. Structure of the natural isomer of tryptorubin A. In this isomer, the Ile4-Trp5 "peptide bridge" lies above the Trp2-Tyr3 crosslink. In the non-natural isomer, this bridge is located below the Trp2-Tyr3 crosslink. For details see[53]. Both Trp2-Tyr3 and Tyr3-Trp5 crosslinks are considered class-defining and thus are highlighted in yellow. B. BGC for tryptorubin A and the sequence of the precursor peptide with the core peptide in red.

Fig. 18.
A. Structure of the class V lanthipeptide cacaoidin. The stereochemistry of the lanthionine is proposed. The class-defining PTMs are yellow. Secondary PTMs are cyan. At present the dimethylated N-terminal lanthionine is present in all known members and is colored yellow. It may be that over time this PTM may turn out not to be class -defining. B. BGC for cacaoidin biosynthesis. C. Structure of cittilin A. D. BGC for citillin A.

Fig. 19.
A. Post-translational modifications resulting in lanthionine and methyllanthionines from Ser/Thr and Cys. B. Two different mechanisms for dehydration utilizing either Glu-tRNA or NTP for activation of the Ser/Thr side chain hydroxyl groups prior to elimination of Glu/phosphate.

Fig. 20.
A. Crystal structure of the NisB homodimer with the NisA LP bound (PDB: 4WD9).[49] Only one monomer is colored for clarity. B. Glu elimination active site with a non-reactive amide-linked Glu bound (PDB: 6M7Y).[67] Two Arg residues recognize the Glu side chain of the glutamylated substrate peptide.

Fig. 21.
A. Crystal structure of the class II lanthipeptide synthetase CylM (PDB: 5DZT).[75] The dehydration domain architecture is similar to that of eukaryotic lipid kinases. The kinase activation domain (KA) holds the activation loop in a defined conformation. B. Phosphorylation active site showing typical features of protein kinases as well as the two residues from the KA domain (Thr and Arg) that are involved in β-elimination of the phosphate group to form the dehydro amino acids.

Fig. 22.

A. Formation of labionin and methyllabionin crosslinks highlighted in yellow. B. Structure of class III lanthipeptide NAI-112 featuring a MeLab. Also unique in RiPPs is the *N*-glycosylation of the Trp indole nitrogen, a secondary modification (cyan). H-denotes a free N-terminus and -OH denotes a free carboxyl C-terminus.

Fig. 23.
A. BGC of microvionin. MFS, Major Facilitator Superfamily; TPP, thiamine pyrophosphate.
B. Proposed biosynthetic pathway to microvionin. A ribosomal peptide is post-translationally modified by decarboxylation of the C-terminal Cys and subsequent cyclization (Fig. 22A) to generate avionin. After LP removal, a fatty acid is attached to the liberated N-terminus. Class-defining PTMs are yellow while secondary PTMs that can vary in structure are cyan.

Fig. 24.
A. BGC of the thiopeptide thiomuracin. B. Biosynthetic pathway to the core structure of thiomuracin showing the obligatory order of thiazole formation, dehydration, and cyclization. The LP is eliminated by TbtD as a C-terminal carboxamide. The thiazoles (yellow) and the 6-membered nitrogen-containing heterocycle (green/purple) are the class-defining PTMs for thiopeptides. The pyridine in the final structure is color-coded to illustrate the origin of the atoms that come from two dehydroalanines of the preceding intermediate.

Fig. 25.
Crystal structure of the glutamylation enzyme TbtB containing 5'-phosphoryl-desmethylglutamycin (PDG), an analog of AMP with an amide-linked glutamate attached to the 3'-position of the ribose (PDB: 6EC8).[67]

Fig. 26.
A. Crystal structure of TbtD, the enzyme that catalyzes the [4+2]-cycloaddition in thiomuracin biosynthesis, bound to the LP of its substrate (PDB: 5WA4).[97] B. A tri-substituted pyridine (TSP) product analog bound in the active site of the orthologous enzyme from the GE2270A biosynthetic pathway (PDB: 5W99). C. Proposed mechanism of pyridine formation by initial [4+2]-cycloaddition to generate a hemiaminal intermediate. Subsequent dehydration and LP elimination yield the pyridine product. The hemiaminal has been intercepted with a slow substrate and was hydrolyzed to the diketone.[98]

CypA: MRSEMTLTSTNSAEALAAQDFANTVLSAAAPGFHADCETPAM
ATPATPTVAQFVIQGSTICLVC

Fig. 27.
Linaridin BGC and structure. A. BGC and precursor peptide sequence of the linaridin cypemycin. The core peptide is in bold with sites of dehydration in red. B. Structure of cypemycin. Unlike other RiPPs for which the C-terminal AviCys ring is generated from Cys and Ser, for cypemycin this structure is formed from two Cys residues by a process that is currently unresolved. Class-defining PTMs are yellow and secondary PTMs are cyan. The stereochemistry at the α-carbon of the AviCys macrocycle has not been definitively established.

Fig. 28.
LAP BGC and structure. A. BGC and precursor peptide sequence of the LAP microcin B17. The core peptide is in bold and residues that are modified are in red. B. Structure of microcin B17. The class-defining azole heterocycles are yellow. C. Biosynthetic scheme for azole installation in LAPs.

Fig. 29.
Mechanistic model for YcaO-catalyzed cyclodehydration.

Fig. 30.
Cyanobactin cyclodehydratases. A. Structure of the TruD dimer (PDB: 4BS9). B. Nucleotide and substrate bound structure of the LynD dimer (PDB: 4V1T). In panels A and B, monomer 1 is colored by domain and monomer 2 is gray. C. Substrate PatE2 is located far from the α-phosphate of ATP, disfavoring a previously suggested adenylation mechanism. RRE: RiPP precursor recognition element (section 4.1.1).

Fig. 31.
Structure and ATP-binding residues of *Ec*-YcaO. A. Structure of nucleotide-bound dimeric *Ec*-YcaO (PDB: 4Q86).[117] Monomer 1 is colored by ATP-bonding domain (green) and tetratricopeptide repeat domain (purple) with monomer 2 in gray. B. ATP-binding residues of *Ec*-YcaO are shown as gold sticks colored according to heteroatoms. AMP is shown as gray stick colored according to heteroatoms.

A. Two thioamitide BGCs: thioholgamide (*tho*) and thioviridamide (*tva*) and the sequence of the ThoA precursor peptide.

ThoA
VDETAFADLVSKIQDAEASMTDEQRAVIDPASGEKALQEL
AGVSPEELQAFLEEKAGISPDEEAQGS**VMAAAATVAFHC**

Thioholgamide A- R:SMe
Thioholgamide B- R:S(=O)Me

Fig. 32.
Thioamitide BGC and structure. A. Two thioamitide BGCs: thioholgamide (*tho*) and
thioviridamide (*tva*) and the sequence of the ThoA precursor peptide. B. Structure of
thioholgamides. Class-defining PTMs are shown in yellow and secondary PTMs in cyan.

Fig. 33.
Proposed mechanism for thioamidation catalyzed by YcaOs.

Fig. 34.
Structures of thioamide-installing YcaOs. A. Nucleotide-bound structure of *Mk*-YcaO
(PDB: 6CI7). B. Nucleotide- and peptide-bound structure of *Mj*-YcaO (PDB: 6PEU).
Structures in panels A and B are colored by secondary structures. Nucleotide in panel A and
B, and peptide substrate in panel B are shown as gray and gold sticks, respectively, and
colored according to heteroatom.

Fig. 35.
Cyanobactin biosynthesis. A. BGC of the cyanobactin patellamide. B. Patellamide biosynthesis beginning with the ribosomal synthesis of the PatE precursor peptide and culminating in the synthesis of two cyanobactins, patellamide A and C. PatD catalyzes cyclodehydration of Cys, Ser, and Thr residues, then PatA cleaves C-terminal to RSII, and PatG cleaves N-terminal to RSIII and cyclizes the peptide. Because PatA is the class-defining enzyme, azol(in)e formation and head-to-tail cyclization are secondary PTMs (cyan).

Fig. 36.
Structure of cyanobactin proteases. A. PatA (PDB: 4H6V) protease domain. B. PagA (PDB: 4H6W) protease domain. Figures in panel A and B are colored by secondary structures. Both PatA[Pro] and PagA[Pro] exhibit a subtilisin-like protease fold. C. and D. Catalytic triad of PatA[Pro] and PagA[Pro], respectively.

Fig. 37.

Bottromycin biosynthesis. A. Bottromycin BGC in *Streptomyces bottropensis*. B. Proposed order of steps for bottromycin biosynthesis.[143,144] In the first three steps, in no particular order, the N-terminal Met is removed by BmbK, thiazolines are installed by BmbD, and Val, Pro and Phe are *C*-methylated by BmbBF. Then the class-defining macrolactamidine is formed by BmbE, the follower peptide is removed by BmbH, and the Asp residue is epimerized by BmbG. In the final two steps, BmbI is thought to oxidize the thiazoline to a thiazole by oxidative decarboxylation and the Asp is methylated by BmbA.

A

mcj A B C D

1 kb

■ precursor peptide

■ leader peptidase

■ lasso cyclase

■ transporter

McjA:

MIKHFHFNKLSSGKKNNVPSPAKGVIQIKKSASQLTK
GGAGHVPEYFVGIGTPISFYG

B

Fig. 38.

Lasso peptide BGC and structure. A. BGC of the lasso peptide microcin J25 (MccJ25). The MccJ25 precursor peptide sequence is shown. The core peptide is shown in bold and residues forming the macrolactam linkage are shown in red. B. Cartoon representation of MccJ25; OH reflects a free carboxyl C-terminus. The class-defining macrolactam linkage is highlighted in yellow.

Fig. 39.
Sactipeptide BGC and structure. A. Subtilosin A BGC and precursor peptide sequence. The core peptide and the residues involved in the class-defining sactionine modification are in bold and red, respectively. B. Structure of subtilosin A. Sactionine linkages are in yellow. The secondary macrolactam modification is highlighted in cyan.

Fig. 40.
Proposed mechanistic schemes for rSAM mediated sactionine installation in sactipeptides. A. Radical mechanism. B. Polar mechanism. Reduction of the rSAM cluster and oxidation of the AISC returns the enzyme to a catalytically active state. The first Fe-S cluster (teal) resides in the SAM-binding domain and is used for the reductive cleavage of SAM and generation of the 5'-dA radical. The second Fe-S cluster (orange) resides in the auxiliary domain and is believed to coordinate the peptide substrate through Cys ligation.

Fig. 41.
Structure of sactisynthase SkfB.[48] SkfB (PDB: 6EFN) features a partial TIM barrel rSAM domain flanked by the N-terminal RRE and the C-terminal twitch domains. The structure is colored according to domains and the [Fe-S] clusters are shown as sticks.

Fig. 42.

Ranthipeptide BGC and structure. A. BGC of the ranthipeptide freyrasin. B. Structure and precursor peptide sequence of freyrasin. The class-defining β-thioether linkages in the structure are yellow and the post-translationally modified Cys/Asp residues in the primary sequence are shown in red.

Fig. 43.
Structure of the ranthipeptide maturase CteB.[187] CteB (PDB: 5WGG) exhibits a tripartite structure composed of rSAM, RRE and SPASM domains. The structure is colored according to domains. The [Fe-S] clusters and Ca^{2+} ions are shown as sticks and spheres, respectively.

Fig. 44.
Streptide BGC and structure. A. BGC and precursor peptide sequence for streptide. The core peptide is shown in bold, and Lys and Trp residues crosslinked in streptide are shown in red. B. Structure of streptide. The class-defining C-C crosslink is shown in yellow.

Fig. 45.

Proposed mechanistic scheme for rSAM-mediated C-C crosslinking in streptides. A. Homolytic mechanism. B. Heterolytic mechanism. In both mechanisms, transfer of an electron from the AISC to the SAM-binding cluster, directly or *via* an external agent returns the enzyme to a catalytically competent state.

Fig. 46.
Structure of the streptide maturase SuiB bound to SuiA (PDB: 5V1T).[193] SuiB exhibits a triple domain architecture akin to other RiPP modifying rSAM enzymes. The structure is colored according to domain and the [Fe-S] clusters are shown as sticks.

Fig. 47.
Proteusin biosynthetic logic and structure of polytheonamide A. A. Overall biosynthetic pathway. B. Structure of polytheonamide A. Since proteusins do not have class-defining PTMs (the NHLP is the class-defining feature, Table 1), a color-coded key identifies the diverse modifications that occur during the maturation process. NHLP, nitrile hydratase-like LP.

Fig. 48.
Structures of aeronamide A and landornamide. Since proteusins do not have class-defining PTMs (Table 1), the color coding is based on the enzymes that install each modification.

Fig. 49.

A. BGC of *yyd*. B. Proposed mechanism of YydG epimerization. YydG catalyzes substrate Cα hydrogen atom abstraction, resulting in the loss of amino acid residue stereochemistry. An active site Cys residue then donates a hydrogen atom to the resulting carbon-centered radical intermediate, resulting in an epimerized substrate. The AISC is believed to quench the resulting thiyl enzyme radical to regenerate the Cys H-atom donor residue. PoyD-type enzymes (section 5.1.1) are thought to use a similar overall mechanism.

A *plp* B A1 D A3A2 X Y

putative hydroxylase

NHLP-type precursor peptide

rSAM epimerase

nif11-type precursor peptide

rSAM splicase

PlpY-type accessory protein

B

PlpA2: MSIENAKSFYERVSTDKQFRTQLENTASAEERQKIIQA
AGFEFTNQEWEIAKEQILATSESNNGELSEAELTAVSGG
VDLSIFELLDEEPLFPIRPLYGLPI

PlpA3: MSIESAKAFYQRMTDDASFRTPFEAELSKEERQQLIKD
SGYDFTAEEWQQAMTEIQAARSNEELNEEELEAIAGG
AVAAMYGVVFPWDNEFPWPRWGG

C

Fig. 50.
A. The *plp* BGC. B. Splicease-mediated tyramine excision and α-keto-β-amino acid generation. One tyramine equivalent is excised from the peptide backbone, which is subsequently reconnected to introduce a ketoamide moiety and extend the backbone by one carbon unit. The exact structure of the excised product has not yet been identified.

Fig. 51.
Graspetide BGC and structure. A. BGC and precursor peptide sequence of the graspetide microviridin J. The *N*-acetyl transferase is located elsewhere in the genome of the producer. The core peptide is in bold. The residues involved in lactone and lactam modifications are in purple and pink, respectively. B. Structure of microviridin J with the class-defining PTMs in yellow and secondary PTMs in cyan.

Fig. 52.
Structure of MdnA bound MdnC dimer (PDB: 5IG9).[212] Monomer 1 is colored by domain and monomer 2 is shown in gray.

Fig. 53.
A. Sequence of the *N*-MT for the biosynthesis of omphalotin A illustrating the enzymatic domain (green), LP (blue), core peptide (orange), and follower peptide (grey). B. Crystal structure of OphA-DeltaC6 (PDB: 5N0Q)[220] with the clasp domain of monomer A in light blue, the remainder of monomer A in dark blue, and monomer B in green.

Fig. 54.
Proposed mechanism of OphMA methylation. A substrate amide proton is removed by a water molecule acting as a base. The resulting imidate is stabilized by H-bonding to Tyr66 and Tyr76.[220] Arg72 is hypothesized to stabilize the tyrosinate that results from proton removal, suggesting the existence of an imidic acid intermediate. Subsequent S_N2 attack on the SAM methyl group by the imidate completes the transformation.

Fig. 55.
A. BGC for ustiloxin biosynthesis. B. Sequence of the ustiloxin precursor peptide showing the LP (top row), the repeats of the core peptide (red) and recognition sequences (black), and the predicted Kex2 protease processing site at the C-terminus of each core sequence (bold). C. BGC for asperipin 2a. D. Sequence of the asperipin 2a precursor peptide showing the LP (top 2 rows), the repeats of the core peptide (teal) and recognition sequences (black), and the predicted Kex2 protease processing site at both the N- and C-terminus of each core sequence (bold). E. Proposed biosynthetic pathway to ustiloxin B. The class-defining PTM is yellow and secondary PTMs are cyan.

Fig. 56.
A-C. Plant-derived compounds with structural homology to asperipin 2a. D. BGC for phomopsins. E. Sequence of the phomopsin precursor peptide showing the LP (top 2 rows), the repeats of two different core peptides (green) and recognition sequences (black), and the predicted Kex2 protease processing site at the C-terminus of each core sequence (bold "KR").

Fig. 57.
POPB-catalyzed cyclization of the core peptide during the biosynthesis of α-amanitin. The class-defining PTMs are highlighted in yellow with secondary PTMs highlighted in cyan.

Fig. 58.
PCY1-catalyzed cyclization of the core peptide during the biosynthesis of the orbitide segetalin A. The endopeptidase OLP1 first removes the LP (blue). The highly conserved 6-amino acid terminal peptide (yellow) makes key interactions with PCY1 in the second proteolytic step to promote intramolecular trapping of the initial acyl-enzyme intermediate by the N-terminal amine.

Fig. 59.

A. BGC for pheganomycin. B. Convergent biosynthetic pathway to pheganomycin in which the ATP-grasp ligase PGM1 connects an α-guanidino acid to a ribosomally synthesized peptide that likely is *C*-methylated in a prior step by a rSAM methyltransferase (PGM3). Class-defining structural features are in yellow; secondary features that may vary are in cyan.

Fig. 60.
A. BGC for PQQ in *Pseudomonas sp*. CMR12a. B. Precursor peptide sequence with the amino acids that are modified to PQQ colored red. C. Biosynthetic pathway and structure of PQQ.

Fig. 61.
A. BGC for mycofactocin biosynthesis. B. Precursor peptide with the amino acids that are turned into mycofactocin highlighted in red. C. Current understanding of the mycofactocin biosynthetic pathway. The membrane-associated glycosyl transferase MftF may glycosylate the phenol group of pre-mycofactocin.[22]

Fig. 62.
Two possible routes to pantocin A depending on whether condensation of the peptide backbone amide with Glu16 by PaaA preceeds (solid arrows) or succeeds (dashed arrows) condensation between the side chains of Glu16 and Glu17 remains to be elucidated. Both routes yield the same bicyclic core, which is subject to subsequent oxidative decarboxylation.

Fig. 63.

A. Structure of methanobactin bound to copper (I). B. BGC of methanobactin from *Methylosinus trichosporium* OB3b C. Sequence of the MbnA precursor peptide D. Hypothetical mechanism for MbnBC-catalyzed generation of oxazolone/thioamide moieties on MbnA.[274] Class-defining PTMs are in yellow, secondary PTMs in cyan.

Fig. 64.

A. BGC for 3-thiaglutamate. B. Proposed mechanism of Cys addition to TglA by the PEARL TglB. Oxygen labeling experiments established that the ester bond to the tRNA is hydrolyzed during the reaction. C. Additional PTMs that lead to 3-thiaglutamate and regenerate TglA.

Fig. 65.
A. Co-crystal structure of NisB with the dehydrated NisA peptide; only the LP is resolved (PDB: 4WD9).[49] The LP binds in antiparallel fashion to β3 of the RRE with further interactions to α3. B. Interactions between a highly conserved motif on the LP of NisA (the FNLD motif) with pockets and amino acids of the RRE of NisB. The Phe and Leu of the motif insert into hydrophobic pockets and the Asp makes an interaction with an Arg on NisB. An adjacent Leu located C-terminal to the motif provides an additional hydrophobic contact.

Fig. 66.
Co-crystal structure of the LP of PatE' (red) bound to the RRE domain of LynD (PDB: 4V1T).[115] The LP binds analogously to how NisA engages with NisB (Fig. 65).

Fig. 67.
Crystal structure of PqqD (PDB: 3G2B).[291] The β3 strand and α3 helix that were shown by NMR[290] to directly engage the PqqA LP are indicated.

Fig. 68.
Co-crystal structures of FusE (TfuB1) and TbiB RRE domains and the LPs of their substrates (blue; PDB: 6JX3 and 5V1V).[161] The overall binding mechanism again involves interactions with the β3 strand and α3 helix of the RRE.

Fig. 69.
Crystal structure of the McbAB2CD complex (PDB: 6GRG).[122] A. Biosynthetic complex containing McbA (cyan), McbB (orange and purple), McbC (green), and McbD (blue) B. LP (cyan) binding to the RRE of one of the monomers of McbB (purple).

Fig. 70.
A. Co-crystal structure of SuiB and SuiA (PDB: 5V1T).[296] Although SuiB contains an RRE depicted in pink, SuiA (orange) does not bind in the canonical antiparallel fashion to the β3 strand of the RRE. B. Interactions that mediate SuiA-SuiB binding.

Fig. 71.
Co-crystal structure of MdnC (purple) and the LP of MdnA (gold) showing substrate recognition via an α-helix in the LP (PDB: 5IG9).[212]

Fig. 72.
Biophysical and biochemical experiments suggest that the loops connecting the capping helices of the dehydratase domain (grey) of class II lanthipeptide synthetases (LanM proteins) mediate LP binding.[76,77] The cyclase domain is shown in purple.

Fig. 73.
A. Structure of microcin C. Class-defining PTMs are in yellow, secondary PTMs are in cyan. B. Substrate recognition by MccB (PDB: 6OM4).[298] The two monomers are shown in gray and salmon and the substrate MccA in magenta. The *N*-formylated N-terminal Met1 and Arg2 are shown in stick format. C. Structure of a microcin C-like compound from *Y. pseudotuberculosis* IP32953.

Fig. 74.
Recognition of the follower peptide on the substrate (gold) by PCY1 (blue) (PDB: 5UW3).
248

Fig. 75.
A. Crystal structure of a PCAT (PDB: 4RY2).[305] B. Cryo-electron microscopy structure of the PCAT in panel A with the substrate bound, showing the α-helical fold of the LP segment recognized by the peptidase domain (PDB: 6V9Z).[306]

Fig. 76.
Crystal structure of the protease domain of the PCAT LahT (teal) covalently linked via a Cys in its active site to a peptide aldehyde corresponding to the C-terminal sequence of the ProcA2.8 LP (gold) (PDB: 6MPZ).[308] The double Gly residues (positions −1 and −2) are indicated as are two key Leu residues (positions −7 and −12) on an α-helix that insert into hydrophobic pockets to mediate substrate engagement.

Fig. 77.
A. Crystal structure of the TldD/E complex (PDB: 5NJC).[319] B. Engagement of the substrate backbone with the protease.

R = H or CH₃

Fig. 78.
Transformations catalyzed by dehydroamino acid reductases to yield a D-amino acid.

Fig. 79.
A. Structure of the thiopeptide nosiheptide. The 3-methyl-2-indolic acid (MIA) fragment is depicted in red. B. Active site of NosL in complex with its substrate L-Trp. C. Summary of two mechanistic proposals for the NosL-catalyzed rearrangement. In both mechanisms, 5'-dA• abstracts a hydrogen atom from the amino group of Trp. Then, two different β-scission reactions cleave either the Cα-Cβ bond to form dehydroglycine (Dhg) and an indole radical (mechanism a) or the Cα-C1 bond (mechanism b) to generate formyl radical. Subsequent steps to explain the observation of 3-methylindole, Dhg, and formaldehyde in addition to the MIA product are shown.

Fig. 80.
A. Radical-based mechanism, and B. Heterolytic mechanistic proposal for TsrM-catalyzed
C-methylation of L-Trp during the biosynthesis of thiostrepton.

Fig. 81.
Proposed mechanism of cobalamin-dependent *C*-methylation catalyzed by PoyB and PoyC illustrated for Val methylation. Reductive cleavage of SAM leads to 5'-dA[•] that abstracts a hydrogen atom from Val in the substrate peptide. The resulting substrate radical then attacks the methyl group of MeCbl forming cob(II)alamin, which is reduced and methylated by SAM to regenerate MeCbl.

Fig. 82.
Proposed mechanisms for *C*-methylation of thiazole by the rSAM protein TbtI. In all three mechanisms, 5'-dA• generated from one SAM molecule abstracts a hydrogen atom from the methyl group of another SAM molecule, and the resulting methylene radical adds to the electrophilic thiazole to form radical **X**. Upon elimination of SAH, three different mechanisms may convert the intermediate radical **Y** to the methylated thiazole product. In mechanism b, U-H is an unidentified redox active amino acid of TbtI.

Fig. 83.

Structures of the *N*-methylated RiPPs divamide A and plantazolicin. Divamides are
cinamycin/duramycin-like class II lanthipeptides and plantazolicin is a LAP. For the
cypemycin structure, see Fig. 27. Class-defining PTMs are yellow while secondary PTMs
are cyan.

Fig. 84.
Proposed mechanisms of NosN catalysis. A. Structures of various proposed or detected intermediates and products in the reaction of NosN with native substrates or substrate analogs. B. Mechanism of methylene transfer and intramolecular trapping by a Glu residue. C. Two mechanisms that differ in whether 5'-dA• abstracts a hydrogen from SAM (mechanism i) or from MTA (mechanism ii).

Fig. 85. Biosynthesis of RiPPs that are methylated on the C-terminus.
A. Structure of aeruginosamide B that is *N*-prenylated and methylated on its C-terminal carboxylate shown in cyan. B. BGC of aeruginosamide B. C. Precursor peptide for aeruginosamide B. D. RiPP BGC in *Lachnospiraceae*. E. Sequences of the seven precursor peptides of the *lah* BGC, some of which are methylated on the C-terminus by LahS$_B$.

Fig. 86.
OlvS$_A$-catalyzed L-Asp O-methyltransfer and formation of L-isoAsp via a succinimide intermediate. OlvS$_A$ orthologs are often encoded in class I lanthipeptide BGCs (section 3.1.1) in Actinobacteria.

Fig. 87.
A. BGC for landornamide. B. Biosynthetic pathway towards landornamide. Since proteusins do not have class-defining PTMs (Table 1), the color-coding is based on the enzymes that install each modification.

Fig. 88.
Proposed mechanism for the conversion of Arg to Orn by OspR during landornamide biosynthesis.

Fig. 89.
Proposed mechanism for phosphorylation of the lasso peptide paeninodin.

Fig. 90.
A. Structures of GE2270 and nosiheptide with the oxidations by characterized oxidative tailoring enzymes indicated in cyan. B. The cyclization of the secondary macrocycle of thiostrepton involves epoxidation of the quinaldic acid and subsequent epoxide ring opening by the N-terminal Ile that is generated by LP removal by TsrB. Cyclization is shown here to occur as the last step of biosynthesis, but this hypothesis has not been experimentally verified as of yet. Dihydroxylation of Ile10, catalyzed by TsrK (TsrR) is shown in cyan.

Fig. 91.
Biosynthesis of quinaldic acid from 2-methyl-L-Trp by TsrV (TsrA) and TsrQ (TsrE) during thiostrepton biosynthesis. For the mechanism of 2-methyl-L-Trp formation, see Fig. 80. For the structure of thiostrepton, see Fig. 90B.

Fig. 92.
Structure of the LAP azolemycin A. Class-defining PTMs are yellow while secondary PTMs are cyan. The N-terminal oxime is believed to be formed by the flavin-dependent monooxygenase AzmF.

Fig. 93.
A. Blocking the N-terminus of peptides from aminopeptidase activity by hydrolysis of dehydroamino acids. B. Blocking the C-terminus of peptides by amidation from a dehydro amino acid by NosA.

Fig. 94.

Overview of peptide modifications discussed in section 7. **Cis-/Trans-binding LP**: Leaderless substrates can be modified by modification enzymes that have their LP covalently bound (*in cis*) or added as a separate molecule (*in trans*) to the reaction (section 7.2). **Chemical ligation**: A molecule is added through a reaction not related to cellular metabolism (*e.g.* click chemistry). **Genetic rearrangement and ring-shuffling**: peptide elements are added, removed, or recombined at the DNA level. **Disulfide to thioether**: replacement of cystine by lanthionine (section 7.4.2). **Chimeric leader**: The LP is comprised of modules from two or more molecules, allowing for modification by PTM enzymes from more than one RiPP system (section 7.2). **Amino acid substitutions**: One or more amino acids are simultaneously replaced by residues that do not naturally occur in those positions (section 7.6). **Noncanonical amino acids**: One or more amino acids are replaced by non-proteinogenic residues through one of several methods (section 7.4). **Leader-independent tailoring**: The peptide is modified by secondary PTM enzymes that recognize a section of the core peptide, instead of a LP.

Fig. 95.

Concept of hybrid RiPP biosynthesis through leader and core peptide hybridization. By combining the key recognition motifs for leader-dependent PTM enzymes, a core peptide can be modified by enzymes from multiple systems. In this example, the HcaDF RS was combined with the NisBC RS to create a hybrid LP. The hybrid core peptide existed of sequences from LAPs and the class I lanthipeptide nisin.[496] The product contained PTMs from LAP (blue) and lanthipeptide (red) biosynthesis.

Fig. 96. Employment of the FIT system in RiPP biosynthesis.

Use of the FIT system for installation of ncAAs in cyclodehydratase substrates and *in vitro* modification by PatD. I) The natural substrates (Ser, Thr and Cys residues) result in oxazolines (Ser/Thr) and thiazoline (Cys). II) PatD installs substituted oxazolines from Thr analogs carrying alkyl or aryl groups on the β-carbon. III) PatD is able to form an imidazoline. IV) Substrates with either a thiol group or amino group (not shown) as the nucleophile at the γ-carbon are modified by PatD. The formation of a six or five membered ring could not be distinguished.[510]

A

goadsporin

B *god*

|	
■ precursor peptide	■ dehydratase (elimination)
■ transporter	■ acetyltransferase
■ cyclodehydratase	■ transcriptional regulator
■ dehydrogenase	□ other
■ dehydratase (glutamylation)	■ self-resistance

Fig. 97. Biosynthesis of goadsporin.
A. Structure of goadsporin which contains features of LAPs (thiazoles and oxazoles; section 3.4) and lanthipeptides (Dha; section 3.1.1). B. BGC for goadsporin containing LAP-type azole-installing machinery (GodDE) as well as a split dehydratase (GodFG; section 3.2). GodH catalyzes the N-terminal acetylation.[437]

Fig. 98. Employment of the FIT system in thiopeptide biosynthesis.
Use of FIT and enzymes from different pathways to reduce the complexity of thiocillin biosynthesis. I) BGC for thiocillin. II) The precursor peptide containing SecPh is produced using FIT, after which the combination of LynD (thiazoline formation) and TbtE (thiazoline dehydrogenase) installs triazoles. The SecPh residues are converted to Dha by H_2O_2, eliminating the need for dehydratases. In a final step, the macrocyclic ring is formed by TclM (section 3.2). Using this pathway, three enzymes are required rather than the original six.[71,490]

Table 1.

Currently known RiPP classes and representative examples. Classes discovered or shown to be RiPPs after 2013 are italicized. When a particular PTM can be installed by multiple types of known enzymes, the enzyme family involved for the class in question is noted in parentheses.

Class	Example	Class-Defining PTM(s) or feature (enzyme responsible)
Amatoxins/phallotoxins	Phalloidin	N-to-C cyclization, Cys-Trp crosslink
Guanidinotides	*Pheganomycin*	*α-guanidino acid containing peptides (ATP-grasp)*
Atropitides	*Tryptorubin*	*Aromatic amino acids crosslinked to give a non-canonical atropisomer*
Autoinducing peptides	AIP-I	Cyclic ester or thioester
Bacterial head-to-tail cyclized peptides	Enterocin AS-48	N-to-C cyclization (DUF95 & ATP-grasp)
Borosins	*Omphalotin*	*Amide backbone N-methylation (N-MT) N-to-C cyclization (POP)*
Bottromycins	Bottromycin A1	Macrolactamidine (YcaO)
Cittilins	*Cittilin A*	*biaryl and aryl-oxygen-aryl ether crosslinks (P450)*
ComX	ComX168	Indole cyclization and prenylation
Conopeptides	Conantokin G	Peptides produced by cone snails
Crocagins	*Crocagin A*	*Indole-backbone cyclization*
Cyanobactins	Patellamides	N-terminal proteolysis (PatA protease)
Cyclotides	Kalata B1	N-to-C cyclization, disulfide(s) (AEP)
Dikaritins	*Ustiloxin*	*Tyr-Xxx ether crosslink (UstY)*
Epipeptides	*YydF*	*D-amino acids (rSAM)*
Glycocins	Sublancin 168	*S*, *O*, or *N*-glycosylation of Ser/Cys
Graspetides	Microviridin J	Macrolactones/lactams (ATP-grasp)
Lanthipeptides	Nisin	(Methyl)lanthionine, labionin
Lasso peptides	Microcin J25	Macrolactam with threaded C-terminal tail (Asn synthetase homolog)
Linaridins	Cypemycin	Dhb, no lanthionines
Linear azol(in)e-containing peptides (LAPs)	Microcin B17	Cys, Ser, or Thr derived azol(in)es (YcaO)
Lipolanthines	*Microvionin*	*C-terminal labionin/avionin containing peptide and N-terminal FAS/PKS segment*
Lyciumins	*Lyciumin A*	*Pyroglutamate, Trp-Gly crosslink*
Streptide	*Streptide*	*Trp-Lys crosslink*
Methanobactins	Methanobactin	Oxazolones (DUF692)
Microcin C	Microcin C	Aminoacyl adenylate or cytidylate with a phosphoramidate linkage (ubiquitin E1 homolog)
Mycofactocin	*Mycofactocin*	*Val-Tyr crosslink (rSAM)*
Orbitides	Cyclolinopeptide A	N-to-C cyclization; no disulfides
Pantocins	Pantocin A	Glu-Glu crosslink (PaaA)
Pearlins	*Thiaglutamate*	*aa-tRNA derived (PEARL)*
Proteusins	Polytheonamide	Nitrile hydratase LP
Pyrroloquinoline quinones	PQQ	Glu-Tyr crosslink (rSAM)
Ranthipeptides	*Freyrasin*	*Sulfur-to-non-Cα thioether crosslink (rSAM)*

Class	Example	Class-Defining PTM(s) or feature (enzyme responsible)
Rotapeptides	*TQQ*	*Oxygen-to-α-carbon crosslink*
Ryptides	*RRR*	*Arg-Tyr crosslink (rSAM)*
Sactipeptides	Subtilosin	Sactionine crosslink (rSAM)
Spliceotides	*PlpA*	*β-amino acids (rSAM)*
Sulfatyrotides	*RaxX*	*Tyrosine sulfation*
Thioamitides	*Thioviridamide*	*Backbone thioamide (YcaO)*
Thiopeptides	Thiostrepton	[4+2] Cycloaddition of two Dha
Thyroid hormones	Triiodothyronine	Iodination of Tyr, excised from thyroglobulin

Abbreviations: AEP, asparaginyl endoprotease; Dha/Dhb, dehydroalanine/dehydrobutyrine; DUF, domain of unknown function; FAS, fatty acid synthase; LP, leader peptide; MT, methyltransferase; PEARL, peptide aminoacyl-tRNA ligase; PKS, polyketide synthase; POP, prolyl oligopeptidase; rSAM, radical SAM.

Table 2.

Comparison of currently available RiPP genome mining tools.

Name	Input	Availability		RiPP classes supported
		Webtool	**Download**	
antiSMASH	genomic data	Yes	Yes	lanthipeptides, rSAM-modified RiPPs, microviridins, head-to-tail cyclized peptides, bottromycins, sactipeptides, lasso peptides, LAPs, glycocins, cyanobactins, linaridins, thiopeptides
BAGEL4	genomic data	Yes	Yes[a]	lanthipeptides, lasso peptides, cyanobactins, microcins, thiopeptides, head-to-tail cyclized peptides, glycocins, sactipeptides, bottromycins, LAPs
NeuRiPP	protein accession number	No	Yes	class independent
RiPP-PRISM	genomic data	Yes	Yes[b]	autoinducing peptides, bottromycins, ComX, cyanobactins, glycocins, head-to-tail cyclized peptides, lanthipeptides, lasso peptides, linaridins, LAPs, microviridins, prochlorosins, proteusins, sactipeptides, streptide, thiopeptides, trifolitoxin, thioviridamide, YM-216391
RiPPER	protein accession number	No	Yes	class independent
RiPPMiner	protein sequence	Yes	No	lanthipeptides, bottromycins, cyanobactins, glycocins, lasso peptides, linaridins, LAPs, microcins, sactipeptides, thiopeptides, ComX, autoinducing peptides, head-to-tail cyclized peptides
RiPPQuest	MSMS data and genome	Yes	No	lanthipeptides, LAPs, lasso peptides, linaridins, proteusins, cyanobactins, methanobactins
RODEO	protein accession number	Yes	Yes	lasso peptides, class I-IV lanthipeptides, ranthipeptides, sactipeptides, thiopeptides
IMG-ABC	data in its database	Yes	No	lanthipeptides, rSAM-modified RiPPs, microviridins, head-to-tail cyclized peptides, bottromycins, sactipeptides, lasso peptides, LAPs, glycocins, cyanobactins, linaridins, thiopeptides
RRE-Finder	protein sequence	Yes (RODEO-integrated)	Yes	RRE-dependent RiPP classes
decRiPPter	genomic data	No	Yes	class-independent
DeepRiPP	genomic data	Yes	Yes	class-independent